bio-datasets/bigbio-ner-merged · Datasets at Hugging Face

answer stringlengths 1 16.1k	id stringlengths 7 56	instruction stringlengths 106 72.6k	ner_tags list	text stringlengths 5 72.4k	tokens list	types list
Angioplasty, syndromes, vessel, stent - like, angioplasty, PTCA, vessel, syndromes, prospective study, patients, myocardial infarction, unstable angina, PTCA, patients, angiography, All, angiograms, measurements, vessel, patients, patients, analysis, risk factors, diabetes mellitus, relative risk, hypertension, stenosis, stents, multivariate analysis, hypertension, risk factors, Diabetes, risk factor, patients, PTCA, occurrence, vessel, patients, PTCA, stents, stenosis, procedure, diabetes, hypertension	ZfuerKardiologie.00890485.eng.abstr_task2	Sentence: Angioplasty in acute coronary syndromes is complicated by a high rate of early vessel reocclusion and restenosis . Therefore , it is recommended to achieve a " stent-like " result by percutaneous transluminal coronary angioplasty ( PTCA ) or otherwise use coronary stenting ( provisional stenting ) . This study sought to determine angiographic and patient-related factors that are associated with early target vessel reocclusion or luminal renarrowing after coronary intervention in acute coronary syndromes ( ACS ) . In an observational prospective study we investigated 161 patients with ACS ( acute myocardial infarction and unstable angina ) submitted to PTCA . In 140 patients a follow-up angiography after 10 days was obtained . All angiograms were quantitatively evaluated by computerized measurements . Target vessel reocclusion and early luminal renarrowing was observed in 10 patients ( 7.1% ) and 19 patients ( 13.6% ) , respectively . Using univariate analysis , significant risk factors ( P 0.05 ) for early reocclusion and renarrowing were diabetes mellitus ( relative risk [ RR ] 6.1 and 5.0 ) , arterial hypertension ( RR 7.7 and 3.3 ) , postprocedural lesion length > =2 . 5mm ( RR 6.8 and 7.1 ) , postprocedural minimal lumen diameter =2 . 5 mm ( RR9.0 and 5.8 ) , residual stenosis > =25% ( RR 4.8 and 3.5 ) and absence of stents ( RR 4.1 and 3.2 ) . Moreover , in multivariate analysis hypertension and postprocedural lesion length could be identified as independent risk factors for reocclusion and renarrowing . Diabetes mellitus was found to be an independent risk factor for renarrowing . Conclusions : In a consecutive series of patients with ACS undergoing PTCA with provisional stenting the occurrence of early target vessel reocclusion and luminal renarrowing is lower than previously reported for this subset of patients treated by PTCA alone . Adverse outcome is related to absence of stents , angiographic factors ( residual stenosis , lesion length , minimal lumen diameter after procedure ) and patient-related factors such as diabetes and hypertension . Instructions: please extract entity words from the input sentence	[ "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O" ]	Angioplasty in acute coronary syndromes is complicated by a high rate of early vessel reocclusion and restenosis . Therefore , it is recommended to achieve a " stent-like " result by percutaneous transluminal coronary angioplasty ( PTCA ) or otherwise use coronary stenting ( provisional stenting ) . This study sought to determine angiographic and patient-related factors that are associated with early target vessel reocclusion or luminal renarrowing after coronary intervention in acute coronary syndromes ( ACS ) . In an observational prospective study we investigated 161 patients with ACS ( acute myocardial infarction and unstable angina ) submitted to PTCA . In 140 patients a follow-up angiography after 10 days was obtained . All angiograms were quantitatively evaluated by computerized measurements . Target vessel reocclusion and early luminal renarrowing was observed in 10 patients ( 7.1% ) and 19 patients ( 13.6% ) , respectively . Using univariate analysis , significant risk factors ( P 0.05 ) for early reocclusion and renarrowing were diabetes mellitus ( relative risk [ RR ] 6.1 and 5.0 ) , arterial hypertension ( RR 7.7 and 3.3 ) , postprocedural lesion length > =2 . 5mm ( RR 6.8 and 7.1 ) , postprocedural minimal lumen diameter =2 . 5 mm ( RR9.0 and 5.8 ) , residual stenosis > =25% ( RR 4.8 and 3.5 ) and absence of stents ( RR 4.1 and 3.2 ) . Moreover , in multivariate analysis hypertension and postprocedural lesion length could be identified as independent risk factors for reocclusion and renarrowing . Diabetes mellitus was found to be an independent risk factor for renarrowing . Conclusions : In a consecutive series of patients with ACS undergoing PTCA with provisional stenting the occurrence of early target vessel reocclusion and luminal renarrowing is lower than previously reported for this subset of patients treated by PTCA alone . Adverse outcome is related to absence of stents , angiographic factors ( residual stenosis , lesion length , minimal lumen diameter after procedure ) and patient-related factors such as diabetes and hypertension .	[ "Angioplasty", "in", "acute", "coronary", "syndromes", "is", "complicated", "by", "a", "high", "rate", "of", "early", "vessel", "reocclusion", "and", "restenosis", ".", "Therefore", ",", "it", "is", "recommended", "to", "achieve", "a", "\"", "stent", "-", "like", "\"", "result", "by", "percutaneous", "transluminal", "coronary", "angioplasty", "(", "PTCA", ")", "or", "otherwise", "use", "coronary", "stenting", "(", "provisional", "stenting", ")", ".", "This", "study", "sought", "to", "determine", "angiographic", "and", "patient", "-", "related", "factors", "that", "are", "associated", "with", "early", "target", "vessel", "reocclusion", "or", "luminal", "renarrowing", "after", "coronary", "intervention", "in", "acute", "coronary", "syndromes", "(", "ACS", ")", ".", "In", "an", "observational", "prospective", "study", "we", "investigated", "161", "patients", "with", "ACS", "(", "acute", "myocardial", "infarction", "and", "unstable", "angina", ")", "submitted", "to", "PTCA", ".", "In", "140", "patients", "a", "follow", "-", "up", "angiography", "after", "10", "days", "was", "obtained", ".", "All", "angiograms", "were", "quantitatively", "evaluated", "by", "computerized", "measurements", ".", "Target", "vessel", "reocclusion", "and", "early", "luminal", "renarrowing", "was", "observed", "in", "10", "patients", "(", "7.1", "%", ")", "and", "19", "patients", "(", "13.6", "%", ")", ",", "respectively", ".", "Using", "univariate", "analysis", ",", "significant", "risk", "factors", "(", "P", "0.05", ")", "for", "early", "reocclusion", "and", "renarrowing", "were", "diabetes", "mellitus", "(", "relative", "risk", "[", "RR", "]", "6.1", "and", "5.0", ")", ",", "arterial", "hypertension", "(", "RR", "7.7", "and", "3.3", ")", ",", "postprocedural", "lesion", "length", ">", "=", "2", ".", "5", "mm", "(", "RR", "6.8", "and", "7.1", ")", ",", "postprocedural", "minimal", "lumen", "diameter", "=", "2", ".", "5", "mm", "(", "RR9.0", "and", "5.8", ")", ",", "residual", "stenosis", ">", "=", "25", "%", "(", "RR", "4.8", "and", "3.5", ")", "and", "absence", "of", "stents", "(", "RR", "4.1", "and", "3.2", ")", ".", "Moreover", ",", "in", "multivariate", "analysis", "hypertension", "and", "postprocedural", "lesion", "length", "could", "be", "identified", "as", "independent", "risk", "factors", "for", "reocclusion", "and", "renarrowing", ".", "Diabetes", "mellitus", "was", "found", "to", "be", "an", "independent", "risk", "factor", "for", "renarrowing", ".", "Conclusions", ":", "In", "a", "consecutive", "series", "of", "patients", "with", "ACS", "undergoing", "PTCA", "with", "provisional", "stenting", "the", "occurrence", "of", "early", "target", "vessel", "reocclusion", "and", "luminal", "renarrowing", "is", "lower", "than", "previously", "reported", "for", "this", "subset", "of", "patients", "treated", "by", "PTCA", "alone", ".", "Adverse", "outcome", "is", "related", "to", "absence", "of", "stents", ",", "angiographic", "factors", "(", "residual", "stenosis", ",", "lesion", "length", ",", "minimal", "lumen", "diameter", "after", "procedure", ")", "and", "patient", "-", "related", "factors", "such", "as", "diabetes", "and", "hypertension", "." ]	[ "umlsterm" ]
U937 cells is a cell_line, antisense RXR - alpha cDNA is a DNA_family_or_group, retinoic acid is an other_organic_compound	54212_task0	Sentence: Stable transfection of U937 cells with sense or antisense RXR-alpha cDNA suggests a role for RXR-alpha in the control of monoblastic differentiation induced by retinoic acid and vitamin D. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: other_organic_compound, DNA_family_or_group, cell_line	[ "O", "O", "O", "B-cell_line", "I-cell_line", "O", "O", "O", "B-DNA_family_or_group", "I-DNA_family_or_group", "I-DNA_family_or_group", "I-DNA_family_or_group", "I-DNA_family_or_group", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-other_organic_compound", "I-other_organic_compound", "O", "O", "O" ]	Stable transfection of U937 cells with sense or antisense RXR-alpha cDNA suggests a role for RXR-alpha in the control of monoblastic differentiation induced by retinoic acid and vitamin D.	[ "Stable", "transfection", "of", "U937", "cells", "with", "sense", "or", "antisense", "RXR", "-", "alpha", "cDNA", "suggests", "a", "role", "for", "RXR", "-", "alpha", "in", "the", "control", "of", "monoblastic", "differentiation", "induced", "by", "retinoic", "acid", "and", "vitamin", "D." ]	[ "protein_family_or_group", "cell_line", "other_organic_compound", "other_name", "DNA_family_or_group", "DNA_domain_or_region", "cell_type", "RNA_molecule", "protein_molecule", "lipid" ]
U937 cells is a cell_line, antisense RXR - alpha cDNA is a DNA_family_or_group, retinoic acid is an other_organic_compound	54212_task1	Sentence: Stable transfection of U937 cells with sense or antisense RXR-alpha cDNA suggests a role for RXR-alpha in the control of monoblastic differentiation induced by retinoic acid and vitamin D. Instructions: please typing these entity words according to sentence: U937 cells, antisense RXR - alpha cDNA, retinoic acid Options: other_organic_compound, DNA_family_or_group, cell_line	[ "O", "O", "O", "B-cell_line", "I-cell_line", "O", "O", "O", "B-DNA_family_or_group", "I-DNA_family_or_group", "I-DNA_family_or_group", "I-DNA_family_or_group", "I-DNA_family_or_group", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-other_organic_compound", "I-other_organic_compound", "O", "O", "O" ]	Stable transfection of U937 cells with sense or antisense RXR-alpha cDNA suggests a role for RXR-alpha in the control of monoblastic differentiation induced by retinoic acid and vitamin D.	[ "Stable", "transfection", "of", "U937", "cells", "with", "sense", "or", "antisense", "RXR", "-", "alpha", "cDNA", "suggests", "a", "role", "for", "RXR", "-", "alpha", "in", "the", "control", "of", "monoblastic", "differentiation", "induced", "by", "retinoic", "acid", "and", "vitamin", "D." ]	[ "protein_family_or_group", "cell_line", "other_organic_compound", "other_name", "DNA_family_or_group", "DNA_domain_or_region", "cell_type", "RNA_molecule", "protein_molecule", "lipid" ]
U937 cells, antisense RXR - alpha cDNA, retinoic acid	54212_task2	Sentence: Stable transfection of U937 cells with sense or antisense RXR-alpha cDNA suggests a role for RXR-alpha in the control of monoblastic differentiation induced by retinoic acid and vitamin D. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "B-cell_line", "I-cell_line", "O", "O", "O", "B-DNA_family_or_group", "I-DNA_family_or_group", "I-DNA_family_or_group", "I-DNA_family_or_group", "I-DNA_family_or_group", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-other_organic_compound", "I-other_organic_compound", "O", "O", "O" ]	Stable transfection of U937 cells with sense or antisense RXR-alpha cDNA suggests a role for RXR-alpha in the control of monoblastic differentiation induced by retinoic acid and vitamin D.	[ "Stable", "transfection", "of", "U937", "cells", "with", "sense", "or", "antisense", "RXR", "-", "alpha", "cDNA", "suggests", "a", "role", "for", "RXR", "-", "alpha", "in", "the", "control", "of", "monoblastic", "differentiation", "induced", "by", "retinoic", "acid", "and", "vitamin", "D." ]	[ "protein_family_or_group", "cell_line", "other_organic_compound", "other_name", "DNA_family_or_group", "DNA_domain_or_region", "cell_type", "RNA_molecule", "protein_molecule", "lipid" ]
schizophrenia : is a Participant_Condition, antipsychotics is a Intervention_Pharmacological, quality of life is a Outcome_Other, symptoms is a Outcome_Other, people with schizophrenia is a Participant_Condition, antipsychotic medications is a Intervention_Pharmacological, more favorable health states is a Outcome_Physical, side effect characteristics is a Outcome_Adverse-effects, quality of life measures is a Outcome_Other, 1,049 patients is a Participant_Sample-size, depression is a Outcome_Physical, akathisia is a Outcome_Physical, perphenazine , olanzapine , risperidone is a Intervention_Pharmacological, quetiapine is a Intervention_Pharmacological, worst health state is a Outcome_Mental	68249_task0	Sentence: Comparing antipsychotic treatments for schizophrenia : a health state approach . The overall impact of first and second generation antipsychotics on quality of life and symptoms of people with schizophrenia remains controversial . We applied health state modeling to data from the Clinical Antipsychotic Trials of Intervention Effectiveness ( CATIE ) Schizophrenia study , a randomized trial of antipsychotic medications , and evaluated the likelihood of patients moving to more favorable health states over time . We applied K-means clustering to the data to create discrete groupings of patients with symptom and side effect characteristics that were then validated using quality of life measures . We compared cluster distributions across medications at baseline and 6 months after randomization . 1,049 patients were included in the initial cluster analysis . Five health states were identified : ( 1 ) low symptoms and low side effects ( LS + LSE ) ( 2 ) low symptoms and obesity ( LS + Ob ) ( 3 ) high symptoms and low side effects ( HS + LSE ) ( 4 ) high symptoms with depression and akathisia ( HS + Dp + Ak ) and ( 5 ) moderate symptoms and high side effects ( MS + HSE ) . Six-month outcomes among patients randomly assigned to perphenazine , olanzapine , risperidone and quetiapine were compared . At baseline , almost 20 % of patients were in the worst health state ( HS + Dp + Ak ) , with greater decreases at 6 months in this health state for perphenazine ( 9.2 % decrease ) and olanzapine ( 11.1 % ) groups compared to risperidone ( 4.7 % ) and quetiapine ( 6.7 % ) . This study demonstrated that health state analysis can provide insight into the overall clinical state of patients beyond the mere comparison of average scores and largely confirmed original CATIE findings . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Outcome_Adverse-effects, Participant_Condition, Outcome_Physical, Participant_Sample-size, Outcome_Other, Outcome_Mental	[ "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "B-Outcome_Other", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Comparing antipsychotic treatments for schizophrenia : a health state approach . The overall impact of first and second generation antipsychotics on quality of life and symptoms of people with schizophrenia remains controversial . We applied health state modeling to data from the Clinical Antipsychotic Trials of Intervention Effectiveness ( CATIE ) Schizophrenia study , a randomized trial of antipsychotic medications , and evaluated the likelihood of patients moving to more favorable health states over time . We applied K-means clustering to the data to create discrete groupings of patients with symptom and side effect characteristics that were then validated using quality of life measures . We compared cluster distributions across medications at baseline and 6 months after randomization . 1,049 patients were included in the initial cluster analysis . Five health states were identified : ( 1 ) low symptoms and low side effects ( LS + LSE ) ( 2 ) low symptoms and obesity ( LS + Ob ) ( 3 ) high symptoms and low side effects ( HS + LSE ) ( 4 ) high symptoms with depression and akathisia ( HS + Dp + Ak ) and ( 5 ) moderate symptoms and high side effects ( MS + HSE ) . Six-month outcomes among patients randomly assigned to perphenazine , olanzapine , risperidone and quetiapine were compared . At baseline , almost 20 % of patients were in the worst health state ( HS + Dp + Ak ) , with greater decreases at 6 months in this health state for perphenazine ( 9.2 % decrease ) and olanzapine ( 11.1 % ) groups compared to risperidone ( 4.7 % ) and quetiapine ( 6.7 % ) . This study demonstrated that health state analysis can provide insight into the overall clinical state of patients beyond the mere comparison of average scores and largely confirmed original CATIE findings .	[ "Comparing", "antipsychotic", "treatments", "for", "schizophrenia", ":", "a", "health", "state", "approach", ".", "The", "overall", "impact", "of", "first", "and", "second", "generation", "antipsychotics", "on", "quality", "of", "life", "and", "symptoms", "of", "people", "with", "schizophrenia", "remains", "controversial", ".", "We", "applied", "health", "state", "modeling", "to", "data", "from", "the", "Clinical", "Antipsychotic", "Trials", "of", "Intervention", "Effectiveness", "(", "CATIE", ")", "Schizophrenia", "study", ",", "a", "randomized", "trial", "of", "antipsychotic", "medications", ",", "and", "evaluated", "the", "likelihood", "of", "patients", "moving", "to", "more", "favorable", "health", "states", "over", "time", ".", "We", "applied", "K", "-", "means", "clustering", "to", "the", "data", "to", "create", "discrete", "groupings", "of", "patients", "with", "symptom", "and", "side", "effect", "characteristics", "that", "were", "then", "validated", "using", "quality", "of", "life", "measures", ".", "We", "compared", "cluster", "distributions", "across", "medications", "at", "baseline", "and", "6", "months", "after", "randomization", ".", "1,049", "patients", "were", "included", "in", "the", "initial", "cluster", "analysis", ".", "Five", "health", "states", "were", "identified", ":", "(", "1", ")", "low", "symptoms", "and", "low", "side", "effects", "(", "LS", "+", "LSE", ")", "(", "2", ")", "low", "symptoms", "and", "obesity", "(", "LS", "+", "Ob", ")", "(", "3", ")", "high", "symptoms", "and", "low", "side", "effects", "(", "HS", "+", "LSE", ")", "(", "4", ")", "high", "symptoms", "with", "depression", "and", "akathisia", "(", "HS", "+", "Dp", "+", "Ak", ")", "and", "(", "5", ")", "moderate", "symptoms", "and", "high", "side", "effects", "(", "MS", "+", "HSE", ")", ".", "Six", "-", "month", "outcomes", "among", "patients", "randomly", "assigned", "to", "perphenazine", ",", "olanzapine", ",", "risperidone", "and", "quetiapine", "were", "compared", ".", "At", "baseline", ",", "almost", "20", "%", "of", "patients", "were", "in", "the", "worst", "health", "state", "(", "HS", "+", "Dp", "+", "Ak", ")", ",", "with", "greater", "decreases", "at", "6", "months", "in", "this", "health", "state", "for", "perphenazine", "(", "9.2", "%", "decrease", ")", "and", "olanzapine", "(", "11.1", "%", ")", "groups", "compared", "to", "risperidone", "(", "4.7", "%", ")", "and", "quetiapine", "(", "6.7", "%", ")", ".", "This", "study", "demonstrated", "that", "health", "state", "analysis", "can", "provide", "insight", "into", "the", "overall", "clinical", "state", "of", "patients", "beyond", "the", "mere", "comparison", "of", "average", "scores", "and", "largely", "confirmed", "original", "CATIE", "findings", "." ]	[ "Intervention_Pharmacological", "Outcome_Physical", "Outcome_Adverse-effects", "Participant_Condition", "Outcome_Other", "Outcome_Mental", "Participant_Sample-size" ]
schizophrenia : is a Participant_Condition, antipsychotics is a Intervention_Pharmacological, quality of life is a Outcome_Other, symptoms is a Outcome_Other, people with schizophrenia is a Participant_Condition, antipsychotic medications is a Intervention_Pharmacological, more favorable health states is a Outcome_Physical, side effect characteristics is a Outcome_Adverse-effects, quality of life measures is a Outcome_Other, 1,049 patients is a Participant_Sample-size, depression is a Outcome_Physical, akathisia is a Outcome_Physical, perphenazine , olanzapine , risperidone is a Intervention_Pharmacological, quetiapine is a Intervention_Pharmacological, worst health state is a Outcome_Mental	68249_task1	Sentence: Comparing antipsychotic treatments for schizophrenia : a health state approach . The overall impact of first and second generation antipsychotics on quality of life and symptoms of people with schizophrenia remains controversial . We applied health state modeling to data from the Clinical Antipsychotic Trials of Intervention Effectiveness ( CATIE ) Schizophrenia study , a randomized trial of antipsychotic medications , and evaluated the likelihood of patients moving to more favorable health states over time . We applied K-means clustering to the data to create discrete groupings of patients with symptom and side effect characteristics that were then validated using quality of life measures . We compared cluster distributions across medications at baseline and 6 months after randomization . 1,049 patients were included in the initial cluster analysis . Five health states were identified : ( 1 ) low symptoms and low side effects ( LS + LSE ) ( 2 ) low symptoms and obesity ( LS + Ob ) ( 3 ) high symptoms and low side effects ( HS + LSE ) ( 4 ) high symptoms with depression and akathisia ( HS + Dp + Ak ) and ( 5 ) moderate symptoms and high side effects ( MS + HSE ) . Six-month outcomes among patients randomly assigned to perphenazine , olanzapine , risperidone and quetiapine were compared . At baseline , almost 20 % of patients were in the worst health state ( HS + Dp + Ak ) , with greater decreases at 6 months in this health state for perphenazine ( 9.2 % decrease ) and olanzapine ( 11.1 % ) groups compared to risperidone ( 4.7 % ) and quetiapine ( 6.7 % ) . This study demonstrated that health state analysis can provide insight into the overall clinical state of patients beyond the mere comparison of average scores and largely confirmed original CATIE findings . Instructions: please typing these entity words according to sentence: schizophrenia :, antipsychotics, quality of life, symptoms, people with schizophrenia, antipsychotic medications, more favorable health states, side effect characteristics, quality of life measures, 1,049 patients, depression, akathisia, perphenazine , olanzapine , risperidone, quetiapine, worst health state Options: Intervention_Pharmacological, Outcome_Adverse-effects, Participant_Condition, Outcome_Physical, Participant_Sample-size, Outcome_Other, Outcome_Mental	[ "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "B-Outcome_Other", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Comparing antipsychotic treatments for schizophrenia : a health state approach . The overall impact of first and second generation antipsychotics on quality of life and symptoms of people with schizophrenia remains controversial . We applied health state modeling to data from the Clinical Antipsychotic Trials of Intervention Effectiveness ( CATIE ) Schizophrenia study , a randomized trial of antipsychotic medications , and evaluated the likelihood of patients moving to more favorable health states over time . We applied K-means clustering to the data to create discrete groupings of patients with symptom and side effect characteristics that were then validated using quality of life measures . We compared cluster distributions across medications at baseline and 6 months after randomization . 1,049 patients were included in the initial cluster analysis . Five health states were identified : ( 1 ) low symptoms and low side effects ( LS + LSE ) ( 2 ) low symptoms and obesity ( LS + Ob ) ( 3 ) high symptoms and low side effects ( HS + LSE ) ( 4 ) high symptoms with depression and akathisia ( HS + Dp + Ak ) and ( 5 ) moderate symptoms and high side effects ( MS + HSE ) . Six-month outcomes among patients randomly assigned to perphenazine , olanzapine , risperidone and quetiapine were compared . At baseline , almost 20 % of patients were in the worst health state ( HS + Dp + Ak ) , with greater decreases at 6 months in this health state for perphenazine ( 9.2 % decrease ) and olanzapine ( 11.1 % ) groups compared to risperidone ( 4.7 % ) and quetiapine ( 6.7 % ) . This study demonstrated that health state analysis can provide insight into the overall clinical state of patients beyond the mere comparison of average scores and largely confirmed original CATIE findings .	[ "Comparing", "antipsychotic", "treatments", "for", "schizophrenia", ":", "a", "health", "state", "approach", ".", "The", "overall", "impact", "of", "first", "and", "second", "generation", "antipsychotics", "on", "quality", "of", "life", "and", "symptoms", "of", "people", "with", "schizophrenia", "remains", "controversial", ".", "We", "applied", "health", "state", "modeling", "to", "data", "from", "the", "Clinical", "Antipsychotic", "Trials", "of", "Intervention", "Effectiveness", "(", "CATIE", ")", "Schizophrenia", "study", ",", "a", "randomized", "trial", "of", "antipsychotic", "medications", ",", "and", "evaluated", "the", "likelihood", "of", "patients", "moving", "to", "more", "favorable", "health", "states", "over", "time", ".", "We", "applied", "K", "-", "means", "clustering", "to", "the", "data", "to", "create", "discrete", "groupings", "of", "patients", "with", "symptom", "and", "side", "effect", "characteristics", "that", "were", "then", "validated", "using", "quality", "of", "life", "measures", ".", "We", "compared", "cluster", "distributions", "across", "medications", "at", "baseline", "and", "6", "months", "after", "randomization", ".", "1,049", "patients", "were", "included", "in", "the", "initial", "cluster", "analysis", ".", "Five", "health", "states", "were", "identified", ":", "(", "1", ")", "low", "symptoms", "and", "low", "side", "effects", "(", "LS", "+", "LSE", ")", "(", "2", ")", "low", "symptoms", "and", "obesity", "(", "LS", "+", "Ob", ")", "(", "3", ")", "high", "symptoms", "and", "low", "side", "effects", "(", "HS", "+", "LSE", ")", "(", "4", ")", "high", "symptoms", "with", "depression", "and", "akathisia", "(", "HS", "+", "Dp", "+", "Ak", ")", "and", "(", "5", ")", "moderate", "symptoms", "and", "high", "side", "effects", "(", "MS", "+", "HSE", ")", ".", "Six", "-", "month", "outcomes", "among", "patients", "randomly", "assigned", "to", "perphenazine", ",", "olanzapine", ",", "risperidone", "and", "quetiapine", "were", "compared", ".", "At", "baseline", ",", "almost", "20", "%", "of", "patients", "were", "in", "the", "worst", "health", "state", "(", "HS", "+", "Dp", "+", "Ak", ")", ",", "with", "greater", "decreases", "at", "6", "months", "in", "this", "health", "state", "for", "perphenazine", "(", "9.2", "%", "decrease", ")", "and", "olanzapine", "(", "11.1", "%", ")", "groups", "compared", "to", "risperidone", "(", "4.7", "%", ")", "and", "quetiapine", "(", "6.7", "%", ")", ".", "This", "study", "demonstrated", "that", "health", "state", "analysis", "can", "provide", "insight", "into", "the", "overall", "clinical", "state", "of", "patients", "beyond", "the", "mere", "comparison", "of", "average", "scores", "and", "largely", "confirmed", "original", "CATIE", "findings", "." ]	[ "Intervention_Pharmacological", "Outcome_Physical", "Outcome_Adverse-effects", "Participant_Condition", "Outcome_Other", "Outcome_Mental", "Participant_Sample-size" ]
schizophrenia :, antipsychotics, quality of life, symptoms, people with schizophrenia, antipsychotic medications, more favorable health states, side effect characteristics, quality of life measures, 1,049 patients, depression, akathisia, perphenazine , olanzapine , risperidone, quetiapine, worst health state	68249_task2	Sentence: Comparing antipsychotic treatments for schizophrenia : a health state approach . The overall impact of first and second generation antipsychotics on quality of life and symptoms of people with schizophrenia remains controversial . We applied health state modeling to data from the Clinical Antipsychotic Trials of Intervention Effectiveness ( CATIE ) Schizophrenia study , a randomized trial of antipsychotic medications , and evaluated the likelihood of patients moving to more favorable health states over time . We applied K-means clustering to the data to create discrete groupings of patients with symptom and side effect characteristics that were then validated using quality of life measures . We compared cluster distributions across medications at baseline and 6 months after randomization . 1,049 patients were included in the initial cluster analysis . Five health states were identified : ( 1 ) low symptoms and low side effects ( LS + LSE ) ( 2 ) low symptoms and obesity ( LS + Ob ) ( 3 ) high symptoms and low side effects ( HS + LSE ) ( 4 ) high symptoms with depression and akathisia ( HS + Dp + Ak ) and ( 5 ) moderate symptoms and high side effects ( MS + HSE ) . Six-month outcomes among patients randomly assigned to perphenazine , olanzapine , risperidone and quetiapine were compared . At baseline , almost 20 % of patients were in the worst health state ( HS + Dp + Ak ) , with greater decreases at 6 months in this health state for perphenazine ( 9.2 % decrease ) and olanzapine ( 11.1 % ) groups compared to risperidone ( 4.7 % ) and quetiapine ( 6.7 % ) . This study demonstrated that health state analysis can provide insight into the overall clinical state of patients beyond the mere comparison of average scores and largely confirmed original CATIE findings . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "B-Outcome_Other", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Comparing antipsychotic treatments for schizophrenia : a health state approach . The overall impact of first and second generation antipsychotics on quality of life and symptoms of people with schizophrenia remains controversial . We applied health state modeling to data from the Clinical Antipsychotic Trials of Intervention Effectiveness ( CATIE ) Schizophrenia study , a randomized trial of antipsychotic medications , and evaluated the likelihood of patients moving to more favorable health states over time . We applied K-means clustering to the data to create discrete groupings of patients with symptom and side effect characteristics that were then validated using quality of life measures . We compared cluster distributions across medications at baseline and 6 months after randomization . 1,049 patients were included in the initial cluster analysis . Five health states were identified : ( 1 ) low symptoms and low side effects ( LS + LSE ) ( 2 ) low symptoms and obesity ( LS + Ob ) ( 3 ) high symptoms and low side effects ( HS + LSE ) ( 4 ) high symptoms with depression and akathisia ( HS + Dp + Ak ) and ( 5 ) moderate symptoms and high side effects ( MS + HSE ) . Six-month outcomes among patients randomly assigned to perphenazine , olanzapine , risperidone and quetiapine were compared . At baseline , almost 20 % of patients were in the worst health state ( HS + Dp + Ak ) , with greater decreases at 6 months in this health state for perphenazine ( 9.2 % decrease ) and olanzapine ( 11.1 % ) groups compared to risperidone ( 4.7 % ) and quetiapine ( 6.7 % ) . This study demonstrated that health state analysis can provide insight into the overall clinical state of patients beyond the mere comparison of average scores and largely confirmed original CATIE findings .	[ "Comparing", "antipsychotic", "treatments", "for", "schizophrenia", ":", "a", "health", "state", "approach", ".", "The", "overall", "impact", "of", "first", "and", "second", "generation", "antipsychotics", "on", "quality", "of", "life", "and", "symptoms", "of", "people", "with", "schizophrenia", "remains", "controversial", ".", "We", "applied", "health", "state", "modeling", "to", "data", "from", "the", "Clinical", "Antipsychotic", "Trials", "of", "Intervention", "Effectiveness", "(", "CATIE", ")", "Schizophrenia", "study", ",", "a", "randomized", "trial", "of", "antipsychotic", "medications", ",", "and", "evaluated", "the", "likelihood", "of", "patients", "moving", "to", "more", "favorable", "health", "states", "over", "time", ".", "We", "applied", "K", "-", "means", "clustering", "to", "the", "data", "to", "create", "discrete", "groupings", "of", "patients", "with", "symptom", "and", "side", "effect", "characteristics", "that", "were", "then", "validated", "using", "quality", "of", "life", "measures", ".", "We", "compared", "cluster", "distributions", "across", "medications", "at", "baseline", "and", "6", "months", "after", "randomization", ".", "1,049", "patients", "were", "included", "in", "the", "initial", "cluster", "analysis", ".", "Five", "health", "states", "were", "identified", ":", "(", "1", ")", "low", "symptoms", "and", "low", "side", "effects", "(", "LS", "+", "LSE", ")", "(", "2", ")", "low", "symptoms", "and", "obesity", "(", "LS", "+", "Ob", ")", "(", "3", ")", "high", "symptoms", "and", "low", "side", "effects", "(", "HS", "+", "LSE", ")", "(", "4", ")", "high", "symptoms", "with", "depression", "and", "akathisia", "(", "HS", "+", "Dp", "+", "Ak", ")", "and", "(", "5", ")", "moderate", "symptoms", "and", "high", "side", "effects", "(", "MS", "+", "HSE", ")", ".", "Six", "-", "month", "outcomes", "among", "patients", "randomly", "assigned", "to", "perphenazine", ",", "olanzapine", ",", "risperidone", "and", "quetiapine", "were", "compared", ".", "At", "baseline", ",", "almost", "20", "%", "of", "patients", "were", "in", "the", "worst", "health", "state", "(", "HS", "+", "Dp", "+", "Ak", ")", ",", "with", "greater", "decreases", "at", "6", "months", "in", "this", "health", "state", "for", "perphenazine", "(", "9.2", "%", "decrease", ")", "and", "olanzapine", "(", "11.1", "%", ")", "groups", "compared", "to", "risperidone", "(", "4.7", "%", ")", "and", "quetiapine", "(", "6.7", "%", ")", ".", "This", "study", "demonstrated", "that", "health", "state", "analysis", "can", "provide", "insight", "into", "the", "overall", "clinical", "state", "of", "patients", "beyond", "the", "mere", "comparison", "of", "average", "scores", "and", "largely", "confirmed", "original", "CATIE", "findings", "." ]	[ "Intervention_Pharmacological", "Outcome_Physical", "Outcome_Adverse-effects", "Participant_Condition", "Outcome_Other", "Outcome_Mental", "Participant_Sample-size" ]
Zic2 is a protein, Sp1 is a protein, Sp3 is a protein, AR1 is a DNA	1.0alpha7.train.1318_task0	Sentence: C, Zic2 competes with Sp1 and Sp3 binding to AR1. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: DNA, protein	[ "O", "O", "O", "B-protein", "O", "O", "O", "B-protein", "O", "O", "B-protein", "O", "O", "O", "B-DNA", "O" ]	C, Zic2 competes with Sp1 and Sp3 binding to AR1.	[ "C", ",", " ", "Zic2", "competes", "with", " ", "Sp1", "and", " ", "Sp3", "binding", "to", " ", "AR1", "." ]	[ "protein", "DNA" ]
Zic2 is a protein, Sp1 is a protein, Sp3 is a protein, AR1 is a DNA	1.0alpha7.train.1318_task1	Sentence: C, Zic2 competes with Sp1 and Sp3 binding to AR1. Instructions: please typing these entity words according to sentence: Zic2, Sp1, Sp3, AR1 Options: DNA, protein	[ "O", "O", "O", "B-protein", "O", "O", "O", "B-protein", "O", "O", "B-protein", "O", "O", "O", "B-DNA", "O" ]	C, Zic2 competes with Sp1 and Sp3 binding to AR1.	[ "C", ",", " ", "Zic2", "competes", "with", " ", "Sp1", "and", " ", "Sp3", "binding", "to", " ", "AR1", "." ]	[ "protein", "DNA" ]
Zic2, Sp1, Sp3, AR1	1.0alpha7.train.1318_task2	Sentence: C, Zic2 competes with Sp1 and Sp3 binding to AR1. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "B-protein", "O", "O", "O", "B-protein", "O", "O", "B-protein", "O", "O", "O", "B-DNA", "O" ]	C, Zic2 competes with Sp1 and Sp3 binding to AR1.	[ "C", ",", " ", "Zic2", "competes", "with", " ", "Sp1", "and", " ", "Sp3", "binding", "to", " ", "AR1", "." ]	[ "protein", "DNA" ]
estradiol is a lipid, polymorphonuclear leukocyte chemotaxis is an other_name	7976_task0	Sentence: Physiological concentration of estradiol inhibits polymorphonuclear leukocyte chemotaxis via a receptor mediated system. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: lipid, other_name	[ "O", "O", "O", "B-lipid", "O", "B-other_name", "I-other_name", "I-other_name", "O", "O", "O", "O", "O", "O" ]	Physiological concentration of estradiol inhibits polymorphonuclear leukocyte chemotaxis via a receptor mediated system.	[ "Physiological", "concentration", "of", "estradiol", "inhibits", "polymorphonuclear", "leukocyte", "chemotaxis", "via", "a", "receptor", "mediated", "system", "." ]	[ "other_name", "cell_type", "lipid", "other_organic_compound" ]
estradiol is a lipid, polymorphonuclear leukocyte chemotaxis is an other_name	7976_task1	Sentence: Physiological concentration of estradiol inhibits polymorphonuclear leukocyte chemotaxis via a receptor mediated system. Instructions: please typing these entity words according to sentence: estradiol, polymorphonuclear leukocyte chemotaxis Options: lipid, other_name	[ "O", "O", "O", "B-lipid", "O", "B-other_name", "I-other_name", "I-other_name", "O", "O", "O", "O", "O", "O" ]	Physiological concentration of estradiol inhibits polymorphonuclear leukocyte chemotaxis via a receptor mediated system.	[ "Physiological", "concentration", "of", "estradiol", "inhibits", "polymorphonuclear", "leukocyte", "chemotaxis", "via", "a", "receptor", "mediated", "system", "." ]	[ "other_name", "cell_type", "lipid", "other_organic_compound" ]
estradiol, polymorphonuclear leukocyte chemotaxis	7976_task2	Sentence: Physiological concentration of estradiol inhibits polymorphonuclear leukocyte chemotaxis via a receptor mediated system. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "B-lipid", "O", "B-other_name", "I-other_name", "I-other_name", "O", "O", "O", "O", "O", "O" ]	Physiological concentration of estradiol inhibits polymorphonuclear leukocyte chemotaxis via a receptor mediated system.	[ "Physiological", "concentration", "of", "estradiol", "inhibits", "polymorphonuclear", "leukocyte", "chemotaxis", "via", "a", "receptor", "mediated", "system", "." ]	[ "other_name", "cell_type", "lipid", "other_organic_compound" ]
Krankenhauspatienten is an umlsterm, Arzneimittel is an umlsterm, Schwindel is an umlsterm, Schwindelbeschwerden is an umlsterm	ZfuerGerontologie+Geriatrie.80310286.ger.abstr_task0	Sentence: Im Rahmen der Sturzpraevention wird u.a. eine routinemaessige Ueberpruefung der Medikation gefordert . In einer Zufallsstichprobe von 276 ueber 75jaehrigen Krankenhauspatienten wurde untersucht , wie haeufig Arzneimittel verordnet werden , die ueber die moegliche Ausloesung von Schwindel das Sturzrisiko erhoehen koennen . Schwindelbeschwerden und Sturzereignisse wurden standardisiert erhoben . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O" ]	Im Rahmen der Sturzpraevention wird u.a. eine routinemaessige Ueberpruefung der Medikation gefordert . In einer Zufallsstichprobe von 276 ueber 75jaehrigen Krankenhauspatienten wurde untersucht , wie haeufig Arzneimittel verordnet werden , die ueber die moegliche Ausloesung von Schwindel das Sturzrisiko erhoehen koennen . Schwindelbeschwerden und Sturzereignisse wurden standardisiert erhoben .	[ "Im", "Rahmen", "der", "Sturzpraevention", "wird", "u.a", ".", "eine", "routinemaessige", "Ueberpruefung", "der", "Medikation", "gefordert", ".", "In", "einer", "Zufallsstichprobe", "von", "276", "ueber", "75jaehrigen", "Krankenhauspatienten", "wurde", "untersucht", ",", "wie", "haeufig", "Arzneimittel", "verordnet", "werden", ",", "die", "ueber", "die", "moegliche", "Ausloesung", "von", "Schwindel", "das", "Sturzrisiko", "erhoehen", "koennen", ".", "Schwindelbeschwerden", "und", "Sturzereignisse", "wurden", "standardisiert", "erhoben", "." ]	[ "umlsterm" ]
Krankenhauspatienten is an umlsterm, Arzneimittel is an umlsterm, Schwindel is an umlsterm, Schwindelbeschwerden is an umlsterm	ZfuerGerontologie+Geriatrie.80310286.ger.abstr_task1	Sentence: Im Rahmen der Sturzpraevention wird u.a. eine routinemaessige Ueberpruefung der Medikation gefordert . In einer Zufallsstichprobe von 276 ueber 75jaehrigen Krankenhauspatienten wurde untersucht , wie haeufig Arzneimittel verordnet werden , die ueber die moegliche Ausloesung von Schwindel das Sturzrisiko erhoehen koennen . Schwindelbeschwerden und Sturzereignisse wurden standardisiert erhoben . Instructions: please typing these entity words according to sentence: Krankenhauspatienten, Arzneimittel, Schwindel, Schwindelbeschwerden Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O" ]	Im Rahmen der Sturzpraevention wird u.a. eine routinemaessige Ueberpruefung der Medikation gefordert . In einer Zufallsstichprobe von 276 ueber 75jaehrigen Krankenhauspatienten wurde untersucht , wie haeufig Arzneimittel verordnet werden , die ueber die moegliche Ausloesung von Schwindel das Sturzrisiko erhoehen koennen . Schwindelbeschwerden und Sturzereignisse wurden standardisiert erhoben .	[ "Im", "Rahmen", "der", "Sturzpraevention", "wird", "u.a", ".", "eine", "routinemaessige", "Ueberpruefung", "der", "Medikation", "gefordert", ".", "In", "einer", "Zufallsstichprobe", "von", "276", "ueber", "75jaehrigen", "Krankenhauspatienten", "wurde", "untersucht", ",", "wie", "haeufig", "Arzneimittel", "verordnet", "werden", ",", "die", "ueber", "die", "moegliche", "Ausloesung", "von", "Schwindel", "das", "Sturzrisiko", "erhoehen", "koennen", ".", "Schwindelbeschwerden", "und", "Sturzereignisse", "wurden", "standardisiert", "erhoben", "." ]	[ "umlsterm" ]
Krankenhauspatienten, Arzneimittel, Schwindel, Schwindelbeschwerden	ZfuerGerontologie+Geriatrie.80310286.ger.abstr_task2	Sentence: Im Rahmen der Sturzpraevention wird u.a. eine routinemaessige Ueberpruefung der Medikation gefordert . In einer Zufallsstichprobe von 276 ueber 75jaehrigen Krankenhauspatienten wurde untersucht , wie haeufig Arzneimittel verordnet werden , die ueber die moegliche Ausloesung von Schwindel das Sturzrisiko erhoehen koennen . Schwindelbeschwerden und Sturzereignisse wurden standardisiert erhoben . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O" ]	Im Rahmen der Sturzpraevention wird u.a. eine routinemaessige Ueberpruefung der Medikation gefordert . In einer Zufallsstichprobe von 276 ueber 75jaehrigen Krankenhauspatienten wurde untersucht , wie haeufig Arzneimittel verordnet werden , die ueber die moegliche Ausloesung von Schwindel das Sturzrisiko erhoehen koennen . Schwindelbeschwerden und Sturzereignisse wurden standardisiert erhoben .	[ "Im", "Rahmen", "der", "Sturzpraevention", "wird", "u.a", ".", "eine", "routinemaessige", "Ueberpruefung", "der", "Medikation", "gefordert", ".", "In", "einer", "Zufallsstichprobe", "von", "276", "ueber", "75jaehrigen", "Krankenhauspatienten", "wurde", "untersucht", ",", "wie", "haeufig", "Arzneimittel", "verordnet", "werden", ",", "die", "ueber", "die", "moegliche", "Ausloesung", "von", "Schwindel", "das", "Sturzrisiko", "erhoehen", "koennen", ".", "Schwindelbeschwerden", "und", "Sturzereignisse", "wurden", "standardisiert", "erhoben", "." ]	[ "umlsterm" ]
drugs is an umlsterm, form is an umlsterm, ventricular tachycardia is an umlsterm, torsade de pointes is an umlsterm, drugs is an umlsterm, antibiotics is an umlsterm, antifungals is an umlsterm, hypokalaemia is an umlsterm, bradycardia is an umlsterm, potassium channel is an umlsterm, review is an umlsterm, knowledge is an umlsterm, risk is an umlsterm, therapy is an umlsterm, syndrome is an umlsterm	IntensiveMedizin.80350557.eng.abstr_task0	Sentence: In recent years a multitude of reports has been published on the effects of various antiarrhythmic and non-antiarrhythmic drugs causing QT-intervall prolongation and thus triggering a characteristic form of polymorphic ventricular tachycardia known as torsade de pointes . These drugs included antiarrhythmics , antibiotics , antifungals , prokinetics and various other substances which often cause QT-prolongation and torsades only in combination with other riskfactors such as hypokalaemia or bradycardia . Most of these substances block the delayed rectifier potassium channel in myocytes . In this review we summarized the current knowledge on electrophysiologic mechanisms , riskfactors , arrhythmogenic risk and therapy of the acquired long-QT syndrome . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]	In recent years a multitude of reports has been published on the effects of various antiarrhythmic and non-antiarrhythmic drugs causing QT-intervall prolongation and thus triggering a characteristic form of polymorphic ventricular tachycardia known as torsade de pointes . These drugs included antiarrhythmics , antibiotics , antifungals , prokinetics and various other substances which often cause QT-prolongation and torsades only in combination with other riskfactors such as hypokalaemia or bradycardia . Most of these substances block the delayed rectifier potassium channel in myocytes . In this review we summarized the current knowledge on electrophysiologic mechanisms , riskfactors , arrhythmogenic risk and therapy of the acquired long-QT syndrome .	[ "In", "recent", "years", "a", "multitude", "of", "reports", "has", "been", "published", "on", "the", "effects", "of", "various", "antiarrhythmic", "and", "non", "-", "antiarrhythmic", "drugs", "causing", "QT", "-", "intervall", "prolongation", "and", "thus", "triggering", "a", "characteristic", "form", "of", "polymorphic", "ventricular", "tachycardia", "known", "as", "torsade", "de", "pointes", ".", "These", "drugs", "included", "antiarrhythmics", ",", "antibiotics", ",", "antifungals", ",", "prokinetics", "and", "various", "other", "substances", "which", "often", "cause", "QT", "-", "prolongation", "and", "torsades", "only", "in", "combination", "with", "other", "riskfactors", "such", "as", "hypokalaemia", "or", "bradycardia", ".", "Most", "of", "these", "substances", "block", "the", "delayed", "rectifier", "potassium", "channel", "in", "myocytes", ".", "In", "this", "review", "we", "summarized", "the", "current", "knowledge", "on", "electrophysiologic", "mechanisms", ",", "riskfactors", ",", "arrhythmogenic", "risk", "and", "therapy", "of", "the", "acquired", "long", "-", "QT", "syndrome", "." ]	[ "umlsterm" ]
drugs is an umlsterm, form is an umlsterm, ventricular tachycardia is an umlsterm, torsade de pointes is an umlsterm, drugs is an umlsterm, antibiotics is an umlsterm, antifungals is an umlsterm, hypokalaemia is an umlsterm, bradycardia is an umlsterm, potassium channel is an umlsterm, review is an umlsterm, knowledge is an umlsterm, risk is an umlsterm, therapy is an umlsterm, syndrome is an umlsterm	IntensiveMedizin.80350557.eng.abstr_task1	Sentence: In recent years a multitude of reports has been published on the effects of various antiarrhythmic and non-antiarrhythmic drugs causing QT-intervall prolongation and thus triggering a characteristic form of polymorphic ventricular tachycardia known as torsade de pointes . These drugs included antiarrhythmics , antibiotics , antifungals , prokinetics and various other substances which often cause QT-prolongation and torsades only in combination with other riskfactors such as hypokalaemia or bradycardia . Most of these substances block the delayed rectifier potassium channel in myocytes . In this review we summarized the current knowledge on electrophysiologic mechanisms , riskfactors , arrhythmogenic risk and therapy of the acquired long-QT syndrome . Instructions: please typing these entity words according to sentence: drugs, form, ventricular tachycardia, torsade de pointes, drugs, antibiotics, antifungals, hypokalaemia, bradycardia, potassium channel, review, knowledge, risk, therapy, syndrome Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]	In recent years a multitude of reports has been published on the effects of various antiarrhythmic and non-antiarrhythmic drugs causing QT-intervall prolongation and thus triggering a characteristic form of polymorphic ventricular tachycardia known as torsade de pointes . These drugs included antiarrhythmics , antibiotics , antifungals , prokinetics and various other substances which often cause QT-prolongation and torsades only in combination with other riskfactors such as hypokalaemia or bradycardia . Most of these substances block the delayed rectifier potassium channel in myocytes . In this review we summarized the current knowledge on electrophysiologic mechanisms , riskfactors , arrhythmogenic risk and therapy of the acquired long-QT syndrome .	[ "In", "recent", "years", "a", "multitude", "of", "reports", "has", "been", "published", "on", "the", "effects", "of", "various", "antiarrhythmic", "and", "non", "-", "antiarrhythmic", "drugs", "causing", "QT", "-", "intervall", "prolongation", "and", "thus", "triggering", "a", "characteristic", "form", "of", "polymorphic", "ventricular", "tachycardia", "known", "as", "torsade", "de", "pointes", ".", "These", "drugs", "included", "antiarrhythmics", ",", "antibiotics", ",", "antifungals", ",", "prokinetics", "and", "various", "other", "substances", "which", "often", "cause", "QT", "-", "prolongation", "and", "torsades", "only", "in", "combination", "with", "other", "riskfactors", "such", "as", "hypokalaemia", "or", "bradycardia", ".", "Most", "of", "these", "substances", "block", "the", "delayed", "rectifier", "potassium", "channel", "in", "myocytes", ".", "In", "this", "review", "we", "summarized", "the", "current", "knowledge", "on", "electrophysiologic", "mechanisms", ",", "riskfactors", ",", "arrhythmogenic", "risk", "and", "therapy", "of", "the", "acquired", "long", "-", "QT", "syndrome", "." ]	[ "umlsterm" ]
drugs, form, ventricular tachycardia, torsade de pointes, drugs, antibiotics, antifungals, hypokalaemia, bradycardia, potassium channel, review, knowledge, risk, therapy, syndrome	IntensiveMedizin.80350557.eng.abstr_task2	Sentence: In recent years a multitude of reports has been published on the effects of various antiarrhythmic and non-antiarrhythmic drugs causing QT-intervall prolongation and thus triggering a characteristic form of polymorphic ventricular tachycardia known as torsade de pointes . These drugs included antiarrhythmics , antibiotics , antifungals , prokinetics and various other substances which often cause QT-prolongation and torsades only in combination with other riskfactors such as hypokalaemia or bradycardia . Most of these substances block the delayed rectifier potassium channel in myocytes . In this review we summarized the current knowledge on electrophysiologic mechanisms , riskfactors , arrhythmogenic risk and therapy of the acquired long-QT syndrome . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]	In recent years a multitude of reports has been published on the effects of various antiarrhythmic and non-antiarrhythmic drugs causing QT-intervall prolongation and thus triggering a characteristic form of polymorphic ventricular tachycardia known as torsade de pointes . These drugs included antiarrhythmics , antibiotics , antifungals , prokinetics and various other substances which often cause QT-prolongation and torsades only in combination with other riskfactors such as hypokalaemia or bradycardia . Most of these substances block the delayed rectifier potassium channel in myocytes . In this review we summarized the current knowledge on electrophysiologic mechanisms , riskfactors , arrhythmogenic risk and therapy of the acquired long-QT syndrome .	[ "In", "recent", "years", "a", "multitude", "of", "reports", "has", "been", "published", "on", "the", "effects", "of", "various", "antiarrhythmic", "and", "non", "-", "antiarrhythmic", "drugs", "causing", "QT", "-", "intervall", "prolongation", "and", "thus", "triggering", "a", "characteristic", "form", "of", "polymorphic", "ventricular", "tachycardia", "known", "as", "torsade", "de", "pointes", ".", "These", "drugs", "included", "antiarrhythmics", ",", "antibiotics", ",", "antifungals", ",", "prokinetics", "and", "various", "other", "substances", "which", "often", "cause", "QT", "-", "prolongation", "and", "torsades", "only", "in", "combination", "with", "other", "riskfactors", "such", "as", "hypokalaemia", "or", "bradycardia", ".", "Most", "of", "these", "substances", "block", "the", "delayed", "rectifier", "potassium", "channel", "in", "myocytes", ".", "In", "this", "review", "we", "summarized", "the", "current", "knowledge", "on", "electrophysiologic", "mechanisms", ",", "riskfactors", ",", "arrhythmogenic", "risk", "and", "therapy", "of", "the", "acquired", "long", "-", "QT", "syndrome", "." ]	[ "umlsterm" ]
serous is a Organism_substance, Serous is a Organism_substance, eyes is a Organ, eyes is a Organ, Choroidal is a Multi-tissue_structure, retinal is a Multi-tissue_structure, eye is a Organ, choroidal is a Multi-tissue_structure, Retinal Pigment Epithelium is a Tissue, RPE is a Tissue, choroidal is a Multi-tissue_structure, retinal is a Multi-tissue_structure, RPE is a Tissue	PMID-18188789_task0	Sentence: [Photodynamic therapy in severe chronic central serous chorioretinopaty] OBJECTIVE: To determine the efficacy of Photodynamic Therapy (PDT) in chronic Central Serous Chorioretinopathy (CSC). METHODS: Patients diagnosed with chronic CSC, with clinical evidence of activity and treated with Photodynamic Therapy, are included in this report. All were assessed by a complete ophthalmological examination, including assessment of the best corrected visual acuity (BCVA) using an ETDRS chart, fluorescein and indocyanine angiography and optical coherence tomography (OCT). The main objective of the study was to determine the mean visual acuity change. RESULTS: 11 eyes of 11 patients were included in the study, which had a mean follow-up period of 11 months. The mean BCVA increased from 20/76 to 20/64. 35% of eyes improved their BCVA by 2 lines or more, 45% remained stable and 18% lost 2 lines or more. Choroidal hyperpermeability was reduced in every case. Neurosensorial retinal detachment decreased in 80% of cases. Only one eye received a second PDT treatment due to choroidal neovascularization. An increase of atrophy over the Retinal Pigment Epithelium (RPE) was observed in another patient. CONCLUSIONS: PDT can reduce the clinical signs of activity, such as choroidal hyperpermeability or neurosensorial retinal detachment, in patients affected by chronic CSC. However, the increase in visual acuity is variable, probably due to the extent of RPE damage. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Multi-tissue_structure, Tissue, Organ, Organism_substance	[ "O", "O", "O", "O", "O", "O", "O", "B-Organism_substance", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism_substance", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organ", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organ", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organ", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "O", "B-Tissue", "I-Tissue", "I-Tissue", "O", "B-Tissue", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "O", "O", "B-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Tissue", "O", "O", "O" ]	[Photodynamic therapy in severe chronic central serous chorioretinopaty] OBJECTIVE: To determine the efficacy of Photodynamic Therapy (PDT) in chronic Central Serous Chorioretinopathy (CSC). METHODS: Patients diagnosed with chronic CSC, with clinical evidence of activity and treated with Photodynamic Therapy, are included in this report. All were assessed by a complete ophthalmological examination, including assessment of the best corrected visual acuity (BCVA) using an ETDRS chart, fluorescein and indocyanine angiography and optical coherence tomography (OCT). The main objective of the study was to determine the mean visual acuity change. RESULTS: 11 eyes of 11 patients were included in the study, which had a mean follow-up period of 11 months. The mean BCVA increased from 20/76 to 20/64. 35% of eyes improved their BCVA by 2 lines or more, 45% remained stable and 18% lost 2 lines or more. Choroidal hyperpermeability was reduced in every case. Neurosensorial retinal detachment decreased in 80% of cases. Only one eye received a second PDT treatment due to choroidal neovascularization. An increase of atrophy over the Retinal Pigment Epithelium (RPE) was observed in another patient. CONCLUSIONS: PDT can reduce the clinical signs of activity, such as choroidal hyperpermeability or neurosensorial retinal detachment, in patients affected by chronic CSC. However, the increase in visual acuity is variable, probably due to the extent of RPE damage.	[ "[", "Photodynamic", "therapy", "in", "severe", "chronic", "central", "serous", "chorioretinopaty", "]", "\n", "OBJECTIVE", ":", "To", "determine", "the", "efficacy", "of", "Photodynamic", "Therapy", "(", "PDT", ")", "in", "chronic", "Central", "Serous", "Chorioretinopathy", "(", "CSC", ")", ".", "METHODS", ":", "Patients", "diagnosed", "with", "chronic", "CSC", ",", "with", "clinical", "evidence", "of", "activity", "and", "treated", "with", "Photodynamic", "Therapy", ",", "are", "included", "in", "this", "report", ".", "All", "were", "assessed", "by", "a", "complete", "ophthalmological", "examination", ",", "including", "assessment", "of", "the", "best", "corrected", "visual", "acuity", "(", "BCVA", ")", "using", "an", "ETDRS", "chart", ",", "fluorescein", "and", "indocyanine", "angiography", "and", "optical", "coherence", "tomography", "(", "OCT", ")", ".", "The", "main", "objective", "of", "the", "study", "was", "to", "determine", "the", "mean", "visual", "acuity", "change", ".", "RESULTS", ":", "11", "eyes", "of", "11", "patients", "were", "included", "in", "the", "study", ",", "which", "had", "a", "mean", "follow", "-", "up", "period", "of", "11", "months", ".", "The", "mean", "BCVA", "increased", "from", "20/76", "to", "20/64", ".", "35", "%", "of", "eyes", "improved", "their", "BCVA", "by", "2", "lines", "or", "more", ",", "45", "%", "remained", "stable", "and", "18", "%", "lost", "2", "lines", "or", "more", ".", "Choroidal", "hyperpermeability", "was", "reduced", "in", "every", "case", ".", "Neurosensorial", "retinal", "detachment", "decreased", "in", "80", "%", "of", "cases", ".", "Only", "one", "eye", "received", "a", "second", "PDT", "treatment", "due", "to", "choroidal", "neovascularization", ".", "An", "increase", "of", "atrophy", "over", "the", "Retinal", "Pigment", "Epithelium", "(", "RPE", ")", "was", "observed", "in", "another", "patient", ".", "CONCLUSIONS", ":", "PDT", "can", "reduce", "the", "clinical", "signs", "of", "activity", ",", "such", "as", "choroidal", "hyperpermeability", "or", "neurosensorial", "retinal", "detachment", ",", "in", "patients", "affected", "by", "chronic", "CSC", ".", "However", ",", "the", "increase", "in", "visual", "acuity", "is", "variable", ",", "probably", "due", "to", "the", "extent", "of", "RPE", "damage", ".", "\n" ]	[ "Tissue", "Multi-tissue_structure", "Organism_substance", "Organ" ]
serous is a Organism_substance, Serous is a Organism_substance, eyes is a Organ, eyes is a Organ, Choroidal is a Multi-tissue_structure, retinal is a Multi-tissue_structure, eye is a Organ, choroidal is a Multi-tissue_structure, Retinal Pigment Epithelium is a Tissue, RPE is a Tissue, choroidal is a Multi-tissue_structure, retinal is a Multi-tissue_structure, RPE is a Tissue	PMID-18188789_task1	Sentence: [Photodynamic therapy in severe chronic central serous chorioretinopaty] OBJECTIVE: To determine the efficacy of Photodynamic Therapy (PDT) in chronic Central Serous Chorioretinopathy (CSC). METHODS: Patients diagnosed with chronic CSC, with clinical evidence of activity and treated with Photodynamic Therapy, are included in this report. All were assessed by a complete ophthalmological examination, including assessment of the best corrected visual acuity (BCVA) using an ETDRS chart, fluorescein and indocyanine angiography and optical coherence tomography (OCT). The main objective of the study was to determine the mean visual acuity change. RESULTS: 11 eyes of 11 patients were included in the study, which had a mean follow-up period of 11 months. The mean BCVA increased from 20/76 to 20/64. 35% of eyes improved their BCVA by 2 lines or more, 45% remained stable and 18% lost 2 lines or more. Choroidal hyperpermeability was reduced in every case. Neurosensorial retinal detachment decreased in 80% of cases. Only one eye received a second PDT treatment due to choroidal neovascularization. An increase of atrophy over the Retinal Pigment Epithelium (RPE) was observed in another patient. CONCLUSIONS: PDT can reduce the clinical signs of activity, such as choroidal hyperpermeability or neurosensorial retinal detachment, in patients affected by chronic CSC. However, the increase in visual acuity is variable, probably due to the extent of RPE damage. Instructions: please typing these entity words according to sentence: serous, Serous, eyes, eyes, Choroidal, retinal, eye, choroidal, Retinal Pigment Epithelium, RPE, choroidal, retinal, RPE Options: Multi-tissue_structure, Tissue, Organ, Organism_substance	[ "O", "O", "O", "O", "O", "O", "O", "B-Organism_substance", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism_substance", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organ", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organ", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organ", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "O", "B-Tissue", "I-Tissue", "I-Tissue", "O", "B-Tissue", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "O", "O", "B-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Tissue", "O", "O", "O" ]	[Photodynamic therapy in severe chronic central serous chorioretinopaty] OBJECTIVE: To determine the efficacy of Photodynamic Therapy (PDT) in chronic Central Serous Chorioretinopathy (CSC). METHODS: Patients diagnosed with chronic CSC, with clinical evidence of activity and treated with Photodynamic Therapy, are included in this report. All were assessed by a complete ophthalmological examination, including assessment of the best corrected visual acuity (BCVA) using an ETDRS chart, fluorescein and indocyanine angiography and optical coherence tomography (OCT). The main objective of the study was to determine the mean visual acuity change. RESULTS: 11 eyes of 11 patients were included in the study, which had a mean follow-up period of 11 months. The mean BCVA increased from 20/76 to 20/64. 35% of eyes improved their BCVA by 2 lines or more, 45% remained stable and 18% lost 2 lines or more. Choroidal hyperpermeability was reduced in every case. Neurosensorial retinal detachment decreased in 80% of cases. Only one eye received a second PDT treatment due to choroidal neovascularization. An increase of atrophy over the Retinal Pigment Epithelium (RPE) was observed in another patient. CONCLUSIONS: PDT can reduce the clinical signs of activity, such as choroidal hyperpermeability or neurosensorial retinal detachment, in patients affected by chronic CSC. However, the increase in visual acuity is variable, probably due to the extent of RPE damage.	[ "[", "Photodynamic", "therapy", "in", "severe", "chronic", "central", "serous", "chorioretinopaty", "]", "\n", "OBJECTIVE", ":", "To", "determine", "the", "efficacy", "of", "Photodynamic", "Therapy", "(", "PDT", ")", "in", "chronic", "Central", "Serous", "Chorioretinopathy", "(", "CSC", ")", ".", "METHODS", ":", "Patients", "diagnosed", "with", "chronic", "CSC", ",", "with", "clinical", "evidence", "of", "activity", "and", "treated", "with", "Photodynamic", "Therapy", ",", "are", "included", "in", "this", "report", ".", "All", "were", "assessed", "by", "a", "complete", "ophthalmological", "examination", ",", "including", "assessment", "of", "the", "best", "corrected", "visual", "acuity", "(", "BCVA", ")", "using", "an", "ETDRS", "chart", ",", "fluorescein", "and", "indocyanine", "angiography", "and", "optical", "coherence", "tomography", "(", "OCT", ")", ".", "The", "main", "objective", "of", "the", "study", "was", "to", "determine", "the", "mean", "visual", "acuity", "change", ".", "RESULTS", ":", "11", "eyes", "of", "11", "patients", "were", "included", "in", "the", "study", ",", "which", "had", "a", "mean", "follow", "-", "up", "period", "of", "11", "months", ".", "The", "mean", "BCVA", "increased", "from", "20/76", "to", "20/64", ".", "35", "%", "of", "eyes", "improved", "their", "BCVA", "by", "2", "lines", "or", "more", ",", "45", "%", "remained", "stable", "and", "18", "%", "lost", "2", "lines", "or", "more", ".", "Choroidal", "hyperpermeability", "was", "reduced", "in", "every", "case", ".", "Neurosensorial", "retinal", "detachment", "decreased", "in", "80", "%", "of", "cases", ".", "Only", "one", "eye", "received", "a", "second", "PDT", "treatment", "due", "to", "choroidal", "neovascularization", ".", "An", "increase", "of", "atrophy", "over", "the", "Retinal", "Pigment", "Epithelium", "(", "RPE", ")", "was", "observed", "in", "another", "patient", ".", "CONCLUSIONS", ":", "PDT", "can", "reduce", "the", "clinical", "signs", "of", "activity", ",", "such", "as", "choroidal", "hyperpermeability", "or", "neurosensorial", "retinal", "detachment", ",", "in", "patients", "affected", "by", "chronic", "CSC", ".", "However", ",", "the", "increase", "in", "visual", "acuity", "is", "variable", ",", "probably", "due", "to", "the", "extent", "of", "RPE", "damage", ".", "\n" ]	[ "Tissue", "Multi-tissue_structure", "Organism_substance", "Organ" ]
serous, Serous, eyes, eyes, Choroidal, retinal, eye, choroidal, Retinal Pigment Epithelium, RPE, choroidal, retinal, RPE	PMID-18188789_task2	Sentence: [Photodynamic therapy in severe chronic central serous chorioretinopaty] OBJECTIVE: To determine the efficacy of Photodynamic Therapy (PDT) in chronic Central Serous Chorioretinopathy (CSC). METHODS: Patients diagnosed with chronic CSC, with clinical evidence of activity and treated with Photodynamic Therapy, are included in this report. All were assessed by a complete ophthalmological examination, including assessment of the best corrected visual acuity (BCVA) using an ETDRS chart, fluorescein and indocyanine angiography and optical coherence tomography (OCT). The main objective of the study was to determine the mean visual acuity change. RESULTS: 11 eyes of 11 patients were included in the study, which had a mean follow-up period of 11 months. The mean BCVA increased from 20/76 to 20/64. 35% of eyes improved their BCVA by 2 lines or more, 45% remained stable and 18% lost 2 lines or more. Choroidal hyperpermeability was reduced in every case. Neurosensorial retinal detachment decreased in 80% of cases. Only one eye received a second PDT treatment due to choroidal neovascularization. An increase of atrophy over the Retinal Pigment Epithelium (RPE) was observed in another patient. CONCLUSIONS: PDT can reduce the clinical signs of activity, such as choroidal hyperpermeability or neurosensorial retinal detachment, in patients affected by chronic CSC. However, the increase in visual acuity is variable, probably due to the extent of RPE damage. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "B-Organism_substance", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism_substance", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organ", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organ", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organ", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "O", "B-Tissue", "I-Tissue", "I-Tissue", "O", "B-Tissue", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "O", "O", "B-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Tissue", "O", "O", "O" ]	[Photodynamic therapy in severe chronic central serous chorioretinopaty] OBJECTIVE: To determine the efficacy of Photodynamic Therapy (PDT) in chronic Central Serous Chorioretinopathy (CSC). METHODS: Patients diagnosed with chronic CSC, with clinical evidence of activity and treated with Photodynamic Therapy, are included in this report. All were assessed by a complete ophthalmological examination, including assessment of the best corrected visual acuity (BCVA) using an ETDRS chart, fluorescein and indocyanine angiography and optical coherence tomography (OCT). The main objective of the study was to determine the mean visual acuity change. RESULTS: 11 eyes of 11 patients were included in the study, which had a mean follow-up period of 11 months. The mean BCVA increased from 20/76 to 20/64. 35% of eyes improved their BCVA by 2 lines or more, 45% remained stable and 18% lost 2 lines or more. Choroidal hyperpermeability was reduced in every case. Neurosensorial retinal detachment decreased in 80% of cases. Only one eye received a second PDT treatment due to choroidal neovascularization. An increase of atrophy over the Retinal Pigment Epithelium (RPE) was observed in another patient. CONCLUSIONS: PDT can reduce the clinical signs of activity, such as choroidal hyperpermeability or neurosensorial retinal detachment, in patients affected by chronic CSC. However, the increase in visual acuity is variable, probably due to the extent of RPE damage.	[ "[", "Photodynamic", "therapy", "in", "severe", "chronic", "central", "serous", "chorioretinopaty", "]", "\n", "OBJECTIVE", ":", "To", "determine", "the", "efficacy", "of", "Photodynamic", "Therapy", "(", "PDT", ")", "in", "chronic", "Central", "Serous", "Chorioretinopathy", "(", "CSC", ")", ".", "METHODS", ":", "Patients", "diagnosed", "with", "chronic", "CSC", ",", "with", "clinical", "evidence", "of", "activity", "and", "treated", "with", "Photodynamic", "Therapy", ",", "are", "included", "in", "this", "report", ".", "All", "were", "assessed", "by", "a", "complete", "ophthalmological", "examination", ",", "including", "assessment", "of", "the", "best", "corrected", "visual", "acuity", "(", "BCVA", ")", "using", "an", "ETDRS", "chart", ",", "fluorescein", "and", "indocyanine", "angiography", "and", "optical", "coherence", "tomography", "(", "OCT", ")", ".", "The", "main", "objective", "of", "the", "study", "was", "to", "determine", "the", "mean", "visual", "acuity", "change", ".", "RESULTS", ":", "11", "eyes", "of", "11", "patients", "were", "included", "in", "the", "study", ",", "which", "had", "a", "mean", "follow", "-", "up", "period", "of", "11", "months", ".", "The", "mean", "BCVA", "increased", "from", "20/76", "to", "20/64", ".", "35", "%", "of", "eyes", "improved", "their", "BCVA", "by", "2", "lines", "or", "more", ",", "45", "%", "remained", "stable", "and", "18", "%", "lost", "2", "lines", "or", "more", ".", "Choroidal", "hyperpermeability", "was", "reduced", "in", "every", "case", ".", "Neurosensorial", "retinal", "detachment", "decreased", "in", "80", "%", "of", "cases", ".", "Only", "one", "eye", "received", "a", "second", "PDT", "treatment", "due", "to", "choroidal", "neovascularization", ".", "An", "increase", "of", "atrophy", "over", "the", "Retinal", "Pigment", "Epithelium", "(", "RPE", ")", "was", "observed", "in", "another", "patient", ".", "CONCLUSIONS", ":", "PDT", "can", "reduce", "the", "clinical", "signs", "of", "activity", ",", "such", "as", "choroidal", "hyperpermeability", "or", "neurosensorial", "retinal", "detachment", ",", "in", "patients", "affected", "by", "chronic", "CSC", ".", "However", ",", "the", "increase", "in", "visual", "acuity", "is", "variable", ",", "probably", "due", "to", "the", "extent", "of", "RPE", "damage", ".", "\n" ]	[ "Tissue", "Multi-tissue_structure", "Organism_substance", "Organ" ]
gunshot injuries is an umlsterm, tissue is an umlsterm, direct is an umlsterm, trauma is an umlsterm, eye is an umlsterm, ear is an umlsterm, rupture is an umlsterm, neck is an umlsterm, vessels is an umlsterm, endoscopy is an umlsterm, imaging is an umlsterm, tissue is an umlsterm, risk of is an umlsterm, wound infection is an umlsterm, gunshot wound is an umlsterm	HNO.70450643.eng.abstr_task0	Sentence: Different types of gunshot injuries caused by warning weapons are demonstrated . Most important are contact shots , causing major tissue damage that can differ from that caused by classical projectiles . Possible consequences , besides direct trauma to the eye and ear , are airway distress because of extensive swelling and rupture of major neck vessels . The detailed examination includes endoscopy and radiologic imaging . Any major permanent cavity in the tissue bears a high risk of wound infection . For different reasons the fact of a gunshot wound may be kept secret by the victims . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O" ]	Different types of gunshot injuries caused by warning weapons are demonstrated . Most important are contact shots , causing major tissue damage that can differ from that caused by classical projectiles . Possible consequences , besides direct trauma to the eye and ear , are airway distress because of extensive swelling and rupture of major neck vessels . The detailed examination includes endoscopy and radiologic imaging . Any major permanent cavity in the tissue bears a high risk of wound infection . For different reasons the fact of a gunshot wound may be kept secret by the victims .	[ "Different", "types", "of", "gunshot", "injuries", "caused", "by", "warning", "weapons", "are", "demonstrated", ".", "Most", "important", "are", "contact", "shots", ",", "causing", "major", "tissue", "damage", "that", "can", "differ", "from", "that", "caused", "by", "classical", "projectiles", ".", "Possible", "consequences", ",", "besides", "direct", "trauma", "to", "the", "eye", "and", "ear", ",", "are", "airway", "distress", "because", "of", "extensive", "swelling", "and", "rupture", "of", "major", "neck", "vessels", ".", "The", "detailed", "examination", "includes", "endoscopy", "and", "radiologic", "imaging", ".", "Any", "major", "permanent", "cavity", "in", "the", "tissue", "bears", "a", "high", "risk", "of", "wound", "infection", ".", "For", "different", "reasons", "the", "fact", "of", "a", "gunshot", "wound", "may", "be", "kept", "secret", "by", "the", "victims", "." ]	[ "umlsterm" ]
gunshot injuries is an umlsterm, tissue is an umlsterm, direct is an umlsterm, trauma is an umlsterm, eye is an umlsterm, ear is an umlsterm, rupture is an umlsterm, neck is an umlsterm, vessels is an umlsterm, endoscopy is an umlsterm, imaging is an umlsterm, tissue is an umlsterm, risk of is an umlsterm, wound infection is an umlsterm, gunshot wound is an umlsterm	HNO.70450643.eng.abstr_task1	Sentence: Different types of gunshot injuries caused by warning weapons are demonstrated . Most important are contact shots , causing major tissue damage that can differ from that caused by classical projectiles . Possible consequences , besides direct trauma to the eye and ear , are airway distress because of extensive swelling and rupture of major neck vessels . The detailed examination includes endoscopy and radiologic imaging . Any major permanent cavity in the tissue bears a high risk of wound infection . For different reasons the fact of a gunshot wound may be kept secret by the victims . Instructions: please typing these entity words according to sentence: gunshot injuries, tissue, direct, trauma, eye, ear, rupture, neck, vessels, endoscopy, imaging, tissue, risk of, wound infection, gunshot wound Options: umlsterm	[ "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O" ]	Different types of gunshot injuries caused by warning weapons are demonstrated . Most important are contact shots , causing major tissue damage that can differ from that caused by classical projectiles . Possible consequences , besides direct trauma to the eye and ear , are airway distress because of extensive swelling and rupture of major neck vessels . The detailed examination includes endoscopy and radiologic imaging . Any major permanent cavity in the tissue bears a high risk of wound infection . For different reasons the fact of a gunshot wound may be kept secret by the victims .	[ "Different", "types", "of", "gunshot", "injuries", "caused", "by", "warning", "weapons", "are", "demonstrated", ".", "Most", "important", "are", "contact", "shots", ",", "causing", "major", "tissue", "damage", "that", "can", "differ", "from", "that", "caused", "by", "classical", "projectiles", ".", "Possible", "consequences", ",", "besides", "direct", "trauma", "to", "the", "eye", "and", "ear", ",", "are", "airway", "distress", "because", "of", "extensive", "swelling", "and", "rupture", "of", "major", "neck", "vessels", ".", "The", "detailed", "examination", "includes", "endoscopy", "and", "radiologic", "imaging", ".", "Any", "major", "permanent", "cavity", "in", "the", "tissue", "bears", "a", "high", "risk", "of", "wound", "infection", ".", "For", "different", "reasons", "the", "fact", "of", "a", "gunshot", "wound", "may", "be", "kept", "secret", "by", "the", "victims", "." ]	[ "umlsterm" ]
gunshot injuries, tissue, direct, trauma, eye, ear, rupture, neck, vessels, endoscopy, imaging, tissue, risk of, wound infection, gunshot wound	HNO.70450643.eng.abstr_task2	Sentence: Different types of gunshot injuries caused by warning weapons are demonstrated . Most important are contact shots , causing major tissue damage that can differ from that caused by classical projectiles . Possible consequences , besides direct trauma to the eye and ear , are airway distress because of extensive swelling and rupture of major neck vessels . The detailed examination includes endoscopy and radiologic imaging . Any major permanent cavity in the tissue bears a high risk of wound infection . For different reasons the fact of a gunshot wound may be kept secret by the victims . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O" ]	Different types of gunshot injuries caused by warning weapons are demonstrated . Most important are contact shots , causing major tissue damage that can differ from that caused by classical projectiles . Possible consequences , besides direct trauma to the eye and ear , are airway distress because of extensive swelling and rupture of major neck vessels . The detailed examination includes endoscopy and radiologic imaging . Any major permanent cavity in the tissue bears a high risk of wound infection . For different reasons the fact of a gunshot wound may be kept secret by the victims .	[ "Different", "types", "of", "gunshot", "injuries", "caused", "by", "warning", "weapons", "are", "demonstrated", ".", "Most", "important", "are", "contact", "shots", ",", "causing", "major", "tissue", "damage", "that", "can", "differ", "from", "that", "caused", "by", "classical", "projectiles", ".", "Possible", "consequences", ",", "besides", "direct", "trauma", "to", "the", "eye", "and", "ear", ",", "are", "airway", "distress", "because", "of", "extensive", "swelling", "and", "rupture", "of", "major", "neck", "vessels", ".", "The", "detailed", "examination", "includes", "endoscopy", "and", "radiologic", "imaging", ".", "Any", "major", "permanent", "cavity", "in", "the", "tissue", "bears", "a", "high", "risk", "of", "wound", "infection", ".", "For", "different", "reasons", "the", "fact", "of", "a", "gunshot", "wound", "may", "be", "kept", "secret", "by", "the", "victims", "." ]	[ "umlsterm" ]
síndrome mieloproliferativo crónico is a MORFOLOGIA_NEOPLASIA, trombocitemia esencial is a MORFOLOGIA_NEOPLASIA, carcinoma adenoide quístico grado 2 is a MORFOLOGIA_NEOPLASIA, micrometástasis is a MORFOLOGIA_NEOPLASIA, pT2N1miM0 is a MORFOLOGIA_NEOPLASIA, nódulos pulmonares is a MORFOLOGIA_NEOPLASIA, metástasis is a MORFOLOGIA_NEOPLASIA, nódulos diafragmáticos is a MORFOLOGIA_NEOPLASIA, implantes tumorales is a MORFOLOGIA_NEOPLASIA, pleura visceral y parietal con lesiones is a MORFOLOGIA_NEOPLASIA, metástasis is a MORFOLOGIA_NEOPLASIA, neoplasia is a MORFOLOGIA_NEOPLASIA, adenoide quístico is a MORFOLOGIA_NEOPLASIA, carcinoma adenoide quístico metastásico is a MORFOLOGIA_NEOPLASIA, afectación pulmonar is a MORFOLOGIA_NEOPLASIA, tumor is a MORFOLOGIA_NEOPLASIA, tumor is a MORFOLOGIA_NEOPLASIA, metástasis is a MORFOLOGIA_NEOPLASIA, recaída sistémica is a MORFOLOGIA_NEOPLASIA, carcinoma adenoide quístico is a MORFOLOGIA_NEOPLASIA	569_task0	Sentence: Anamnesis En este caso se presenta una mujer de 79 años, no fumadora ni bebedora, que, como antecedente destacable, presenta síndrome mieloproliferativo crónico, probable trombocitemia esencial con aumento ligero-moderado de megacariocitos en médula ósea, no displásicos, de disposición anómala paratrabecular en acúmulos, con ligero aumento de trama reticulínica. En tratamiento con indapamida retard, ispágula, omeprazol, ácido ibandrónico, alopurinol, hidroxicarbamida, ácido acetil salicílico y lorazepam. Vive con su marido. La paciente debuta con un nódulo sospechoso de 15 mm en mama izquierda en enero de 2017, por el que se le estudia con las correspondientes pruebas de imagen (TC y gammagrafía ósea) y examen histopatológico (biopsia por tru-cut), decidiéndose realizar tumorectomía con biopsia selectiva del ganglio centinela más radioterapia tras la negatividad en el estudio de extensión previamente realizado. En la Anatomía Patológica se diagnostica de carcinoma adenoide quístico grado 2, bordes quirúrgicos libres, con un ganglio linfático de un total de dos con micrometástasis y en la inmunohistoquímica se cataloga como triple negativo (pT2N1miM0). Comienza revisiones. En febrero de 2019, acude a Urgencias por comenzar con disnea progresiva sobre todo con ortopnea o esfuerzo moderado. En Urgencias objetivan derrame pleural derecho, por lo que se ingresa para estudio. Exploración física Durante la exploración física, no se palpaban adenopatías periféricas, masas ni nódulos mamarios. Auscultación respiratoria con hipoventilación en base derecha hasta tercio superior, izquierda normal. El resto de la exploración física por aparatos no tiene alteraciones. ignos de TVP Pruebas complementarias En las pruebas de imagen realizadas (TC-TAP y gammagrafía ósea) se objetiva derrame pleural derecho, nódulos pulmonares y pleurales bilaterales sugestivos de metástasis y nódulos diafragmáticos derechos anteriores en probable relación con adenopatías versus implantes tumorales. Se le realizó drenaje del líquido pleural más talcaje con resultado de líquido negativo para celularidad. Se decide realizar toracoscopia en la que se observa pleura visceral y parietal con lesiones sospechosas de metástasis. Se procede a la aspiración de líquido pleural y biopsia de lesiones de pleura parietal, obteniendo como resultado en la anatomía patológica de infiltración pleural compatible con neoplasia de origen mamario previa (adenoide quístico). Diagnóstico Finalmente, la paciente es diagnosticada de carcinoma adenoide quístico metastásico de origen mamario, con afectación pulmonar y pleural. Tratamiento Revisada la literatura, no existe evidencia sobre la actitud terapéutica sobre este tipo de tumor. Normalmente es un tumor con un curso indolente con una SLE a 10 años del 90-100 %, y las metástasis a distancia son raras y lentamente progresivas, sólo reportadas en forma de casos clínicos. Sin embargo, en este caso se presenta una recaída sistémica sintomática a los 2 años del primario, lo que es extremadamente infrecuente. No existe evidencia sólida sobre el tratamiento de quimioterapia más adecuado, si bien la recomendación es tratarlo como un carcinoma adenoide quístico de glándulas salivares. El esquema con una evidencia más sólida es el CAP (ciclofosfamida [500 mg/m2], doxorrubicina [50 mg/m2], cisplatino [50 mg/m2]) con una tasa de respuestas del 28 %. Pero al tratarse de una paciente frágil, se opta por un esquema de tratamiento en monoterapia con una toxicidad más manejable. El esquema en monoterapia con una mayor tasa de respuestas (15-44 %) es la vinorelbina, por lo que la paciente inicia el primer ciclo de vinorelbina oral a 60 mg/m2 días 1 y 8 cada 21 días, el día 11 de marzo de 20193,4. Evolución La paciente hasta el día de hoy sigue en tratamiento, habiendo recibido cuatro ciclos con muy buena tolerancia al mismo y sin evidencia de progresión clínica, sólo destacando como toxicidad asociada al tratamiento astenia G1. Dentro de unos días, antes del quinto ciclo, se realizará TC de valoración de respuesta. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: MORFOLOGIA_NEOPLASIA	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Anamnesis En este caso se presenta una mujer de 79 años, no fumadora ni bebedora, que, como antecedente destacable, presenta síndrome mieloproliferativo crónico, probable trombocitemia esencial con aumento ligero-moderado de megacariocitos en médula ósea, no displásicos, de disposición anómala paratrabecular en acúmulos, con ligero aumento de trama reticulínica. En tratamiento con indapamida retard, ispágula, omeprazol, ácido ibandrónico, alopurinol, hidroxicarbamida, ácido acetil salicílico y lorazepam. Vive con su marido. La paciente debuta con un nódulo sospechoso de 15 mm en mama izquierda en enero de 2017, por el que se le estudia con las correspondientes pruebas de imagen (TC y gammagrafía ósea) y examen histopatológico (biopsia por tru-cut), decidiéndose realizar tumorectomía con biopsia selectiva del ganglio centinela más radioterapia tras la negatividad en el estudio de extensión previamente realizado. En la Anatomía Patológica se diagnostica de carcinoma adenoide quístico grado 2, bordes quirúrgicos libres, con un ganglio linfático de un total de dos con micrometástasis y en la inmunohistoquímica se cataloga como triple negativo (pT2N1miM0). Comienza revisiones. En febrero de 2019, acude a Urgencias por comenzar con disnea progresiva sobre todo con ortopnea o esfuerzo moderado. En Urgencias objetivan derrame pleural derecho, por lo que se ingresa para estudio. Exploración física Durante la exploración física, no se palpaban adenopatías periféricas, masas ni nódulos mamarios. Auscultación respiratoria con hipoventilación en base derecha hasta tercio superior, izquierda normal. El resto de la exploración física por aparatos no tiene alteraciones. ignos de TVP Pruebas complementarias En las pruebas de imagen realizadas (TC-TAP y gammagrafía ósea) se objetiva derrame pleural derecho, nódulos pulmonares y pleurales bilaterales sugestivos de metástasis y nódulos diafragmáticos derechos anteriores en probable relación con adenopatías versus implantes tumorales. Se le realizó drenaje del líquido pleural más talcaje con resultado de líquido negativo para celularidad. Se decide realizar toracoscopia en la que se observa pleura visceral y parietal con lesiones sospechosas de metástasis. Se procede a la aspiración de líquido pleural y biopsia de lesiones de pleura parietal, obteniendo como resultado en la anatomía patológica de infiltración pleural compatible con neoplasia de origen mamario previa (adenoide quístico). Diagnóstico Finalmente, la paciente es diagnosticada de carcinoma adenoide quístico metastásico de origen mamario, con afectación pulmonar y pleural. Tratamiento Revisada la literatura, no existe evidencia sobre la actitud terapéutica sobre este tipo de tumor. Normalmente es un tumor con un curso indolente con una SLE a 10 años del 90-100 %, y las metástasis a distancia son raras y lentamente progresivas, sólo reportadas en forma de casos clínicos. Sin embargo, en este caso se presenta una recaída sistémica sintomática a los 2 años del primario, lo que es extremadamente infrecuente. No existe evidencia sólida sobre el tratamiento de quimioterapia más adecuado, si bien la recomendación es tratarlo como un carcinoma adenoide quístico de glándulas salivares. El esquema con una evidencia más sólida es el CAP (ciclofosfamida [500 mg/m2], doxorrubicina [50 mg/m2], cisplatino [50 mg/m2]) con una tasa de respuestas del 28 %. Pero al tratarse de una paciente frágil, se opta por un esquema de tratamiento en monoterapia con una toxicidad más manejable. El esquema en monoterapia con una mayor tasa de respuestas (15-44 %) es la vinorelbina, por lo que la paciente inicia el primer ciclo de vinorelbina oral a 60 mg/m2 días 1 y 8 cada 21 días, el día 11 de marzo de 20193,4. Evolución La paciente hasta el día de hoy sigue en tratamiento, habiendo recibido cuatro ciclos con muy buena tolerancia al mismo y sin evidencia de progresión clínica, sólo destacando como toxicidad asociada al tratamiento astenia G1. Dentro de unos días, antes del quinto ciclo, se realizará TC de valoración de respuesta.	[ "Anamnesis", "\n", "En", "este", "caso", "se", "presenta", "una", "mujer", "de", "79", "años", ",", "no", "fumadora", "ni", "bebedora", ",", "que", ",", "como", "antecedente", "destacable", ",", "presenta", "síndrome", "mieloproliferativo", "crónico", ",", "probable", "trombocitemia", "esencial", "con", "aumento", "ligero", "-", "moderado", "de", "megacariocitos", "en", "médula", "ósea", ",", "no", "displásicos", ",", "de", "disposición", "anómala", "paratrabecular", "en", "acúmulos", ",", "con", "ligero", "aumento", "de", "trama", "reticulínica", ".", "En", "tratamiento", "con", "indapamida", "retard", ",", "ispágula", ",", "omeprazol", ",", "ácido", "ibandrónico", ",", "alopurinol", ",", "hidroxicarbamida", ",", "ácido", "acetil", "salicílico", "y", "lorazepam", ".", "Vive", "con", "su", "marido", ".", "\n", "La", "paciente", "debuta", "con", "un", "nódulo", "sospechoso", "de", "15", "mm", "en", "mama", "izquierda", "en", "enero", "de", "2017", ",", "por", "el", "que", "se", "le", "estudia", "con", "las", "correspondientes", "pruebas", "de", "imagen", "(", "TC", "y", "gammagrafía", "ósea", ")", "y", "examen", "histopatológico", "(", "biopsia", "por", "tru", "-", "cut", ")", ",", "decidiéndose", "realizar", "tumorectomía", "con", "biopsia", "selectiva", "del", "ganglio", "centinela", "más", "radioterapia", "tras", "la", "negatividad", "en", "el", "estudio", "de", "extensión", "previamente", "realizado", ".", "En", "la", "Anatomía", "Patológica", "se", "diagnostica", "de", "carcinoma", "adenoide", "quístico", "grado", "2", ",", "bordes", "quirúrgicos", "libres", ",", "con", "un", "ganglio", "linfático", "de", "un", "total", "de", "dos", "con", "micrometástasis", "y", "en", "la", "inmunohistoquímica", "se", "cataloga", "como", "triple", "negativo", "(", "pT2N1miM0", ")", ".", "Comienza", "revisiones", ".", "\n", "En", "febrero", "de", "2019", ",", "acude", "a", "Urgencias", "por", "comenzar", "con", "disnea", "progresiva", "sobre", "todo", "con", "ortopnea", "o", "esfuerzo", "moderado", ".", "En", "Urgencias", "objetivan", "derrame", "pleural", "derecho", ",", "por", "lo", "que", "se", "ingresa", "para", "estudio", ".", "\n\n", "Exploración", "física", "\n", "Durante", "la", "exploración", "física", ",", "no", "se", "palpaban", "adenopatías", "periféricas", ",", "masas", "ni", "nódulos", "mamarios", ".", "Auscultación", "respiratoria", "con", "hipoventilación", "en", "base", "derecha", "hasta", "tercio", "superior", ",", "izquierda", "normal", ".", "El", "resto", "de", "la", "exploración", "física", "por", "aparatos", "no", "tiene", "alteraciones", ".", "\n", "ignos", "de", "TVP", "\n\n", "Pruebas", "complementarias", "\n", "En", "las", "pruebas", "de", "imagen", "realizadas", "(", "TC", "-", "TAP", "y", "gammagrafía", "ósea", ")", "se", "objetiva", "derrame", "pleural", "derecho", ",", "nódulos", "pulmonares", "y", "pleurales", "bilaterales", "sugestivos", "de", "metástasis", "y", "nódulos", "diafragmáticos", "derechos", "anteriores", "en", "probable", "relación", "con", "adenopatías", "versus", "implantes", "tumorales", ".", "Se", "le", "realizó", "drenaje", "del", "líquido", "pleural", "más", "talcaje", "con", "resultado", "de", "líquido", "negativo", "para", "celularidad", ".", "Se", "decide", "realizar", "toracoscopia", "en", "la", "que", "se", "observa", "pleura", "visceral", "y", "parietal", "con", "lesiones", "sospechosas", "de", "metástasis", ".", "Se", "procede", "a", "la", "aspiración", "de", "líquido", "pleural", "y", "biopsia", "de", "lesiones", "de", "pleura", "parietal", ",", "obteniendo", "como", "resultado", "en", "la", "anatomía", "patológica", "de", "infiltración", "pleural", "compatible", "con", "neoplasia", "de", "origen", "mamario", "previa", "(", "adenoide", "quístico", ")", ".", "\n\n", "Diagnóstico", "\n", "Finalmente", ",", "la", "paciente", "es", "diagnosticada", "de", "carcinoma", "adenoide", "quístico", "metastásico", "de", "origen", "mamario", ",", "con", "afectación", "pulmonar", "y", "pleural", ".", "\n\n", "Tratamiento", "\n", "Revisada", "la", "literatura", ",", "no", "existe", "evidencia", "sobre", "la", "actitud", "terapéutica", "sobre", "este", "tipo", "de", "tumor", ".", "Normalmente", "es", "un", "tumor", "con", "un", "curso", "indolente", "con", "una", "SLE", "a", "10", "años", "del", "90", "-", "100", "%", ",", "y", "las", "metástasis", "a", "distancia", "son", "raras", "y", "lentamente", "progresivas", ",", "sólo", "reportadas", "en", "forma", "de", "casos", "clínicos", ".", "Sin", "embargo", ",", "en", "este", "caso", "se", "presenta", "una", "recaída", "sistémica", "sintomática", "a", "los", "2", "años", "del", "primario", ",", "lo", "que", "es", "extremadamente", "infrecuente", ".", "\n", "No", "existe", "evidencia", "sólida", "sobre", "el", "tratamiento", "de", "quimioterapia", "más", "adecuado", ",", "si", "bien", "la", "recomendación", "es", "tratarlo", "como", "un", "carcinoma", "adenoide", "quístico", "de", "glándulas", "salivares", ".", "El", "esquema", "con", "una", "evidencia", "más", "sólida", "es", "el", "CAP", "(", "ciclofosfamida", "[", "500", "mg", "/", "m2", "]", ",", "doxorrubicina", "[", "50", "mg", "/", "m2", "]", ",", "cisplatino", "[", "50", "mg", "/", "m2", "]", ")", "con", "una", "tasa", "de", "respuestas", "del", "28", "%", ".", "Pero", "al", "tratarse", "de", "una", "paciente", "frágil", ",", "se", "opta", "por", "un", "esquema", "de", "tratamiento", "en", "monoterapia", "con", "una", "toxicidad", "más", "manejable", ".", "El", "esquema", "en", "monoterapia", "con", "una", "mayor", "tasa", "de", "respuestas", "(", "15", "-", "44", "%", ")", "es", "la", "vinorelbina", ",", "por", "lo", "que", "la", "paciente", "inicia", "el", "primer", "ciclo", "de", "vinorelbina", "oral", "a", "60", "mg", "/", "m2", "días", "1", "y", "8", "cada", "21", "días", ",", "el", "día", "11", "de", "marzo", "de", "20193,4", ".", "\n\n", "Evolución", "\n", "La", "paciente", "hasta", "el", "día", "de", "hoy", "sigue", "en", "tratamiento", ",", "habiendo", "recibido", "cuatro", "ciclos", "con", "muy", "buena", "tolerancia", "al", "mismo", "y", "sin", "evidencia", "de", "progresión", "clínica", ",", "sólo", "destacando", "como", "toxicidad", "asociada", "al", "tratamiento", "astenia", "G1", ".", "Dentro", "de", "unos", "días", ",", "antes", "del", "quinto", "ciclo", ",", "se", "realizará", "TC", "de", "valoración", "de", "respuesta", "." ]	[ "MORFOLOGIA_NEOPLASIA" ]
síndrome mieloproliferativo crónico is a MORFOLOGIA_NEOPLASIA, trombocitemia esencial is a MORFOLOGIA_NEOPLASIA, carcinoma adenoide quístico grado 2 is a MORFOLOGIA_NEOPLASIA, micrometástasis is a MORFOLOGIA_NEOPLASIA, pT2N1miM0 is a MORFOLOGIA_NEOPLASIA, nódulos pulmonares is a MORFOLOGIA_NEOPLASIA, metástasis is a MORFOLOGIA_NEOPLASIA, nódulos diafragmáticos is a MORFOLOGIA_NEOPLASIA, implantes tumorales is a MORFOLOGIA_NEOPLASIA, pleura visceral y parietal con lesiones is a MORFOLOGIA_NEOPLASIA, metástasis is a MORFOLOGIA_NEOPLASIA, neoplasia is a MORFOLOGIA_NEOPLASIA, adenoide quístico is a MORFOLOGIA_NEOPLASIA, carcinoma adenoide quístico metastásico is a MORFOLOGIA_NEOPLASIA, afectación pulmonar is a MORFOLOGIA_NEOPLASIA, tumor is a MORFOLOGIA_NEOPLASIA, tumor is a MORFOLOGIA_NEOPLASIA, metástasis is a MORFOLOGIA_NEOPLASIA, recaída sistémica is a MORFOLOGIA_NEOPLASIA, carcinoma adenoide quístico is a MORFOLOGIA_NEOPLASIA	569_task1	Sentence: Anamnesis En este caso se presenta una mujer de 79 años, no fumadora ni bebedora, que, como antecedente destacable, presenta síndrome mieloproliferativo crónico, probable trombocitemia esencial con aumento ligero-moderado de megacariocitos en médula ósea, no displásicos, de disposición anómala paratrabecular en acúmulos, con ligero aumento de trama reticulínica. En tratamiento con indapamida retard, ispágula, omeprazol, ácido ibandrónico, alopurinol, hidroxicarbamida, ácido acetil salicílico y lorazepam. Vive con su marido. La paciente debuta con un nódulo sospechoso de 15 mm en mama izquierda en enero de 2017, por el que se le estudia con las correspondientes pruebas de imagen (TC y gammagrafía ósea) y examen histopatológico (biopsia por tru-cut), decidiéndose realizar tumorectomía con biopsia selectiva del ganglio centinela más radioterapia tras la negatividad en el estudio de extensión previamente realizado. En la Anatomía Patológica se diagnostica de carcinoma adenoide quístico grado 2, bordes quirúrgicos libres, con un ganglio linfático de un total de dos con micrometástasis y en la inmunohistoquímica se cataloga como triple negativo (pT2N1miM0). Comienza revisiones. En febrero de 2019, acude a Urgencias por comenzar con disnea progresiva sobre todo con ortopnea o esfuerzo moderado. En Urgencias objetivan derrame pleural derecho, por lo que se ingresa para estudio. Exploración física Durante la exploración física, no se palpaban adenopatías periféricas, masas ni nódulos mamarios. Auscultación respiratoria con hipoventilación en base derecha hasta tercio superior, izquierda normal. El resto de la exploración física por aparatos no tiene alteraciones. ignos de TVP Pruebas complementarias En las pruebas de imagen realizadas (TC-TAP y gammagrafía ósea) se objetiva derrame pleural derecho, nódulos pulmonares y pleurales bilaterales sugestivos de metástasis y nódulos diafragmáticos derechos anteriores en probable relación con adenopatías versus implantes tumorales. Se le realizó drenaje del líquido pleural más talcaje con resultado de líquido negativo para celularidad. Se decide realizar toracoscopia en la que se observa pleura visceral y parietal con lesiones sospechosas de metástasis. Se procede a la aspiración de líquido pleural y biopsia de lesiones de pleura parietal, obteniendo como resultado en la anatomía patológica de infiltración pleural compatible con neoplasia de origen mamario previa (adenoide quístico). Diagnóstico Finalmente, la paciente es diagnosticada de carcinoma adenoide quístico metastásico de origen mamario, con afectación pulmonar y pleural. Tratamiento Revisada la literatura, no existe evidencia sobre la actitud terapéutica sobre este tipo de tumor. Normalmente es un tumor con un curso indolente con una SLE a 10 años del 90-100 %, y las metástasis a distancia son raras y lentamente progresivas, sólo reportadas en forma de casos clínicos. Sin embargo, en este caso se presenta una recaída sistémica sintomática a los 2 años del primario, lo que es extremadamente infrecuente. No existe evidencia sólida sobre el tratamiento de quimioterapia más adecuado, si bien la recomendación es tratarlo como un carcinoma adenoide quístico de glándulas salivares. El esquema con una evidencia más sólida es el CAP (ciclofosfamida [500 mg/m2], doxorrubicina [50 mg/m2], cisplatino [50 mg/m2]) con una tasa de respuestas del 28 %. Pero al tratarse de una paciente frágil, se opta por un esquema de tratamiento en monoterapia con una toxicidad más manejable. El esquema en monoterapia con una mayor tasa de respuestas (15-44 %) es la vinorelbina, por lo que la paciente inicia el primer ciclo de vinorelbina oral a 60 mg/m2 días 1 y 8 cada 21 días, el día 11 de marzo de 20193,4. Evolución La paciente hasta el día de hoy sigue en tratamiento, habiendo recibido cuatro ciclos con muy buena tolerancia al mismo y sin evidencia de progresión clínica, sólo destacando como toxicidad asociada al tratamiento astenia G1. Dentro de unos días, antes del quinto ciclo, se realizará TC de valoración de respuesta. Instructions: please typing these entity words according to sentence: síndrome mieloproliferativo crónico, trombocitemia esencial, carcinoma adenoide quístico grado 2, micrometástasis, pT2N1miM0, nódulos pulmonares, metástasis, nódulos diafragmáticos, implantes tumorales, pleura visceral y parietal con lesiones, metástasis, neoplasia, adenoide quístico, carcinoma adenoide quístico metastásico, afectación pulmonar, tumor, tumor, metástasis, recaída sistémica, carcinoma adenoide quístico Options: MORFOLOGIA_NEOPLASIA	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Anamnesis En este caso se presenta una mujer de 79 años, no fumadora ni bebedora, que, como antecedente destacable, presenta síndrome mieloproliferativo crónico, probable trombocitemia esencial con aumento ligero-moderado de megacariocitos en médula ósea, no displásicos, de disposición anómala paratrabecular en acúmulos, con ligero aumento de trama reticulínica. En tratamiento con indapamida retard, ispágula, omeprazol, ácido ibandrónico, alopurinol, hidroxicarbamida, ácido acetil salicílico y lorazepam. Vive con su marido. La paciente debuta con un nódulo sospechoso de 15 mm en mama izquierda en enero de 2017, por el que se le estudia con las correspondientes pruebas de imagen (TC y gammagrafía ósea) y examen histopatológico (biopsia por tru-cut), decidiéndose realizar tumorectomía con biopsia selectiva del ganglio centinela más radioterapia tras la negatividad en el estudio de extensión previamente realizado. En la Anatomía Patológica se diagnostica de carcinoma adenoide quístico grado 2, bordes quirúrgicos libres, con un ganglio linfático de un total de dos con micrometástasis y en la inmunohistoquímica se cataloga como triple negativo (pT2N1miM0). Comienza revisiones. En febrero de 2019, acude a Urgencias por comenzar con disnea progresiva sobre todo con ortopnea o esfuerzo moderado. En Urgencias objetivan derrame pleural derecho, por lo que se ingresa para estudio. Exploración física Durante la exploración física, no se palpaban adenopatías periféricas, masas ni nódulos mamarios. Auscultación respiratoria con hipoventilación en base derecha hasta tercio superior, izquierda normal. El resto de la exploración física por aparatos no tiene alteraciones. ignos de TVP Pruebas complementarias En las pruebas de imagen realizadas (TC-TAP y gammagrafía ósea) se objetiva derrame pleural derecho, nódulos pulmonares y pleurales bilaterales sugestivos de metástasis y nódulos diafragmáticos derechos anteriores en probable relación con adenopatías versus implantes tumorales. Se le realizó drenaje del líquido pleural más talcaje con resultado de líquido negativo para celularidad. Se decide realizar toracoscopia en la que se observa pleura visceral y parietal con lesiones sospechosas de metástasis. Se procede a la aspiración de líquido pleural y biopsia de lesiones de pleura parietal, obteniendo como resultado en la anatomía patológica de infiltración pleural compatible con neoplasia de origen mamario previa (adenoide quístico). Diagnóstico Finalmente, la paciente es diagnosticada de carcinoma adenoide quístico metastásico de origen mamario, con afectación pulmonar y pleural. Tratamiento Revisada la literatura, no existe evidencia sobre la actitud terapéutica sobre este tipo de tumor. Normalmente es un tumor con un curso indolente con una SLE a 10 años del 90-100 %, y las metástasis a distancia son raras y lentamente progresivas, sólo reportadas en forma de casos clínicos. Sin embargo, en este caso se presenta una recaída sistémica sintomática a los 2 años del primario, lo que es extremadamente infrecuente. No existe evidencia sólida sobre el tratamiento de quimioterapia más adecuado, si bien la recomendación es tratarlo como un carcinoma adenoide quístico de glándulas salivares. El esquema con una evidencia más sólida es el CAP (ciclofosfamida [500 mg/m2], doxorrubicina [50 mg/m2], cisplatino [50 mg/m2]) con una tasa de respuestas del 28 %. Pero al tratarse de una paciente frágil, se opta por un esquema de tratamiento en monoterapia con una toxicidad más manejable. El esquema en monoterapia con una mayor tasa de respuestas (15-44 %) es la vinorelbina, por lo que la paciente inicia el primer ciclo de vinorelbina oral a 60 mg/m2 días 1 y 8 cada 21 días, el día 11 de marzo de 20193,4. Evolución La paciente hasta el día de hoy sigue en tratamiento, habiendo recibido cuatro ciclos con muy buena tolerancia al mismo y sin evidencia de progresión clínica, sólo destacando como toxicidad asociada al tratamiento astenia G1. Dentro de unos días, antes del quinto ciclo, se realizará TC de valoración de respuesta.	[ "Anamnesis", "\n", "En", "este", "caso", "se", "presenta", "una", "mujer", "de", "79", "años", ",", "no", "fumadora", "ni", "bebedora", ",", "que", ",", "como", "antecedente", "destacable", ",", "presenta", "síndrome", "mieloproliferativo", "crónico", ",", "probable", "trombocitemia", "esencial", "con", "aumento", "ligero", "-", "moderado", "de", "megacariocitos", "en", "médula", "ósea", ",", "no", "displásicos", ",", "de", "disposición", "anómala", "paratrabecular", "en", "acúmulos", ",", "con", "ligero", "aumento", "de", "trama", "reticulínica", ".", "En", "tratamiento", "con", "indapamida", "retard", ",", "ispágula", ",", "omeprazol", ",", "ácido", "ibandrónico", ",", "alopurinol", ",", "hidroxicarbamida", ",", "ácido", "acetil", "salicílico", "y", "lorazepam", ".", "Vive", "con", "su", "marido", ".", "\n", "La", "paciente", "debuta", "con", "un", "nódulo", "sospechoso", "de", "15", "mm", "en", "mama", "izquierda", "en", "enero", "de", "2017", ",", "por", "el", "que", "se", "le", "estudia", "con", "las", "correspondientes", "pruebas", "de", "imagen", "(", "TC", "y", "gammagrafía", "ósea", ")", "y", "examen", "histopatológico", "(", "biopsia", "por", "tru", "-", "cut", ")", ",", "decidiéndose", "realizar", "tumorectomía", "con", "biopsia", "selectiva", "del", "ganglio", "centinela", "más", "radioterapia", "tras", "la", "negatividad", "en", "el", "estudio", "de", "extensión", "previamente", "realizado", ".", "En", "la", "Anatomía", "Patológica", "se", "diagnostica", "de", "carcinoma", "adenoide", "quístico", "grado", "2", ",", "bordes", "quirúrgicos", "libres", ",", "con", "un", "ganglio", "linfático", "de", "un", "total", "de", "dos", "con", "micrometástasis", "y", "en", "la", "inmunohistoquímica", "se", "cataloga", "como", "triple", "negativo", "(", "pT2N1miM0", ")", ".", "Comienza", "revisiones", ".", "\n", "En", "febrero", "de", "2019", ",", "acude", "a", "Urgencias", "por", "comenzar", "con", "disnea", "progresiva", "sobre", "todo", "con", "ortopnea", "o", "esfuerzo", "moderado", ".", "En", "Urgencias", "objetivan", "derrame", "pleural", "derecho", ",", "por", "lo", "que", "se", "ingresa", "para", "estudio", ".", "\n\n", "Exploración", "física", "\n", "Durante", "la", "exploración", "física", ",", "no", "se", "palpaban", "adenopatías", "periféricas", ",", "masas", "ni", "nódulos", "mamarios", ".", "Auscultación", "respiratoria", "con", "hipoventilación", "en", "base", "derecha", "hasta", "tercio", "superior", ",", "izquierda", "normal", ".", "El", "resto", "de", "la", "exploración", "física", "por", "aparatos", "no", "tiene", "alteraciones", ".", "\n", "ignos", "de", "TVP", "\n\n", "Pruebas", "complementarias", "\n", "En", "las", "pruebas", "de", "imagen", "realizadas", "(", "TC", "-", "TAP", "y", "gammagrafía", "ósea", ")", "se", "objetiva", "derrame", "pleural", "derecho", ",", "nódulos", "pulmonares", "y", "pleurales", "bilaterales", "sugestivos", "de", "metástasis", "y", "nódulos", "diafragmáticos", "derechos", "anteriores", "en", "probable", "relación", "con", "adenopatías", "versus", "implantes", "tumorales", ".", "Se", "le", "realizó", "drenaje", "del", "líquido", "pleural", "más", "talcaje", "con", "resultado", "de", "líquido", "negativo", "para", "celularidad", ".", "Se", "decide", "realizar", "toracoscopia", "en", "la", "que", "se", "observa", "pleura", "visceral", "y", "parietal", "con", "lesiones", "sospechosas", "de", "metástasis", ".", "Se", "procede", "a", "la", "aspiración", "de", "líquido", "pleural", "y", "biopsia", "de", "lesiones", "de", "pleura", "parietal", ",", "obteniendo", "como", "resultado", "en", "la", "anatomía", "patológica", "de", "infiltración", "pleural", "compatible", "con", "neoplasia", "de", "origen", "mamario", "previa", "(", "adenoide", "quístico", ")", ".", "\n\n", "Diagnóstico", "\n", "Finalmente", ",", "la", "paciente", "es", "diagnosticada", "de", "carcinoma", "adenoide", "quístico", "metastásico", "de", "origen", "mamario", ",", "con", "afectación", "pulmonar", "y", "pleural", ".", "\n\n", "Tratamiento", "\n", "Revisada", "la", "literatura", ",", "no", "existe", "evidencia", "sobre", "la", "actitud", "terapéutica", "sobre", "este", "tipo", "de", "tumor", ".", "Normalmente", "es", "un", "tumor", "con", "un", "curso", "indolente", "con", "una", "SLE", "a", "10", "años", "del", "90", "-", "100", "%", ",", "y", "las", "metástasis", "a", "distancia", "son", "raras", "y", "lentamente", "progresivas", ",", "sólo", "reportadas", "en", "forma", "de", "casos", "clínicos", ".", "Sin", "embargo", ",", "en", "este", "caso", "se", "presenta", "una", "recaída", "sistémica", "sintomática", "a", "los", "2", "años", "del", "primario", ",", "lo", "que", "es", "extremadamente", "infrecuente", ".", "\n", "No", "existe", "evidencia", "sólida", "sobre", "el", "tratamiento", "de", "quimioterapia", "más", "adecuado", ",", "si", "bien", "la", "recomendación", "es", "tratarlo", "como", "un", "carcinoma", "adenoide", "quístico", "de", "glándulas", "salivares", ".", "El", "esquema", "con", "una", "evidencia", "más", "sólida", "es", "el", "CAP", "(", "ciclofosfamida", "[", "500", "mg", "/", "m2", "]", ",", "doxorrubicina", "[", "50", "mg", "/", "m2", "]", ",", "cisplatino", "[", "50", "mg", "/", "m2", "]", ")", "con", "una", "tasa", "de", "respuestas", "del", "28", "%", ".", "Pero", "al", "tratarse", "de", "una", "paciente", "frágil", ",", "se", "opta", "por", "un", "esquema", "de", "tratamiento", "en", "monoterapia", "con", "una", "toxicidad", "más", "manejable", ".", "El", "esquema", "en", "monoterapia", "con", "una", "mayor", "tasa", "de", "respuestas", "(", "15", "-", "44", "%", ")", "es", "la", "vinorelbina", ",", "por", "lo", "que", "la", "paciente", "inicia", "el", "primer", "ciclo", "de", "vinorelbina", "oral", "a", "60", "mg", "/", "m2", "días", "1", "y", "8", "cada", "21", "días", ",", "el", "día", "11", "de", "marzo", "de", "20193,4", ".", "\n\n", "Evolución", "\n", "La", "paciente", "hasta", "el", "día", "de", "hoy", "sigue", "en", "tratamiento", ",", "habiendo", "recibido", "cuatro", "ciclos", "con", "muy", "buena", "tolerancia", "al", "mismo", "y", "sin", "evidencia", "de", "progresión", "clínica", ",", "sólo", "destacando", "como", "toxicidad", "asociada", "al", "tratamiento", "astenia", "G1", ".", "Dentro", "de", "unos", "días", ",", "antes", "del", "quinto", "ciclo", ",", "se", "realizará", "TC", "de", "valoración", "de", "respuesta", "." ]	[ "MORFOLOGIA_NEOPLASIA" ]
síndrome mieloproliferativo crónico, trombocitemia esencial, carcinoma adenoide quístico grado 2, micrometástasis, pT2N1miM0, nódulos pulmonares, metástasis, nódulos diafragmáticos, implantes tumorales, pleura visceral y parietal con lesiones, metástasis, neoplasia, adenoide quístico, carcinoma adenoide quístico metastásico, afectación pulmonar, tumor, tumor, metástasis, recaída sistémica, carcinoma adenoide quístico	569_task2	Sentence: Anamnesis En este caso se presenta una mujer de 79 años, no fumadora ni bebedora, que, como antecedente destacable, presenta síndrome mieloproliferativo crónico, probable trombocitemia esencial con aumento ligero-moderado de megacariocitos en médula ósea, no displásicos, de disposición anómala paratrabecular en acúmulos, con ligero aumento de trama reticulínica. En tratamiento con indapamida retard, ispágula, omeprazol, ácido ibandrónico, alopurinol, hidroxicarbamida, ácido acetil salicílico y lorazepam. Vive con su marido. La paciente debuta con un nódulo sospechoso de 15 mm en mama izquierda en enero de 2017, por el que se le estudia con las correspondientes pruebas de imagen (TC y gammagrafía ósea) y examen histopatológico (biopsia por tru-cut), decidiéndose realizar tumorectomía con biopsia selectiva del ganglio centinela más radioterapia tras la negatividad en el estudio de extensión previamente realizado. En la Anatomía Patológica se diagnostica de carcinoma adenoide quístico grado 2, bordes quirúrgicos libres, con un ganglio linfático de un total de dos con micrometástasis y en la inmunohistoquímica se cataloga como triple negativo (pT2N1miM0). Comienza revisiones. En febrero de 2019, acude a Urgencias por comenzar con disnea progresiva sobre todo con ortopnea o esfuerzo moderado. En Urgencias objetivan derrame pleural derecho, por lo que se ingresa para estudio. Exploración física Durante la exploración física, no se palpaban adenopatías periféricas, masas ni nódulos mamarios. Auscultación respiratoria con hipoventilación en base derecha hasta tercio superior, izquierda normal. El resto de la exploración física por aparatos no tiene alteraciones. ignos de TVP Pruebas complementarias En las pruebas de imagen realizadas (TC-TAP y gammagrafía ósea) se objetiva derrame pleural derecho, nódulos pulmonares y pleurales bilaterales sugestivos de metástasis y nódulos diafragmáticos derechos anteriores en probable relación con adenopatías versus implantes tumorales. Se le realizó drenaje del líquido pleural más talcaje con resultado de líquido negativo para celularidad. Se decide realizar toracoscopia en la que se observa pleura visceral y parietal con lesiones sospechosas de metástasis. Se procede a la aspiración de líquido pleural y biopsia de lesiones de pleura parietal, obteniendo como resultado en la anatomía patológica de infiltración pleural compatible con neoplasia de origen mamario previa (adenoide quístico). Diagnóstico Finalmente, la paciente es diagnosticada de carcinoma adenoide quístico metastásico de origen mamario, con afectación pulmonar y pleural. Tratamiento Revisada la literatura, no existe evidencia sobre la actitud terapéutica sobre este tipo de tumor. Normalmente es un tumor con un curso indolente con una SLE a 10 años del 90-100 %, y las metástasis a distancia son raras y lentamente progresivas, sólo reportadas en forma de casos clínicos. Sin embargo, en este caso se presenta una recaída sistémica sintomática a los 2 años del primario, lo que es extremadamente infrecuente. No existe evidencia sólida sobre el tratamiento de quimioterapia más adecuado, si bien la recomendación es tratarlo como un carcinoma adenoide quístico de glándulas salivares. El esquema con una evidencia más sólida es el CAP (ciclofosfamida [500 mg/m2], doxorrubicina [50 mg/m2], cisplatino [50 mg/m2]) con una tasa de respuestas del 28 %. Pero al tratarse de una paciente frágil, se opta por un esquema de tratamiento en monoterapia con una toxicidad más manejable. El esquema en monoterapia con una mayor tasa de respuestas (15-44 %) es la vinorelbina, por lo que la paciente inicia el primer ciclo de vinorelbina oral a 60 mg/m2 días 1 y 8 cada 21 días, el día 11 de marzo de 20193,4. Evolución La paciente hasta el día de hoy sigue en tratamiento, habiendo recibido cuatro ciclos con muy buena tolerancia al mismo y sin evidencia de progresión clínica, sólo destacando como toxicidad asociada al tratamiento astenia G1. Dentro de unos días, antes del quinto ciclo, se realizará TC de valoración de respuesta. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Anamnesis En este caso se presenta una mujer de 79 años, no fumadora ni bebedora, que, como antecedente destacable, presenta síndrome mieloproliferativo crónico, probable trombocitemia esencial con aumento ligero-moderado de megacariocitos en médula ósea, no displásicos, de disposición anómala paratrabecular en acúmulos, con ligero aumento de trama reticulínica. En tratamiento con indapamida retard, ispágula, omeprazol, ácido ibandrónico, alopurinol, hidroxicarbamida, ácido acetil salicílico y lorazepam. Vive con su marido. La paciente debuta con un nódulo sospechoso de 15 mm en mama izquierda en enero de 2017, por el que se le estudia con las correspondientes pruebas de imagen (TC y gammagrafía ósea) y examen histopatológico (biopsia por tru-cut), decidiéndose realizar tumorectomía con biopsia selectiva del ganglio centinela más radioterapia tras la negatividad en el estudio de extensión previamente realizado. En la Anatomía Patológica se diagnostica de carcinoma adenoide quístico grado 2, bordes quirúrgicos libres, con un ganglio linfático de un total de dos con micrometástasis y en la inmunohistoquímica se cataloga como triple negativo (pT2N1miM0). Comienza revisiones. En febrero de 2019, acude a Urgencias por comenzar con disnea progresiva sobre todo con ortopnea o esfuerzo moderado. En Urgencias objetivan derrame pleural derecho, por lo que se ingresa para estudio. Exploración física Durante la exploración física, no se palpaban adenopatías periféricas, masas ni nódulos mamarios. Auscultación respiratoria con hipoventilación en base derecha hasta tercio superior, izquierda normal. El resto de la exploración física por aparatos no tiene alteraciones. ignos de TVP Pruebas complementarias En las pruebas de imagen realizadas (TC-TAP y gammagrafía ósea) se objetiva derrame pleural derecho, nódulos pulmonares y pleurales bilaterales sugestivos de metástasis y nódulos diafragmáticos derechos anteriores en probable relación con adenopatías versus implantes tumorales. Se le realizó drenaje del líquido pleural más talcaje con resultado de líquido negativo para celularidad. Se decide realizar toracoscopia en la que se observa pleura visceral y parietal con lesiones sospechosas de metástasis. Se procede a la aspiración de líquido pleural y biopsia de lesiones de pleura parietal, obteniendo como resultado en la anatomía patológica de infiltración pleural compatible con neoplasia de origen mamario previa (adenoide quístico). Diagnóstico Finalmente, la paciente es diagnosticada de carcinoma adenoide quístico metastásico de origen mamario, con afectación pulmonar y pleural. Tratamiento Revisada la literatura, no existe evidencia sobre la actitud terapéutica sobre este tipo de tumor. Normalmente es un tumor con un curso indolente con una SLE a 10 años del 90-100 %, y las metástasis a distancia son raras y lentamente progresivas, sólo reportadas en forma de casos clínicos. Sin embargo, en este caso se presenta una recaída sistémica sintomática a los 2 años del primario, lo que es extremadamente infrecuente. No existe evidencia sólida sobre el tratamiento de quimioterapia más adecuado, si bien la recomendación es tratarlo como un carcinoma adenoide quístico de glándulas salivares. El esquema con una evidencia más sólida es el CAP (ciclofosfamida [500 mg/m2], doxorrubicina [50 mg/m2], cisplatino [50 mg/m2]) con una tasa de respuestas del 28 %. Pero al tratarse de una paciente frágil, se opta por un esquema de tratamiento en monoterapia con una toxicidad más manejable. El esquema en monoterapia con una mayor tasa de respuestas (15-44 %) es la vinorelbina, por lo que la paciente inicia el primer ciclo de vinorelbina oral a 60 mg/m2 días 1 y 8 cada 21 días, el día 11 de marzo de 20193,4. Evolución La paciente hasta el día de hoy sigue en tratamiento, habiendo recibido cuatro ciclos con muy buena tolerancia al mismo y sin evidencia de progresión clínica, sólo destacando como toxicidad asociada al tratamiento astenia G1. Dentro de unos días, antes del quinto ciclo, se realizará TC de valoración de respuesta.	[ "Anamnesis", "\n", "En", "este", "caso", "se", "presenta", "una", "mujer", "de", "79", "años", ",", "no", "fumadora", "ni", "bebedora", ",", "que", ",", "como", "antecedente", "destacable", ",", "presenta", "síndrome", "mieloproliferativo", "crónico", ",", "probable", "trombocitemia", "esencial", "con", "aumento", "ligero", "-", "moderado", "de", "megacariocitos", "en", "médula", "ósea", ",", "no", "displásicos", ",", "de", "disposición", "anómala", "paratrabecular", "en", "acúmulos", ",", "con", "ligero", "aumento", "de", "trama", "reticulínica", ".", "En", "tratamiento", "con", "indapamida", "retard", ",", "ispágula", ",", "omeprazol", ",", "ácido", "ibandrónico", ",", "alopurinol", ",", "hidroxicarbamida", ",", "ácido", "acetil", "salicílico", "y", "lorazepam", ".", "Vive", "con", "su", "marido", ".", "\n", "La", "paciente", "debuta", "con", "un", "nódulo", "sospechoso", "de", "15", "mm", "en", "mama", "izquierda", "en", "enero", "de", "2017", ",", "por", "el", "que", "se", "le", "estudia", "con", "las", "correspondientes", "pruebas", "de", "imagen", "(", "TC", "y", "gammagrafía", "ósea", ")", "y", "examen", "histopatológico", "(", "biopsia", "por", "tru", "-", "cut", ")", ",", "decidiéndose", "realizar", "tumorectomía", "con", "biopsia", "selectiva", "del", "ganglio", "centinela", "más", "radioterapia", "tras", "la", "negatividad", "en", "el", "estudio", "de", "extensión", "previamente", "realizado", ".", "En", "la", "Anatomía", "Patológica", "se", "diagnostica", "de", "carcinoma", "adenoide", "quístico", "grado", "2", ",", "bordes", "quirúrgicos", "libres", ",", "con", "un", "ganglio", "linfático", "de", "un", "total", "de", "dos", "con", "micrometástasis", "y", "en", "la", "inmunohistoquímica", "se", "cataloga", "como", "triple", "negativo", "(", "pT2N1miM0", ")", ".", "Comienza", "revisiones", ".", "\n", "En", "febrero", "de", "2019", ",", "acude", "a", "Urgencias", "por", "comenzar", "con", "disnea", "progresiva", "sobre", "todo", "con", "ortopnea", "o", "esfuerzo", "moderado", ".", "En", "Urgencias", "objetivan", "derrame", "pleural", "derecho", ",", "por", "lo", "que", "se", "ingresa", "para", "estudio", ".", "\n\n", "Exploración", "física", "\n", "Durante", "la", "exploración", "física", ",", "no", "se", "palpaban", "adenopatías", "periféricas", ",", "masas", "ni", "nódulos", "mamarios", ".", "Auscultación", "respiratoria", "con", "hipoventilación", "en", "base", "derecha", "hasta", "tercio", "superior", ",", "izquierda", "normal", ".", "El", "resto", "de", "la", "exploración", "física", "por", "aparatos", "no", "tiene", "alteraciones", ".", "\n", "ignos", "de", "TVP", "\n\n", "Pruebas", "complementarias", "\n", "En", "las", "pruebas", "de", "imagen", "realizadas", "(", "TC", "-", "TAP", "y", "gammagrafía", "ósea", ")", "se", "objetiva", "derrame", "pleural", "derecho", ",", "nódulos", "pulmonares", "y", "pleurales", "bilaterales", "sugestivos", "de", "metástasis", "y", "nódulos", "diafragmáticos", "derechos", "anteriores", "en", "probable", "relación", "con", "adenopatías", "versus", "implantes", "tumorales", ".", "Se", "le", "realizó", "drenaje", "del", "líquido", "pleural", "más", "talcaje", "con", "resultado", "de", "líquido", "negativo", "para", "celularidad", ".", "Se", "decide", "realizar", "toracoscopia", "en", "la", "que", "se", "observa", "pleura", "visceral", "y", "parietal", "con", "lesiones", "sospechosas", "de", "metástasis", ".", "Se", "procede", "a", "la", "aspiración", "de", "líquido", "pleural", "y", "biopsia", "de", "lesiones", "de", "pleura", "parietal", ",", "obteniendo", "como", "resultado", "en", "la", "anatomía", "patológica", "de", "infiltración", "pleural", "compatible", "con", "neoplasia", "de", "origen", "mamario", "previa", "(", "adenoide", "quístico", ")", ".", "\n\n", "Diagnóstico", "\n", "Finalmente", ",", "la", "paciente", "es", "diagnosticada", "de", "carcinoma", "adenoide", "quístico", "metastásico", "de", "origen", "mamario", ",", "con", "afectación", "pulmonar", "y", "pleural", ".", "\n\n", "Tratamiento", "\n", "Revisada", "la", "literatura", ",", "no", "existe", "evidencia", "sobre", "la", "actitud", "terapéutica", "sobre", "este", "tipo", "de", "tumor", ".", "Normalmente", "es", "un", "tumor", "con", "un", "curso", "indolente", "con", "una", "SLE", "a", "10", "años", "del", "90", "-", "100", "%", ",", "y", "las", "metástasis", "a", "distancia", "son", "raras", "y", "lentamente", "progresivas", ",", "sólo", "reportadas", "en", "forma", "de", "casos", "clínicos", ".", "Sin", "embargo", ",", "en", "este", "caso", "se", "presenta", "una", "recaída", "sistémica", "sintomática", "a", "los", "2", "años", "del", "primario", ",", "lo", "que", "es", "extremadamente", "infrecuente", ".", "\n", "No", "existe", "evidencia", "sólida", "sobre", "el", "tratamiento", "de", "quimioterapia", "más", "adecuado", ",", "si", "bien", "la", "recomendación", "es", "tratarlo", "como", "un", "carcinoma", "adenoide", "quístico", "de", "glándulas", "salivares", ".", "El", "esquema", "con", "una", "evidencia", "más", "sólida", "es", "el", "CAP", "(", "ciclofosfamida", "[", "500", "mg", "/", "m2", "]", ",", "doxorrubicina", "[", "50", "mg", "/", "m2", "]", ",", "cisplatino", "[", "50", "mg", "/", "m2", "]", ")", "con", "una", "tasa", "de", "respuestas", "del", "28", "%", ".", "Pero", "al", "tratarse", "de", "una", "paciente", "frágil", ",", "se", "opta", "por", "un", "esquema", "de", "tratamiento", "en", "monoterapia", "con", "una", "toxicidad", "más", "manejable", ".", "El", "esquema", "en", "monoterapia", "con", "una", "mayor", "tasa", "de", "respuestas", "(", "15", "-", "44", "%", ")", "es", "la", "vinorelbina", ",", "por", "lo", "que", "la", "paciente", "inicia", "el", "primer", "ciclo", "de", "vinorelbina", "oral", "a", "60", "mg", "/", "m2", "días", "1", "y", "8", "cada", "21", "días", ",", "el", "día", "11", "de", "marzo", "de", "20193,4", ".", "\n\n", "Evolución", "\n", "La", "paciente", "hasta", "el", "día", "de", "hoy", "sigue", "en", "tratamiento", ",", "habiendo", "recibido", "cuatro", "ciclos", "con", "muy", "buena", "tolerancia", "al", "mismo", "y", "sin", "evidencia", "de", "progresión", "clínica", ",", "sólo", "destacando", "como", "toxicidad", "asociada", "al", "tratamiento", "astenia", "G1", ".", "Dentro", "de", "unos", "días", ",", "antes", "del", "quinto", "ciclo", ",", "se", "realizará", "TC", "de", "valoración", "de", "respuesta", "." ]	[ "MORFOLOGIA_NEOPLASIA" ]
Erytheme is an umlsterm, Hautveraenderungen is an umlsterm, Kind is an umlsterm, Hautveraenderungen is an umlsterm, Extremitaeten is an umlsterm, Streptokokken is an umlsterm, Dermatitis is an umlsterm, Kinder is an umlsterm, Kandidose is an umlsterm, Ekzem is an umlsterm, Behandlung is an umlsterm, Hautveraenderungen is an umlsterm, Therapie is an umlsterm	DerHautarzt.00510086.ger.abstr_task0	Sentence: Bei 2 Jungen im Alter von 6 und 9 Jahren liessen sich ueber einen langen Zeitraum bestehende scharf begrenzte perianale Erytheme , die bei einem Jungen die alleinigen Hautveraenderungen darstellen , bei dem anderen Kind mit zusaetzlichen Hautveraenderungen am Genitale sowie den Extremitaeten einhergingen , durch den kulturellen Nachweis von Streptokokken dem Krankheitsbild der perianalen streptogenen Dermatitis " " zuordnen . Diese v.a. Kinder , betreffende Erkrankung muss differendialdiagnostisch v.a. gegenueber der Kandidose und dem perianalen atopischen Ekzem abgegrenzt werden . Wie auch im Fall der beiden hier beschriebenen Jungen fuehrt eine topische Behandlung in der Regel nicht zur Abheilung der Hautveraenderungen . Die orale Penzillingabe stellt die Therapie der Wahl dar . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]	Bei 2 Jungen im Alter von 6 und 9 Jahren liessen sich ueber einen langen Zeitraum bestehende scharf begrenzte perianale Erytheme , die bei einem Jungen die alleinigen Hautveraenderungen darstellen , bei dem anderen Kind mit zusaetzlichen Hautveraenderungen am Genitale sowie den Extremitaeten einhergingen , durch den kulturellen Nachweis von Streptokokken dem Krankheitsbild der perianalen streptogenen Dermatitis " " zuordnen . Diese v.a. Kinder , betreffende Erkrankung muss differendialdiagnostisch v.a. gegenueber der Kandidose und dem perianalen atopischen Ekzem abgegrenzt werden . Wie auch im Fall der beiden hier beschriebenen Jungen fuehrt eine topische Behandlung in der Regel nicht zur Abheilung der Hautveraenderungen . Die orale Penzillingabe stellt die Therapie der Wahl dar .	[ "Bei", "2", "Jungen", "im", "Alter", "von", "6", "und", "9", "Jahren", "liessen", "sich", "ueber", "einen", "langen", "Zeitraum", "bestehende", "scharf", "begrenzte", "perianale", "Erytheme", ",", "die", "bei", "einem", "Jungen", "die", "alleinigen", "Hautveraenderungen", "darstellen", ",", "bei", "dem", "anderen", "Kind", "mit", "zusaetzlichen", "Hautveraenderungen", "am", "Genitale", "sowie", "den", "Extremitaeten", "einhergingen", ",", "durch", "den", "kulturellen", "Nachweis", "von", "Streptokokken", "dem", "Krankheitsbild", "der", "perianalen", "streptogenen", "Dermatitis", "\"", "\"", "zuordnen", ".", "Diese", "v.a", ".", "Kinder", ",", "betreffende", "Erkrankung", "muss", "differendialdiagnostisch", "v.a", ".", "gegenueber", "der", "Kandidose", "und", "dem", "perianalen", "atopischen", "Ekzem", "abgegrenzt", "werden", ".", "Wie", "auch", "im", "Fall", "der", "beiden", "hier", "beschriebenen", "Jungen", "fuehrt", "eine", "topische", "Behandlung", "in", "der", "Regel", "nicht", "zur", "Abheilung", "der", "Hautveraenderungen", ".", "Die", "orale", "Penzillingabe", "stellt", "die", "Therapie", "der", "Wahl", "dar", "." ]	[ "umlsterm" ]
Erytheme is an umlsterm, Hautveraenderungen is an umlsterm, Kind is an umlsterm, Hautveraenderungen is an umlsterm, Extremitaeten is an umlsterm, Streptokokken is an umlsterm, Dermatitis is an umlsterm, Kinder is an umlsterm, Kandidose is an umlsterm, Ekzem is an umlsterm, Behandlung is an umlsterm, Hautveraenderungen is an umlsterm, Therapie is an umlsterm	DerHautarzt.00510086.ger.abstr_task1	Sentence: Bei 2 Jungen im Alter von 6 und 9 Jahren liessen sich ueber einen langen Zeitraum bestehende scharf begrenzte perianale Erytheme , die bei einem Jungen die alleinigen Hautveraenderungen darstellen , bei dem anderen Kind mit zusaetzlichen Hautveraenderungen am Genitale sowie den Extremitaeten einhergingen , durch den kulturellen Nachweis von Streptokokken dem Krankheitsbild der perianalen streptogenen Dermatitis " " zuordnen . Diese v.a. Kinder , betreffende Erkrankung muss differendialdiagnostisch v.a. gegenueber der Kandidose und dem perianalen atopischen Ekzem abgegrenzt werden . Wie auch im Fall der beiden hier beschriebenen Jungen fuehrt eine topische Behandlung in der Regel nicht zur Abheilung der Hautveraenderungen . Die orale Penzillingabe stellt die Therapie der Wahl dar . Instructions: please typing these entity words according to sentence: Erytheme, Hautveraenderungen, Kind, Hautveraenderungen, Extremitaeten, Streptokokken, Dermatitis, Kinder, Kandidose, Ekzem, Behandlung, Hautveraenderungen, Therapie Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]	Bei 2 Jungen im Alter von 6 und 9 Jahren liessen sich ueber einen langen Zeitraum bestehende scharf begrenzte perianale Erytheme , die bei einem Jungen die alleinigen Hautveraenderungen darstellen , bei dem anderen Kind mit zusaetzlichen Hautveraenderungen am Genitale sowie den Extremitaeten einhergingen , durch den kulturellen Nachweis von Streptokokken dem Krankheitsbild der perianalen streptogenen Dermatitis " " zuordnen . Diese v.a. Kinder , betreffende Erkrankung muss differendialdiagnostisch v.a. gegenueber der Kandidose und dem perianalen atopischen Ekzem abgegrenzt werden . Wie auch im Fall der beiden hier beschriebenen Jungen fuehrt eine topische Behandlung in der Regel nicht zur Abheilung der Hautveraenderungen . Die orale Penzillingabe stellt die Therapie der Wahl dar .	[ "Bei", "2", "Jungen", "im", "Alter", "von", "6", "und", "9", "Jahren", "liessen", "sich", "ueber", "einen", "langen", "Zeitraum", "bestehende", "scharf", "begrenzte", "perianale", "Erytheme", ",", "die", "bei", "einem", "Jungen", "die", "alleinigen", "Hautveraenderungen", "darstellen", ",", "bei", "dem", "anderen", "Kind", "mit", "zusaetzlichen", "Hautveraenderungen", "am", "Genitale", "sowie", "den", "Extremitaeten", "einhergingen", ",", "durch", "den", "kulturellen", "Nachweis", "von", "Streptokokken", "dem", "Krankheitsbild", "der", "perianalen", "streptogenen", "Dermatitis", "\"", "\"", "zuordnen", ".", "Diese", "v.a", ".", "Kinder", ",", "betreffende", "Erkrankung", "muss", "differendialdiagnostisch", "v.a", ".", "gegenueber", "der", "Kandidose", "und", "dem", "perianalen", "atopischen", "Ekzem", "abgegrenzt", "werden", ".", "Wie", "auch", "im", "Fall", "der", "beiden", "hier", "beschriebenen", "Jungen", "fuehrt", "eine", "topische", "Behandlung", "in", "der", "Regel", "nicht", "zur", "Abheilung", "der", "Hautveraenderungen", ".", "Die", "orale", "Penzillingabe", "stellt", "die", "Therapie", "der", "Wahl", "dar", "." ]	[ "umlsterm" ]
Erytheme, Hautveraenderungen, Kind, Hautveraenderungen, Extremitaeten, Streptokokken, Dermatitis, Kinder, Kandidose, Ekzem, Behandlung, Hautveraenderungen, Therapie	DerHautarzt.00510086.ger.abstr_task2	Sentence: Bei 2 Jungen im Alter von 6 und 9 Jahren liessen sich ueber einen langen Zeitraum bestehende scharf begrenzte perianale Erytheme , die bei einem Jungen die alleinigen Hautveraenderungen darstellen , bei dem anderen Kind mit zusaetzlichen Hautveraenderungen am Genitale sowie den Extremitaeten einhergingen , durch den kulturellen Nachweis von Streptokokken dem Krankheitsbild der perianalen streptogenen Dermatitis " " zuordnen . Diese v.a. Kinder , betreffende Erkrankung muss differendialdiagnostisch v.a. gegenueber der Kandidose und dem perianalen atopischen Ekzem abgegrenzt werden . Wie auch im Fall der beiden hier beschriebenen Jungen fuehrt eine topische Behandlung in der Regel nicht zur Abheilung der Hautveraenderungen . Die orale Penzillingabe stellt die Therapie der Wahl dar . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]	Bei 2 Jungen im Alter von 6 und 9 Jahren liessen sich ueber einen langen Zeitraum bestehende scharf begrenzte perianale Erytheme , die bei einem Jungen die alleinigen Hautveraenderungen darstellen , bei dem anderen Kind mit zusaetzlichen Hautveraenderungen am Genitale sowie den Extremitaeten einhergingen , durch den kulturellen Nachweis von Streptokokken dem Krankheitsbild der perianalen streptogenen Dermatitis " " zuordnen . Diese v.a. Kinder , betreffende Erkrankung muss differendialdiagnostisch v.a. gegenueber der Kandidose und dem perianalen atopischen Ekzem abgegrenzt werden . Wie auch im Fall der beiden hier beschriebenen Jungen fuehrt eine topische Behandlung in der Regel nicht zur Abheilung der Hautveraenderungen . Die orale Penzillingabe stellt die Therapie der Wahl dar .	[ "Bei", "2", "Jungen", "im", "Alter", "von", "6", "und", "9", "Jahren", "liessen", "sich", "ueber", "einen", "langen", "Zeitraum", "bestehende", "scharf", "begrenzte", "perianale", "Erytheme", ",", "die", "bei", "einem", "Jungen", "die", "alleinigen", "Hautveraenderungen", "darstellen", ",", "bei", "dem", "anderen", "Kind", "mit", "zusaetzlichen", "Hautveraenderungen", "am", "Genitale", "sowie", "den", "Extremitaeten", "einhergingen", ",", "durch", "den", "kulturellen", "Nachweis", "von", "Streptokokken", "dem", "Krankheitsbild", "der", "perianalen", "streptogenen", "Dermatitis", "\"", "\"", "zuordnen", ".", "Diese", "v.a", ".", "Kinder", ",", "betreffende", "Erkrankung", "muss", "differendialdiagnostisch", "v.a", ".", "gegenueber", "der", "Kandidose", "und", "dem", "perianalen", "atopischen", "Ekzem", "abgegrenzt", "werden", ".", "Wie", "auch", "im", "Fall", "der", "beiden", "hier", "beschriebenen", "Jungen", "fuehrt", "eine", "topische", "Behandlung", "in", "der", "Regel", "nicht", "zur", "Abheilung", "der", "Hautveraenderungen", ".", "Die", "orale", "Penzillingabe", "stellt", "die", "Therapie", "der", "Wahl", "dar", "." ]	[ "umlsterm" ]
Atherosklerose is an umlsterm, T - Lymphozyten is an umlsterm, Makrophagen is an umlsterm, Risikofaktoren is an umlsterm, Marker is an umlsterm, Entzuendung is an umlsterm, Leukozyten is an umlsterm, Protein is an umlsterm, Serumamyloid is an umlsterm, Interleukin is an umlsterm, Lipoproteine is an umlsterm, Lipoproteine is an umlsterm, Elemente is an umlsterm, Makrophagen is an umlsterm	Herz.00250117.ger.abstr_task0	Sentence: Die Atherosklerose besitzt viele Merkmale einer chronisch entzuendlichen Erkrankung . Atherosklerotische Laesionen enthalten Entzuendungszellen , aktivierte T-Lymphozyten und Makrophagen . Auch nach Korrektur fuer etablierte kardiovaskulaere Risikofaktoren koennen systemische Marker einer Entzuendung , wie Leukozyten , C-reaktives Protein , Serumamyloid A , Interleukin 6 und loesliche Adhaesionsmolekuele , zur Abschaetzung des Risikos fuer kuenftige kardiovaskulaere Ereignisse beitragen . Atherogene Lipoproteine , insbesondere modifizierte Lipoproteine niedriger Dichte ( LDL ) , verursachen entzuendliche Reaktionen zellulaerer Elemente der Gefaesswand , zum Beispiel Stoerungen den Endothelzellfunktion oder die Aktivierung von Makrophagen . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]	Die Atherosklerose besitzt viele Merkmale einer chronisch entzuendlichen Erkrankung . Atherosklerotische Laesionen enthalten Entzuendungszellen , aktivierte T-Lymphozyten und Makrophagen . Auch nach Korrektur fuer etablierte kardiovaskulaere Risikofaktoren koennen systemische Marker einer Entzuendung , wie Leukozyten , C-reaktives Protein , Serumamyloid A , Interleukin 6 und loesliche Adhaesionsmolekuele , zur Abschaetzung des Risikos fuer kuenftige kardiovaskulaere Ereignisse beitragen . Atherogene Lipoproteine , insbesondere modifizierte Lipoproteine niedriger Dichte ( LDL ) , verursachen entzuendliche Reaktionen zellulaerer Elemente der Gefaesswand , zum Beispiel Stoerungen den Endothelzellfunktion oder die Aktivierung von Makrophagen .	[ "Die", "Atherosklerose", "besitzt", "viele", "Merkmale", "einer", "chronisch", "entzuendlichen", "Erkrankung", ".", "Atherosklerotische", "Laesionen", "enthalten", "Entzuendungszellen", ",", "aktivierte", "T", "-", "Lymphozyten", "und", "Makrophagen", ".", "Auch", "nach", "Korrektur", "fuer", "etablierte", "kardiovaskulaere", "Risikofaktoren", "koennen", "systemische", "Marker", "einer", "Entzuendung", ",", "wie", "Leukozyten", ",", "C", "-", "reaktives", "Protein", ",", "Serumamyloid", "A", ",", "Interleukin", "6", "und", "loesliche", "Adhaesionsmolekuele", ",", "zur", "Abschaetzung", "des", "Risikos", "fuer", "kuenftige", "kardiovaskulaere", "Ereignisse", "beitragen", ".", "Atherogene", "Lipoproteine", ",", "insbesondere", "modifizierte", "Lipoproteine", "niedriger", "Dichte", "(", "LDL", ")", ",", "verursachen", "entzuendliche", "Reaktionen", "zellulaerer", "Elemente", "der", "Gefaesswand", ",", "zum", "Beispiel", "Stoerungen", "den", "Endothelzellfunktion", "oder", "die", "Aktivierung", "von", "Makrophagen", "." ]	[ "umlsterm" ]
Atherosklerose is an umlsterm, T - Lymphozyten is an umlsterm, Makrophagen is an umlsterm, Risikofaktoren is an umlsterm, Marker is an umlsterm, Entzuendung is an umlsterm, Leukozyten is an umlsterm, Protein is an umlsterm, Serumamyloid is an umlsterm, Interleukin is an umlsterm, Lipoproteine is an umlsterm, Lipoproteine is an umlsterm, Elemente is an umlsterm, Makrophagen is an umlsterm	Herz.00250117.ger.abstr_task1	Sentence: Die Atherosklerose besitzt viele Merkmale einer chronisch entzuendlichen Erkrankung . Atherosklerotische Laesionen enthalten Entzuendungszellen , aktivierte T-Lymphozyten und Makrophagen . Auch nach Korrektur fuer etablierte kardiovaskulaere Risikofaktoren koennen systemische Marker einer Entzuendung , wie Leukozyten , C-reaktives Protein , Serumamyloid A , Interleukin 6 und loesliche Adhaesionsmolekuele , zur Abschaetzung des Risikos fuer kuenftige kardiovaskulaere Ereignisse beitragen . Atherogene Lipoproteine , insbesondere modifizierte Lipoproteine niedriger Dichte ( LDL ) , verursachen entzuendliche Reaktionen zellulaerer Elemente der Gefaesswand , zum Beispiel Stoerungen den Endothelzellfunktion oder die Aktivierung von Makrophagen . Instructions: please typing these entity words according to sentence: Atherosklerose, T - Lymphozyten, Makrophagen, Risikofaktoren, Marker, Entzuendung, Leukozyten, Protein, Serumamyloid, Interleukin, Lipoproteine, Lipoproteine, Elemente, Makrophagen Options: umlsterm	[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]	Die Atherosklerose besitzt viele Merkmale einer chronisch entzuendlichen Erkrankung . Atherosklerotische Laesionen enthalten Entzuendungszellen , aktivierte T-Lymphozyten und Makrophagen . Auch nach Korrektur fuer etablierte kardiovaskulaere Risikofaktoren koennen systemische Marker einer Entzuendung , wie Leukozyten , C-reaktives Protein , Serumamyloid A , Interleukin 6 und loesliche Adhaesionsmolekuele , zur Abschaetzung des Risikos fuer kuenftige kardiovaskulaere Ereignisse beitragen . Atherogene Lipoproteine , insbesondere modifizierte Lipoproteine niedriger Dichte ( LDL ) , verursachen entzuendliche Reaktionen zellulaerer Elemente der Gefaesswand , zum Beispiel Stoerungen den Endothelzellfunktion oder die Aktivierung von Makrophagen .	[ "Die", "Atherosklerose", "besitzt", "viele", "Merkmale", "einer", "chronisch", "entzuendlichen", "Erkrankung", ".", "Atherosklerotische", "Laesionen", "enthalten", "Entzuendungszellen", ",", "aktivierte", "T", "-", "Lymphozyten", "und", "Makrophagen", ".", "Auch", "nach", "Korrektur", "fuer", "etablierte", "kardiovaskulaere", "Risikofaktoren", "koennen", "systemische", "Marker", "einer", "Entzuendung", ",", "wie", "Leukozyten", ",", "C", "-", "reaktives", "Protein", ",", "Serumamyloid", "A", ",", "Interleukin", "6", "und", "loesliche", "Adhaesionsmolekuele", ",", "zur", "Abschaetzung", "des", "Risikos", "fuer", "kuenftige", "kardiovaskulaere", "Ereignisse", "beitragen", ".", "Atherogene", "Lipoproteine", ",", "insbesondere", "modifizierte", "Lipoproteine", "niedriger", "Dichte", "(", "LDL", ")", ",", "verursachen", "entzuendliche", "Reaktionen", "zellulaerer", "Elemente", "der", "Gefaesswand", ",", "zum", "Beispiel", "Stoerungen", "den", "Endothelzellfunktion", "oder", "die", "Aktivierung", "von", "Makrophagen", "." ]	[ "umlsterm" ]
Atherosklerose, T - Lymphozyten, Makrophagen, Risikofaktoren, Marker, Entzuendung, Leukozyten, Protein, Serumamyloid, Interleukin, Lipoproteine, Lipoproteine, Elemente, Makrophagen	Herz.00250117.ger.abstr_task2	Sentence: Die Atherosklerose besitzt viele Merkmale einer chronisch entzuendlichen Erkrankung . Atherosklerotische Laesionen enthalten Entzuendungszellen , aktivierte T-Lymphozyten und Makrophagen . Auch nach Korrektur fuer etablierte kardiovaskulaere Risikofaktoren koennen systemische Marker einer Entzuendung , wie Leukozyten , C-reaktives Protein , Serumamyloid A , Interleukin 6 und loesliche Adhaesionsmolekuele , zur Abschaetzung des Risikos fuer kuenftige kardiovaskulaere Ereignisse beitragen . Atherogene Lipoproteine , insbesondere modifizierte Lipoproteine niedriger Dichte ( LDL ) , verursachen entzuendliche Reaktionen zellulaerer Elemente der Gefaesswand , zum Beispiel Stoerungen den Endothelzellfunktion oder die Aktivierung von Makrophagen . Instructions: please extract entity words from the input sentence	[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]	Die Atherosklerose besitzt viele Merkmale einer chronisch entzuendlichen Erkrankung . Atherosklerotische Laesionen enthalten Entzuendungszellen , aktivierte T-Lymphozyten und Makrophagen . Auch nach Korrektur fuer etablierte kardiovaskulaere Risikofaktoren koennen systemische Marker einer Entzuendung , wie Leukozyten , C-reaktives Protein , Serumamyloid A , Interleukin 6 und loesliche Adhaesionsmolekuele , zur Abschaetzung des Risikos fuer kuenftige kardiovaskulaere Ereignisse beitragen . Atherogene Lipoproteine , insbesondere modifizierte Lipoproteine niedriger Dichte ( LDL ) , verursachen entzuendliche Reaktionen zellulaerer Elemente der Gefaesswand , zum Beispiel Stoerungen den Endothelzellfunktion oder die Aktivierung von Makrophagen .	[ "Die", "Atherosklerose", "besitzt", "viele", "Merkmale", "einer", "chronisch", "entzuendlichen", "Erkrankung", ".", "Atherosklerotische", "Laesionen", "enthalten", "Entzuendungszellen", ",", "aktivierte", "T", "-", "Lymphozyten", "und", "Makrophagen", ".", "Auch", "nach", "Korrektur", "fuer", "etablierte", "kardiovaskulaere", "Risikofaktoren", "koennen", "systemische", "Marker", "einer", "Entzuendung", ",", "wie", "Leukozyten", ",", "C", "-", "reaktives", "Protein", ",", "Serumamyloid", "A", ",", "Interleukin", "6", "und", "loesliche", "Adhaesionsmolekuele", ",", "zur", "Abschaetzung", "des", "Risikos", "fuer", "kuenftige", "kardiovaskulaere", "Ereignisse", "beitragen", ".", "Atherogene", "Lipoproteine", ",", "insbesondere", "modifizierte", "Lipoproteine", "niedriger", "Dichte", "(", "LDL", ")", ",", "verursachen", "entzuendliche", "Reaktionen", "zellulaerer", "Elemente", "der", "Gefaesswand", ",", "zum", "Beispiel", "Stoerungen", "den", "Endothelzellfunktion", "oder", "die", "Aktivierung", "von", "Makrophagen", "." ]	[ "umlsterm" ]
research is an umlsterm, development is an umlsterm, treatment is an umlsterm, atrial fibrillation is an umlsterm, therapies is an umlsterm, clinical research is an umlsterm, development is an umlsterm, electrode is an umlsterm, cardioversion is an umlsterm, devices is an umlsterm	Herzschrittmachertherapie.80090076.eng.abstr_task0	Sentence: Over the past 5-7 years , there has been a renewed research interest into the mechanism as well as the development of newer " emerging " treatment modalities for atrial fibrillation . One of these novel therapies is the implantable atrial defibrillator . In this article we will review the basic and clinical research which has been used in the development of electrode systems and shock waveforms utilized by commercially-available implantable atrial cardioversion devices . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O" ]	Over the past 5-7 years , there has been a renewed research interest into the mechanism as well as the development of newer " emerging " treatment modalities for atrial fibrillation . One of these novel therapies is the implantable atrial defibrillator . In this article we will review the basic and clinical research which has been used in the development of electrode systems and shock waveforms utilized by commercially-available implantable atrial cardioversion devices .	[ "Over", "the", "past", "5", "-", "7", "years", ",", "there", "has", "been", "a", "renewed", "research", "interest", "into", "the", "mechanism", "as", "well", "as", "the", "development", "of", "newer", "\"", "emerging", "\"", "treatment", "modalities", "for", "atrial", "fibrillation", ".", "One", "of", "these", "novel", "therapies", "is", "the", "implantable", "atrial", "defibrillator", ".", "In", "this", "article", "we", "will", "review", "the", "basic", "and", "clinical", "research", "which", "has", "been", "used", "in", "the", "development", "of", "electrode", "systems", "and", "shock", "waveforms", "utilized", "by", "commercially", "-", "available", "implantable", "atrial", "cardioversion", "devices", "." ]	[ "umlsterm" ]
research is an umlsterm, development is an umlsterm, treatment is an umlsterm, atrial fibrillation is an umlsterm, therapies is an umlsterm, clinical research is an umlsterm, development is an umlsterm, electrode is an umlsterm, cardioversion is an umlsterm, devices is an umlsterm	Herzschrittmachertherapie.80090076.eng.abstr_task1	Sentence: Over the past 5-7 years , there has been a renewed research interest into the mechanism as well as the development of newer " emerging " treatment modalities for atrial fibrillation . One of these novel therapies is the implantable atrial defibrillator . In this article we will review the basic and clinical research which has been used in the development of electrode systems and shock waveforms utilized by commercially-available implantable atrial cardioversion devices . Instructions: please typing these entity words according to sentence: research, development, treatment, atrial fibrillation, therapies, clinical research, development, electrode, cardioversion, devices Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O" ]	Over the past 5-7 years , there has been a renewed research interest into the mechanism as well as the development of newer " emerging " treatment modalities for atrial fibrillation . One of these novel therapies is the implantable atrial defibrillator . In this article we will review the basic and clinical research which has been used in the development of electrode systems and shock waveforms utilized by commercially-available implantable atrial cardioversion devices .	[ "Over", "the", "past", "5", "-", "7", "years", ",", "there", "has", "been", "a", "renewed", "research", "interest", "into", "the", "mechanism", "as", "well", "as", "the", "development", "of", "newer", "\"", "emerging", "\"", "treatment", "modalities", "for", "atrial", "fibrillation", ".", "One", "of", "these", "novel", "therapies", "is", "the", "implantable", "atrial", "defibrillator", ".", "In", "this", "article", "we", "will", "review", "the", "basic", "and", "clinical", "research", "which", "has", "been", "used", "in", "the", "development", "of", "electrode", "systems", "and", "shock", "waveforms", "utilized", "by", "commercially", "-", "available", "implantable", "atrial", "cardioversion", "devices", "." ]	[ "umlsterm" ]
research, development, treatment, atrial fibrillation, therapies, clinical research, development, electrode, cardioversion, devices	Herzschrittmachertherapie.80090076.eng.abstr_task2	Sentence: Over the past 5-7 years , there has been a renewed research interest into the mechanism as well as the development of newer " emerging " treatment modalities for atrial fibrillation . One of these novel therapies is the implantable atrial defibrillator . In this article we will review the basic and clinical research which has been used in the development of electrode systems and shock waveforms utilized by commercially-available implantable atrial cardioversion devices . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O" ]	Over the past 5-7 years , there has been a renewed research interest into the mechanism as well as the development of newer " emerging " treatment modalities for atrial fibrillation . One of these novel therapies is the implantable atrial defibrillator . In this article we will review the basic and clinical research which has been used in the development of electrode systems and shock waveforms utilized by commercially-available implantable atrial cardioversion devices .	[ "Over", "the", "past", "5", "-", "7", "years", ",", "there", "has", "been", "a", "renewed", "research", "interest", "into", "the", "mechanism", "as", "well", "as", "the", "development", "of", "newer", "\"", "emerging", "\"", "treatment", "modalities", "for", "atrial", "fibrillation", ".", "One", "of", "these", "novel", "therapies", "is", "the", "implantable", "atrial", "defibrillator", ".", "In", "this", "article", "we", "will", "review", "the", "basic", "and", "clinical", "research", "which", "has", "been", "used", "in", "the", "development", "of", "electrode", "systems", "and", "shock", "waveforms", "utilized", "by", "commercially", "-", "available", "implantable", "atrial", "cardioversion", "devices", "." ]	[ "umlsterm" ]
administration is an umlsterm, GP IIb / IIIa is an umlsterm, antagonists is an umlsterm, myocardial infarction is an umlsterm, death is an umlsterm, PTCA is an umlsterm, prospective study is an umlsterm, abciximab is an umlsterm, vessel is an umlsterm, Methods is an umlsterm, vessel is an umlsterm, patients is an umlsterm, PTCA is an umlsterm, patients is an umlsterm, unstable angina is an umlsterm, Abciximab is an umlsterm, intravenous infusion is an umlsterm, PTCA is an umlsterm, administration is an umlsterm, abciximab is an umlsterm, procedure is an umlsterm, control is an umlsterm, angiography is an umlsterm, patients is an umlsterm, abciximab is an umlsterm, therapy is an umlsterm, patients is an umlsterm, stent is an umlsterm, implantation is an umlsterm, PTCA is an umlsterm, angiography is an umlsterm, vessels is an umlsterm, patients is an umlsterm, patients is an umlsterm, emergency is an umlsterm, vessel is an umlsterm, PTCA is an umlsterm, surgery is an umlsterm, control is an umlsterm, angiography is an umlsterm, vessel is an umlsterm, MACE is an umlsterm, patients is an umlsterm, abciximab is an umlsterm, therapy is an umlsterm, PTCA is an umlsterm, use is an umlsterm, abciximab is an umlsterm, prophylactic is an umlsterm, abciximab is an umlsterm, treatment is an umlsterm	ZfuerKardiologie.00890722.eng.abstr_task0	Sentence: The administration of GP IIb/IIIa antagonists has been shown to be effective in reducing myocardial infarction and cardial death when given before PTCA . This prospective study was performed to determine the efficacy of abciximab in a bail-out situation to manage threatened or acute vessel closure . Methods : Acute or threatened vessel closure was observed in 104 ( 5.5% ) out of 1903 consecutive patients treated with PTCA in our institution . Of the 104 patients 46 ( 44% ) were treated for unstable angina ( CCS IV ) . Abciximab was administered in bail-out situations in a dosage of 0.25mg/kg given as a bolus , which was followed by an intravenous infusion of 10µg/min over 12 hours . Repeat PTCA was performed shortly after the administration of the abciximab bolus . After the procedure , the sheathe was left in place and control angiography was carried out 24 h later . Results : In 100 of the 104 patients TIMI flow III could be restored by abciximab therapy and RePTCA . In 4 patients an additional stent implantation was necessary due to persistent flow limitation . One day post PTCA , early follow-up angiography demonstrated patency of all vessels except two . In-hospital events occurred in 4 patients . Three of these patients underwent emergency CABG due to subacute vessel closure a few hours after PTCA and died during or directly after surgery . Follow-up after one year included clinical status and control angiography of the target vessel . During long-term follow-up , MACE occured in 15 patients ( 2 MI , 8 CABG and 5 RePTCA ) . Conclusion : The results of this prospective trial demonstrate the efficacy of abciximab therapy in bail-out situations occurring during or early after PTCA . The use of abciximab in bail-out situations appears clinically beneficial . Further studies have to compare the efficacy of this approach with prophylactic abciximab treatment . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O" ]	The administration of GP IIb/IIIa antagonists has been shown to be effective in reducing myocardial infarction and cardial death when given before PTCA . This prospective study was performed to determine the efficacy of abciximab in a bail-out situation to manage threatened or acute vessel closure . Methods : Acute or threatened vessel closure was observed in 104 ( 5.5% ) out of 1903 consecutive patients treated with PTCA in our institution . Of the 104 patients 46 ( 44% ) were treated for unstable angina ( CCS IV ) . Abciximab was administered in bail-out situations in a dosage of 0.25mg/kg given as a bolus , which was followed by an intravenous infusion of 10µg/min over 12 hours . Repeat PTCA was performed shortly after the administration of the abciximab bolus . After the procedure , the sheathe was left in place and control angiography was carried out 24 h later . Results : In 100 of the 104 patients TIMI flow III could be restored by abciximab therapy and RePTCA . In 4 patients an additional stent implantation was necessary due to persistent flow limitation . One day post PTCA , early follow-up angiography demonstrated patency of all vessels except two . In-hospital events occurred in 4 patients . Three of these patients underwent emergency CABG due to subacute vessel closure a few hours after PTCA and died during or directly after surgery . Follow-up after one year included clinical status and control angiography of the target vessel . During long-term follow-up , MACE occured in 15 patients ( 2 MI , 8 CABG and 5 RePTCA ) . Conclusion : The results of this prospective trial demonstrate the efficacy of abciximab therapy in bail-out situations occurring during or early after PTCA . The use of abciximab in bail-out situations appears clinically beneficial . Further studies have to compare the efficacy of this approach with prophylactic abciximab treatment .	[ "The", "administration", "of", "GP", "IIb", "/", "IIIa", "antagonists", "has", "been", "shown", "to", "be", "effective", "in", "reducing", "myocardial", "infarction", "and", "cardial", "death", "when", "given", "before", "PTCA", ".", "This", "prospective", "study", "was", "performed", "to", "determine", "the", "efficacy", "of", "abciximab", "in", "a", "bail", "-", "out", "situation", "to", "manage", "threatened", "or", "acute", "vessel", "closure", ".", "Methods", ":", "Acute", "or", "threatened", "vessel", "closure", "was", "observed", "in", "104", "(", "5.5", "%", ")", "out", "of", "1903", "consecutive", "patients", "treated", "with", "PTCA", "in", "our", "institution", ".", "Of", "the", "104", "patients", "46", "(", "44", "%", ")", "were", "treated", "for", "unstable", "angina", "(", "CCS", "IV", ")", ".", "Abciximab", "was", "administered", "in", "bail", "-", "out", "situations", "in", "a", "dosage", "of", "0.25mg", "/", "kg", "given", "as", "a", "bolus", ",", "which", "was", "followed", "by", "an", "intravenous", "infusion", "of", "10µg", "/", "min", "over", "12", "hours", ".", "Repeat", "PTCA", "was", "performed", "shortly", "after", "the", "administration", "of", "the", "abciximab", "bolus", ".", "After", "the", "procedure", ",", "the", "sheathe", "was", "left", "in", "place", "and", "control", "angiography", "was", "carried", "out", "24", "h", "later", ".", "Results", ":", "In", "100", "of", "the", "104", "patients", "TIMI", "flow", "III", "could", "be", "restored", "by", "abciximab", "therapy", "and", "RePTCA", ".", "In", "4", "patients", "an", "additional", "stent", "implantation", "was", "necessary", "due", "to", "persistent", "flow", "limitation", ".", "One", "day", "post", "PTCA", ",", "early", "follow", "-", "up", "angiography", "demonstrated", "patency", "of", "all", "vessels", "except", "two", ".", "In", "-", "hospital", "events", "occurred", "in", "4", "patients", ".", "Three", "of", "these", "patients", "underwent", "emergency", "CABG", "due", "to", "subacute", "vessel", "closure", "a", "few", "hours", "after", "PTCA", "and", "died", "during", "or", "directly", "after", "surgery", ".", "Follow", "-", "up", "after", "one", "year", "included", "clinical", "status", "and", "control", "angiography", "of", "the", "target", "vessel", ".", "During", "long", "-", "term", "follow", "-", "up", ",", "MACE", "occured", "in", "15", "patients", "(", "2", "MI", ",", "8", "CABG", "and", "5", "RePTCA", ")", ".", "Conclusion", ":", "The", "results", "of", "this", "prospective", "trial", "demonstrate", "the", "efficacy", "of", "abciximab", "therapy", "in", "bail", "-", "out", "situations", "occurring", "during", "or", "early", "after", "PTCA", ".", "The", "use", "of", "abciximab", "in", "bail", "-", "out", "situations", "appears", "clinically", "beneficial", ".", "Further", "studies", "have", "to", "compare", "the", "efficacy", "of", "this", "approach", "with", "prophylactic", "abciximab", "treatment", "." ]	[ "umlsterm" ]
administration is an umlsterm, GP IIb / IIIa is an umlsterm, antagonists is an umlsterm, myocardial infarction is an umlsterm, death is an umlsterm, PTCA is an umlsterm, prospective study is an umlsterm, abciximab is an umlsterm, vessel is an umlsterm, Methods is an umlsterm, vessel is an umlsterm, patients is an umlsterm, PTCA is an umlsterm, patients is an umlsterm, unstable angina is an umlsterm, Abciximab is an umlsterm, intravenous infusion is an umlsterm, PTCA is an umlsterm, administration is an umlsterm, abciximab is an umlsterm, procedure is an umlsterm, control is an umlsterm, angiography is an umlsterm, patients is an umlsterm, abciximab is an umlsterm, therapy is an umlsterm, patients is an umlsterm, stent is an umlsterm, implantation is an umlsterm, PTCA is an umlsterm, angiography is an umlsterm, vessels is an umlsterm, patients is an umlsterm, patients is an umlsterm, emergency is an umlsterm, vessel is an umlsterm, PTCA is an umlsterm, surgery is an umlsterm, control is an umlsterm, angiography is an umlsterm, vessel is an umlsterm, MACE is an umlsterm, patients is an umlsterm, abciximab is an umlsterm, therapy is an umlsterm, PTCA is an umlsterm, use is an umlsterm, abciximab is an umlsterm, prophylactic is an umlsterm, abciximab is an umlsterm, treatment is an umlsterm	ZfuerKardiologie.00890722.eng.abstr_task1	Sentence: The administration of GP IIb/IIIa antagonists has been shown to be effective in reducing myocardial infarction and cardial death when given before PTCA . This prospective study was performed to determine the efficacy of abciximab in a bail-out situation to manage threatened or acute vessel closure . Methods : Acute or threatened vessel closure was observed in 104 ( 5.5% ) out of 1903 consecutive patients treated with PTCA in our institution . Of the 104 patients 46 ( 44% ) were treated for unstable angina ( CCS IV ) . Abciximab was administered in bail-out situations in a dosage of 0.25mg/kg given as a bolus , which was followed by an intravenous infusion of 10µg/min over 12 hours . Repeat PTCA was performed shortly after the administration of the abciximab bolus . After the procedure , the sheathe was left in place and control angiography was carried out 24 h later . Results : In 100 of the 104 patients TIMI flow III could be restored by abciximab therapy and RePTCA . In 4 patients an additional stent implantation was necessary due to persistent flow limitation . One day post PTCA , early follow-up angiography demonstrated patency of all vessels except two . In-hospital events occurred in 4 patients . Three of these patients underwent emergency CABG due to subacute vessel closure a few hours after PTCA and died during or directly after surgery . Follow-up after one year included clinical status and control angiography of the target vessel . During long-term follow-up , MACE occured in 15 patients ( 2 MI , 8 CABG and 5 RePTCA ) . Conclusion : The results of this prospective trial demonstrate the efficacy of abciximab therapy in bail-out situations occurring during or early after PTCA . The use of abciximab in bail-out situations appears clinically beneficial . Further studies have to compare the efficacy of this approach with prophylactic abciximab treatment . Instructions: please typing these entity words according to sentence: administration, GP IIb / IIIa, antagonists, myocardial infarction, death, PTCA, prospective study, abciximab, vessel, Methods, vessel, patients, PTCA, patients, unstable angina, Abciximab, intravenous infusion, PTCA, administration, abciximab, procedure, control, angiography, patients, abciximab, therapy, patients, stent, implantation, PTCA, angiography, vessels, patients, patients, emergency, vessel, PTCA, surgery, control, angiography, vessel, MACE, patients, abciximab, therapy, PTCA, use, abciximab, prophylactic, abciximab, treatment Options: umlsterm	[ "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O" ]	The administration of GP IIb/IIIa antagonists has been shown to be effective in reducing myocardial infarction and cardial death when given before PTCA . This prospective study was performed to determine the efficacy of abciximab in a bail-out situation to manage threatened or acute vessel closure . Methods : Acute or threatened vessel closure was observed in 104 ( 5.5% ) out of 1903 consecutive patients treated with PTCA in our institution . Of the 104 patients 46 ( 44% ) were treated for unstable angina ( CCS IV ) . Abciximab was administered in bail-out situations in a dosage of 0.25mg/kg given as a bolus , which was followed by an intravenous infusion of 10µg/min over 12 hours . Repeat PTCA was performed shortly after the administration of the abciximab bolus . After the procedure , the sheathe was left in place and control angiography was carried out 24 h later . Results : In 100 of the 104 patients TIMI flow III could be restored by abciximab therapy and RePTCA . In 4 patients an additional stent implantation was necessary due to persistent flow limitation . One day post PTCA , early follow-up angiography demonstrated patency of all vessels except two . In-hospital events occurred in 4 patients . Three of these patients underwent emergency CABG due to subacute vessel closure a few hours after PTCA and died during or directly after surgery . Follow-up after one year included clinical status and control angiography of the target vessel . During long-term follow-up , MACE occured in 15 patients ( 2 MI , 8 CABG and 5 RePTCA ) . Conclusion : The results of this prospective trial demonstrate the efficacy of abciximab therapy in bail-out situations occurring during or early after PTCA . The use of abciximab in bail-out situations appears clinically beneficial . Further studies have to compare the efficacy of this approach with prophylactic abciximab treatment .	[ "The", "administration", "of", "GP", "IIb", "/", "IIIa", "antagonists", "has", "been", "shown", "to", "be", "effective", "in", "reducing", "myocardial", "infarction", "and", "cardial", "death", "when", "given", "before", "PTCA", ".", "This", "prospective", "study", "was", "performed", "to", "determine", "the", "efficacy", "of", "abciximab", "in", "a", "bail", "-", "out", "situation", "to", "manage", "threatened", "or", "acute", "vessel", "closure", ".", "Methods", ":", "Acute", "or", "threatened", "vessel", "closure", "was", "observed", "in", "104", "(", "5.5", "%", ")", "out", "of", "1903", "consecutive", "patients", "treated", "with", "PTCA", "in", "our", "institution", ".", "Of", "the", "104", "patients", "46", "(", "44", "%", ")", "were", "treated", "for", "unstable", "angina", "(", "CCS", "IV", ")", ".", "Abciximab", "was", "administered", "in", "bail", "-", "out", "situations", "in", "a", "dosage", "of", "0.25mg", "/", "kg", "given", "as", "a", "bolus", ",", "which", "was", "followed", "by", "an", "intravenous", "infusion", "of", "10µg", "/", "min", "over", "12", "hours", ".", "Repeat", "PTCA", "was", "performed", "shortly", "after", "the", "administration", "of", "the", "abciximab", "bolus", ".", "After", "the", "procedure", ",", "the", "sheathe", "was", "left", "in", "place", "and", "control", "angiography", "was", "carried", "out", "24", "h", "later", ".", "Results", ":", "In", "100", "of", "the", "104", "patients", "TIMI", "flow", "III", "could", "be", "restored", "by", "abciximab", "therapy", "and", "RePTCA", ".", "In", "4", "patients", "an", "additional", "stent", "implantation", "was", "necessary", "due", "to", "persistent", "flow", "limitation", ".", "One", "day", "post", "PTCA", ",", "early", "follow", "-", "up", "angiography", "demonstrated", "patency", "of", "all", "vessels", "except", "two", ".", "In", "-", "hospital", "events", "occurred", "in", "4", "patients", ".", "Three", "of", "these", "patients", "underwent", "emergency", "CABG", "due", "to", "subacute", "vessel", "closure", "a", "few", "hours", "after", "PTCA", "and", "died", "during", "or", "directly", "after", "surgery", ".", "Follow", "-", "up", "after", "one", "year", "included", "clinical", "status", "and", "control", "angiography", "of", "the", "target", "vessel", ".", "During", "long", "-", "term", "follow", "-", "up", ",", "MACE", "occured", "in", "15", "patients", "(", "2", "MI", ",", "8", "CABG", "and", "5", "RePTCA", ")", ".", "Conclusion", ":", "The", "results", "of", "this", "prospective", "trial", "demonstrate", "the", "efficacy", "of", "abciximab", "therapy", "in", "bail", "-", "out", "situations", "occurring", "during", "or", "early", "after", "PTCA", ".", "The", "use", "of", "abciximab", "in", "bail", "-", "out", "situations", "appears", "clinically", "beneficial", ".", "Further", "studies", "have", "to", "compare", "the", "efficacy", "of", "this", "approach", "with", "prophylactic", "abciximab", "treatment", "." ]	[ "umlsterm" ]
administration, GP IIb / IIIa, antagonists, myocardial infarction, death, PTCA, prospective study, abciximab, vessel, Methods, vessel, patients, PTCA, patients, unstable angina, Abciximab, intravenous infusion, PTCA, administration, abciximab, procedure, control, angiography, patients, abciximab, therapy, patients, stent, implantation, PTCA, angiography, vessels, patients, patients, emergency, vessel, PTCA, surgery, control, angiography, vessel, MACE, patients, abciximab, therapy, PTCA, use, abciximab, prophylactic, abciximab, treatment	ZfuerKardiologie.00890722.eng.abstr_task2	Sentence: The administration of GP IIb/IIIa antagonists has been shown to be effective in reducing myocardial infarction and cardial death when given before PTCA . This prospective study was performed to determine the efficacy of abciximab in a bail-out situation to manage threatened or acute vessel closure . Methods : Acute or threatened vessel closure was observed in 104 ( 5.5% ) out of 1903 consecutive patients treated with PTCA in our institution . Of the 104 patients 46 ( 44% ) were treated for unstable angina ( CCS IV ) . Abciximab was administered in bail-out situations in a dosage of 0.25mg/kg given as a bolus , which was followed by an intravenous infusion of 10µg/min over 12 hours . Repeat PTCA was performed shortly after the administration of the abciximab bolus . After the procedure , the sheathe was left in place and control angiography was carried out 24 h later . Results : In 100 of the 104 patients TIMI flow III could be restored by abciximab therapy and RePTCA . In 4 patients an additional stent implantation was necessary due to persistent flow limitation . One day post PTCA , early follow-up angiography demonstrated patency of all vessels except two . In-hospital events occurred in 4 patients . Three of these patients underwent emergency CABG due to subacute vessel closure a few hours after PTCA and died during or directly after surgery . Follow-up after one year included clinical status and control angiography of the target vessel . During long-term follow-up , MACE occured in 15 patients ( 2 MI , 8 CABG and 5 RePTCA ) . Conclusion : The results of this prospective trial demonstrate the efficacy of abciximab therapy in bail-out situations occurring during or early after PTCA . The use of abciximab in bail-out situations appears clinically beneficial . Further studies have to compare the efficacy of this approach with prophylactic abciximab treatment . Instructions: please extract entity words from the input sentence	[ "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O" ]	The administration of GP IIb/IIIa antagonists has been shown to be effective in reducing myocardial infarction and cardial death when given before PTCA . This prospective study was performed to determine the efficacy of abciximab in a bail-out situation to manage threatened or acute vessel closure . Methods : Acute or threatened vessel closure was observed in 104 ( 5.5% ) out of 1903 consecutive patients treated with PTCA in our institution . Of the 104 patients 46 ( 44% ) were treated for unstable angina ( CCS IV ) . Abciximab was administered in bail-out situations in a dosage of 0.25mg/kg given as a bolus , which was followed by an intravenous infusion of 10µg/min over 12 hours . Repeat PTCA was performed shortly after the administration of the abciximab bolus . After the procedure , the sheathe was left in place and control angiography was carried out 24 h later . Results : In 100 of the 104 patients TIMI flow III could be restored by abciximab therapy and RePTCA . In 4 patients an additional stent implantation was necessary due to persistent flow limitation . One day post PTCA , early follow-up angiography demonstrated patency of all vessels except two . In-hospital events occurred in 4 patients . Three of these patients underwent emergency CABG due to subacute vessel closure a few hours after PTCA and died during or directly after surgery . Follow-up after one year included clinical status and control angiography of the target vessel . During long-term follow-up , MACE occured in 15 patients ( 2 MI , 8 CABG and 5 RePTCA ) . Conclusion : The results of this prospective trial demonstrate the efficacy of abciximab therapy in bail-out situations occurring during or early after PTCA . The use of abciximab in bail-out situations appears clinically beneficial . Further studies have to compare the efficacy of this approach with prophylactic abciximab treatment .	[ "The", "administration", "of", "GP", "IIb", "/", "IIIa", "antagonists", "has", "been", "shown", "to", "be", "effective", "in", "reducing", "myocardial", "infarction", "and", "cardial", "death", "when", "given", "before", "PTCA", ".", "This", "prospective", "study", "was", "performed", "to", "determine", "the", "efficacy", "of", "abciximab", "in", "a", "bail", "-", "out", "situation", "to", "manage", "threatened", "or", "acute", "vessel", "closure", ".", "Methods", ":", "Acute", "or", "threatened", "vessel", "closure", "was", "observed", "in", "104", "(", "5.5", "%", ")", "out", "of", "1903", "consecutive", "patients", "treated", "with", "PTCA", "in", "our", "institution", ".", "Of", "the", "104", "patients", "46", "(", "44", "%", ")", "were", "treated", "for", "unstable", "angina", "(", "CCS", "IV", ")", ".", "Abciximab", "was", "administered", "in", "bail", "-", "out", "situations", "in", "a", "dosage", "of", "0.25mg", "/", "kg", "given", "as", "a", "bolus", ",", "which", "was", "followed", "by", "an", "intravenous", "infusion", "of", "10µg", "/", "min", "over", "12", "hours", ".", "Repeat", "PTCA", "was", "performed", "shortly", "after", "the", "administration", "of", "the", "abciximab", "bolus", ".", "After", "the", "procedure", ",", "the", "sheathe", "was", "left", "in", "place", "and", "control", "angiography", "was", "carried", "out", "24", "h", "later", ".", "Results", ":", "In", "100", "of", "the", "104", "patients", "TIMI", "flow", "III", "could", "be", "restored", "by", "abciximab", "therapy", "and", "RePTCA", ".", "In", "4", "patients", "an", "additional", "stent", "implantation", "was", "necessary", "due", "to", "persistent", "flow", "limitation", ".", "One", "day", "post", "PTCA", ",", "early", "follow", "-", "up", "angiography", "demonstrated", "patency", "of", "all", "vessels", "except", "two", ".", "In", "-", "hospital", "events", "occurred", "in", "4", "patients", ".", "Three", "of", "these", "patients", "underwent", "emergency", "CABG", "due", "to", "subacute", "vessel", "closure", "a", "few", "hours", "after", "PTCA", "and", "died", "during", "or", "directly", "after", "surgery", ".", "Follow", "-", "up", "after", "one", "year", "included", "clinical", "status", "and", "control", "angiography", "of", "the", "target", "vessel", ".", "During", "long", "-", "term", "follow", "-", "up", ",", "MACE", "occured", "in", "15", "patients", "(", "2", "MI", ",", "8", "CABG", "and", "5", "RePTCA", ")", ".", "Conclusion", ":", "The", "results", "of", "this", "prospective", "trial", "demonstrate", "the", "efficacy", "of", "abciximab", "therapy", "in", "bail", "-", "out", "situations", "occurring", "during", "or", "early", "after", "PTCA", ".", "The", "use", "of", "abciximab", "in", "bail", "-", "out", "situations", "appears", "clinically", "beneficial", ".", "Further", "studies", "have", "to", "compare", "the", "efficacy", "of", "this", "approach", "with", "prophylactic", "abciximab", "treatment", "." ]	[ "umlsterm" ]
epidermal growth factor receptor is a Intervention_Pharmacological, tumor differentiation is a Outcome_Physical, radiotherapy is a Intervention_Physical, squamous cell carcinomas of the head and neck is a Participant_Condition, disease specific survival is a Outcome_Mortality, squamous cell carcinomas of the head and neck ( HNSCC is a Participant_Condition, Eight hundred and three patients is a Participant_Sample-size, prominent separation of response is a Outcome_Other, expression of EGFr is a Outcome_Physical	21199_task0	Sentence: The influence of epidermal growth factor receptor and tumor differentiation on the response to accelerated radiotherapy of squamous cell carcinomas of the head and neck in the randomized DAHANCA 6 and 7 study . BACKGROUND AND PURPOSE Reduction of the overall treatment time of radiotherapy has increased locoregional control and disease specific survival in squamous cell carcinomas of the head and neck ( HNSCC ) , but the response is heterogeneous . EGFr is often overexpressed in HNSCC and has been related to the repopulation taking place during radiotherapy . The aim of the current study was to address the influence of EGFr and histopathological differentiation when the overall treatment time of radiotherapy was moderately reduced . PATIENTS AND METHODS Eight hundred and three patients with representative pretreatment tissue samples from the randomized DAHANCA 6 and 7 study of 5 vs. 6 fx/wk of radiotherapy . EGFr was visualized using immunohistochemistry and separated into high and low expression before correlation with clinical data . RESULTS Tumors with high EGFr ( 84 % ) responded better to moderately accelerated radiotherapy , than carcinomas with low EGFr , using locoregional control as endpoint and a similar pattern was seen , stratifying by well/moderate vs. poor tumor differentiation . Therefore , a combined parameter was constructed showing a more prominent separation of response : tumors with high EGFr and well/moderate differentiation did benefit from moderate acceleration of treatment regarding locoregional control , HR 0.54 ( 0.37-0.78 ) , whereas such an effect was not seen in tumors with low EGFr and/or poor differentiation , HR 0.8 ( 0.51-1.25 ) . These results reflected the disease specific survival as well and were confirmed in multivariable analyses . CONCLUSIONS Moderately accelerated fractionation is superior to conventional treatment in HNSCC but the response is heterogeneous and may be predicted by high expression of EGFr and well/moderate tumor differentiation . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Intervention_Physical, Participant_Condition, Outcome_Mortality, Outcome_Physical, Participant_Sample-size, Outcome_Other	[ "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "B-Intervention_Physical", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O" ]	The influence of epidermal growth factor receptor and tumor differentiation on the response to accelerated radiotherapy of squamous cell carcinomas of the head and neck in the randomized DAHANCA 6 and 7 study . BACKGROUND AND PURPOSE Reduction of the overall treatment time of radiotherapy has increased locoregional control and disease specific survival in squamous cell carcinomas of the head and neck ( HNSCC ) , but the response is heterogeneous . EGFr is often overexpressed in HNSCC and has been related to the repopulation taking place during radiotherapy . The aim of the current study was to address the influence of EGFr and histopathological differentiation when the overall treatment time of radiotherapy was moderately reduced . PATIENTS AND METHODS Eight hundred and three patients with representative pretreatment tissue samples from the randomized DAHANCA 6 and 7 study of 5 vs. 6 fx/wk of radiotherapy . EGFr was visualized using immunohistochemistry and separated into high and low expression before correlation with clinical data . RESULTS Tumors with high EGFr ( 84 % ) responded better to moderately accelerated radiotherapy , than carcinomas with low EGFr , using locoregional control as endpoint and a similar pattern was seen , stratifying by well/moderate vs. poor tumor differentiation . Therefore , a combined parameter was constructed showing a more prominent separation of response : tumors with high EGFr and well/moderate differentiation did benefit from moderate acceleration of treatment regarding locoregional control , HR 0.54 ( 0.37-0.78 ) , whereas such an effect was not seen in tumors with low EGFr and/or poor differentiation , HR 0.8 ( 0.51-1.25 ) . These results reflected the disease specific survival as well and were confirmed in multivariable analyses . CONCLUSIONS Moderately accelerated fractionation is superior to conventional treatment in HNSCC but the response is heterogeneous and may be predicted by high expression of EGFr and well/moderate tumor differentiation .	[ "The", "influence", "of", "epidermal", "growth", "factor", "receptor", "and", "tumor", "differentiation", "on", "the", "response", "to", "accelerated", "radiotherapy", "of", "squamous", "cell", "carcinomas", "of", "the", "head", "and", "neck", "in", "the", "randomized", "DAHANCA", "6", "and", "7", "study", ".", "BACKGROUND", "AND", "PURPOSE", "Reduction", "of", "the", "overall", "treatment", "time", "of", "radiotherapy", "has", "increased", "locoregional", "control", "and", "disease", "specific", "survival", "in", "squamous", "cell", "carcinomas", "of", "the", "head", "and", "neck", "(", "HNSCC", ")", ",", "but", "the", "response", "is", "heterogeneous", ".", "EGFr", "is", "often", "overexpressed", "in", "HNSCC", "and", "has", "been", "related", "to", "the", "repopulation", "taking", "place", "during", "radiotherapy", ".", "The", "aim", "of", "the", "current", "study", "was", "to", "address", "the", "influence", "of", "EGFr", "and", "histopathological", "differentiation", "when", "the", "overall", "treatment", "time", "of", "radiotherapy", "was", "moderately", "reduced", ".", "PATIENTS", "AND", "METHODS", "Eight", "hundred", "and", "three", "patients", "with", "representative", "pretreatment", "tissue", "samples", "from", "the", "randomized", "DAHANCA", "6", "and", "7", "study", "of", "5", "vs", ".", "6", "fx", "/", "wk", "of", "radiotherapy", ".", "EGFr", "was", "visualized", "using", "immunohistochemistry", "and", "separated", "into", "high", "and", "low", "expression", "before", "correlation", "with", "clinical", "data", ".", "RESULTS", "Tumors", "with", "high", "EGFr", "(", "84", "%", ")", "responded", "better", "to", "moderately", "accelerated", "radiotherapy", ",", "than", "carcinomas", "with", "low", "EGFr", ",", "using", "locoregional", "control", "as", "endpoint", "and", "a", "similar", "pattern", "was", "seen", ",", "stratifying", "by", "well", "/", "moderate", "vs", ".", "poor", "tumor", "differentiation", ".", "Therefore", ",", "a", "combined", "parameter", "was", "constructed", "showing", "a", "more", "prominent", "separation", "of", "response", ":", "tumors", "with", "high", "EGFr", "and", "well", "/", "moderate", "differentiation", "did", "benefit", "from", "moderate", "acceleration", "of", "treatment", "regarding", "locoregional", "control", ",", "HR", "0.54", "(", "0.37", "-", "0.78", ")", ",", "whereas", "such", "an", "effect", "was", "not", "seen", "in", "tumors", "with", "low", "EGFr", "and", "/", "or", "poor", "differentiation", ",", "HR", "0.8", "(", "0.51", "-", "1.25", ")", ".", "These", "results", "reflected", "the", "disease", "specific", "survival", "as", "well", "and", "were", "confirmed", "in", "multivariable", "analyses", ".", "CONCLUSIONS", "Moderately", "accelerated", "fractionation", "is", "superior", "to", "conventional", "treatment", "in", "HNSCC", "but", "the", "response", "is", "heterogeneous", "and", "may", "be", "predicted", "by", "high", "expression", "of", "EGFr", "and", "well", "/", "moderate", "tumor", "differentiation", "." ]	[ "Participant_Condition", "Intervention_Pharmacological", "Outcome_Other", "Participant_Sample-size", "Outcome_Mortality", "Outcome_Physical", "Intervention_Physical" ]
epidermal growth factor receptor is a Intervention_Pharmacological, tumor differentiation is a Outcome_Physical, radiotherapy is a Intervention_Physical, squamous cell carcinomas of the head and neck is a Participant_Condition, disease specific survival is a Outcome_Mortality, squamous cell carcinomas of the head and neck ( HNSCC is a Participant_Condition, Eight hundred and three patients is a Participant_Sample-size, prominent separation of response is a Outcome_Other, expression of EGFr is a Outcome_Physical	21199_task1	Sentence: The influence of epidermal growth factor receptor and tumor differentiation on the response to accelerated radiotherapy of squamous cell carcinomas of the head and neck in the randomized DAHANCA 6 and 7 study . BACKGROUND AND PURPOSE Reduction of the overall treatment time of radiotherapy has increased locoregional control and disease specific survival in squamous cell carcinomas of the head and neck ( HNSCC ) , but the response is heterogeneous . EGFr is often overexpressed in HNSCC and has been related to the repopulation taking place during radiotherapy . The aim of the current study was to address the influence of EGFr and histopathological differentiation when the overall treatment time of radiotherapy was moderately reduced . PATIENTS AND METHODS Eight hundred and three patients with representative pretreatment tissue samples from the randomized DAHANCA 6 and 7 study of 5 vs. 6 fx/wk of radiotherapy . EGFr was visualized using immunohistochemistry and separated into high and low expression before correlation with clinical data . RESULTS Tumors with high EGFr ( 84 % ) responded better to moderately accelerated radiotherapy , than carcinomas with low EGFr , using locoregional control as endpoint and a similar pattern was seen , stratifying by well/moderate vs. poor tumor differentiation . Therefore , a combined parameter was constructed showing a more prominent separation of response : tumors with high EGFr and well/moderate differentiation did benefit from moderate acceleration of treatment regarding locoregional control , HR 0.54 ( 0.37-0.78 ) , whereas such an effect was not seen in tumors with low EGFr and/or poor differentiation , HR 0.8 ( 0.51-1.25 ) . These results reflected the disease specific survival as well and were confirmed in multivariable analyses . CONCLUSIONS Moderately accelerated fractionation is superior to conventional treatment in HNSCC but the response is heterogeneous and may be predicted by high expression of EGFr and well/moderate tumor differentiation . Instructions: please typing these entity words according to sentence: epidermal growth factor receptor, tumor differentiation, radiotherapy, squamous cell carcinomas of the head and neck, disease specific survival, squamous cell carcinomas of the head and neck ( HNSCC, Eight hundred and three patients, prominent separation of response, expression of EGFr Options: Intervention_Pharmacological, Intervention_Physical, Participant_Condition, Outcome_Mortality, Outcome_Physical, Participant_Sample-size, Outcome_Other	[ "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "B-Intervention_Physical", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O" ]	The influence of epidermal growth factor receptor and tumor differentiation on the response to accelerated radiotherapy of squamous cell carcinomas of the head and neck in the randomized DAHANCA 6 and 7 study . BACKGROUND AND PURPOSE Reduction of the overall treatment time of radiotherapy has increased locoregional control and disease specific survival in squamous cell carcinomas of the head and neck ( HNSCC ) , but the response is heterogeneous . EGFr is often overexpressed in HNSCC and has been related to the repopulation taking place during radiotherapy . The aim of the current study was to address the influence of EGFr and histopathological differentiation when the overall treatment time of radiotherapy was moderately reduced . PATIENTS AND METHODS Eight hundred and three patients with representative pretreatment tissue samples from the randomized DAHANCA 6 and 7 study of 5 vs. 6 fx/wk of radiotherapy . EGFr was visualized using immunohistochemistry and separated into high and low expression before correlation with clinical data . RESULTS Tumors with high EGFr ( 84 % ) responded better to moderately accelerated radiotherapy , than carcinomas with low EGFr , using locoregional control as endpoint and a similar pattern was seen , stratifying by well/moderate vs. poor tumor differentiation . Therefore , a combined parameter was constructed showing a more prominent separation of response : tumors with high EGFr and well/moderate differentiation did benefit from moderate acceleration of treatment regarding locoregional control , HR 0.54 ( 0.37-0.78 ) , whereas such an effect was not seen in tumors with low EGFr and/or poor differentiation , HR 0.8 ( 0.51-1.25 ) . These results reflected the disease specific survival as well and were confirmed in multivariable analyses . CONCLUSIONS Moderately accelerated fractionation is superior to conventional treatment in HNSCC but the response is heterogeneous and may be predicted by high expression of EGFr and well/moderate tumor differentiation .	[ "The", "influence", "of", "epidermal", "growth", "factor", "receptor", "and", "tumor", "differentiation", "on", "the", "response", "to", "accelerated", "radiotherapy", "of", "squamous", "cell", "carcinomas", "of", "the", "head", "and", "neck", "in", "the", "randomized", "DAHANCA", "6", "and", "7", "study", ".", "BACKGROUND", "AND", "PURPOSE", "Reduction", "of", "the", "overall", "treatment", "time", "of", "radiotherapy", "has", "increased", "locoregional", "control", "and", "disease", "specific", "survival", "in", "squamous", "cell", "carcinomas", "of", "the", "head", "and", "neck", "(", "HNSCC", ")", ",", "but", "the", "response", "is", "heterogeneous", ".", "EGFr", "is", "often", "overexpressed", "in", "HNSCC", "and", "has", "been", "related", "to", "the", "repopulation", "taking", "place", "during", "radiotherapy", ".", "The", "aim", "of", "the", "current", "study", "was", "to", "address", "the", "influence", "of", "EGFr", "and", "histopathological", "differentiation", "when", "the", "overall", "treatment", "time", "of", "radiotherapy", "was", "moderately", "reduced", ".", "PATIENTS", "AND", "METHODS", "Eight", "hundred", "and", "three", "patients", "with", "representative", "pretreatment", "tissue", "samples", "from", "the", "randomized", "DAHANCA", "6", "and", "7", "study", "of", "5", "vs", ".", "6", "fx", "/", "wk", "of", "radiotherapy", ".", "EGFr", "was", "visualized", "using", "immunohistochemistry", "and", "separated", "into", "high", "and", "low", "expression", "before", "correlation", "with", "clinical", "data", ".", "RESULTS", "Tumors", "with", "high", "EGFr", "(", "84", "%", ")", "responded", "better", "to", "moderately", "accelerated", "radiotherapy", ",", "than", "carcinomas", "with", "low", "EGFr", ",", "using", "locoregional", "control", "as", "endpoint", "and", "a", "similar", "pattern", "was", "seen", ",", "stratifying", "by", "well", "/", "moderate", "vs", ".", "poor", "tumor", "differentiation", ".", "Therefore", ",", "a", "combined", "parameter", "was", "constructed", "showing", "a", "more", "prominent", "separation", "of", "response", ":", "tumors", "with", "high", "EGFr", "and", "well", "/", "moderate", "differentiation", "did", "benefit", "from", "moderate", "acceleration", "of", "treatment", "regarding", "locoregional", "control", ",", "HR", "0.54", "(", "0.37", "-", "0.78", ")", ",", "whereas", "such", "an", "effect", "was", "not", "seen", "in", "tumors", "with", "low", "EGFr", "and", "/", "or", "poor", "differentiation", ",", "HR", "0.8", "(", "0.51", "-", "1.25", ")", ".", "These", "results", "reflected", "the", "disease", "specific", "survival", "as", "well", "and", "were", "confirmed", "in", "multivariable", "analyses", ".", "CONCLUSIONS", "Moderately", "accelerated", "fractionation", "is", "superior", "to", "conventional", "treatment", "in", "HNSCC", "but", "the", "response", "is", "heterogeneous", "and", "may", "be", "predicted", "by", "high", "expression", "of", "EGFr", "and", "well", "/", "moderate", "tumor", "differentiation", "." ]	[ "Participant_Condition", "Intervention_Pharmacological", "Outcome_Other", "Participant_Sample-size", "Outcome_Mortality", "Outcome_Physical", "Intervention_Physical" ]
epidermal growth factor receptor, tumor differentiation, radiotherapy, squamous cell carcinomas of the head and neck, disease specific survival, squamous cell carcinomas of the head and neck ( HNSCC, Eight hundred and three patients, prominent separation of response, expression of EGFr	21199_task2	Sentence: The influence of epidermal growth factor receptor and tumor differentiation on the response to accelerated radiotherapy of squamous cell carcinomas of the head and neck in the randomized DAHANCA 6 and 7 study . BACKGROUND AND PURPOSE Reduction of the overall treatment time of radiotherapy has increased locoregional control and disease specific survival in squamous cell carcinomas of the head and neck ( HNSCC ) , but the response is heterogeneous . EGFr is often overexpressed in HNSCC and has been related to the repopulation taking place during radiotherapy . The aim of the current study was to address the influence of EGFr and histopathological differentiation when the overall treatment time of radiotherapy was moderately reduced . PATIENTS AND METHODS Eight hundred and three patients with representative pretreatment tissue samples from the randomized DAHANCA 6 and 7 study of 5 vs. 6 fx/wk of radiotherapy . EGFr was visualized using immunohistochemistry and separated into high and low expression before correlation with clinical data . RESULTS Tumors with high EGFr ( 84 % ) responded better to moderately accelerated radiotherapy , than carcinomas with low EGFr , using locoregional control as endpoint and a similar pattern was seen , stratifying by well/moderate vs. poor tumor differentiation . Therefore , a combined parameter was constructed showing a more prominent separation of response : tumors with high EGFr and well/moderate differentiation did benefit from moderate acceleration of treatment regarding locoregional control , HR 0.54 ( 0.37-0.78 ) , whereas such an effect was not seen in tumors with low EGFr and/or poor differentiation , HR 0.8 ( 0.51-1.25 ) . These results reflected the disease specific survival as well and were confirmed in multivariable analyses . CONCLUSIONS Moderately accelerated fractionation is superior to conventional treatment in HNSCC but the response is heterogeneous and may be predicted by high expression of EGFr and well/moderate tumor differentiation . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "B-Intervention_Physical", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O" ]	The influence of epidermal growth factor receptor and tumor differentiation on the response to accelerated radiotherapy of squamous cell carcinomas of the head and neck in the randomized DAHANCA 6 and 7 study . BACKGROUND AND PURPOSE Reduction of the overall treatment time of radiotherapy has increased locoregional control and disease specific survival in squamous cell carcinomas of the head and neck ( HNSCC ) , but the response is heterogeneous . EGFr is often overexpressed in HNSCC and has been related to the repopulation taking place during radiotherapy . The aim of the current study was to address the influence of EGFr and histopathological differentiation when the overall treatment time of radiotherapy was moderately reduced . PATIENTS AND METHODS Eight hundred and three patients with representative pretreatment tissue samples from the randomized DAHANCA 6 and 7 study of 5 vs. 6 fx/wk of radiotherapy . EGFr was visualized using immunohistochemistry and separated into high and low expression before correlation with clinical data . RESULTS Tumors with high EGFr ( 84 % ) responded better to moderately accelerated radiotherapy , than carcinomas with low EGFr , using locoregional control as endpoint and a similar pattern was seen , stratifying by well/moderate vs. poor tumor differentiation . Therefore , a combined parameter was constructed showing a more prominent separation of response : tumors with high EGFr and well/moderate differentiation did benefit from moderate acceleration of treatment regarding locoregional control , HR 0.54 ( 0.37-0.78 ) , whereas such an effect was not seen in tumors with low EGFr and/or poor differentiation , HR 0.8 ( 0.51-1.25 ) . These results reflected the disease specific survival as well and were confirmed in multivariable analyses . CONCLUSIONS Moderately accelerated fractionation is superior to conventional treatment in HNSCC but the response is heterogeneous and may be predicted by high expression of EGFr and well/moderate tumor differentiation .	[ "The", "influence", "of", "epidermal", "growth", "factor", "receptor", "and", "tumor", "differentiation", "on", "the", "response", "to", "accelerated", "radiotherapy", "of", "squamous", "cell", "carcinomas", "of", "the", "head", "and", "neck", "in", "the", "randomized", "DAHANCA", "6", "and", "7", "study", ".", "BACKGROUND", "AND", "PURPOSE", "Reduction", "of", "the", "overall", "treatment", "time", "of", "radiotherapy", "has", "increased", "locoregional", "control", "and", "disease", "specific", "survival", "in", "squamous", "cell", "carcinomas", "of", "the", "head", "and", "neck", "(", "HNSCC", ")", ",", "but", "the", "response", "is", "heterogeneous", ".", "EGFr", "is", "often", "overexpressed", "in", "HNSCC", "and", "has", "been", "related", "to", "the", "repopulation", "taking", "place", "during", "radiotherapy", ".", "The", "aim", "of", "the", "current", "study", "was", "to", "address", "the", "influence", "of", "EGFr", "and", "histopathological", "differentiation", "when", "the", "overall", "treatment", "time", "of", "radiotherapy", "was", "moderately", "reduced", ".", "PATIENTS", "AND", "METHODS", "Eight", "hundred", "and", "three", "patients", "with", "representative", "pretreatment", "tissue", "samples", "from", "the", "randomized", "DAHANCA", "6", "and", "7", "study", "of", "5", "vs", ".", "6", "fx", "/", "wk", "of", "radiotherapy", ".", "EGFr", "was", "visualized", "using", "immunohistochemistry", "and", "separated", "into", "high", "and", "low", "expression", "before", "correlation", "with", "clinical", "data", ".", "RESULTS", "Tumors", "with", "high", "EGFr", "(", "84", "%", ")", "responded", "better", "to", "moderately", "accelerated", "radiotherapy", ",", "than", "carcinomas", "with", "low", "EGFr", ",", "using", "locoregional", "control", "as", "endpoint", "and", "a", "similar", "pattern", "was", "seen", ",", "stratifying", "by", "well", "/", "moderate", "vs", ".", "poor", "tumor", "differentiation", ".", "Therefore", ",", "a", "combined", "parameter", "was", "constructed", "showing", "a", "more", "prominent", "separation", "of", "response", ":", "tumors", "with", "high", "EGFr", "and", "well", "/", "moderate", "differentiation", "did", "benefit", "from", "moderate", "acceleration", "of", "treatment", "regarding", "locoregional", "control", ",", "HR", "0.54", "(", "0.37", "-", "0.78", ")", ",", "whereas", "such", "an", "effect", "was", "not", "seen", "in", "tumors", "with", "low", "EGFr", "and", "/", "or", "poor", "differentiation", ",", "HR", "0.8", "(", "0.51", "-", "1.25", ")", ".", "These", "results", "reflected", "the", "disease", "specific", "survival", "as", "well", "and", "were", "confirmed", "in", "multivariable", "analyses", ".", "CONCLUSIONS", "Moderately", "accelerated", "fractionation", "is", "superior", "to", "conventional", "treatment", "in", "HNSCC", "but", "the", "response", "is", "heterogeneous", "and", "may", "be", "predicted", "by", "high", "expression", "of", "EGFr", "and", "well", "/", "moderate", "tumor", "differentiation", "." ]	[ "Participant_Condition", "Intervention_Pharmacological", "Outcome_Other", "Participant_Sample-size", "Outcome_Mortality", "Outcome_Physical", "Intervention_Physical" ]
Renal replacement therapy is an umlsterm, treatment is an umlsterm, acute renal failure is an umlsterm, renal replacement therapy is an umlsterm, intensive care unit is an umlsterm, patients is an umlsterm, renal replacement therapy is an umlsterm	IntensiveMedizin.70340040.eng.abstr_task0	Sentence: Renal replacement therapy is of primary importance for the treatment of acute renal failure associated with multiple system organ failure . If renal replacement therapy is not available in the intensive care unit , patients must be transferred to specialized units , where renal replacement therapy can be applied . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O" ]	Renal replacement therapy is of primary importance for the treatment of acute renal failure associated with multiple system organ failure . If renal replacement therapy is not available in the intensive care unit , patients must be transferred to specialized units , where renal replacement therapy can be applied .	[ "Renal", "replacement", "therapy", "is", "of", "primary", "importance", "for", "the", "treatment", "of", "acute", "renal", "failure", "associated", "with", "multiple", "system", "organ", "failure", ".", "If", "renal", "replacement", "therapy", "is", "not", "available", "in", "the", "intensive", "care", "unit", ",", "patients", "must", "be", "transferred", "to", "specialized", "units", ",", "where", "renal", "replacement", "therapy", "can", "be", "applied", "." ]	[ "umlsterm" ]
Renal replacement therapy is an umlsterm, treatment is an umlsterm, acute renal failure is an umlsterm, renal replacement therapy is an umlsterm, intensive care unit is an umlsterm, patients is an umlsterm, renal replacement therapy is an umlsterm	IntensiveMedizin.70340040.eng.abstr_task1	Sentence: Renal replacement therapy is of primary importance for the treatment of acute renal failure associated with multiple system organ failure . If renal replacement therapy is not available in the intensive care unit , patients must be transferred to specialized units , where renal replacement therapy can be applied . Instructions: please typing these entity words according to sentence: Renal replacement therapy, treatment, acute renal failure, renal replacement therapy, intensive care unit, patients, renal replacement therapy Options: umlsterm	[ "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O" ]	Renal replacement therapy is of primary importance for the treatment of acute renal failure associated with multiple system organ failure . If renal replacement therapy is not available in the intensive care unit , patients must be transferred to specialized units , where renal replacement therapy can be applied .	[ "Renal", "replacement", "therapy", "is", "of", "primary", "importance", "for", "the", "treatment", "of", "acute", "renal", "failure", "associated", "with", "multiple", "system", "organ", "failure", ".", "If", "renal", "replacement", "therapy", "is", "not", "available", "in", "the", "intensive", "care", "unit", ",", "patients", "must", "be", "transferred", "to", "specialized", "units", ",", "where", "renal", "replacement", "therapy", "can", "be", "applied", "." ]	[ "umlsterm" ]
Renal replacement therapy, treatment, acute renal failure, renal replacement therapy, intensive care unit, patients, renal replacement therapy	IntensiveMedizin.70340040.eng.abstr_task2	Sentence: Renal replacement therapy is of primary importance for the treatment of acute renal failure associated with multiple system organ failure . If renal replacement therapy is not available in the intensive care unit , patients must be transferred to specialized units , where renal replacement therapy can be applied . Instructions: please extract entity words from the input sentence	[ "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O" ]	Renal replacement therapy is of primary importance for the treatment of acute renal failure associated with multiple system organ failure . If renal replacement therapy is not available in the intensive care unit , patients must be transferred to specialized units , where renal replacement therapy can be applied .	[ "Renal", "replacement", "therapy", "is", "of", "primary", "importance", "for", "the", "treatment", "of", "acute", "renal", "failure", "associated", "with", "multiple", "system", "organ", "failure", ".", "If", "renal", "replacement", "therapy", "is", "not", "available", "in", "the", "intensive", "care", "unit", ",", "patients", "must", "be", "transferred", "to", "specialized", "units", ",", "where", "renal", "replacement", "therapy", "can", "be", "applied", "." ]	[ "umlsterm" ]
paper is an umlsterm, contrast is an umlsterm, injection is an umlsterm, techniques is an umlsterm, vessel is an umlsterm, contrast is an umlsterm, angiography is an umlsterm, vessel is an umlsterm, contrast is an umlsterm, contrast is an umlsterm, injection is an umlsterm, injection is an umlsterm, techniques is an umlsterm, standard is an umlsterm, technique is an umlsterm, contrast is an umlsterm, patients is an umlsterm, adjustment is an umlsterm, individual differences is an umlsterm, use is an umlsterm, contrast agent is an umlsterm, patient is an umlsterm, mathematical models is an umlsterm, contrast is an umlsterm, patient is an umlsterm, contrast is an umlsterm, techniques is an umlsterm	DerRadiologe.90390093.eng.abstr_task0	Sentence: This paper compares different contrast injection techniques for optimizing vessel contrast in CT angiography ( CTA ) . The optimal vessel contrast shall be defined as constant strong enhancement confined to the scanning interval . This " plateau enhancement " guarantees high-quality CTA images and should therefore be approximated during every CTA examination by an appropriate contrast injection protocol . With well-established injection techniques such as the standard bolus technique ( constant uniphasic contrast bolus for all patients ) or adjustment of the scan delay , considerable individual differences in the arterial enhancement can be observed , and a nondiagnostic examination or an inefficient use of contrast agent might be the result in a particular patient . Therefore , two sophisticated mathematical models have recently been developed for analyzing the individual enhancement characteristics . These models can be exploited to predict the arterial enhancement for any given intravenous contrast bolus in any patient and to optimize the contrast bolus in order to approach the ideal " plateau enhancement " . These techniques have to prove their effectiveness in larger clinical series . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	This paper compares different contrast injection techniques for optimizing vessel contrast in CT angiography ( CTA ) . The optimal vessel contrast shall be defined as constant strong enhancement confined to the scanning interval . This " plateau enhancement " guarantees high-quality CTA images and should therefore be approximated during every CTA examination by an appropriate contrast injection protocol . With well-established injection techniques such as the standard bolus technique ( constant uniphasic contrast bolus for all patients ) or adjustment of the scan delay , considerable individual differences in the arterial enhancement can be observed , and a nondiagnostic examination or an inefficient use of contrast agent might be the result in a particular patient . Therefore , two sophisticated mathematical models have recently been developed for analyzing the individual enhancement characteristics . These models can be exploited to predict the arterial enhancement for any given intravenous contrast bolus in any patient and to optimize the contrast bolus in order to approach the ideal " plateau enhancement " . These techniques have to prove their effectiveness in larger clinical series .	[ "This", "paper", "compares", "different", "contrast", "injection", "techniques", "for", "optimizing", "vessel", "contrast", "in", "CT", "angiography", "(", "CTA", ")", ".", "The", "optimal", "vessel", "contrast", "shall", "be", "defined", "as", "constant", "strong", "enhancement", "confined", "to", "the", "scanning", "interval", ".", "This", "\"", "plateau", "enhancement", "\"", "guarantees", "high", "-", "quality", "CTA", "images", "and", "should", "therefore", "be", "approximated", "during", "every", "CTA", "examination", "by", "an", "appropriate", "contrast", "injection", "protocol", ".", "With", "well", "-", "established", "injection", "techniques", "such", "as", "the", "standard", "bolus", "technique", "(", "constant", "uniphasic", "contrast", "bolus", "for", "all", "patients", ")", "or", "adjustment", "of", "the", "scan", "delay", ",", "considerable", "individual", "differences", "in", "the", "arterial", "enhancement", "can", "be", "observed", ",", "and", "a", "nondiagnostic", "examination", "or", "an", "inefficient", "use", "of", "contrast", "agent", "might", "be", "the", "result", "in", "a", "particular", "patient", ".", "Therefore", ",", "two", "sophisticated", "mathematical", "models", "have", "recently", "been", "developed", "for", "analyzing", "the", "individual", "enhancement", "characteristics", ".", "These", "models", "can", "be", "exploited", "to", "predict", "the", "arterial", "enhancement", "for", "any", "given", "intravenous", "contrast", "bolus", "in", "any", "patient", "and", "to", "optimize", "the", "contrast", "bolus", "in", "order", "to", "approach", "the", "ideal", "\"", "plateau", "enhancement", "\"", ".", "These", "techniques", "have", "to", "prove", "their", "effectiveness", "in", "larger", "clinical", "series", "." ]	[ "umlsterm" ]
paper is an umlsterm, contrast is an umlsterm, injection is an umlsterm, techniques is an umlsterm, vessel is an umlsterm, contrast is an umlsterm, angiography is an umlsterm, vessel is an umlsterm, contrast is an umlsterm, contrast is an umlsterm, injection is an umlsterm, injection is an umlsterm, techniques is an umlsterm, standard is an umlsterm, technique is an umlsterm, contrast is an umlsterm, patients is an umlsterm, adjustment is an umlsterm, individual differences is an umlsterm, use is an umlsterm, contrast agent is an umlsterm, patient is an umlsterm, mathematical models is an umlsterm, contrast is an umlsterm, patient is an umlsterm, contrast is an umlsterm, techniques is an umlsterm	DerRadiologe.90390093.eng.abstr_task1	Sentence: This paper compares different contrast injection techniques for optimizing vessel contrast in CT angiography ( CTA ) . The optimal vessel contrast shall be defined as constant strong enhancement confined to the scanning interval . This " plateau enhancement " guarantees high-quality CTA images and should therefore be approximated during every CTA examination by an appropriate contrast injection protocol . With well-established injection techniques such as the standard bolus technique ( constant uniphasic contrast bolus for all patients ) or adjustment of the scan delay , considerable individual differences in the arterial enhancement can be observed , and a nondiagnostic examination or an inefficient use of contrast agent might be the result in a particular patient . Therefore , two sophisticated mathematical models have recently been developed for analyzing the individual enhancement characteristics . These models can be exploited to predict the arterial enhancement for any given intravenous contrast bolus in any patient and to optimize the contrast bolus in order to approach the ideal " plateau enhancement " . These techniques have to prove their effectiveness in larger clinical series . Instructions: please typing these entity words according to sentence: paper, contrast, injection, techniques, vessel, contrast, angiography, vessel, contrast, contrast, injection, injection, techniques, standard, technique, contrast, patients, adjustment, individual differences, use, contrast agent, patient, mathematical models, contrast, patient, contrast, techniques Options: umlsterm	[ "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	This paper compares different contrast injection techniques for optimizing vessel contrast in CT angiography ( CTA ) . The optimal vessel contrast shall be defined as constant strong enhancement confined to the scanning interval . This " plateau enhancement " guarantees high-quality CTA images and should therefore be approximated during every CTA examination by an appropriate contrast injection protocol . With well-established injection techniques such as the standard bolus technique ( constant uniphasic contrast bolus for all patients ) or adjustment of the scan delay , considerable individual differences in the arterial enhancement can be observed , and a nondiagnostic examination or an inefficient use of contrast agent might be the result in a particular patient . Therefore , two sophisticated mathematical models have recently been developed for analyzing the individual enhancement characteristics . These models can be exploited to predict the arterial enhancement for any given intravenous contrast bolus in any patient and to optimize the contrast bolus in order to approach the ideal " plateau enhancement " . These techniques have to prove their effectiveness in larger clinical series .	[ "This", "paper", "compares", "different", "contrast", "injection", "techniques", "for", "optimizing", "vessel", "contrast", "in", "CT", "angiography", "(", "CTA", ")", ".", "The", "optimal", "vessel", "contrast", "shall", "be", "defined", "as", "constant", "strong", "enhancement", "confined", "to", "the", "scanning", "interval", ".", "This", "\"", "plateau", "enhancement", "\"", "guarantees", "high", "-", "quality", "CTA", "images", "and", "should", "therefore", "be", "approximated", "during", "every", "CTA", "examination", "by", "an", "appropriate", "contrast", "injection", "protocol", ".", "With", "well", "-", "established", "injection", "techniques", "such", "as", "the", "standard", "bolus", "technique", "(", "constant", "uniphasic", "contrast", "bolus", "for", "all", "patients", ")", "or", "adjustment", "of", "the", "scan", "delay", ",", "considerable", "individual", "differences", "in", "the", "arterial", "enhancement", "can", "be", "observed", ",", "and", "a", "nondiagnostic", "examination", "or", "an", "inefficient", "use", "of", "contrast", "agent", "might", "be", "the", "result", "in", "a", "particular", "patient", ".", "Therefore", ",", "two", "sophisticated", "mathematical", "models", "have", "recently", "been", "developed", "for", "analyzing", "the", "individual", "enhancement", "characteristics", ".", "These", "models", "can", "be", "exploited", "to", "predict", "the", "arterial", "enhancement", "for", "any", "given", "intravenous", "contrast", "bolus", "in", "any", "patient", "and", "to", "optimize", "the", "contrast", "bolus", "in", "order", "to", "approach", "the", "ideal", "\"", "plateau", "enhancement", "\"", ".", "These", "techniques", "have", "to", "prove", "their", "effectiveness", "in", "larger", "clinical", "series", "." ]	[ "umlsterm" ]
paper, contrast, injection, techniques, vessel, contrast, angiography, vessel, contrast, contrast, injection, injection, techniques, standard, technique, contrast, patients, adjustment, individual differences, use, contrast agent, patient, mathematical models, contrast, patient, contrast, techniques	DerRadiologe.90390093.eng.abstr_task2	Sentence: This paper compares different contrast injection techniques for optimizing vessel contrast in CT angiography ( CTA ) . The optimal vessel contrast shall be defined as constant strong enhancement confined to the scanning interval . This " plateau enhancement " guarantees high-quality CTA images and should therefore be approximated during every CTA examination by an appropriate contrast injection protocol . With well-established injection techniques such as the standard bolus technique ( constant uniphasic contrast bolus for all patients ) or adjustment of the scan delay , considerable individual differences in the arterial enhancement can be observed , and a nondiagnostic examination or an inefficient use of contrast agent might be the result in a particular patient . Therefore , two sophisticated mathematical models have recently been developed for analyzing the individual enhancement characteristics . These models can be exploited to predict the arterial enhancement for any given intravenous contrast bolus in any patient and to optimize the contrast bolus in order to approach the ideal " plateau enhancement " . These techniques have to prove their effectiveness in larger clinical series . Instructions: please extract entity words from the input sentence	[ "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	This paper compares different contrast injection techniques for optimizing vessel contrast in CT angiography ( CTA ) . The optimal vessel contrast shall be defined as constant strong enhancement confined to the scanning interval . This " plateau enhancement " guarantees high-quality CTA images and should therefore be approximated during every CTA examination by an appropriate contrast injection protocol . With well-established injection techniques such as the standard bolus technique ( constant uniphasic contrast bolus for all patients ) or adjustment of the scan delay , considerable individual differences in the arterial enhancement can be observed , and a nondiagnostic examination or an inefficient use of contrast agent might be the result in a particular patient . Therefore , two sophisticated mathematical models have recently been developed for analyzing the individual enhancement characteristics . These models can be exploited to predict the arterial enhancement for any given intravenous contrast bolus in any patient and to optimize the contrast bolus in order to approach the ideal " plateau enhancement " . These techniques have to prove their effectiveness in larger clinical series .	[ "This", "paper", "compares", "different", "contrast", "injection", "techniques", "for", "optimizing", "vessel", "contrast", "in", "CT", "angiography", "(", "CTA", ")", ".", "The", "optimal", "vessel", "contrast", "shall", "be", "defined", "as", "constant", "strong", "enhancement", "confined", "to", "the", "scanning", "interval", ".", "This", "\"", "plateau", "enhancement", "\"", "guarantees", "high", "-", "quality", "CTA", "images", "and", "should", "therefore", "be", "approximated", "during", "every", "CTA", "examination", "by", "an", "appropriate", "contrast", "injection", "protocol", ".", "With", "well", "-", "established", "injection", "techniques", "such", "as", "the", "standard", "bolus", "technique", "(", "constant", "uniphasic", "contrast", "bolus", "for", "all", "patients", ")", "or", "adjustment", "of", "the", "scan", "delay", ",", "considerable", "individual", "differences", "in", "the", "arterial", "enhancement", "can", "be", "observed", ",", "and", "a", "nondiagnostic", "examination", "or", "an", "inefficient", "use", "of", "contrast", "agent", "might", "be", "the", "result", "in", "a", "particular", "patient", ".", "Therefore", ",", "two", "sophisticated", "mathematical", "models", "have", "recently", "been", "developed", "for", "analyzing", "the", "individual", "enhancement", "characteristics", ".", "These", "models", "can", "be", "exploited", "to", "predict", "the", "arterial", "enhancement", "for", "any", "given", "intravenous", "contrast", "bolus", "in", "any", "patient", "and", "to", "optimize", "the", "contrast", "bolus", "in", "order", "to", "approach", "the", "ideal", "\"", "plateau", "enhancement", "\"", ".", "These", "techniques", "have", "to", "prove", "their", "effectiveness", "in", "larger", "clinical", "series", "." ]	[ "umlsterm" ]
Efficacy is a Outcome_Other, tolerability is a Outcome_Other, donepezil is a Intervention_Pharmacological, vascular dementia is a Participant_Condition, placebo - controlled is a Intervention_Control, cholinesterase inhibitors is a Intervention_Pharmacological, efficacy is a Outcome_Other, safety is a Outcome_Other, mean age , 73.9 years is a Participant_Age, improvement in cognition is a Outcome_Mental, Alzheimer ' s Disease Assessment Scale - cognitive subscale is a Outcome_Mental, patients ' global function is a Outcome_Physical, Clinician ' s Interview - Based Impression of Change - Plus version is a Outcome_Mental, Sum of the Boxes of the Clinical Dementia Rating is a Outcome_Physical, activities of daily living is a Outcome_Physical, Alzheimer ' s Disease Functional Assessment and Change Scale is a Outcome_Mental, Withdrawal rates is a Outcome_Other, adverse events is a Outcome_Adverse-effects	13897_task0	Sentence: Efficacy and tolerability of donepezil in vascular dementia : positive results of a 24-week , multicenter , international , randomized , placebo-controlled clinical trial . BACKGROUND AND PURPOSE Clinical observations suggest that patients with vascular dementia ( VaD ) may benefit from treatment with cholinesterase inhibitors . This study evaluated the efficacy and safety of donepezil for relieving symptoms of dementia in VaD . METHODS Patients ( n=603 ; mean age , 73.9 years ; 55.2 % men ) with probable ( 70.5 % ) or possible ( 29.5 % ) VaD , according to criteria of the National Institute of Neurological Disorders and Stroke ( NINDS ) and the Association Internationale pour la Recherche et l'Enseignement en Neurosciences ( AIREN ) , were randomized to 24 weeks of treatment with donepezil 5 mg/d ( n=198 ) , donepezil 10 mg/d ( 5 mg/d for first 28 days ; n=206 ) , or placebo ( n=199 ) . Analyses were based on the intent-to-treat population . RESULTS At week 24 , both donepezil groups showed significant improvement in cognition versus placebo on the Alzheimer 's Disease Assessment Scale-cognitive subscale ( mean change from baseline score effect size : donepezil 5 mg/d , -1.90 ; P=0.001 ; donepezil 10 mg/d , -2.33 ; P < 0.001 ) . Significant improvements in patients ' global function were seen versus placebo at week 24 ( observed cases ) , on the Clinician 's Interview-Based Impression of Change-Plus version only for patients on donepezil 5 mg/d ( P=0.014 ) , and on the Sum of the Boxes of the Clinical Dementia Rating only for patients on 10 mg/d ( P=0.007 ) . Donepezil-treated patients showed significant benefits in activities of daily living over placebo on the Alzheimer 's Disease Functional Assessment and Change Scale ( mean change from baseline score effect size at week 24 : donepezil 5 mg/d , -1.31 , P=0.02 ; donepezil 10 mg/d , -1.31 , P=0.02 ) . Donepezil was well tolerated . Withdrawal rates due to adverse events were relatively low ( placebo , 11.1 % ; donepezil 5 mg/d , 11.1 % ; donepezil 10 mg/d , 21.8 % ; P=0.005 versus placebo ) . CONCLUSIONS These data demonstrate that donepezil is an effective and well-tolerated treatment for VaD and show it may have an important place in the management of this condition . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Outcome_Adverse-effects, Intervention_Control, Participant_Condition, Participant_Age, Outcome_Physical, Outcome_Other, Outcome_Mental	[ "B-Outcome_Other", "O", "B-Outcome_Other", "O", "B-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Efficacy and tolerability of donepezil in vascular dementia : positive results of a 24-week , multicenter , international , randomized , placebo-controlled clinical trial . BACKGROUND AND PURPOSE Clinical observations suggest that patients with vascular dementia ( VaD ) may benefit from treatment with cholinesterase inhibitors . This study evaluated the efficacy and safety of donepezil for relieving symptoms of dementia in VaD . METHODS Patients ( n=603 ; mean age , 73.9 years ; 55.2 % men ) with probable ( 70.5 % ) or possible ( 29.5 % ) VaD , according to criteria of the National Institute of Neurological Disorders and Stroke ( NINDS ) and the Association Internationale pour la Recherche et l'Enseignement en Neurosciences ( AIREN ) , were randomized to 24 weeks of treatment with donepezil 5 mg/d ( n=198 ) , donepezil 10 mg/d ( 5 mg/d for first 28 days ; n=206 ) , or placebo ( n=199 ) . Analyses were based on the intent-to-treat population . RESULTS At week 24 , both donepezil groups showed significant improvement in cognition versus placebo on the Alzheimer 's Disease Assessment Scale-cognitive subscale ( mean change from baseline score effect size : donepezil 5 mg/d , -1.90 ; P=0.001 ; donepezil 10 mg/d , -2.33 ; P < 0.001 ) . Significant improvements in patients ' global function were seen versus placebo at week 24 ( observed cases ) , on the Clinician 's Interview-Based Impression of Change-Plus version only for patients on donepezil 5 mg/d ( P=0.014 ) , and on the Sum of the Boxes of the Clinical Dementia Rating only for patients on 10 mg/d ( P=0.007 ) . Donepezil-treated patients showed significant benefits in activities of daily living over placebo on the Alzheimer 's Disease Functional Assessment and Change Scale ( mean change from baseline score effect size at week 24 : donepezil 5 mg/d , -1.31 , P=0.02 ; donepezil 10 mg/d , -1.31 , P=0.02 ) . Donepezil was well tolerated . Withdrawal rates due to adverse events were relatively low ( placebo , 11.1 % ; donepezil 5 mg/d , 11.1 % ; donepezil 10 mg/d , 21.8 % ; P=0.005 versus placebo ) . CONCLUSIONS These data demonstrate that donepezil is an effective and well-tolerated treatment for VaD and show it may have an important place in the management of this condition .	[ "Efficacy", "and", "tolerability", "of", "donepezil", "in", "vascular", "dementia", ":", "positive", "results", "of", "a", "24-week", ",", "multicenter", ",", "international", ",", "randomized", ",", "placebo", "-", "controlled", "clinical", "trial", ".", "BACKGROUND", "AND", "PURPOSE", "Clinical", "observations", "suggest", "that", "patients", "with", "vascular", "dementia", "(", "VaD", ")", "may", "benefit", "from", "treatment", "with", "cholinesterase", "inhibitors", ".", "This", "study", "evaluated", "the", "efficacy", "and", "safety", "of", "donepezil", "for", "relieving", "symptoms", "of", "dementia", "in", "VaD", ".", "METHODS", "Patients", "(", "n=603", ";", "mean", "age", ",", "73.9", "years", ";", "55.2", "%", "men", ")", "with", "probable", "(", "70.5", "%", ")", "or", "possible", "(", "29.5", "%", ")", "VaD", ",", "according", "to", "criteria", "of", "the", "National", "Institute", "of", "Neurological", "Disorders", "and", "Stroke", "(", "NINDS", ")", "and", "the", "Association", "Internationale", "pour", "la", "Recherche", "et", "l'Enseignement", "en", "Neurosciences", "(", "AIREN", ")", ",", "were", "randomized", "to", "24", "weeks", "of", "treatment", "with", "donepezil", "5", "mg", "/", "d", "(", "n=198", ")", ",", "donepezil", "10", "mg", "/", "d", "(", "5", "mg", "/", "d", "for", "first", "28", "days", ";", "n=206", ")", ",", "or", "placebo", "(", "n=199", ")", ".", "Analyses", "were", "based", "on", "the", "intent", "-", "to", "-", "treat", "population", ".", "RESULTS", "At", "week", "24", ",", "both", "donepezil", "groups", "showed", "significant", "improvement", "in", "cognition", "versus", "placebo", "on", "the", "Alzheimer", "'", "s", "Disease", "Assessment", "Scale", "-", "cognitive", "subscale", "(", "mean", "change", "from", "baseline", "score", "effect", "size", ":", "donepezil", "5", "mg", "/", "d", ",", "-1.90", ";", "P=0.001", ";", "donepezil", "10", "mg", "/", "d", ",", "-2.33", ";", "P", "<", "0.001", ")", ".", "Significant", "improvements", "in", "patients", "'", "global", "function", "were", "seen", "versus", "placebo", "at", "week", "24", "(", "observed", "cases", ")", ",", "on", "the", "Clinician", "'", "s", "Interview", "-", "Based", "Impression", "of", "Change", "-", "Plus", "version", "only", "for", "patients", "on", "donepezil", "5", "mg", "/", "d", "(", "P=0.014", ")", ",", "and", "on", "the", "Sum", "of", "the", "Boxes", "of", "the", "Clinical", "Dementia", "Rating", "only", "for", "patients", "on", "10", "mg", "/", "d", "(", "P=0.007", ")", ".", "Donepezil", "-", "treated", "patients", "showed", "significant", "benefits", "in", "activities", "of", "daily", "living", "over", "placebo", "on", "the", "Alzheimer", "'", "s", "Disease", "Functional", "Assessment", "and", "Change", "Scale", "(", "mean", "change", "from", "baseline", "score", "effect", "size", "at", "week", "24", ":", "donepezil", "5", "mg", "/", "d", ",", "-1.31", ",", "P=0.02", ";", "donepezil", "10", "mg", "/", "d", ",", "-1.31", ",", "P=0.02", ")", ".", "Donepezil", "was", "well", "tolerated", ".", "Withdrawal", "rates", "due", "to", "adverse", "events", "were", "relatively", "low", "(", "placebo", ",", "11.1", "%", ";", "donepezil", "5", "mg", "/", "d", ",", "11.1", "%", ";", "donepezil", "10", "mg", "/", "d", ",", "21.8", "%", ";", "P=0.005", "versus", "placebo", ")", ".", "CONCLUSIONS", "These", "data", "demonstrate", "that", "donepezil", "is", "an", "effective", "and", "well", "-", "tolerated", "treatment", "for", "VaD", "and", "show", "it", "may", "have", "an", "important", "place", "in", "the", "management", "of", "this", "condition", "." ]	[ "Outcome_Mental", "Outcome_Physical", "Intervention_Pharmacological", "Participant_Age", "Intervention_Control", "Participant_Condition", "Outcome_Other", "Outcome_Adverse-effects", "Participant_Sex" ]
Efficacy is a Outcome_Other, tolerability is a Outcome_Other, donepezil is a Intervention_Pharmacological, vascular dementia is a Participant_Condition, placebo - controlled is a Intervention_Control, cholinesterase inhibitors is a Intervention_Pharmacological, efficacy is a Outcome_Other, safety is a Outcome_Other, mean age , 73.9 years is a Participant_Age, improvement in cognition is a Outcome_Mental, Alzheimer ' s Disease Assessment Scale - cognitive subscale is a Outcome_Mental, patients ' global function is a Outcome_Physical, Clinician ' s Interview - Based Impression of Change - Plus version is a Outcome_Mental, Sum of the Boxes of the Clinical Dementia Rating is a Outcome_Physical, activities of daily living is a Outcome_Physical, Alzheimer ' s Disease Functional Assessment and Change Scale is a Outcome_Mental, Withdrawal rates is a Outcome_Other, adverse events is a Outcome_Adverse-effects	13897_task1	Sentence: Efficacy and tolerability of donepezil in vascular dementia : positive results of a 24-week , multicenter , international , randomized , placebo-controlled clinical trial . BACKGROUND AND PURPOSE Clinical observations suggest that patients with vascular dementia ( VaD ) may benefit from treatment with cholinesterase inhibitors . This study evaluated the efficacy and safety of donepezil for relieving symptoms of dementia in VaD . METHODS Patients ( n=603 ; mean age , 73.9 years ; 55.2 % men ) with probable ( 70.5 % ) or possible ( 29.5 % ) VaD , according to criteria of the National Institute of Neurological Disorders and Stroke ( NINDS ) and the Association Internationale pour la Recherche et l'Enseignement en Neurosciences ( AIREN ) , were randomized to 24 weeks of treatment with donepezil 5 mg/d ( n=198 ) , donepezil 10 mg/d ( 5 mg/d for first 28 days ; n=206 ) , or placebo ( n=199 ) . Analyses were based on the intent-to-treat population . RESULTS At week 24 , both donepezil groups showed significant improvement in cognition versus placebo on the Alzheimer 's Disease Assessment Scale-cognitive subscale ( mean change from baseline score effect size : donepezil 5 mg/d , -1.90 ; P=0.001 ; donepezil 10 mg/d , -2.33 ; P < 0.001 ) . Significant improvements in patients ' global function were seen versus placebo at week 24 ( observed cases ) , on the Clinician 's Interview-Based Impression of Change-Plus version only for patients on donepezil 5 mg/d ( P=0.014 ) , and on the Sum of the Boxes of the Clinical Dementia Rating only for patients on 10 mg/d ( P=0.007 ) . Donepezil-treated patients showed significant benefits in activities of daily living over placebo on the Alzheimer 's Disease Functional Assessment and Change Scale ( mean change from baseline score effect size at week 24 : donepezil 5 mg/d , -1.31 , P=0.02 ; donepezil 10 mg/d , -1.31 , P=0.02 ) . Donepezil was well tolerated . Withdrawal rates due to adverse events were relatively low ( placebo , 11.1 % ; donepezil 5 mg/d , 11.1 % ; donepezil 10 mg/d , 21.8 % ; P=0.005 versus placebo ) . CONCLUSIONS These data demonstrate that donepezil is an effective and well-tolerated treatment for VaD and show it may have an important place in the management of this condition . Instructions: please typing these entity words according to sentence: Efficacy, tolerability, donepezil, vascular dementia, placebo - controlled, cholinesterase inhibitors, efficacy, safety, mean age , 73.9 years, improvement in cognition, Alzheimer ' s Disease Assessment Scale - cognitive subscale, patients ' global function, Clinician ' s Interview - Based Impression of Change - Plus version, Sum of the Boxes of the Clinical Dementia Rating, activities of daily living, Alzheimer ' s Disease Functional Assessment and Change Scale, Withdrawal rates, adverse events Options: Intervention_Pharmacological, Outcome_Adverse-effects, Intervention_Control, Participant_Condition, Participant_Age, Outcome_Physical, Outcome_Other, Outcome_Mental	[ "B-Outcome_Other", "O", "B-Outcome_Other", "O", "B-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Efficacy and tolerability of donepezil in vascular dementia : positive results of a 24-week , multicenter , international , randomized , placebo-controlled clinical trial . BACKGROUND AND PURPOSE Clinical observations suggest that patients with vascular dementia ( VaD ) may benefit from treatment with cholinesterase inhibitors . This study evaluated the efficacy and safety of donepezil for relieving symptoms of dementia in VaD . METHODS Patients ( n=603 ; mean age , 73.9 years ; 55.2 % men ) with probable ( 70.5 % ) or possible ( 29.5 % ) VaD , according to criteria of the National Institute of Neurological Disorders and Stroke ( NINDS ) and the Association Internationale pour la Recherche et l'Enseignement en Neurosciences ( AIREN ) , were randomized to 24 weeks of treatment with donepezil 5 mg/d ( n=198 ) , donepezil 10 mg/d ( 5 mg/d for first 28 days ; n=206 ) , or placebo ( n=199 ) . Analyses were based on the intent-to-treat population . RESULTS At week 24 , both donepezil groups showed significant improvement in cognition versus placebo on the Alzheimer 's Disease Assessment Scale-cognitive subscale ( mean change from baseline score effect size : donepezil 5 mg/d , -1.90 ; P=0.001 ; donepezil 10 mg/d , -2.33 ; P < 0.001 ) . Significant improvements in patients ' global function were seen versus placebo at week 24 ( observed cases ) , on the Clinician 's Interview-Based Impression of Change-Plus version only for patients on donepezil 5 mg/d ( P=0.014 ) , and on the Sum of the Boxes of the Clinical Dementia Rating only for patients on 10 mg/d ( P=0.007 ) . Donepezil-treated patients showed significant benefits in activities of daily living over placebo on the Alzheimer 's Disease Functional Assessment and Change Scale ( mean change from baseline score effect size at week 24 : donepezil 5 mg/d , -1.31 , P=0.02 ; donepezil 10 mg/d , -1.31 , P=0.02 ) . Donepezil was well tolerated . Withdrawal rates due to adverse events were relatively low ( placebo , 11.1 % ; donepezil 5 mg/d , 11.1 % ; donepezil 10 mg/d , 21.8 % ; P=0.005 versus placebo ) . CONCLUSIONS These data demonstrate that donepezil is an effective and well-tolerated treatment for VaD and show it may have an important place in the management of this condition .	[ "Efficacy", "and", "tolerability", "of", "donepezil", "in", "vascular", "dementia", ":", "positive", "results", "of", "a", "24-week", ",", "multicenter", ",", "international", ",", "randomized", ",", "placebo", "-", "controlled", "clinical", "trial", ".", "BACKGROUND", "AND", "PURPOSE", "Clinical", "observations", "suggest", "that", "patients", "with", "vascular", "dementia", "(", "VaD", ")", "may", "benefit", "from", "treatment", "with", "cholinesterase", "inhibitors", ".", "This", "study", "evaluated", "the", "efficacy", "and", "safety", "of", "donepezil", "for", "relieving", "symptoms", "of", "dementia", "in", "VaD", ".", "METHODS", "Patients", "(", "n=603", ";", "mean", "age", ",", "73.9", "years", ";", "55.2", "%", "men", ")", "with", "probable", "(", "70.5", "%", ")", "or", "possible", "(", "29.5", "%", ")", "VaD", ",", "according", "to", "criteria", "of", "the", "National", "Institute", "of", "Neurological", "Disorders", "and", "Stroke", "(", "NINDS", ")", "and", "the", "Association", "Internationale", "pour", "la", "Recherche", "et", "l'Enseignement", "en", "Neurosciences", "(", "AIREN", ")", ",", "were", "randomized", "to", "24", "weeks", "of", "treatment", "with", "donepezil", "5", "mg", "/", "d", "(", "n=198", ")", ",", "donepezil", "10", "mg", "/", "d", "(", "5", "mg", "/", "d", "for", "first", "28", "days", ";", "n=206", ")", ",", "or", "placebo", "(", "n=199", ")", ".", "Analyses", "were", "based", "on", "the", "intent", "-", "to", "-", "treat", "population", ".", "RESULTS", "At", "week", "24", ",", "both", "donepezil", "groups", "showed", "significant", "improvement", "in", "cognition", "versus", "placebo", "on", "the", "Alzheimer", "'", "s", "Disease", "Assessment", "Scale", "-", "cognitive", "subscale", "(", "mean", "change", "from", "baseline", "score", "effect", "size", ":", "donepezil", "5", "mg", "/", "d", ",", "-1.90", ";", "P=0.001", ";", "donepezil", "10", "mg", "/", "d", ",", "-2.33", ";", "P", "<", "0.001", ")", ".", "Significant", "improvements", "in", "patients", "'", "global", "function", "were", "seen", "versus", "placebo", "at", "week", "24", "(", "observed", "cases", ")", ",", "on", "the", "Clinician", "'", "s", "Interview", "-", "Based", "Impression", "of", "Change", "-", "Plus", "version", "only", "for", "patients", "on", "donepezil", "5", "mg", "/", "d", "(", "P=0.014", ")", ",", "and", "on", "the", "Sum", "of", "the", "Boxes", "of", "the", "Clinical", "Dementia", "Rating", "only", "for", "patients", "on", "10", "mg", "/", "d", "(", "P=0.007", ")", ".", "Donepezil", "-", "treated", "patients", "showed", "significant", "benefits", "in", "activities", "of", "daily", "living", "over", "placebo", "on", "the", "Alzheimer", "'", "s", "Disease", "Functional", "Assessment", "and", "Change", "Scale", "(", "mean", "change", "from", "baseline", "score", "effect", "size", "at", "week", "24", ":", "donepezil", "5", "mg", "/", "d", ",", "-1.31", ",", "P=0.02", ";", "donepezil", "10", "mg", "/", "d", ",", "-1.31", ",", "P=0.02", ")", ".", "Donepezil", "was", "well", "tolerated", ".", "Withdrawal", "rates", "due", "to", "adverse", "events", "were", "relatively", "low", "(", "placebo", ",", "11.1", "%", ";", "donepezil", "5", "mg", "/", "d", ",", "11.1", "%", ";", "donepezil", "10", "mg", "/", "d", ",", "21.8", "%", ";", "P=0.005", "versus", "placebo", ")", ".", "CONCLUSIONS", "These", "data", "demonstrate", "that", "donepezil", "is", "an", "effective", "and", "well", "-", "tolerated", "treatment", "for", "VaD", "and", "show", "it", "may", "have", "an", "important", "place", "in", "the", "management", "of", "this", "condition", "." ]	[ "Outcome_Mental", "Outcome_Physical", "Intervention_Pharmacological", "Participant_Age", "Intervention_Control", "Participant_Condition", "Outcome_Other", "Outcome_Adverse-effects", "Participant_Sex" ]
Efficacy, tolerability, donepezil, vascular dementia, placebo - controlled, cholinesterase inhibitors, efficacy, safety, mean age , 73.9 years, improvement in cognition, Alzheimer ' s Disease Assessment Scale - cognitive subscale, patients ' global function, Clinician ' s Interview - Based Impression of Change - Plus version, Sum of the Boxes of the Clinical Dementia Rating, activities of daily living, Alzheimer ' s Disease Functional Assessment and Change Scale, Withdrawal rates, adverse events	13897_task2	Sentence: Efficacy and tolerability of donepezil in vascular dementia : positive results of a 24-week , multicenter , international , randomized , placebo-controlled clinical trial . BACKGROUND AND PURPOSE Clinical observations suggest that patients with vascular dementia ( VaD ) may benefit from treatment with cholinesterase inhibitors . This study evaluated the efficacy and safety of donepezil for relieving symptoms of dementia in VaD . METHODS Patients ( n=603 ; mean age , 73.9 years ; 55.2 % men ) with probable ( 70.5 % ) or possible ( 29.5 % ) VaD , according to criteria of the National Institute of Neurological Disorders and Stroke ( NINDS ) and the Association Internationale pour la Recherche et l'Enseignement en Neurosciences ( AIREN ) , were randomized to 24 weeks of treatment with donepezil 5 mg/d ( n=198 ) , donepezil 10 mg/d ( 5 mg/d for first 28 days ; n=206 ) , or placebo ( n=199 ) . Analyses were based on the intent-to-treat population . RESULTS At week 24 , both donepezil groups showed significant improvement in cognition versus placebo on the Alzheimer 's Disease Assessment Scale-cognitive subscale ( mean change from baseline score effect size : donepezil 5 mg/d , -1.90 ; P=0.001 ; donepezil 10 mg/d , -2.33 ; P < 0.001 ) . Significant improvements in patients ' global function were seen versus placebo at week 24 ( observed cases ) , on the Clinician 's Interview-Based Impression of Change-Plus version only for patients on donepezil 5 mg/d ( P=0.014 ) , and on the Sum of the Boxes of the Clinical Dementia Rating only for patients on 10 mg/d ( P=0.007 ) . Donepezil-treated patients showed significant benefits in activities of daily living over placebo on the Alzheimer 's Disease Functional Assessment and Change Scale ( mean change from baseline score effect size at week 24 : donepezil 5 mg/d , -1.31 , P=0.02 ; donepezil 10 mg/d , -1.31 , P=0.02 ) . Donepezil was well tolerated . Withdrawal rates due to adverse events were relatively low ( placebo , 11.1 % ; donepezil 5 mg/d , 11.1 % ; donepezil 10 mg/d , 21.8 % ; P=0.005 versus placebo ) . CONCLUSIONS These data demonstrate that donepezil is an effective and well-tolerated treatment for VaD and show it may have an important place in the management of this condition . Instructions: please extract entity words from the input sentence	[ "B-Outcome_Other", "O", "B-Outcome_Other", "O", "B-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Efficacy and tolerability of donepezil in vascular dementia : positive results of a 24-week , multicenter , international , randomized , placebo-controlled clinical trial . BACKGROUND AND PURPOSE Clinical observations suggest that patients with vascular dementia ( VaD ) may benefit from treatment with cholinesterase inhibitors . This study evaluated the efficacy and safety of donepezil for relieving symptoms of dementia in VaD . METHODS Patients ( n=603 ; mean age , 73.9 years ; 55.2 % men ) with probable ( 70.5 % ) or possible ( 29.5 % ) VaD , according to criteria of the National Institute of Neurological Disorders and Stroke ( NINDS ) and the Association Internationale pour la Recherche et l'Enseignement en Neurosciences ( AIREN ) , were randomized to 24 weeks of treatment with donepezil 5 mg/d ( n=198 ) , donepezil 10 mg/d ( 5 mg/d for first 28 days ; n=206 ) , or placebo ( n=199 ) . Analyses were based on the intent-to-treat population . RESULTS At week 24 , both donepezil groups showed significant improvement in cognition versus placebo on the Alzheimer 's Disease Assessment Scale-cognitive subscale ( mean change from baseline score effect size : donepezil 5 mg/d , -1.90 ; P=0.001 ; donepezil 10 mg/d , -2.33 ; P < 0.001 ) . Significant improvements in patients ' global function were seen versus placebo at week 24 ( observed cases ) , on the Clinician 's Interview-Based Impression of Change-Plus version only for patients on donepezil 5 mg/d ( P=0.014 ) , and on the Sum of the Boxes of the Clinical Dementia Rating only for patients on 10 mg/d ( P=0.007 ) . Donepezil-treated patients showed significant benefits in activities of daily living over placebo on the Alzheimer 's Disease Functional Assessment and Change Scale ( mean change from baseline score effect size at week 24 : donepezil 5 mg/d , -1.31 , P=0.02 ; donepezil 10 mg/d , -1.31 , P=0.02 ) . Donepezil was well tolerated . Withdrawal rates due to adverse events were relatively low ( placebo , 11.1 % ; donepezil 5 mg/d , 11.1 % ; donepezil 10 mg/d , 21.8 % ; P=0.005 versus placebo ) . CONCLUSIONS These data demonstrate that donepezil is an effective and well-tolerated treatment for VaD and show it may have an important place in the management of this condition .	[ "Efficacy", "and", "tolerability", "of", "donepezil", "in", "vascular", "dementia", ":", "positive", "results", "of", "a", "24-week", ",", "multicenter", ",", "international", ",", "randomized", ",", "placebo", "-", "controlled", "clinical", "trial", ".", "BACKGROUND", "AND", "PURPOSE", "Clinical", "observations", "suggest", "that", "patients", "with", "vascular", "dementia", "(", "VaD", ")", "may", "benefit", "from", "treatment", "with", "cholinesterase", "inhibitors", ".", "This", "study", "evaluated", "the", "efficacy", "and", "safety", "of", "donepezil", "for", "relieving", "symptoms", "of", "dementia", "in", "VaD", ".", "METHODS", "Patients", "(", "n=603", ";", "mean", "age", ",", "73.9", "years", ";", "55.2", "%", "men", ")", "with", "probable", "(", "70.5", "%", ")", "or", "possible", "(", "29.5", "%", ")", "VaD", ",", "according", "to", "criteria", "of", "the", "National", "Institute", "of", "Neurological", "Disorders", "and", "Stroke", "(", "NINDS", ")", "and", "the", "Association", "Internationale", "pour", "la", "Recherche", "et", "l'Enseignement", "en", "Neurosciences", "(", "AIREN", ")", ",", "were", "randomized", "to", "24", "weeks", "of", "treatment", "with", "donepezil", "5", "mg", "/", "d", "(", "n=198", ")", ",", "donepezil", "10", "mg", "/", "d", "(", "5", "mg", "/", "d", "for", "first", "28", "days", ";", "n=206", ")", ",", "or", "placebo", "(", "n=199", ")", ".", "Analyses", "were", "based", "on", "the", "intent", "-", "to", "-", "treat", "population", ".", "RESULTS", "At", "week", "24", ",", "both", "donepezil", "groups", "showed", "significant", "improvement", "in", "cognition", "versus", "placebo", "on", "the", "Alzheimer", "'", "s", "Disease", "Assessment", "Scale", "-", "cognitive", "subscale", "(", "mean", "change", "from", "baseline", "score", "effect", "size", ":", "donepezil", "5", "mg", "/", "d", ",", "-1.90", ";", "P=0.001", ";", "donepezil", "10", "mg", "/", "d", ",", "-2.33", ";", "P", "<", "0.001", ")", ".", "Significant", "improvements", "in", "patients", "'", "global", "function", "were", "seen", "versus", "placebo", "at", "week", "24", "(", "observed", "cases", ")", ",", "on", "the", "Clinician", "'", "s", "Interview", "-", "Based", "Impression", "of", "Change", "-", "Plus", "version", "only", "for", "patients", "on", "donepezil", "5", "mg", "/", "d", "(", "P=0.014", ")", ",", "and", "on", "the", "Sum", "of", "the", "Boxes", "of", "the", "Clinical", "Dementia", "Rating", "only", "for", "patients", "on", "10", "mg", "/", "d", "(", "P=0.007", ")", ".", "Donepezil", "-", "treated", "patients", "showed", "significant", "benefits", "in", "activities", "of", "daily", "living", "over", "placebo", "on", "the", "Alzheimer", "'", "s", "Disease", "Functional", "Assessment", "and", "Change", "Scale", "(", "mean", "change", "from", "baseline", "score", "effect", "size", "at", "week", "24", ":", "donepezil", "5", "mg", "/", "d", ",", "-1.31", ",", "P=0.02", ";", "donepezil", "10", "mg", "/", "d", ",", "-1.31", ",", "P=0.02", ")", ".", "Donepezil", "was", "well", "tolerated", ".", "Withdrawal", "rates", "due", "to", "adverse", "events", "were", "relatively", "low", "(", "placebo", ",", "11.1", "%", ";", "donepezil", "5", "mg", "/", "d", ",", "11.1", "%", ";", "donepezil", "10", "mg", "/", "d", ",", "21.8", "%", ";", "P=0.005", "versus", "placebo", ")", ".", "CONCLUSIONS", "These", "data", "demonstrate", "that", "donepezil", "is", "an", "effective", "and", "well", "-", "tolerated", "treatment", "for", "VaD", "and", "show", "it", "may", "have", "an", "important", "place", "in", "the", "management", "of", "this", "condition", "." ]	[ "Outcome_Mental", "Outcome_Physical", "Intervention_Pharmacological", "Participant_Age", "Intervention_Control", "Participant_Condition", "Outcome_Other", "Outcome_Adverse-effects", "Participant_Sex" ]
dermatomyositis - like is an umlsterm, maintenance is an umlsterm, therapy is an umlsterm, hydroxyurea is an umlsterm, patients is an umlsterm, chronic myelogenous leukaemia is an umlsterm, CML is an umlsterm, side effects is an umlsterm, pruritus is an umlsterm, hyperpigmentation is an umlsterm, patients is an umlsterm, skin is an umlsterm, hands is an umlsterm, fingers is an umlsterm, erythema is an umlsterm, face is an umlsterm, patients is an umlsterm, oedema is an umlsterm, eyelids is an umlsterm, patient is an umlsterm, dermatomyositis - like is an umlsterm, signs is an umlsterm, muscle - specific is an umlsterm, enzymes is an umlsterm, normal ranges is an umlsterm, Skin is an umlsterm, biopsy is an umlsterm, dermatitis is an umlsterm, cell is an umlsterm, cells is an umlsterm, keratinocytes is an umlsterm, telangiectases is an umlsterm, dermis is an umlsterm, histopathological is an umlsterm, findings is an umlsterm, lichen is an umlsterm, planus - like is an umlsterm, skin is an umlsterm, hands is an umlsterm, hydroxyurea is an umlsterm, therapy is an umlsterm, skin is an umlsterm, dermatomyositis - like is an umlsterm, lichen is an umlsterm, planus - like is an umlsterm, patients is an umlsterm, hydroxyurea is an umlsterm, therapy is an umlsterm	DerHautarzt.50460717.eng.abstr_task0	Sentence: We report on dermatomyositis-like adverse cutaneous reactions following long-term maintenance therapy with hydroxyurea in two patients suffering from chronic myelogenous leukaemia ( CML ) . In addition to non-specific side effects , such as xerosis , pruritus and hyperpigmentation , both patients presented with more specific skin changes , i.e. erythematous lesions , scaling , and partially atrophic areas distributed in a linear fashion on the dorsal aspects of the hands and fingers . In addition , teleangiectatic erythema of the face was present in both patients , and this was associated with oedema of the eyelids in one patient . Despite these dermatomyositis-like features there were no clinical signs of muscular involvement , and muscle-specific enzymes were within normal ranges . Skin biopsy specimens revealed an interface dermatitis characterized by a lichenoid cell infiltrate , vacuolar alteration of basal cells , necrotic keratinocytes within the spinous zone , focal hypergranulosis , orthohyperkeratosis and telangiectases in the upper part of the dermis . Analogous histopathological findings have been documented in lichen planus-like skin changes on the hands following hydroxyurea therapy . It seems doubtful whether there are actually any major differences between those skin changes described as dermatomyositis-like and those interpreted as lichen planus-like in patients receiving long-term hydroxyurea therapy . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O" ]	We report on dermatomyositis-like adverse cutaneous reactions following long-term maintenance therapy with hydroxyurea in two patients suffering from chronic myelogenous leukaemia ( CML ) . In addition to non-specific side effects , such as xerosis , pruritus and hyperpigmentation , both patients presented with more specific skin changes , i.e. erythematous lesions , scaling , and partially atrophic areas distributed in a linear fashion on the dorsal aspects of the hands and fingers . In addition , teleangiectatic erythema of the face was present in both patients , and this was associated with oedema of the eyelids in one patient . Despite these dermatomyositis-like features there were no clinical signs of muscular involvement , and muscle-specific enzymes were within normal ranges . Skin biopsy specimens revealed an interface dermatitis characterized by a lichenoid cell infiltrate , vacuolar alteration of basal cells , necrotic keratinocytes within the spinous zone , focal hypergranulosis , orthohyperkeratosis and telangiectases in the upper part of the dermis . Analogous histopathological findings have been documented in lichen planus-like skin changes on the hands following hydroxyurea therapy . It seems doubtful whether there are actually any major differences between those skin changes described as dermatomyositis-like and those interpreted as lichen planus-like in patients receiving long-term hydroxyurea therapy .	[ "We", "report", "on", "dermatomyositis", "-", "like", "adverse", "cutaneous", "reactions", "following", "long", "-", "term", "maintenance", "therapy", "with", "hydroxyurea", "in", "two", "patients", "suffering", "from", "chronic", "myelogenous", "leukaemia", "(", "CML", ")", ".", "In", "addition", "to", "non", "-", "specific", "side", "effects", ",", "such", "as", "xerosis", ",", "pruritus", "and", "hyperpigmentation", ",", "both", "patients", "presented", "with", "more", "specific", "skin", "changes", ",", "i.e", ".", "erythematous", "lesions", ",", "scaling", ",", "and", "partially", "atrophic", "areas", "distributed", "in", "a", "linear", "fashion", "on", "the", "dorsal", "aspects", "of", "the", "hands", "and", "fingers", ".", "In", "addition", ",", "teleangiectatic", "erythema", "of", "the", "face", "was", "present", "in", "both", "patients", ",", "and", "this", "was", "associated", "with", "oedema", "of", "the", "eyelids", "in", "one", "patient", ".", "Despite", "these", "dermatomyositis", "-", "like", "features", "there", "were", "no", "clinical", "signs", "of", "muscular", "involvement", ",", "and", "muscle", "-", "specific", "enzymes", "were", "within", "normal", "ranges", ".", "Skin", "biopsy", "specimens", "revealed", "an", "interface", "dermatitis", "characterized", "by", "a", "lichenoid", "cell", "infiltrate", ",", "vacuolar", "alteration", "of", "basal", "cells", ",", "necrotic", "keratinocytes", "within", "the", "spinous", "zone", ",", "focal", "hypergranulosis", ",", "orthohyperkeratosis", "and", "telangiectases", "in", "the", "upper", "part", "of", "the", "dermis", ".", "Analogous", "histopathological", "findings", "have", "been", "documented", "in", "lichen", "planus", "-", "like", "skin", "changes", "on", "the", "hands", "following", "hydroxyurea", "therapy", ".", "It", "seems", "doubtful", "whether", "there", "are", "actually", "any", "major", "differences", "between", "those", "skin", "changes", "described", "as", "dermatomyositis", "-", "like", "and", "those", "interpreted", "as", "lichen", "planus", "-", "like", "in", "patients", "receiving", "long", "-", "term", "hydroxyurea", "therapy", "." ]	[ "umlsterm" ]
dermatomyositis - like is an umlsterm, maintenance is an umlsterm, therapy is an umlsterm, hydroxyurea is an umlsterm, patients is an umlsterm, chronic myelogenous leukaemia is an umlsterm, CML is an umlsterm, side effects is an umlsterm, pruritus is an umlsterm, hyperpigmentation is an umlsterm, patients is an umlsterm, skin is an umlsterm, hands is an umlsterm, fingers is an umlsterm, erythema is an umlsterm, face is an umlsterm, patients is an umlsterm, oedema is an umlsterm, eyelids is an umlsterm, patient is an umlsterm, dermatomyositis - like is an umlsterm, signs is an umlsterm, muscle - specific is an umlsterm, enzymes is an umlsterm, normal ranges is an umlsterm, Skin is an umlsterm, biopsy is an umlsterm, dermatitis is an umlsterm, cell is an umlsterm, cells is an umlsterm, keratinocytes is an umlsterm, telangiectases is an umlsterm, dermis is an umlsterm, histopathological is an umlsterm, findings is an umlsterm, lichen is an umlsterm, planus - like is an umlsterm, skin is an umlsterm, hands is an umlsterm, hydroxyurea is an umlsterm, therapy is an umlsterm, skin is an umlsterm, dermatomyositis - like is an umlsterm, lichen is an umlsterm, planus - like is an umlsterm, patients is an umlsterm, hydroxyurea is an umlsterm, therapy is an umlsterm	DerHautarzt.50460717.eng.abstr_task1	Sentence: We report on dermatomyositis-like adverse cutaneous reactions following long-term maintenance therapy with hydroxyurea in two patients suffering from chronic myelogenous leukaemia ( CML ) . In addition to non-specific side effects , such as xerosis , pruritus and hyperpigmentation , both patients presented with more specific skin changes , i.e. erythematous lesions , scaling , and partially atrophic areas distributed in a linear fashion on the dorsal aspects of the hands and fingers . In addition , teleangiectatic erythema of the face was present in both patients , and this was associated with oedema of the eyelids in one patient . Despite these dermatomyositis-like features there were no clinical signs of muscular involvement , and muscle-specific enzymes were within normal ranges . Skin biopsy specimens revealed an interface dermatitis characterized by a lichenoid cell infiltrate , vacuolar alteration of basal cells , necrotic keratinocytes within the spinous zone , focal hypergranulosis , orthohyperkeratosis and telangiectases in the upper part of the dermis . Analogous histopathological findings have been documented in lichen planus-like skin changes on the hands following hydroxyurea therapy . It seems doubtful whether there are actually any major differences between those skin changes described as dermatomyositis-like and those interpreted as lichen planus-like in patients receiving long-term hydroxyurea therapy . Instructions: please typing these entity words according to sentence: dermatomyositis - like, maintenance, therapy, hydroxyurea, patients, chronic myelogenous leukaemia, CML, side effects, pruritus, hyperpigmentation, patients, skin, hands, fingers, erythema, face, patients, oedema, eyelids, patient, dermatomyositis - like, signs, muscle - specific, enzymes, normal ranges, Skin, biopsy, dermatitis, cell, cells, keratinocytes, telangiectases, dermis, histopathological, findings, lichen, planus - like, skin, hands, hydroxyurea, therapy, skin, dermatomyositis - like, lichen, planus - like, patients, hydroxyurea, therapy Options: umlsterm	[ "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O" ]	We report on dermatomyositis-like adverse cutaneous reactions following long-term maintenance therapy with hydroxyurea in two patients suffering from chronic myelogenous leukaemia ( CML ) . In addition to non-specific side effects , such as xerosis , pruritus and hyperpigmentation , both patients presented with more specific skin changes , i.e. erythematous lesions , scaling , and partially atrophic areas distributed in a linear fashion on the dorsal aspects of the hands and fingers . In addition , teleangiectatic erythema of the face was present in both patients , and this was associated with oedema of the eyelids in one patient . Despite these dermatomyositis-like features there were no clinical signs of muscular involvement , and muscle-specific enzymes were within normal ranges . Skin biopsy specimens revealed an interface dermatitis characterized by a lichenoid cell infiltrate , vacuolar alteration of basal cells , necrotic keratinocytes within the spinous zone , focal hypergranulosis , orthohyperkeratosis and telangiectases in the upper part of the dermis . Analogous histopathological findings have been documented in lichen planus-like skin changes on the hands following hydroxyurea therapy . It seems doubtful whether there are actually any major differences between those skin changes described as dermatomyositis-like and those interpreted as lichen planus-like in patients receiving long-term hydroxyurea therapy .	[ "We", "report", "on", "dermatomyositis", "-", "like", "adverse", "cutaneous", "reactions", "following", "long", "-", "term", "maintenance", "therapy", "with", "hydroxyurea", "in", "two", "patients", "suffering", "from", "chronic", "myelogenous", "leukaemia", "(", "CML", ")", ".", "In", "addition", "to", "non", "-", "specific", "side", "effects", ",", "such", "as", "xerosis", ",", "pruritus", "and", "hyperpigmentation", ",", "both", "patients", "presented", "with", "more", "specific", "skin", "changes", ",", "i.e", ".", "erythematous", "lesions", ",", "scaling", ",", "and", "partially", "atrophic", "areas", "distributed", "in", "a", "linear", "fashion", "on", "the", "dorsal", "aspects", "of", "the", "hands", "and", "fingers", ".", "In", "addition", ",", "teleangiectatic", "erythema", "of", "the", "face", "was", "present", "in", "both", "patients", ",", "and", "this", "was", "associated", "with", "oedema", "of", "the", "eyelids", "in", "one", "patient", ".", "Despite", "these", "dermatomyositis", "-", "like", "features", "there", "were", "no", "clinical", "signs", "of", "muscular", "involvement", ",", "and", "muscle", "-", "specific", "enzymes", "were", "within", "normal", "ranges", ".", "Skin", "biopsy", "specimens", "revealed", "an", "interface", "dermatitis", "characterized", "by", "a", "lichenoid", "cell", "infiltrate", ",", "vacuolar", "alteration", "of", "basal", "cells", ",", "necrotic", "keratinocytes", "within", "the", "spinous", "zone", ",", "focal", "hypergranulosis", ",", "orthohyperkeratosis", "and", "telangiectases", "in", "the", "upper", "part", "of", "the", "dermis", ".", "Analogous", "histopathological", "findings", "have", "been", "documented", "in", "lichen", "planus", "-", "like", "skin", "changes", "on", "the", "hands", "following", "hydroxyurea", "therapy", ".", "It", "seems", "doubtful", "whether", "there", "are", "actually", "any", "major", "differences", "between", "those", "skin", "changes", "described", "as", "dermatomyositis", "-", "like", "and", "those", "interpreted", "as", "lichen", "planus", "-", "like", "in", "patients", "receiving", "long", "-", "term", "hydroxyurea", "therapy", "." ]	[ "umlsterm" ]
dermatomyositis - like, maintenance, therapy, hydroxyurea, patients, chronic myelogenous leukaemia, CML, side effects, pruritus, hyperpigmentation, patients, skin, hands, fingers, erythema, face, patients, oedema, eyelids, patient, dermatomyositis - like, signs, muscle - specific, enzymes, normal ranges, Skin, biopsy, dermatitis, cell, cells, keratinocytes, telangiectases, dermis, histopathological, findings, lichen, planus - like, skin, hands, hydroxyurea, therapy, skin, dermatomyositis - like, lichen, planus - like, patients, hydroxyurea, therapy	DerHautarzt.50460717.eng.abstr_task2	Sentence: We report on dermatomyositis-like adverse cutaneous reactions following long-term maintenance therapy with hydroxyurea in two patients suffering from chronic myelogenous leukaemia ( CML ) . In addition to non-specific side effects , such as xerosis , pruritus and hyperpigmentation , both patients presented with more specific skin changes , i.e. erythematous lesions , scaling , and partially atrophic areas distributed in a linear fashion on the dorsal aspects of the hands and fingers . In addition , teleangiectatic erythema of the face was present in both patients , and this was associated with oedema of the eyelids in one patient . Despite these dermatomyositis-like features there were no clinical signs of muscular involvement , and muscle-specific enzymes were within normal ranges . Skin biopsy specimens revealed an interface dermatitis characterized by a lichenoid cell infiltrate , vacuolar alteration of basal cells , necrotic keratinocytes within the spinous zone , focal hypergranulosis , orthohyperkeratosis and telangiectases in the upper part of the dermis . Analogous histopathological findings have been documented in lichen planus-like skin changes on the hands following hydroxyurea therapy . It seems doubtful whether there are actually any major differences between those skin changes described as dermatomyositis-like and those interpreted as lichen planus-like in patients receiving long-term hydroxyurea therapy . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O" ]	We report on dermatomyositis-like adverse cutaneous reactions following long-term maintenance therapy with hydroxyurea in two patients suffering from chronic myelogenous leukaemia ( CML ) . In addition to non-specific side effects , such as xerosis , pruritus and hyperpigmentation , both patients presented with more specific skin changes , i.e. erythematous lesions , scaling , and partially atrophic areas distributed in a linear fashion on the dorsal aspects of the hands and fingers . In addition , teleangiectatic erythema of the face was present in both patients , and this was associated with oedema of the eyelids in one patient . Despite these dermatomyositis-like features there were no clinical signs of muscular involvement , and muscle-specific enzymes were within normal ranges . Skin biopsy specimens revealed an interface dermatitis characterized by a lichenoid cell infiltrate , vacuolar alteration of basal cells , necrotic keratinocytes within the spinous zone , focal hypergranulosis , orthohyperkeratosis and telangiectases in the upper part of the dermis . Analogous histopathological findings have been documented in lichen planus-like skin changes on the hands following hydroxyurea therapy . It seems doubtful whether there are actually any major differences between those skin changes described as dermatomyositis-like and those interpreted as lichen planus-like in patients receiving long-term hydroxyurea therapy .	[ "We", "report", "on", "dermatomyositis", "-", "like", "adverse", "cutaneous", "reactions", "following", "long", "-", "term", "maintenance", "therapy", "with", "hydroxyurea", "in", "two", "patients", "suffering", "from", "chronic", "myelogenous", "leukaemia", "(", "CML", ")", ".", "In", "addition", "to", "non", "-", "specific", "side", "effects", ",", "such", "as", "xerosis", ",", "pruritus", "and", "hyperpigmentation", ",", "both", "patients", "presented", "with", "more", "specific", "skin", "changes", ",", "i.e", ".", "erythematous", "lesions", ",", "scaling", ",", "and", "partially", "atrophic", "areas", "distributed", "in", "a", "linear", "fashion", "on", "the", "dorsal", "aspects", "of", "the", "hands", "and", "fingers", ".", "In", "addition", ",", "teleangiectatic", "erythema", "of", "the", "face", "was", "present", "in", "both", "patients", ",", "and", "this", "was", "associated", "with", "oedema", "of", "the", "eyelids", "in", "one", "patient", ".", "Despite", "these", "dermatomyositis", "-", "like", "features", "there", "were", "no", "clinical", "signs", "of", "muscular", "involvement", ",", "and", "muscle", "-", "specific", "enzymes", "were", "within", "normal", "ranges", ".", "Skin", "biopsy", "specimens", "revealed", "an", "interface", "dermatitis", "characterized", "by", "a", "lichenoid", "cell", "infiltrate", ",", "vacuolar", "alteration", "of", "basal", "cells", ",", "necrotic", "keratinocytes", "within", "the", "spinous", "zone", ",", "focal", "hypergranulosis", ",", "orthohyperkeratosis", "and", "telangiectases", "in", "the", "upper", "part", "of", "the", "dermis", ".", "Analogous", "histopathological", "findings", "have", "been", "documented", "in", "lichen", "planus", "-", "like", "skin", "changes", "on", "the", "hands", "following", "hydroxyurea", "therapy", ".", "It", "seems", "doubtful", "whether", "there", "are", "actually", "any", "major", "differences", "between", "those", "skin", "changes", "described", "as", "dermatomyositis", "-", "like", "and", "those", "interpreted", "as", "lichen", "planus", "-", "like", "in", "patients", "receiving", "long", "-", "term", "hydroxyurea", "therapy", "." ]	[ "umlsterm" ]
sequence alterations is an other_name, upstream regulatory region is a DNA_domain_or_region, estrogen receptor gene is a DNA_domain_or_region, ER - negative breast cancer cell line is a cell_line	64115_task0	Sentence: Identification of sequence alterations in the upstream regulatory region of the estrogen receptor gene in an ER-negative breast cancer cell line. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: DNA_domain_or_region, cell_line, other_name	[ "O", "O", "B-other_name", "I-other_name", "O", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "O", "B-cell_line", "I-cell_line", "I-cell_line", "I-cell_line", "I-cell_line", "I-cell_line", "I-cell_line", "O" ]	Identification of sequence alterations in the upstream regulatory region of the estrogen receptor gene in an ER-negative breast cancer cell line.	[ "Identification", "of", "sequence", "alterations", "in", "the", "upstream", "regulatory", "region", "of", "the", "estrogen", "receptor", "gene", "in", "an", "ER", "-", "negative", "breast", "cancer", "cell", "line", "." ]	[ "cell_line", "other_name", "DNA_domain_or_region", "protein_molecule", "tissue", "body_part" ]
sequence alterations is an other_name, upstream regulatory region is a DNA_domain_or_region, estrogen receptor gene is a DNA_domain_or_region, ER - negative breast cancer cell line is a cell_line	64115_task1	Sentence: Identification of sequence alterations in the upstream regulatory region of the estrogen receptor gene in an ER-negative breast cancer cell line. Instructions: please typing these entity words according to sentence: sequence alterations, upstream regulatory region, estrogen receptor gene, ER - negative breast cancer cell line Options: DNA_domain_or_region, cell_line, other_name	[ "O", "O", "B-other_name", "I-other_name", "O", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "O", "B-cell_line", "I-cell_line", "I-cell_line", "I-cell_line", "I-cell_line", "I-cell_line", "I-cell_line", "O" ]	Identification of sequence alterations in the upstream regulatory region of the estrogen receptor gene in an ER-negative breast cancer cell line.	[ "Identification", "of", "sequence", "alterations", "in", "the", "upstream", "regulatory", "region", "of", "the", "estrogen", "receptor", "gene", "in", "an", "ER", "-", "negative", "breast", "cancer", "cell", "line", "." ]	[ "cell_line", "other_name", "DNA_domain_or_region", "protein_molecule", "tissue", "body_part" ]
sequence alterations, upstream regulatory region, estrogen receptor gene, ER - negative breast cancer cell line	64115_task2	Sentence: Identification of sequence alterations in the upstream regulatory region of the estrogen receptor gene in an ER-negative breast cancer cell line. Instructions: please extract entity words from the input sentence	[ "O", "O", "B-other_name", "I-other_name", "O", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "O", "B-cell_line", "I-cell_line", "I-cell_line", "I-cell_line", "I-cell_line", "I-cell_line", "I-cell_line", "O" ]	Identification of sequence alterations in the upstream regulatory region of the estrogen receptor gene in an ER-negative breast cancer cell line.	[ "Identification", "of", "sequence", "alterations", "in", "the", "upstream", "regulatory", "region", "of", "the", "estrogen", "receptor", "gene", "in", "an", "ER", "-", "negative", "breast", "cancer", "cell", "line", "." ]	[ "cell_line", "other_name", "DNA_domain_or_region", "protein_molecule", "tissue", "body_part" ]
cellular networks is a Multi-tissue_structure	PMID-21596785_task0	Sentence: mirAct: a web tool for evaluating microRNA activity based on gene expression data. MicroRNAs (miRNAs) are critical regulators in the complex cellular networks. The mirAct web server (http://sysbio.ustc.edu.cn/software/mirAct) is a tool designed to investigate miRNA activity based on gene-expression data by using the negative regulation relationship between miRNAs and their target genes. mirAct supports multiple-class data and enables clustering analysis based on computationally determined miRNA activity. Here, we describe the framework of mirAct, demonstrate its performance by comparing with other similar programs and exemplify its applications using case studies. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Multi-tissue_structure	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	mirAct: a web tool for evaluating microRNA activity based on gene expression data. MicroRNAs (miRNAs) are critical regulators in the complex cellular networks. The mirAct web server (http://sysbio.ustc.edu.cn/software/mirAct) is a tool designed to investigate miRNA activity based on gene-expression data by using the negative regulation relationship between miRNAs and their target genes. mirAct supports multiple-class data and enables clustering analysis based on computationally determined miRNA activity. Here, we describe the framework of mirAct, demonstrate its performance by comparing with other similar programs and exemplify its applications using case studies.	[ "mirAct", ":", "a", "web", "tool", "for", "evaluating", "microRNA", "activity", "based", "on", "gene", "expression", "data", ".", "\n", "MicroRNAs", "(", "miRNAs", ")", "are", "critical", "regulators", "in", "the", "complex", "cellular", "networks", ".", "The", "mirAct", "web", "server", "(", "http://sysbio.ustc.edu.cn/software/mirAct", ")", "is", "a", "tool", "designed", "to", "investigate", "miRNA", "activity", "based", "on", "gene", "-", "expression", "data", "by", "using", "the", "negative", "regulation", "relationship", "between", "miRNAs", "and", "their", "target", "genes", ".", "mirAct", "supports", "multiple", "-", "class", "data", "and", "enables", "clustering", "analysis", "based", "on", "computationally", "determined", "miRNA", "activity", ".", "Here", ",", "we", "describe", "the", "framework", "of", "mirAct", ",", "demonstrate", "its", "performance", "by", "comparing", "with", "other", "similar", "programs", "and", "exemplify", "its", "applications", "using", "case", "studies", ".", "\n" ]	[ "Multi-tissue_structure" ]
cellular networks is a Multi-tissue_structure	PMID-21596785_task1	Sentence: mirAct: a web tool for evaluating microRNA activity based on gene expression data. MicroRNAs (miRNAs) are critical regulators in the complex cellular networks. The mirAct web server (http://sysbio.ustc.edu.cn/software/mirAct) is a tool designed to investigate miRNA activity based on gene-expression data by using the negative regulation relationship between miRNAs and their target genes. mirAct supports multiple-class data and enables clustering analysis based on computationally determined miRNA activity. Here, we describe the framework of mirAct, demonstrate its performance by comparing with other similar programs and exemplify its applications using case studies. Instructions: please typing these entity words according to sentence: cellular networks Options: Multi-tissue_structure	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	mirAct: a web tool for evaluating microRNA activity based on gene expression data. MicroRNAs (miRNAs) are critical regulators in the complex cellular networks. The mirAct web server (http://sysbio.ustc.edu.cn/software/mirAct) is a tool designed to investigate miRNA activity based on gene-expression data by using the negative regulation relationship between miRNAs and their target genes. mirAct supports multiple-class data and enables clustering analysis based on computationally determined miRNA activity. Here, we describe the framework of mirAct, demonstrate its performance by comparing with other similar programs and exemplify its applications using case studies.	[ "mirAct", ":", "a", "web", "tool", "for", "evaluating", "microRNA", "activity", "based", "on", "gene", "expression", "data", ".", "\n", "MicroRNAs", "(", "miRNAs", ")", "are", "critical", "regulators", "in", "the", "complex", "cellular", "networks", ".", "The", "mirAct", "web", "server", "(", "http://sysbio.ustc.edu.cn/software/mirAct", ")", "is", "a", "tool", "designed", "to", "investigate", "miRNA", "activity", "based", "on", "gene", "-", "expression", "data", "by", "using", "the", "negative", "regulation", "relationship", "between", "miRNAs", "and", "their", "target", "genes", ".", "mirAct", "supports", "multiple", "-", "class", "data", "and", "enables", "clustering", "analysis", "based", "on", "computationally", "determined", "miRNA", "activity", ".", "Here", ",", "we", "describe", "the", "framework", "of", "mirAct", ",", "demonstrate", "its", "performance", "by", "comparing", "with", "other", "similar", "programs", "and", "exemplify", "its", "applications", "using", "case", "studies", ".", "\n" ]	[ "Multi-tissue_structure" ]
cellular networks	PMID-21596785_task2	Sentence: mirAct: a web tool for evaluating microRNA activity based on gene expression data. MicroRNAs (miRNAs) are critical regulators in the complex cellular networks. The mirAct web server (http://sysbio.ustc.edu.cn/software/mirAct) is a tool designed to investigate miRNA activity based on gene-expression data by using the negative regulation relationship between miRNAs and their target genes. mirAct supports multiple-class data and enables clustering analysis based on computationally determined miRNA activity. Here, we describe the framework of mirAct, demonstrate its performance by comparing with other similar programs and exemplify its applications using case studies. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	mirAct: a web tool for evaluating microRNA activity based on gene expression data. MicroRNAs (miRNAs) are critical regulators in the complex cellular networks. The mirAct web server (http://sysbio.ustc.edu.cn/software/mirAct) is a tool designed to investigate miRNA activity based on gene-expression data by using the negative regulation relationship between miRNAs and their target genes. mirAct supports multiple-class data and enables clustering analysis based on computationally determined miRNA activity. Here, we describe the framework of mirAct, demonstrate its performance by comparing with other similar programs and exemplify its applications using case studies.	[ "mirAct", ":", "a", "web", "tool", "for", "evaluating", "microRNA", "activity", "based", "on", "gene", "expression", "data", ".", "\n", "MicroRNAs", "(", "miRNAs", ")", "are", "critical", "regulators", "in", "the", "complex", "cellular", "networks", ".", "The", "mirAct", "web", "server", "(", "http://sysbio.ustc.edu.cn/software/mirAct", ")", "is", "a", "tool", "designed", "to", "investigate", "miRNA", "activity", "based", "on", "gene", "-", "expression", "data", "by", "using", "the", "negative", "regulation", "relationship", "between", "miRNAs", "and", "their", "target", "genes", ".", "mirAct", "supports", "multiple", "-", "class", "data", "and", "enables", "clustering", "analysis", "based", "on", "computationally", "determined", "miRNA", "activity", ".", "Here", ",", "we", "describe", "the", "framework", "of", "mirAct", ",", "demonstrate", "its", "performance", "by", "comparing", "with", "other", "similar", "programs", "and", "exemplify", "its", "applications", "using", "case", "studies", ".", "\n" ]	[ "Multi-tissue_structure" ]
Munc18 - 2 is a Individual_protein, Sec1 is a Individual_protein, syntaxin 3 is a Individual_protein, t - SNARE is a Protein_family_or_group	78_task0	Sentence: Munc18-2 is a Sec1 homologue enriched in epithelial cells and forms a complex with syntaxin 3, a t-SNARE localized to the apical plasma membrane. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Individual_protein, Protein_family_or_group	[ "B-Individual_protein", "I-Individual_protein", "I-Individual_protein", "O", "O", "B-Individual_protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "I-Individual_protein", "O", "O", "B-Protein_family_or_group", "I-Protein_family_or_group", "I-Protein_family_or_group", "O", "O", "O", "O", "O", "O", "O" ]	Munc18-2 is a Sec1 homologue enriched in epithelial cells and forms a complex with syntaxin 3, a t-SNARE localized to the apical plasma membrane.	[ "Munc18", "-", "2", "is", "a", "Sec1", "homologue", "enriched", "in", "epithelial", "cells", "and", "forms", "a", "complex", "with", "syntaxin", "3", ",", "a", "t", "-", "SNARE", "localized", "to", "the", "apical", "plasma", "membrane", "." ]	[ "Individual_protein", "Protein_family_or_group" ]
Munc18 - 2 is a Individual_protein, Sec1 is a Individual_protein, syntaxin 3 is a Individual_protein, t - SNARE is a Protein_family_or_group	78_task1	Sentence: Munc18-2 is a Sec1 homologue enriched in epithelial cells and forms a complex with syntaxin 3, a t-SNARE localized to the apical plasma membrane. Instructions: please typing these entity words according to sentence: Munc18 - 2, Sec1, syntaxin 3, t - SNARE Options: Individual_protein, Protein_family_or_group	[ "B-Individual_protein", "I-Individual_protein", "I-Individual_protein", "O", "O", "B-Individual_protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "I-Individual_protein", "O", "O", "B-Protein_family_or_group", "I-Protein_family_or_group", "I-Protein_family_or_group", "O", "O", "O", "O", "O", "O", "O" ]	Munc18-2 is a Sec1 homologue enriched in epithelial cells and forms a complex with syntaxin 3, a t-SNARE localized to the apical plasma membrane.	[ "Munc18", "-", "2", "is", "a", "Sec1", "homologue", "enriched", "in", "epithelial", "cells", "and", "forms", "a", "complex", "with", "syntaxin", "3", ",", "a", "t", "-", "SNARE", "localized", "to", "the", "apical", "plasma", "membrane", "." ]	[ "Individual_protein", "Protein_family_or_group" ]
Munc18 - 2, Sec1, syntaxin 3, t - SNARE	78_task2	Sentence: Munc18-2 is a Sec1 homologue enriched in epithelial cells and forms a complex with syntaxin 3, a t-SNARE localized to the apical plasma membrane. Instructions: please extract entity words from the input sentence	[ "B-Individual_protein", "I-Individual_protein", "I-Individual_protein", "O", "O", "B-Individual_protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "I-Individual_protein", "O", "O", "B-Protein_family_or_group", "I-Protein_family_or_group", "I-Protein_family_or_group", "O", "O", "O", "O", "O", "O", "O" ]	Munc18-2 is a Sec1 homologue enriched in epithelial cells and forms a complex with syntaxin 3, a t-SNARE localized to the apical plasma membrane.	[ "Munc18", "-", "2", "is", "a", "Sec1", "homologue", "enriched", "in", "epithelial", "cells", "and", "forms", "a", "complex", "with", "syntaxin", "3", ",", "a", "t", "-", "SNARE", "localized", "to", "the", "apical", "plasma", "membrane", "." ]	[ "Individual_protein", "Protein_family_or_group" ]
chicken ovalbumin upstream promoter - transcription factor II is a Gene_or_gene_product, human is a Organism, colorectal cancer is a Cancer, Chicken ovalbumin upstream promoter - transcription factor II is a Gene_or_gene_product, COUP - TFII is a Gene_or_gene_product, COUP - TFII is a Gene_or_gene_product, human is a Organism, lung carcinoma cells is a Cell, COUP - TFII is a Gene_or_gene_product, colorectal cancer is a Cancer, COUP - TFII is a Gene_or_gene_product, colorectal cancer is a Cancer, COUP - TFII is a Gene_or_gene_product, colorectal cancer is a Cancer, COUP - TFII is a Gene_or_gene_product, human is a Organism, colorectal cancer tissues is a Tissue, normal tissues is a Tissue, colorectal cancer is a Cancer, patients is a Organism, COUP - TFII is a Gene_or_gene_product, patients is a Organism, tumors is a Cancer, COUP - TFII is a Gene_or_gene_product, COUP - TFII is a Gene_or_gene_product, vessel is a Multi-tissue_structure, carcinoembryonic antigen is a Gene_or_gene_product, CEA is a Gene_or_gene_product, COUP - TFII is a Gene_or_gene_product, COUP - TFII is a Gene_or_gene_product, COUP - TFII is a Gene_or_gene_product, colorectal cancer is a Cancer	280_task0	Sentence: Clinical significance of chicken ovalbumin upstream promoter-transcription factor II expression in human colorectal cancer. Chicken ovalbumin upstream promoter-transcription factor II (COUP-TFII) plays an essential role in angiogenesis and development. A previous study showed that the expression of COUP-TFII enhanced invasiveness of human lung carcinoma cells. However, no published data are available concerning the biological and clinical significance of COUP-TFII expression in colorectal cancer. Thus, our objective was to explore the expression of COUP-TFII in colorectal cancer as well as its association with clinicopathological features, and to evaluate the role of COUP-TFII as a prognostic indicator in colorectal cancer. We investigated the presence of COUP-TFII in human colorectal cancer tissues and adjacent normal tissues from 95 primary colorectal cancer patients by immunohistochemistry. The correlation between the expression of COUP-TFII and clinicopathologic features was investigated. The 3-year disease-free survival (DFS) and overall survival (OS) of patients with tumors expressing different levels of COUP-TFII were evaluated by the Kaplan-Meier method. No significant correlation was found between COUP-TFII expression and age at surgery, gender, histopathologic differentiation, vessel invasion, carcinoembryonic antigen (CEA), or nodal involvement. However, survival analysis showed that the COUP-TFII-positive group had a significantly better OS compared to COUP-TFII-negative group (80.4% vs. 57.7%, P=0.0491). Based on our results, COUP-TFII may represent a biomarker for good prognosis in colorectal cancer. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Multi-tissue_structure, Tissue, Organism, Cancer, Gene_or_gene_product, Cell	[ "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "B-Organism", "B-Cancer", "I-Cancer", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "B-Organism", "B-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "B-Cancer", "I-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Cancer", "I-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Organism", "B-Tissue", "I-Tissue", "I-Tissue", "O", "O", "B-Tissue", "I-Tissue", "O", "O", "O", "B-Cancer", "I-Cancer", "B-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "O", "B-Cancer", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "O", "O" ]	Clinical significance of chicken ovalbumin upstream promoter-transcription factor II expression in human colorectal cancer. Chicken ovalbumin upstream promoter-transcription factor II (COUP-TFII) plays an essential role in angiogenesis and development. A previous study showed that the expression of COUP-TFII enhanced invasiveness of human lung carcinoma cells. However, no published data are available concerning the biological and clinical significance of COUP-TFII expression in colorectal cancer. Thus, our objective was to explore the expression of COUP-TFII in colorectal cancer as well as its association with clinicopathological features, and to evaluate the role of COUP-TFII as a prognostic indicator in colorectal cancer. We investigated the presence of COUP-TFII in human colorectal cancer tissues and adjacent normal tissues from 95 primary colorectal cancer patients by immunohistochemistry. The correlation between the expression of COUP-TFII and clinicopathologic features was investigated. The 3-year disease-free survival (DFS) and overall survival (OS) of patients with tumors expressing different levels of COUP-TFII were evaluated by the Kaplan-Meier method. No significant correlation was found between COUP-TFII expression and age at surgery, gender, histopathologic differentiation, vessel invasion, carcinoembryonic antigen (CEA), or nodal involvement. However, survival analysis showed that the COUP-TFII-positive group had a significantly better OS compared to COUP-TFII-negative group (80.4% vs. 57.7%, P=0.0491). Based on our results, COUP-TFII may represent a biomarker for good prognosis in colorectal cancer.	[ "Clinical", "significance", "of", "chicken", "ovalbumin", "upstream", "promoter", "-", "transcription", "factor", "II", "expression", "in", "human", "colorectal", "cancer", ".", "\n", "Chicken", "ovalbumin", "upstream", "promoter", "-", "transcription", "factor", "II", "(", "COUP", "-", "TFII", ")", "plays", "an", "essential", "role", "in", "angiogenesis", "and", "development", ".", "A", "previous", "study", "showed", "that", "the", "expression", "of", "COUP", "-", "TFII", "enhanced", "invasiveness", "of", "human", "lung", "carcinoma", "cells", ".", "However", ",", "no", "published", "data", "are", "available", "concerning", "the", "biological", "and", "clinical", "significance", "of", "COUP", "-", "TFII", "expression", "in", "colorectal", "cancer", ".", "Thus", ",", "our", "objective", "was", "to", "explore", "the", "expression", "of", "COUP", "-", "TFII", "in", "colorectal", "cancer", "as", "well", "as", "its", "association", "with", "clinicopathological", "features", ",", "and", "to", "evaluate", "the", "role", "of", "COUP", "-", "TFII", "as", "a", "prognostic", "indicator", "in", "colorectal", "cancer", ".", "We", "investigated", "the", "presence", "of", "COUP", "-", "TFII", "in", "human", "colorectal", "cancer", "tissues", "and", "adjacent", "normal", "tissues", "from", "95", "primary", "colorectal", "cancer", "patients", "by", "immunohistochemistry", ".", "The", "correlation", "between", "the", "expression", "of", "COUP", "-", "TFII", "and", "clinicopathologic", "features", "was", "investigated", ".", "The", "3-year", "disease", "-", "free", "survival", "(", "DFS", ")", "and", "overall", "survival", "(", "OS", ")", "of", "patients", "with", "tumors", "expressing", "different", "levels", "of", "COUP", "-", "TFII", "were", "evaluated", "by", "the", "Kaplan", "-", "Meier", "method", ".", "No", "significant", "correlation", "was", "found", "between", "COUP", "-", "TFII", "expression", "and", "age", "at", "surgery", ",", "gender", ",", "histopathologic", "differentiation", ",", "vessel", "invasion", ",", "carcinoembryonic", "antigen", "(", "CEA", ")", ",", "or", "nodal", "involvement", ".", "However", ",", "survival", "analysis", "showed", "that", "the", "COUP", "-", "TFII", "-", "positive", "group", "had", "a", "significantly", "better", "OS", "compared", "to", "COUP", "-", "TFII", "-", "negative", "group", "(", "80.4", "%", "vs", ".", "57.7", "%", ",", "P=0.0491", ")", ".", "Based", "on", "our", "results", ",", "COUP", "-", "TFII", "may", "represent", "a", "biomarker", "for", "good", "prognosis", "in", "colorectal", "cancer", ".", "\n" ]	[ "Gene_or_gene_product", "Tissue", "Cell", "Cancer", "Organism", "Multi-tissue_structure" ]
chicken ovalbumin upstream promoter - transcription factor II is a Gene_or_gene_product, human is a Organism, colorectal cancer is a Cancer, Chicken ovalbumin upstream promoter - transcription factor II is a Gene_or_gene_product, COUP - TFII is a Gene_or_gene_product, COUP - TFII is a Gene_or_gene_product, human is a Organism, lung carcinoma cells is a Cell, COUP - TFII is a Gene_or_gene_product, colorectal cancer is a Cancer, COUP - TFII is a Gene_or_gene_product, colorectal cancer is a Cancer, COUP - TFII is a Gene_or_gene_product, colorectal cancer is a Cancer, COUP - TFII is a Gene_or_gene_product, human is a Organism, colorectal cancer tissues is a Tissue, normal tissues is a Tissue, colorectal cancer is a Cancer, patients is a Organism, COUP - TFII is a Gene_or_gene_product, patients is a Organism, tumors is a Cancer, COUP - TFII is a Gene_or_gene_product, COUP - TFII is a Gene_or_gene_product, vessel is a Multi-tissue_structure, carcinoembryonic antigen is a Gene_or_gene_product, CEA is a Gene_or_gene_product, COUP - TFII is a Gene_or_gene_product, COUP - TFII is a Gene_or_gene_product, COUP - TFII is a Gene_or_gene_product, colorectal cancer is a Cancer	280_task1	Sentence: Clinical significance of chicken ovalbumin upstream promoter-transcription factor II expression in human colorectal cancer. Chicken ovalbumin upstream promoter-transcription factor II (COUP-TFII) plays an essential role in angiogenesis and development. A previous study showed that the expression of COUP-TFII enhanced invasiveness of human lung carcinoma cells. However, no published data are available concerning the biological and clinical significance of COUP-TFII expression in colorectal cancer. Thus, our objective was to explore the expression of COUP-TFII in colorectal cancer as well as its association with clinicopathological features, and to evaluate the role of COUP-TFII as a prognostic indicator in colorectal cancer. We investigated the presence of COUP-TFII in human colorectal cancer tissues and adjacent normal tissues from 95 primary colorectal cancer patients by immunohistochemistry. The correlation between the expression of COUP-TFII and clinicopathologic features was investigated. The 3-year disease-free survival (DFS) and overall survival (OS) of patients with tumors expressing different levels of COUP-TFII were evaluated by the Kaplan-Meier method. No significant correlation was found between COUP-TFII expression and age at surgery, gender, histopathologic differentiation, vessel invasion, carcinoembryonic antigen (CEA), or nodal involvement. However, survival analysis showed that the COUP-TFII-positive group had a significantly better OS compared to COUP-TFII-negative group (80.4% vs. 57.7%, P=0.0491). Based on our results, COUP-TFII may represent a biomarker for good prognosis in colorectal cancer. Instructions: please typing these entity words according to sentence: chicken ovalbumin upstream promoter - transcription factor II, human, colorectal cancer, Chicken ovalbumin upstream promoter - transcription factor II, COUP - TFII, COUP - TFII, human, lung carcinoma cells, COUP - TFII, colorectal cancer, COUP - TFII, colorectal cancer, COUP - TFII, colorectal cancer, COUP - TFII, human, colorectal cancer tissues, normal tissues, colorectal cancer, patients, COUP - TFII, patients, tumors, COUP - TFII, COUP - TFII, vessel, carcinoembryonic antigen, CEA, COUP - TFII, COUP - TFII, COUP - TFII, colorectal cancer Options: Multi-tissue_structure, Tissue, Organism, Cancer, Gene_or_gene_product, Cell	[ "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "B-Organism", "B-Cancer", "I-Cancer", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "B-Organism", "B-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "B-Cancer", "I-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Cancer", "I-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Organism", "B-Tissue", "I-Tissue", "I-Tissue", "O", "O", "B-Tissue", "I-Tissue", "O", "O", "O", "B-Cancer", "I-Cancer", "B-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "O", "B-Cancer", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "O", "O" ]	Clinical significance of chicken ovalbumin upstream promoter-transcription factor II expression in human colorectal cancer. Chicken ovalbumin upstream promoter-transcription factor II (COUP-TFII) plays an essential role in angiogenesis and development. A previous study showed that the expression of COUP-TFII enhanced invasiveness of human lung carcinoma cells. However, no published data are available concerning the biological and clinical significance of COUP-TFII expression in colorectal cancer. Thus, our objective was to explore the expression of COUP-TFII in colorectal cancer as well as its association with clinicopathological features, and to evaluate the role of COUP-TFII as a prognostic indicator in colorectal cancer. We investigated the presence of COUP-TFII in human colorectal cancer tissues and adjacent normal tissues from 95 primary colorectal cancer patients by immunohistochemistry. The correlation between the expression of COUP-TFII and clinicopathologic features was investigated. The 3-year disease-free survival (DFS) and overall survival (OS) of patients with tumors expressing different levels of COUP-TFII were evaluated by the Kaplan-Meier method. No significant correlation was found between COUP-TFII expression and age at surgery, gender, histopathologic differentiation, vessel invasion, carcinoembryonic antigen (CEA), or nodal involvement. However, survival analysis showed that the COUP-TFII-positive group had a significantly better OS compared to COUP-TFII-negative group (80.4% vs. 57.7%, P=0.0491). Based on our results, COUP-TFII may represent a biomarker for good prognosis in colorectal cancer.	[ "Clinical", "significance", "of", "chicken", "ovalbumin", "upstream", "promoter", "-", "transcription", "factor", "II", "expression", "in", "human", "colorectal", "cancer", ".", "\n", "Chicken", "ovalbumin", "upstream", "promoter", "-", "transcription", "factor", "II", "(", "COUP", "-", "TFII", ")", "plays", "an", "essential", "role", "in", "angiogenesis", "and", "development", ".", "A", "previous", "study", "showed", "that", "the", "expression", "of", "COUP", "-", "TFII", "enhanced", "invasiveness", "of", "human", "lung", "carcinoma", "cells", ".", "However", ",", "no", "published", "data", "are", "available", "concerning", "the", "biological", "and", "clinical", "significance", "of", "COUP", "-", "TFII", "expression", "in", "colorectal", "cancer", ".", "Thus", ",", "our", "objective", "was", "to", "explore", "the", "expression", "of", "COUP", "-", "TFII", "in", "colorectal", "cancer", "as", "well", "as", "its", "association", "with", "clinicopathological", "features", ",", "and", "to", "evaluate", "the", "role", "of", "COUP", "-", "TFII", "as", "a", "prognostic", "indicator", "in", "colorectal", "cancer", ".", "We", "investigated", "the", "presence", "of", "COUP", "-", "TFII", "in", "human", "colorectal", "cancer", "tissues", "and", "adjacent", "normal", "tissues", "from", "95", "primary", "colorectal", "cancer", "patients", "by", "immunohistochemistry", ".", "The", "correlation", "between", "the", "expression", "of", "COUP", "-", "TFII", "and", "clinicopathologic", "features", "was", "investigated", ".", "The", "3-year", "disease", "-", "free", "survival", "(", "DFS", ")", "and", "overall", "survival", "(", "OS", ")", "of", "patients", "with", "tumors", "expressing", "different", "levels", "of", "COUP", "-", "TFII", "were", "evaluated", "by", "the", "Kaplan", "-", "Meier", "method", ".", "No", "significant", "correlation", "was", "found", "between", "COUP", "-", "TFII", "expression", "and", "age", "at", "surgery", ",", "gender", ",", "histopathologic", "differentiation", ",", "vessel", "invasion", ",", "carcinoembryonic", "antigen", "(", "CEA", ")", ",", "or", "nodal", "involvement", ".", "However", ",", "survival", "analysis", "showed", "that", "the", "COUP", "-", "TFII", "-", "positive", "group", "had", "a", "significantly", "better", "OS", "compared", "to", "COUP", "-", "TFII", "-", "negative", "group", "(", "80.4", "%", "vs", ".", "57.7", "%", ",", "P=0.0491", ")", ".", "Based", "on", "our", "results", ",", "COUP", "-", "TFII", "may", "represent", "a", "biomarker", "for", "good", "prognosis", "in", "colorectal", "cancer", ".", "\n" ]	[ "Gene_or_gene_product", "Tissue", "Cell", "Cancer", "Organism", "Multi-tissue_structure" ]
chicken ovalbumin upstream promoter - transcription factor II, human, colorectal cancer, Chicken ovalbumin upstream promoter - transcription factor II, COUP - TFII, COUP - TFII, human, lung carcinoma cells, COUP - TFII, colorectal cancer, COUP - TFII, colorectal cancer, COUP - TFII, colorectal cancer, COUP - TFII, human, colorectal cancer tissues, normal tissues, colorectal cancer, patients, COUP - TFII, patients, tumors, COUP - TFII, COUP - TFII, vessel, carcinoembryonic antigen, CEA, COUP - TFII, COUP - TFII, COUP - TFII, colorectal cancer	280_task2	Sentence: Clinical significance of chicken ovalbumin upstream promoter-transcription factor II expression in human colorectal cancer. Chicken ovalbumin upstream promoter-transcription factor II (COUP-TFII) plays an essential role in angiogenesis and development. A previous study showed that the expression of COUP-TFII enhanced invasiveness of human lung carcinoma cells. However, no published data are available concerning the biological and clinical significance of COUP-TFII expression in colorectal cancer. Thus, our objective was to explore the expression of COUP-TFII in colorectal cancer as well as its association with clinicopathological features, and to evaluate the role of COUP-TFII as a prognostic indicator in colorectal cancer. We investigated the presence of COUP-TFII in human colorectal cancer tissues and adjacent normal tissues from 95 primary colorectal cancer patients by immunohistochemistry. The correlation between the expression of COUP-TFII and clinicopathologic features was investigated. The 3-year disease-free survival (DFS) and overall survival (OS) of patients with tumors expressing different levels of COUP-TFII were evaluated by the Kaplan-Meier method. No significant correlation was found between COUP-TFII expression and age at surgery, gender, histopathologic differentiation, vessel invasion, carcinoembryonic antigen (CEA), or nodal involvement. However, survival analysis showed that the COUP-TFII-positive group had a significantly better OS compared to COUP-TFII-negative group (80.4% vs. 57.7%, P=0.0491). Based on our results, COUP-TFII may represent a biomarker for good prognosis in colorectal cancer. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "B-Organism", "B-Cancer", "I-Cancer", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "B-Organism", "B-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "B-Cancer", "I-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Cancer", "I-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Organism", "B-Tissue", "I-Tissue", "I-Tissue", "O", "O", "B-Tissue", "I-Tissue", "O", "O", "O", "B-Cancer", "I-Cancer", "B-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "O", "B-Cancer", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "O", "O" ]	Clinical significance of chicken ovalbumin upstream promoter-transcription factor II expression in human colorectal cancer. Chicken ovalbumin upstream promoter-transcription factor II (COUP-TFII) plays an essential role in angiogenesis and development. A previous study showed that the expression of COUP-TFII enhanced invasiveness of human lung carcinoma cells. However, no published data are available concerning the biological and clinical significance of COUP-TFII expression in colorectal cancer. Thus, our objective was to explore the expression of COUP-TFII in colorectal cancer as well as its association with clinicopathological features, and to evaluate the role of COUP-TFII as a prognostic indicator in colorectal cancer. We investigated the presence of COUP-TFII in human colorectal cancer tissues and adjacent normal tissues from 95 primary colorectal cancer patients by immunohistochemistry. The correlation between the expression of COUP-TFII and clinicopathologic features was investigated. The 3-year disease-free survival (DFS) and overall survival (OS) of patients with tumors expressing different levels of COUP-TFII were evaluated by the Kaplan-Meier method. No significant correlation was found between COUP-TFII expression and age at surgery, gender, histopathologic differentiation, vessel invasion, carcinoembryonic antigen (CEA), or nodal involvement. However, survival analysis showed that the COUP-TFII-positive group had a significantly better OS compared to COUP-TFII-negative group (80.4% vs. 57.7%, P=0.0491). Based on our results, COUP-TFII may represent a biomarker for good prognosis in colorectal cancer.	[ "Clinical", "significance", "of", "chicken", "ovalbumin", "upstream", "promoter", "-", "transcription", "factor", "II", "expression", "in", "human", "colorectal", "cancer", ".", "\n", "Chicken", "ovalbumin", "upstream", "promoter", "-", "transcription", "factor", "II", "(", "COUP", "-", "TFII", ")", "plays", "an", "essential", "role", "in", "angiogenesis", "and", "development", ".", "A", "previous", "study", "showed", "that", "the", "expression", "of", "COUP", "-", "TFII", "enhanced", "invasiveness", "of", "human", "lung", "carcinoma", "cells", ".", "However", ",", "no", "published", "data", "are", "available", "concerning", "the", "biological", "and", "clinical", "significance", "of", "COUP", "-", "TFII", "expression", "in", "colorectal", "cancer", ".", "Thus", ",", "our", "objective", "was", "to", "explore", "the", "expression", "of", "COUP", "-", "TFII", "in", "colorectal", "cancer", "as", "well", "as", "its", "association", "with", "clinicopathological", "features", ",", "and", "to", "evaluate", "the", "role", "of", "COUP", "-", "TFII", "as", "a", "prognostic", "indicator", "in", "colorectal", "cancer", ".", "We", "investigated", "the", "presence", "of", "COUP", "-", "TFII", "in", "human", "colorectal", "cancer", "tissues", "and", "adjacent", "normal", "tissues", "from", "95", "primary", "colorectal", "cancer", "patients", "by", "immunohistochemistry", ".", "The", "correlation", "between", "the", "expression", "of", "COUP", "-", "TFII", "and", "clinicopathologic", "features", "was", "investigated", ".", "The", "3-year", "disease", "-", "free", "survival", "(", "DFS", ")", "and", "overall", "survival", "(", "OS", ")", "of", "patients", "with", "tumors", "expressing", "different", "levels", "of", "COUP", "-", "TFII", "were", "evaluated", "by", "the", "Kaplan", "-", "Meier", "method", ".", "No", "significant", "correlation", "was", "found", "between", "COUP", "-", "TFII", "expression", "and", "age", "at", "surgery", ",", "gender", ",", "histopathologic", "differentiation", ",", "vessel", "invasion", ",", "carcinoembryonic", "antigen", "(", "CEA", ")", ",", "or", "nodal", "involvement", ".", "However", ",", "survival", "analysis", "showed", "that", "the", "COUP", "-", "TFII", "-", "positive", "group", "had", "a", "significantly", "better", "OS", "compared", "to", "COUP", "-", "TFII", "-", "negative", "group", "(", "80.4", "%", "vs", ".", "57.7", "%", ",", "P=0.0491", ")", ".", "Based", "on", "our", "results", ",", "COUP", "-", "TFII", "may", "represent", "a", "biomarker", "for", "good", "prognosis", "in", "colorectal", "cancer", ".", "\n" ]	[ "Gene_or_gene_product", "Tissue", "Cell", "Cancer", "Organism", "Multi-tissue_structure" ]
Kind is an umlsterm, Hodentorsion is an umlsterm, Hydatidentorsion is an umlsterm, Oedem is an umlsterm, Haematom is an umlsterm, Haematoms is an umlsterm, Nebennierenblutung is an umlsterm, Hodentorsion is an umlsterm, Hodenfreilegung is an umlsterm, Hoden is an umlsterm, Nebennierenblutung is an umlsterm, Nebennierenblutung is an umlsterm, Nebennierenblutungen is an umlsterm, Geburtsgewicht is an umlsterm, Hypoxie is an umlsterm, Asphyxie is an umlsterm, Kindern is an umlsterm, Kindes is an umlsterm, Therapie is an umlsterm	DerUrologeA.00390048.ger.abstr_task0	Sentence: Die haeufigsten Ursachen des akuten Skrotums " " beim Kind sind Hodentorsion Hydatidentorsion , Epididymoorchitis , idiopathisches Oedem und Haematom . , Selten kann der Ursprung eines skrotalen Haematoms eine extra- oder intraperitoneale Nebennierenblutung sein . Bislang wurden 12 Faelle beschrieben . Wir berichten ueber 3 weitere Faelle , die zwischen 1992 und 1997 in unserer Klinik behandelt wurden . Im ersten Fall erfolgte bei Verdacht auf Hodentorsion die operative Hodenfreilegung , und es fand sich neben einem unauffaelligen Hoden nur blutig-seroese Fluessigkeit . Sonographisch konnte postoperativ eine ipsilaterale Nebennierenblutung nachgewiesen werden . In den uebrigen 2 Faellen wurde die Nebennierenblutung als Ursache der skrotalen Schwellung primaer erkannt und auf eine Operation verzichtet . Ursaechlich fuer Nebennierenblutungen beim Neugeborenen sind vor allem Geburtstrauma , grosses Geburtsgewicht , Hypoxie und Asphyxie . Dies war auch bei unseren Kindern der Fall . Kann die klinische Situation des Kindes beherrscht werden , so ist die vollstaendige Ausheilung unter konservativer Therapie zu erwarten . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]	Die haeufigsten Ursachen des akuten Skrotums " " beim Kind sind Hodentorsion Hydatidentorsion , Epididymoorchitis , idiopathisches Oedem und Haematom . , Selten kann der Ursprung eines skrotalen Haematoms eine extra- oder intraperitoneale Nebennierenblutung sein . Bislang wurden 12 Faelle beschrieben . Wir berichten ueber 3 weitere Faelle , die zwischen 1992 und 1997 in unserer Klinik behandelt wurden . Im ersten Fall erfolgte bei Verdacht auf Hodentorsion die operative Hodenfreilegung , und es fand sich neben einem unauffaelligen Hoden nur blutig-seroese Fluessigkeit . Sonographisch konnte postoperativ eine ipsilaterale Nebennierenblutung nachgewiesen werden . In den uebrigen 2 Faellen wurde die Nebennierenblutung als Ursache der skrotalen Schwellung primaer erkannt und auf eine Operation verzichtet . Ursaechlich fuer Nebennierenblutungen beim Neugeborenen sind vor allem Geburtstrauma , grosses Geburtsgewicht , Hypoxie und Asphyxie . Dies war auch bei unseren Kindern der Fall . Kann die klinische Situation des Kindes beherrscht werden , so ist die vollstaendige Ausheilung unter konservativer Therapie zu erwarten .	[ "Die", "haeufigsten", "Ursachen", "des", "akuten", "Skrotums", "\"", "\"", "beim", "Kind", "sind", "Hodentorsion", "Hydatidentorsion", ",", "Epididymoorchitis", ",", "idiopathisches", "Oedem", "und", "Haematom", ".", ",", "Selten", "kann", "der", "Ursprung", "eines", "skrotalen", "Haematoms", "eine", "extra-", "oder", "intraperitoneale", "Nebennierenblutung", "sein", ".", "Bislang", "wurden", "12", "Faelle", "beschrieben", ".", "Wir", "berichten", "ueber", "3", "weitere", "Faelle", ",", "die", "zwischen", "1992", "und", "1997", "in", "unserer", "Klinik", "behandelt", "wurden", ".", "Im", "ersten", "Fall", "erfolgte", "bei", "Verdacht", "auf", "Hodentorsion", "die", "operative", "Hodenfreilegung", ",", "und", "es", "fand", "sich", "neben", "einem", "unauffaelligen", "Hoden", "nur", "blutig", "-", "seroese", "Fluessigkeit", ".", "Sonographisch", "konnte", "postoperativ", "eine", "ipsilaterale", "Nebennierenblutung", "nachgewiesen", "werden", ".", "In", "den", "uebrigen", "2", "Faellen", "wurde", "die", "Nebennierenblutung", "als", "Ursache", "der", "skrotalen", "Schwellung", "primaer", "erkannt", "und", "auf", "eine", "Operation", "verzichtet", ".", "Ursaechlich", "fuer", "Nebennierenblutungen", "beim", "Neugeborenen", "sind", "vor", "allem", "Geburtstrauma", ",", "grosses", "Geburtsgewicht", ",", "Hypoxie", "und", "Asphyxie", ".", "Dies", "war", "auch", "bei", "unseren", "Kindern", "der", "Fall", ".", "Kann", "die", "klinische", "Situation", "des", "Kindes", "beherrscht", "werden", ",", "so", "ist", "die", "vollstaendige", "Ausheilung", "unter", "konservativer", "Therapie", "zu", "erwarten", "." ]	[ "umlsterm" ]
Kind is an umlsterm, Hodentorsion is an umlsterm, Hydatidentorsion is an umlsterm, Oedem is an umlsterm, Haematom is an umlsterm, Haematoms is an umlsterm, Nebennierenblutung is an umlsterm, Hodentorsion is an umlsterm, Hodenfreilegung is an umlsterm, Hoden is an umlsterm, Nebennierenblutung is an umlsterm, Nebennierenblutung is an umlsterm, Nebennierenblutungen is an umlsterm, Geburtsgewicht is an umlsterm, Hypoxie is an umlsterm, Asphyxie is an umlsterm, Kindern is an umlsterm, Kindes is an umlsterm, Therapie is an umlsterm	DerUrologeA.00390048.ger.abstr_task1	Sentence: Die haeufigsten Ursachen des akuten Skrotums " " beim Kind sind Hodentorsion Hydatidentorsion , Epididymoorchitis , idiopathisches Oedem und Haematom . , Selten kann der Ursprung eines skrotalen Haematoms eine extra- oder intraperitoneale Nebennierenblutung sein . Bislang wurden 12 Faelle beschrieben . Wir berichten ueber 3 weitere Faelle , die zwischen 1992 und 1997 in unserer Klinik behandelt wurden . Im ersten Fall erfolgte bei Verdacht auf Hodentorsion die operative Hodenfreilegung , und es fand sich neben einem unauffaelligen Hoden nur blutig-seroese Fluessigkeit . Sonographisch konnte postoperativ eine ipsilaterale Nebennierenblutung nachgewiesen werden . In den uebrigen 2 Faellen wurde die Nebennierenblutung als Ursache der skrotalen Schwellung primaer erkannt und auf eine Operation verzichtet . Ursaechlich fuer Nebennierenblutungen beim Neugeborenen sind vor allem Geburtstrauma , grosses Geburtsgewicht , Hypoxie und Asphyxie . Dies war auch bei unseren Kindern der Fall . Kann die klinische Situation des Kindes beherrscht werden , so ist die vollstaendige Ausheilung unter konservativer Therapie zu erwarten . Instructions: please typing these entity words according to sentence: Kind, Hodentorsion, Hydatidentorsion, Oedem, Haematom, Haematoms, Nebennierenblutung, Hodentorsion, Hodenfreilegung, Hoden, Nebennierenblutung, Nebennierenblutung, Nebennierenblutungen, Geburtsgewicht, Hypoxie, Asphyxie, Kindern, Kindes, Therapie Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]	Die haeufigsten Ursachen des akuten Skrotums " " beim Kind sind Hodentorsion Hydatidentorsion , Epididymoorchitis , idiopathisches Oedem und Haematom . , Selten kann der Ursprung eines skrotalen Haematoms eine extra- oder intraperitoneale Nebennierenblutung sein . Bislang wurden 12 Faelle beschrieben . Wir berichten ueber 3 weitere Faelle , die zwischen 1992 und 1997 in unserer Klinik behandelt wurden . Im ersten Fall erfolgte bei Verdacht auf Hodentorsion die operative Hodenfreilegung , und es fand sich neben einem unauffaelligen Hoden nur blutig-seroese Fluessigkeit . Sonographisch konnte postoperativ eine ipsilaterale Nebennierenblutung nachgewiesen werden . In den uebrigen 2 Faellen wurde die Nebennierenblutung als Ursache der skrotalen Schwellung primaer erkannt und auf eine Operation verzichtet . Ursaechlich fuer Nebennierenblutungen beim Neugeborenen sind vor allem Geburtstrauma , grosses Geburtsgewicht , Hypoxie und Asphyxie . Dies war auch bei unseren Kindern der Fall . Kann die klinische Situation des Kindes beherrscht werden , so ist die vollstaendige Ausheilung unter konservativer Therapie zu erwarten .	[ "Die", "haeufigsten", "Ursachen", "des", "akuten", "Skrotums", "\"", "\"", "beim", "Kind", "sind", "Hodentorsion", "Hydatidentorsion", ",", "Epididymoorchitis", ",", "idiopathisches", "Oedem", "und", "Haematom", ".", ",", "Selten", "kann", "der", "Ursprung", "eines", "skrotalen", "Haematoms", "eine", "extra-", "oder", "intraperitoneale", "Nebennierenblutung", "sein", ".", "Bislang", "wurden", "12", "Faelle", "beschrieben", ".", "Wir", "berichten", "ueber", "3", "weitere", "Faelle", ",", "die", "zwischen", "1992", "und", "1997", "in", "unserer", "Klinik", "behandelt", "wurden", ".", "Im", "ersten", "Fall", "erfolgte", "bei", "Verdacht", "auf", "Hodentorsion", "die", "operative", "Hodenfreilegung", ",", "und", "es", "fand", "sich", "neben", "einem", "unauffaelligen", "Hoden", "nur", "blutig", "-", "seroese", "Fluessigkeit", ".", "Sonographisch", "konnte", "postoperativ", "eine", "ipsilaterale", "Nebennierenblutung", "nachgewiesen", "werden", ".", "In", "den", "uebrigen", "2", "Faellen", "wurde", "die", "Nebennierenblutung", "als", "Ursache", "der", "skrotalen", "Schwellung", "primaer", "erkannt", "und", "auf", "eine", "Operation", "verzichtet", ".", "Ursaechlich", "fuer", "Nebennierenblutungen", "beim", "Neugeborenen", "sind", "vor", "allem", "Geburtstrauma", ",", "grosses", "Geburtsgewicht", ",", "Hypoxie", "und", "Asphyxie", ".", "Dies", "war", "auch", "bei", "unseren", "Kindern", "der", "Fall", ".", "Kann", "die", "klinische", "Situation", "des", "Kindes", "beherrscht", "werden", ",", "so", "ist", "die", "vollstaendige", "Ausheilung", "unter", "konservativer", "Therapie", "zu", "erwarten", "." ]	[ "umlsterm" ]
Kind, Hodentorsion, Hydatidentorsion, Oedem, Haematom, Haematoms, Nebennierenblutung, Hodentorsion, Hodenfreilegung, Hoden, Nebennierenblutung, Nebennierenblutung, Nebennierenblutungen, Geburtsgewicht, Hypoxie, Asphyxie, Kindern, Kindes, Therapie	DerUrologeA.00390048.ger.abstr_task2	Sentence: Die haeufigsten Ursachen des akuten Skrotums " " beim Kind sind Hodentorsion Hydatidentorsion , Epididymoorchitis , idiopathisches Oedem und Haematom . , Selten kann der Ursprung eines skrotalen Haematoms eine extra- oder intraperitoneale Nebennierenblutung sein . Bislang wurden 12 Faelle beschrieben . Wir berichten ueber 3 weitere Faelle , die zwischen 1992 und 1997 in unserer Klinik behandelt wurden . Im ersten Fall erfolgte bei Verdacht auf Hodentorsion die operative Hodenfreilegung , und es fand sich neben einem unauffaelligen Hoden nur blutig-seroese Fluessigkeit . Sonographisch konnte postoperativ eine ipsilaterale Nebennierenblutung nachgewiesen werden . In den uebrigen 2 Faellen wurde die Nebennierenblutung als Ursache der skrotalen Schwellung primaer erkannt und auf eine Operation verzichtet . Ursaechlich fuer Nebennierenblutungen beim Neugeborenen sind vor allem Geburtstrauma , grosses Geburtsgewicht , Hypoxie und Asphyxie . Dies war auch bei unseren Kindern der Fall . Kann die klinische Situation des Kindes beherrscht werden , so ist die vollstaendige Ausheilung unter konservativer Therapie zu erwarten . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]	Die haeufigsten Ursachen des akuten Skrotums " " beim Kind sind Hodentorsion Hydatidentorsion , Epididymoorchitis , idiopathisches Oedem und Haematom . , Selten kann der Ursprung eines skrotalen Haematoms eine extra- oder intraperitoneale Nebennierenblutung sein . Bislang wurden 12 Faelle beschrieben . Wir berichten ueber 3 weitere Faelle , die zwischen 1992 und 1997 in unserer Klinik behandelt wurden . Im ersten Fall erfolgte bei Verdacht auf Hodentorsion die operative Hodenfreilegung , und es fand sich neben einem unauffaelligen Hoden nur blutig-seroese Fluessigkeit . Sonographisch konnte postoperativ eine ipsilaterale Nebennierenblutung nachgewiesen werden . In den uebrigen 2 Faellen wurde die Nebennierenblutung als Ursache der skrotalen Schwellung primaer erkannt und auf eine Operation verzichtet . Ursaechlich fuer Nebennierenblutungen beim Neugeborenen sind vor allem Geburtstrauma , grosses Geburtsgewicht , Hypoxie und Asphyxie . Dies war auch bei unseren Kindern der Fall . Kann die klinische Situation des Kindes beherrscht werden , so ist die vollstaendige Ausheilung unter konservativer Therapie zu erwarten .	[ "Die", "haeufigsten", "Ursachen", "des", "akuten", "Skrotums", "\"", "\"", "beim", "Kind", "sind", "Hodentorsion", "Hydatidentorsion", ",", "Epididymoorchitis", ",", "idiopathisches", "Oedem", "und", "Haematom", ".", ",", "Selten", "kann", "der", "Ursprung", "eines", "skrotalen", "Haematoms", "eine", "extra-", "oder", "intraperitoneale", "Nebennierenblutung", "sein", ".", "Bislang", "wurden", "12", "Faelle", "beschrieben", ".", "Wir", "berichten", "ueber", "3", "weitere", "Faelle", ",", "die", "zwischen", "1992", "und", "1997", "in", "unserer", "Klinik", "behandelt", "wurden", ".", "Im", "ersten", "Fall", "erfolgte", "bei", "Verdacht", "auf", "Hodentorsion", "die", "operative", "Hodenfreilegung", ",", "und", "es", "fand", "sich", "neben", "einem", "unauffaelligen", "Hoden", "nur", "blutig", "-", "seroese", "Fluessigkeit", ".", "Sonographisch", "konnte", "postoperativ", "eine", "ipsilaterale", "Nebennierenblutung", "nachgewiesen", "werden", ".", "In", "den", "uebrigen", "2", "Faellen", "wurde", "die", "Nebennierenblutung", "als", "Ursache", "der", "skrotalen", "Schwellung", "primaer", "erkannt", "und", "auf", "eine", "Operation", "verzichtet", ".", "Ursaechlich", "fuer", "Nebennierenblutungen", "beim", "Neugeborenen", "sind", "vor", "allem", "Geburtstrauma", ",", "grosses", "Geburtsgewicht", ",", "Hypoxie", "und", "Asphyxie", ".", "Dies", "war", "auch", "bei", "unseren", "Kindern", "der", "Fall", ".", "Kann", "die", "klinische", "Situation", "des", "Kindes", "beherrscht", "werden", ",", "so", "ist", "die", "vollstaendige", "Ausheilung", "unter", "konservativer", "Therapie", "zu", "erwarten", "." ]	[ "umlsterm" ]
nuclear factor of activated T cells is a protein_molecule, Jurkat cell clones is a cell_line	30368_task0	Sentence: Regulation of the nuclear factor of activated T cells in stably transfected Jurkat cell clones. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: cell_line, protein_molecule	[ "O", "O", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "O", "O", "B-cell_line", "I-cell_line", "I-cell_line", "O" ]	Regulation of the nuclear factor of activated T cells in stably transfected Jurkat cell clones.	[ "Regulation", "of", "the", "nuclear", "factor", "of", "activated", "T", "cells", "in", "stably", "transfected", "Jurkat", "cell", "clones", "." ]	[ "protein_molecule", "other_organic_compound", "other_name", "cell_line", "DNA_family_or_group", "cell_type", "nucleotide" ]
nuclear factor of activated T cells is a protein_molecule, Jurkat cell clones is a cell_line	30368_task1	Sentence: Regulation of the nuclear factor of activated T cells in stably transfected Jurkat cell clones. Instructions: please typing these entity words according to sentence: nuclear factor of activated T cells, Jurkat cell clones Options: cell_line, protein_molecule	[ "O", "O", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "O", "O", "B-cell_line", "I-cell_line", "I-cell_line", "O" ]	Regulation of the nuclear factor of activated T cells in stably transfected Jurkat cell clones.	[ "Regulation", "of", "the", "nuclear", "factor", "of", "activated", "T", "cells", "in", "stably", "transfected", "Jurkat", "cell", "clones", "." ]	[ "protein_molecule", "other_organic_compound", "other_name", "cell_line", "DNA_family_or_group", "cell_type", "nucleotide" ]
nuclear factor of activated T cells, Jurkat cell clones	30368_task2	Sentence: Regulation of the nuclear factor of activated T cells in stably transfected Jurkat cell clones. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "O", "O", "B-cell_line", "I-cell_line", "I-cell_line", "O" ]	Regulation of the nuclear factor of activated T cells in stably transfected Jurkat cell clones.	[ "Regulation", "of", "the", "nuclear", "factor", "of", "activated", "T", "cells", "in", "stably", "transfected", "Jurkat", "cell", "clones", "." ]	[ "protein_molecule", "other_organic_compound", "other_name", "cell_line", "DNA_family_or_group", "cell_type", "nucleotide" ]
p65 subunit is a protein_subunit, NF - kappa B is a protein_molecule, I kappa B is a protein_molecule	81704_task0	Sentence: The p65 subunit of NF-kappa B regulates I kappa B by two distinct mechanisms. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: protein_molecule, protein_subunit	[ "O", "B-protein_subunit", "I-protein_subunit", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "O", "O", "O", "O" ]	The p65 subunit of NF-kappa B regulates I kappa B by two distinct mechanisms.	[ "The", "p65", "subunit", "of", "NF", "-", "kappa", "B", "regulates", "I", "kappa", "B", "by", "two", "distinct", "mechanisms", "." ]	[ "(AND cell_type cell_type)", "other_name", "RNA_molecule", "protein_subunit", "protein_molecule", "cell_component", "", "protein_complex" ]
p65 subunit is a protein_subunit, NF - kappa B is a protein_molecule, I kappa B is a protein_molecule	81704_task1	Sentence: The p65 subunit of NF-kappa B regulates I kappa B by two distinct mechanisms. Instructions: please typing these entity words according to sentence: p65 subunit, NF - kappa B, I kappa B Options: protein_molecule, protein_subunit	[ "O", "B-protein_subunit", "I-protein_subunit", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "O", "O", "O", "O" ]	The p65 subunit of NF-kappa B regulates I kappa B by two distinct mechanisms.	[ "The", "p65", "subunit", "of", "NF", "-", "kappa", "B", "regulates", "I", "kappa", "B", "by", "two", "distinct", "mechanisms", "." ]	[ "(AND cell_type cell_type)", "other_name", "RNA_molecule", "protein_subunit", "protein_molecule", "cell_component", "", "protein_complex" ]
p65 subunit, NF - kappa B, I kappa B	81704_task2	Sentence: The p65 subunit of NF-kappa B regulates I kappa B by two distinct mechanisms. Instructions: please extract entity words from the input sentence	[ "O", "B-protein_subunit", "I-protein_subunit", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "O", "O", "O", "O" ]	The p65 subunit of NF-kappa B regulates I kappa B by two distinct mechanisms.	[ "The", "p65", "subunit", "of", "NF", "-", "kappa", "B", "regulates", "I", "kappa", "B", "by", "two", "distinct", "mechanisms", "." ]	[ "(AND cell_type cell_type)", "other_name", "RNA_molecule", "protein_subunit", "protein_molecule", "cell_component", "", "protein_complex" ]
Dacryocystorhinostomy is an umlsterm, standard is an umlsterm, procedure is an umlsterm, stenosis is an umlsterm, nasolacrimal duct is an umlsterm, methods is an umlsterm, polyurethane is an umlsterm, stent is an umlsterm, nasolacrimal duct is an umlsterm, complications is an umlsterm, method is an umlsterm, prospective study is an umlsterm	DerOpthalmologe.90960658.eng.abstr_task0	Sentence: Dacryocystorhinostomy is still the standard procedure complete stenosis of the nasolacrimal duct . New methods try to preserve the natural lacrimal pathway . Song implanted in 1995 a nasolacrimal polyurethane stent through the nasolacrimal duct . The results and complications of this new method are described in this prospective study . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]	Dacryocystorhinostomy is still the standard procedure complete stenosis of the nasolacrimal duct . New methods try to preserve the natural lacrimal pathway . Song implanted in 1995 a nasolacrimal polyurethane stent through the nasolacrimal duct . The results and complications of this new method are described in this prospective study .	[ "Dacryocystorhinostomy", "is", "still", "the", "standard", "procedure", "complete", "stenosis", "of", "the", "nasolacrimal", "duct", ".", "New", "methods", "try", "to", "preserve", "the", "natural", "lacrimal", "pathway", ".", "Song", "implanted", "in", "1995", "a", "nasolacrimal", "polyurethane", "stent", "through", "the", "nasolacrimal", "duct", ".", "The", "results", "and", "complications", "of", "this", "new", "method", "are", "described", "in", "this", "prospective", "study", "." ]	[ "umlsterm" ]
Dacryocystorhinostomy is an umlsterm, standard is an umlsterm, procedure is an umlsterm, stenosis is an umlsterm, nasolacrimal duct is an umlsterm, methods is an umlsterm, polyurethane is an umlsterm, stent is an umlsterm, nasolacrimal duct is an umlsterm, complications is an umlsterm, method is an umlsterm, prospective study is an umlsterm	DerOpthalmologe.90960658.eng.abstr_task1	Sentence: Dacryocystorhinostomy is still the standard procedure complete stenosis of the nasolacrimal duct . New methods try to preserve the natural lacrimal pathway . Song implanted in 1995 a nasolacrimal polyurethane stent through the nasolacrimal duct . The results and complications of this new method are described in this prospective study . Instructions: please typing these entity words according to sentence: Dacryocystorhinostomy, standard, procedure, stenosis, nasolacrimal duct, methods, polyurethane, stent, nasolacrimal duct, complications, method, prospective study Options: umlsterm	[ "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]	Dacryocystorhinostomy is still the standard procedure complete stenosis of the nasolacrimal duct . New methods try to preserve the natural lacrimal pathway . Song implanted in 1995 a nasolacrimal polyurethane stent through the nasolacrimal duct . The results and complications of this new method are described in this prospective study .	[ "Dacryocystorhinostomy", "is", "still", "the", "standard", "procedure", "complete", "stenosis", "of", "the", "nasolacrimal", "duct", ".", "New", "methods", "try", "to", "preserve", "the", "natural", "lacrimal", "pathway", ".", "Song", "implanted", "in", "1995", "a", "nasolacrimal", "polyurethane", "stent", "through", "the", "nasolacrimal", "duct", ".", "The", "results", "and", "complications", "of", "this", "new", "method", "are", "described", "in", "this", "prospective", "study", "." ]	[ "umlsterm" ]
Dacryocystorhinostomy, standard, procedure, stenosis, nasolacrimal duct, methods, polyurethane, stent, nasolacrimal duct, complications, method, prospective study	DerOpthalmologe.90960658.eng.abstr_task2	Sentence: Dacryocystorhinostomy is still the standard procedure complete stenosis of the nasolacrimal duct . New methods try to preserve the natural lacrimal pathway . Song implanted in 1995 a nasolacrimal polyurethane stent through the nasolacrimal duct . The results and complications of this new method are described in this prospective study . Instructions: please extract entity words from the input sentence	[ "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]	Dacryocystorhinostomy is still the standard procedure complete stenosis of the nasolacrimal duct . New methods try to preserve the natural lacrimal pathway . Song implanted in 1995 a nasolacrimal polyurethane stent through the nasolacrimal duct . The results and complications of this new method are described in this prospective study .	[ "Dacryocystorhinostomy", "is", "still", "the", "standard", "procedure", "complete", "stenosis", "of", "the", "nasolacrimal", "duct", ".", "New", "methods", "try", "to", "preserve", "the", "natural", "lacrimal", "pathway", ".", "Song", "implanted", "in", "1995", "a", "nasolacrimal", "polyurethane", "stent", "through", "the", "nasolacrimal", "duct", ".", "The", "results", "and", "complications", "of", "this", "new", "method", "are", "described", "in", "this", "prospective", "study", "." ]	[ "umlsterm" ]
paricalcitol is a CHEMICAL, doxercalciferol is a CHEMICAL	20204178_task0	Sentence: Comparison of the pharmacological effects of paricalcitol and doxercalciferol on the factors involved in mineral homeostasis. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: CHEMICAL	[ "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O" ]	Comparison of the pharmacological effects of paricalcitol and doxercalciferol on the factors involved in mineral homeostasis.	[ "Comparison", "of", "the", "pharmacological", "effects", "of", "paricalcitol", "and", "doxercalciferol", "on", "the", "factors", "involved", "in", "mineral", "homeostasis", "." ]	[ "GENE-Y", "CHEMICAL", "GENE-N" ]
paricalcitol is a CHEMICAL, doxercalciferol is a CHEMICAL	20204178_task1	Sentence: Comparison of the pharmacological effects of paricalcitol and doxercalciferol on the factors involved in mineral homeostasis. Instructions: please typing these entity words according to sentence: paricalcitol, doxercalciferol Options: CHEMICAL	[ "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O" ]	Comparison of the pharmacological effects of paricalcitol and doxercalciferol on the factors involved in mineral homeostasis.	[ "Comparison", "of", "the", "pharmacological", "effects", "of", "paricalcitol", "and", "doxercalciferol", "on", "the", "factors", "involved", "in", "mineral", "homeostasis", "." ]	[ "GENE-Y", "CHEMICAL", "GENE-N" ]
paricalcitol, doxercalciferol	20204178_task2	Sentence: Comparison of the pharmacological effects of paricalcitol and doxercalciferol on the factors involved in mineral homeostasis. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O" ]	Comparison of the pharmacological effects of paricalcitol and doxercalciferol on the factors involved in mineral homeostasis.	[ "Comparison", "of", "the", "pharmacological", "effects", "of", "paricalcitol", "and", "doxercalciferol", "on", "the", "factors", "involved", "in", "mineral", "homeostasis", "." ]	[ "GENE-Y", "CHEMICAL", "GENE-N" ]
Arg is an amino-acid, F - actin is a protein	1.0alpha7.train.1151_task0	Sentence: The convex shape of the Scatchard plot indicated that Arg binds to F-actin with positive cooperativity (Fig. 1 G; ref. 19). Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: amino-acid, protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-amino-acid", "O", "O", "O", "B-protein", "I-protein", "I-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	The convex shape of the Scatchard plot indicated that Arg binds to F-actin with positive cooperativity (Fig. 1 G; ref. 19).	[ "The", "convex", "shape", "of", "the", "Scatchard", "plot", "indicated", "that", " ", "Arg", "binds", "to", " ", "F", "-", "actin", "with", "positive", "cooperativity", "(", "Fig", ".", " ", "1", "G", ";", "ref", ".", " ", "19", ")", "." ]	[ "protein", "protein-family", "amino-acid" ]
Arg is an amino-acid, F - actin is a protein	1.0alpha7.train.1151_task1	Sentence: The convex shape of the Scatchard plot indicated that Arg binds to F-actin with positive cooperativity (Fig. 1 G; ref. 19). Instructions: please typing these entity words according to sentence: Arg, F - actin Options: amino-acid, protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-amino-acid", "O", "O", "O", "B-protein", "I-protein", "I-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	The convex shape of the Scatchard plot indicated that Arg binds to F-actin with positive cooperativity (Fig. 1 G; ref. 19).	[ "The", "convex", "shape", "of", "the", "Scatchard", "plot", "indicated", "that", " ", "Arg", "binds", "to", " ", "F", "-", "actin", "with", "positive", "cooperativity", "(", "Fig", ".", " ", "1", "G", ";", "ref", ".", " ", "19", ")", "." ]	[ "protein", "protein-family", "amino-acid" ]
Arg, F - actin	1.0alpha7.train.1151_task2	Sentence: The convex shape of the Scatchard plot indicated that Arg binds to F-actin with positive cooperativity (Fig. 1 G; ref. 19). Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-amino-acid", "O", "O", "O", "B-protein", "I-protein", "I-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	The convex shape of the Scatchard plot indicated that Arg binds to F-actin with positive cooperativity (Fig. 1 G; ref. 19).	[ "The", "convex", "shape", "of", "the", "Scatchard", "plot", "indicated", "that", " ", "Arg", "binds", "to", " ", "F", "-", "actin", "with", "positive", "cooperativity", "(", "Fig", ".", " ", "1", "G", ";", "ref", ".", " ", "19", ")", "." ]	[ "protein", "protein-family", "amino-acid" ]
AT1 is a GENE-Y, eprosartan is a CHEMICAL	12927226_task0	Sentence: AT1 antagonism by eprosartan lowers heart rate variability and baroreflex gain. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y, CHEMICAL	[ "B-GENE-Y", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O" ]	AT1 antagonism by eprosartan lowers heart rate variability and baroreflex gain.	[ "AT1", "antagonism", "by", "eprosartan", "lowers", "heart", "rate", "variability", "and", "baroreflex", "gain", "." ]	[ "GENE-Y", "CHEMICAL" ]
AT1 is a GENE-Y, eprosartan is a CHEMICAL	12927226_task1	Sentence: AT1 antagonism by eprosartan lowers heart rate variability and baroreflex gain. Instructions: please typing these entity words according to sentence: AT1, eprosartan Options: GENE-Y, CHEMICAL	[ "B-GENE-Y", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O" ]	AT1 antagonism by eprosartan lowers heart rate variability and baroreflex gain.	[ "AT1", "antagonism", "by", "eprosartan", "lowers", "heart", "rate", "variability", "and", "baroreflex", "gain", "." ]	[ "GENE-Y", "CHEMICAL" ]
AT1, eprosartan	12927226_task2	Sentence: AT1 antagonism by eprosartan lowers heart rate variability and baroreflex gain. Instructions: please extract entity words from the input sentence	[ "B-GENE-Y", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O" ]	AT1 antagonism by eprosartan lowers heart rate variability and baroreflex gain.	[ "AT1", "antagonism", "by", "eprosartan", "lowers", "heart", "rate", "variability", "and", "baroreflex", "gain", "." ]	[ "GENE-Y", "CHEMICAL" ]
aim is an umlsterm, paper is an umlsterm, attention is an umlsterm, short - term psychotherapy is an umlsterm, rehabilitative is an umlsterm, treatment is an umlsterm, training is an umlsterm, method is an umlsterm, psychotherapy is an umlsterm, therapeutic process is an umlsterm, orientation is an umlsterm, therapy is an umlsterm, treatment is an umlsterm	Psychotherapeut.90440020.eng.abstr_task0	Sentence: It is the aim of this paper to draw attention to the problems of short-term psychotherapy in rehabilitative psychosomatical treatment with high demands in a professional training situation . It shows how the focal method of psychotherapy can help in this situation . The focus sets limits on the therapeutic process and as a central theme it provides orientation in therapy . It also provides for a better structure in treatment and is useful for the cooperation of the team and its integration , too . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	It is the aim of this paper to draw attention to the problems of short-term psychotherapy in rehabilitative psychosomatical treatment with high demands in a professional training situation . It shows how the focal method of psychotherapy can help in this situation . The focus sets limits on the therapeutic process and as a central theme it provides orientation in therapy . It also provides for a better structure in treatment and is useful for the cooperation of the team and its integration , too .	[ "It", "is", "the", "aim", "of", "this", "paper", "to", "draw", "attention", "to", "the", "problems", "of", "short", "-", "term", "psychotherapy", "in", "rehabilitative", "psychosomatical", "treatment", "with", "high", "demands", "in", "a", "professional", "training", "situation", ".", "It", "shows", "how", "the", "focal", "method", "of", "psychotherapy", "can", "help", "in", "this", "situation", ".", "The", "focus", "sets", "limits", "on", "the", "therapeutic", "process", "and", "as", "a", "central", "theme", "it", "provides", "orientation", "in", "therapy", ".", "It", "also", "provides", "for", "a", "better", "structure", "in", "treatment", "and", "is", "useful", "for", "the", "cooperation", "of", "the", "team", "and", "its", "integration", ",", "too", "." ]	[ "umlsterm" ]
aim is an umlsterm, paper is an umlsterm, attention is an umlsterm, short - term psychotherapy is an umlsterm, rehabilitative is an umlsterm, treatment is an umlsterm, training is an umlsterm, method is an umlsterm, psychotherapy is an umlsterm, therapeutic process is an umlsterm, orientation is an umlsterm, therapy is an umlsterm, treatment is an umlsterm	Psychotherapeut.90440020.eng.abstr_task1	Sentence: It is the aim of this paper to draw attention to the problems of short-term psychotherapy in rehabilitative psychosomatical treatment with high demands in a professional training situation . It shows how the focal method of psychotherapy can help in this situation . The focus sets limits on the therapeutic process and as a central theme it provides orientation in therapy . It also provides for a better structure in treatment and is useful for the cooperation of the team and its integration , too . Instructions: please typing these entity words according to sentence: aim, paper, attention, short - term psychotherapy, rehabilitative, treatment, training, method, psychotherapy, therapeutic process, orientation, therapy, treatment Options: umlsterm	[ "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	It is the aim of this paper to draw attention to the problems of short-term psychotherapy in rehabilitative psychosomatical treatment with high demands in a professional training situation . It shows how the focal method of psychotherapy can help in this situation . The focus sets limits on the therapeutic process and as a central theme it provides orientation in therapy . It also provides for a better structure in treatment and is useful for the cooperation of the team and its integration , too .	[ "It", "is", "the", "aim", "of", "this", "paper", "to", "draw", "attention", "to", "the", "problems", "of", "short", "-", "term", "psychotherapy", "in", "rehabilitative", "psychosomatical", "treatment", "with", "high", "demands", "in", "a", "professional", "training", "situation", ".", "It", "shows", "how", "the", "focal", "method", "of", "psychotherapy", "can", "help", "in", "this", "situation", ".", "The", "focus", "sets", "limits", "on", "the", "therapeutic", "process", "and", "as", "a", "central", "theme", "it", "provides", "orientation", "in", "therapy", ".", "It", "also", "provides", "for", "a", "better", "structure", "in", "treatment", "and", "is", "useful", "for", "the", "cooperation", "of", "the", "team", "and", "its", "integration", ",", "too", "." ]	[ "umlsterm" ]
aim, paper, attention, short - term psychotherapy, rehabilitative, treatment, training, method, psychotherapy, therapeutic process, orientation, therapy, treatment	Psychotherapeut.90440020.eng.abstr_task2	Sentence: It is the aim of this paper to draw attention to the problems of short-term psychotherapy in rehabilitative psychosomatical treatment with high demands in a professional training situation . It shows how the focal method of psychotherapy can help in this situation . The focus sets limits on the therapeutic process and as a central theme it provides orientation in therapy . It also provides for a better structure in treatment and is useful for the cooperation of the team and its integration , too . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	It is the aim of this paper to draw attention to the problems of short-term psychotherapy in rehabilitative psychosomatical treatment with high demands in a professional training situation . It shows how the focal method of psychotherapy can help in this situation . The focus sets limits on the therapeutic process and as a central theme it provides orientation in therapy . It also provides for a better structure in treatment and is useful for the cooperation of the team and its integration , too .	[ "It", "is", "the", "aim", "of", "this", "paper", "to", "draw", "attention", "to", "the", "problems", "of", "short", "-", "term", "psychotherapy", "in", "rehabilitative", "psychosomatical", "treatment", "with", "high", "demands", "in", "a", "professional", "training", "situation", ".", "It", "shows", "how", "the", "focal", "method", "of", "psychotherapy", "can", "help", "in", "this", "situation", ".", "The", "focus", "sets", "limits", "on", "the", "therapeutic", "process", "and", "as", "a", "central", "theme", "it", "provides", "orientation", "in", "therapy", ".", "It", "also", "provides", "for", "a", "better", "structure", "in", "treatment", "and", "is", "useful", "for", "the", "cooperation", "of", "the", "team", "and", "its", "integration", ",", "too", "." ]	[ "umlsterm" ]
chirurgischen Fachgebiete is an umlsterm, Gefaess - Medizin is an umlsterm, Praxis is an umlsterm, Literatur is an umlsterm, Chirurgie is an umlsterm	Gefaesschirurgie.80030132.ger.abstr_task0	Sentence: Die Gefaesschirurgie ist immer noch eines der wenigen chirurgischen Fachgebiete , fuer das es kein begleitendes medizinisches Spezialgebiet gibt . Ich erkenne durchaus an , dass die Gefaess-Medizin " " an Bedeutung gewinnt , dennoch ist sie fast ausschliesslich forschungsorientiert und zahlenmaessig begrenzt . Bis heute ist ihre Anwendung in der Praxis gering . Deshalb muss der Gefaesschirurg vertraut sein mit der zahlreichen Literatur zum gesamten Gefaesssystem und darf sich unter keinen Umstaenden auf die rein technischen Aspekte der Chirurgie beschraenken . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]	Die Gefaesschirurgie ist immer noch eines der wenigen chirurgischen Fachgebiete , fuer das es kein begleitendes medizinisches Spezialgebiet gibt . Ich erkenne durchaus an , dass die Gefaess-Medizin " " an Bedeutung gewinnt , dennoch ist sie fast ausschliesslich forschungsorientiert und zahlenmaessig begrenzt . Bis heute ist ihre Anwendung in der Praxis gering . Deshalb muss der Gefaesschirurg vertraut sein mit der zahlreichen Literatur zum gesamten Gefaesssystem und darf sich unter keinen Umstaenden auf die rein technischen Aspekte der Chirurgie beschraenken .	[ "Die", "Gefaesschirurgie", "ist", "immer", "noch", "eines", "der", "wenigen", "chirurgischen", "Fachgebiete", ",", "fuer", "das", "es", "kein", "begleitendes", "medizinisches", "Spezialgebiet", "gibt", ".", "Ich", "erkenne", "durchaus", "an", ",", "dass", "die", "Gefaess", "-", "Medizin", "\"", "\"", "an", "Bedeutung", "gewinnt", ",", "dennoch", "ist", "sie", "fast", "ausschliesslich", "forschungsorientiert", "und", "zahlenmaessig", "begrenzt", ".", "Bis", "heute", "ist", "ihre", "Anwendung", "in", "der", "Praxis", "gering", ".", "Deshalb", "muss", "der", "Gefaesschirurg", "vertraut", "sein", "mit", "der", "zahlreichen", "Literatur", "zum", "gesamten", "Gefaesssystem", "und", "darf", "sich", "unter", "keinen", "Umstaenden", "auf", "die", "rein", "technischen", "Aspekte", "der", "Chirurgie", "beschraenken", "." ]	[ "umlsterm" ]
chirurgischen Fachgebiete is an umlsterm, Gefaess - Medizin is an umlsterm, Praxis is an umlsterm, Literatur is an umlsterm, Chirurgie is an umlsterm	Gefaesschirurgie.80030132.ger.abstr_task1	Sentence: Die Gefaesschirurgie ist immer noch eines der wenigen chirurgischen Fachgebiete , fuer das es kein begleitendes medizinisches Spezialgebiet gibt . Ich erkenne durchaus an , dass die Gefaess-Medizin " " an Bedeutung gewinnt , dennoch ist sie fast ausschliesslich forschungsorientiert und zahlenmaessig begrenzt . Bis heute ist ihre Anwendung in der Praxis gering . Deshalb muss der Gefaesschirurg vertraut sein mit der zahlreichen Literatur zum gesamten Gefaesssystem und darf sich unter keinen Umstaenden auf die rein technischen Aspekte der Chirurgie beschraenken . Instructions: please typing these entity words according to sentence: chirurgischen Fachgebiete, Gefaess - Medizin, Praxis, Literatur, Chirurgie Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]	Die Gefaesschirurgie ist immer noch eines der wenigen chirurgischen Fachgebiete , fuer das es kein begleitendes medizinisches Spezialgebiet gibt . Ich erkenne durchaus an , dass die Gefaess-Medizin " " an Bedeutung gewinnt , dennoch ist sie fast ausschliesslich forschungsorientiert und zahlenmaessig begrenzt . Bis heute ist ihre Anwendung in der Praxis gering . Deshalb muss der Gefaesschirurg vertraut sein mit der zahlreichen Literatur zum gesamten Gefaesssystem und darf sich unter keinen Umstaenden auf die rein technischen Aspekte der Chirurgie beschraenken .	[ "Die", "Gefaesschirurgie", "ist", "immer", "noch", "eines", "der", "wenigen", "chirurgischen", "Fachgebiete", ",", "fuer", "das", "es", "kein", "begleitendes", "medizinisches", "Spezialgebiet", "gibt", ".", "Ich", "erkenne", "durchaus", "an", ",", "dass", "die", "Gefaess", "-", "Medizin", "\"", "\"", "an", "Bedeutung", "gewinnt", ",", "dennoch", "ist", "sie", "fast", "ausschliesslich", "forschungsorientiert", "und", "zahlenmaessig", "begrenzt", ".", "Bis", "heute", "ist", "ihre", "Anwendung", "in", "der", "Praxis", "gering", ".", "Deshalb", "muss", "der", "Gefaesschirurg", "vertraut", "sein", "mit", "der", "zahlreichen", "Literatur", "zum", "gesamten", "Gefaesssystem", "und", "darf", "sich", "unter", "keinen", "Umstaenden", "auf", "die", "rein", "technischen", "Aspekte", "der", "Chirurgie", "beschraenken", "." ]	[ "umlsterm" ]
chirurgischen Fachgebiete, Gefaess - Medizin, Praxis, Literatur, Chirurgie	Gefaesschirurgie.80030132.ger.abstr_task2	Sentence: Die Gefaesschirurgie ist immer noch eines der wenigen chirurgischen Fachgebiete , fuer das es kein begleitendes medizinisches Spezialgebiet gibt . Ich erkenne durchaus an , dass die Gefaess-Medizin " " an Bedeutung gewinnt , dennoch ist sie fast ausschliesslich forschungsorientiert und zahlenmaessig begrenzt . Bis heute ist ihre Anwendung in der Praxis gering . Deshalb muss der Gefaesschirurg vertraut sein mit der zahlreichen Literatur zum gesamten Gefaesssystem und darf sich unter keinen Umstaenden auf die rein technischen Aspekte der Chirurgie beschraenken . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]	Die Gefaesschirurgie ist immer noch eines der wenigen chirurgischen Fachgebiete , fuer das es kein begleitendes medizinisches Spezialgebiet gibt . Ich erkenne durchaus an , dass die Gefaess-Medizin " " an Bedeutung gewinnt , dennoch ist sie fast ausschliesslich forschungsorientiert und zahlenmaessig begrenzt . Bis heute ist ihre Anwendung in der Praxis gering . Deshalb muss der Gefaesschirurg vertraut sein mit der zahlreichen Literatur zum gesamten Gefaesssystem und darf sich unter keinen Umstaenden auf die rein technischen Aspekte der Chirurgie beschraenken .	[ "Die", "Gefaesschirurgie", "ist", "immer", "noch", "eines", "der", "wenigen", "chirurgischen", "Fachgebiete", ",", "fuer", "das", "es", "kein", "begleitendes", "medizinisches", "Spezialgebiet", "gibt", ".", "Ich", "erkenne", "durchaus", "an", ",", "dass", "die", "Gefaess", "-", "Medizin", "\"", "\"", "an", "Bedeutung", "gewinnt", ",", "dennoch", "ist", "sie", "fast", "ausschliesslich", "forschungsorientiert", "und", "zahlenmaessig", "begrenzt", ".", "Bis", "heute", "ist", "ihre", "Anwendung", "in", "der", "Praxis", "gering", ".", "Deshalb", "muss", "der", "Gefaesschirurg", "vertraut", "sein", "mit", "der", "zahlreichen", "Literatur", "zum", "gesamten", "Gefaesssystem", "und", "darf", "sich", "unter", "keinen", "Umstaenden", "auf", "die", "rein", "technischen", "Aspekte", "der", "Chirurgie", "beschraenken", "." ]	[ "umlsterm" ]
Pathophysiologie is an umlsterm, Fibromyalgie is an umlsterm, Fibromyalgie is an umlsterm, Konzentration is an umlsterm, Urin is an umlsterm, Patienten is an umlsterm, Methoden is an umlsterm, Patienten is an umlsterm, Fibromyalgie is an umlsterm, Urin- is an umlsterm, knochenumbaudeterminierende is an umlsterm, Marker is an umlsterm, Kollagenstoffwechsels is an umlsterm, HPLC is an umlsterm, Hydroxyprolinspiegel is an umlsterm, Marker is an umlsterm, Urin is an umlsterm, Urin is an umlsterm, Ausbildung is an umlsterm, Kollagenablagerungen is an umlsterm, Nervenfasern is an umlsterm, Haut is an umlsterm, Schmerzschwelle is an umlsterm, Analyse is an umlsterm, Urin is an umlsterm, Fibromyalgie is an umlsterm	ZfuerRheumatologie.8057s052.ger.abstr_task0	Sentence: Einleitung : Das Fehlen von Daten zur Pathophysiologie der Fibromyalgie sowie von kranheitsspezifischen Laborparametern bereitet Schwierigkeiten , die Erkrankung als Entitaet anzuerkennen . Auf der Suche nach charakteristischen Merkmalen der Fibromyalgie bestimmten wir die Konzentration der Kollagen-Crosslinks im Urin und im Serum der Patienten . Methoden : Die Patienten mit Fibromyalgie wurden entsprechend den American College of Rheumatology-Klassifikationskriterien in die Studie eingeschlossen . Von 39 Fibromyalgie-Patienten und von 55 gesunden Kontrollpersonen wurden unter standardisierten Bedingungen Urin- und Serumproben genommen . Pyridinolin Pyd ) und Desoxypyridinolin ( ( Dpyd ) , lysyloxidasevermittelte Produkte und bindegewebs- und knochenumbaudeterminierende Marker des Kollagenstoffwechsels , wurden mittels HPLC detektiert . Hydroxyprolinspiegel ( Hyp ) , ein Marker des Kollagen-Turnover , wurden ebenfalls gemessen . Die Ergebnisse wurden auf den Kreatininspiegel normiert und der Pyd/Dpyd-Quotient gebildet . Ergebnisse : Die Pyd/Dpyd-Ratio in Urin und Serum und der Hyp-Spiegel im Urin waren bei den Fibromyalgie-Patienten im Vergleich zu den Kontrollpersonen signifikant vermindert . Schlussfolgerung : Die gefundenen , verminderten Kollagen-Crosslinks-Spiegel sind moeglicherweise auf ein Remodelling der extrazellulaeren Matrix und der Ausbildung von Kollagenablagerungen um preterminale Nervenfasern in der Haut von Fibromyalgie-Patienten ( abgesenkte Schmerzschwelle ? ) zurueckzufuehren . Die Analyse eines gestoerten Kollagenmetabolismus durch histologische Untersuchungen oder , besser , durch HPLC-Analyse der Kollagen-Crosslinks im Urin oder Serum kann moeglicherweise zum weiteren Verstaendnis der Pathogenese der Fibromyalgie beitragen . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]	Einleitung : Das Fehlen von Daten zur Pathophysiologie der Fibromyalgie sowie von kranheitsspezifischen Laborparametern bereitet Schwierigkeiten , die Erkrankung als Entitaet anzuerkennen . Auf der Suche nach charakteristischen Merkmalen der Fibromyalgie bestimmten wir die Konzentration der Kollagen-Crosslinks im Urin und im Serum der Patienten . Methoden : Die Patienten mit Fibromyalgie wurden entsprechend den American College of Rheumatology-Klassifikationskriterien in die Studie eingeschlossen . Von 39 Fibromyalgie-Patienten und von 55 gesunden Kontrollpersonen wurden unter standardisierten Bedingungen Urin- und Serumproben genommen . Pyridinolin Pyd ) und Desoxypyridinolin ( ( Dpyd ) , lysyloxidasevermittelte Produkte und bindegewebs- und knochenumbaudeterminierende Marker des Kollagenstoffwechsels , wurden mittels HPLC detektiert . Hydroxyprolinspiegel ( Hyp ) , ein Marker des Kollagen-Turnover , wurden ebenfalls gemessen . Die Ergebnisse wurden auf den Kreatininspiegel normiert und der Pyd/Dpyd-Quotient gebildet . Ergebnisse : Die Pyd/Dpyd-Ratio in Urin und Serum und der Hyp-Spiegel im Urin waren bei den Fibromyalgie-Patienten im Vergleich zu den Kontrollpersonen signifikant vermindert . Schlussfolgerung : Die gefundenen , verminderten Kollagen-Crosslinks-Spiegel sind moeglicherweise auf ein Remodelling der extrazellulaeren Matrix und der Ausbildung von Kollagenablagerungen um preterminale Nervenfasern in der Haut von Fibromyalgie-Patienten ( abgesenkte Schmerzschwelle ? ) zurueckzufuehren . Die Analyse eines gestoerten Kollagenmetabolismus durch histologische Untersuchungen oder , besser , durch HPLC-Analyse der Kollagen-Crosslinks im Urin oder Serum kann moeglicherweise zum weiteren Verstaendnis der Pathogenese der Fibromyalgie beitragen .	[ "Einleitung", ":", "Das", "Fehlen", "von", "Daten", "zur", "Pathophysiologie", "der", "Fibromyalgie", "sowie", "von", "kranheitsspezifischen", "Laborparametern", "bereitet", "Schwierigkeiten", ",", "die", "Erkrankung", "als", "Entitaet", "anzuerkennen", ".", "Auf", "der", "Suche", "nach", "charakteristischen", "Merkmalen", "der", "Fibromyalgie", "bestimmten", "wir", "die", "Konzentration", "der", "Kollagen", "-", "Crosslinks", "im", "Urin", "und", "im", "Serum", "der", "Patienten", ".", "Methoden", ":", "Die", "Patienten", "mit", "Fibromyalgie", "wurden", "entsprechend", "den", "American", "College", "of", "Rheumatology", "-", "Klassifikationskriterien", "in", "die", "Studie", "eingeschlossen", ".", "Von", "39", "Fibromyalgie", "-", "Patienten", "und", "von", "55", "gesunden", "Kontrollpersonen", "wurden", "unter", "standardisierten", "Bedingungen", "Urin-", "und", "Serumproben", "genommen", ".", "Pyridinolin", "Pyd", ")", "und", "Desoxypyridinolin", "(", "(", "Dpyd", ")", ",", "lysyloxidasevermittelte", "Produkte", "und", "bindegewebs-", "und", "knochenumbaudeterminierende", "Marker", "des", "Kollagenstoffwechsels", ",", "wurden", "mittels", "HPLC", "detektiert", ".", "Hydroxyprolinspiegel", "(", "Hyp", ")", ",", "ein", "Marker", "des", "Kollagen", "-", "Turnover", ",", "wurden", "ebenfalls", "gemessen", ".", "Die", "Ergebnisse", "wurden", "auf", "den", "Kreatininspiegel", "normiert", "und", "der", "Pyd", "/", "Dpyd", "-", "Quotient", "gebildet", ".", "Ergebnisse", ":", "Die", "Pyd", "/", "Dpyd", "-", "Ratio", "in", "Urin", "und", "Serum", "und", "der", "Hyp", "-", "Spiegel", "im", "Urin", "waren", "bei", "den", "Fibromyalgie", "-", "Patienten", "im", "Vergleich", "zu", "den", "Kontrollpersonen", "signifikant", "vermindert", ".", "Schlussfolgerung", ":", "Die", "gefundenen", ",", "verminderten", "Kollagen", "-", "Crosslinks", "-", "Spiegel", "sind", "moeglicherweise", "auf", "ein", "Remodelling", "der", "extrazellulaeren", "Matrix", "und", "der", "Ausbildung", "von", "Kollagenablagerungen", "um", "preterminale", "Nervenfasern", "in", "der", "Haut", "von", "Fibromyalgie", "-", "Patienten", "(", "abgesenkte", "Schmerzschwelle", "?", ")", "zurueckzufuehren", ".", "Die", "Analyse", "eines", "gestoerten", "Kollagenmetabolismus", "durch", "histologische", "Untersuchungen", "oder", ",", "besser", ",", "durch", "HPLC", "-", "Analyse", "der", "Kollagen", "-", "Crosslinks", "im", "Urin", "oder", "Serum", "kann", "moeglicherweise", "zum", "weiteren", "Verstaendnis", "der", "Pathogenese", "der", "Fibromyalgie", "beitragen", "." ]	[ "umlsterm" ]
Pathophysiologie is an umlsterm, Fibromyalgie is an umlsterm, Fibromyalgie is an umlsterm, Konzentration is an umlsterm, Urin is an umlsterm, Patienten is an umlsterm, Methoden is an umlsterm, Patienten is an umlsterm, Fibromyalgie is an umlsterm, Urin- is an umlsterm, knochenumbaudeterminierende is an umlsterm, Marker is an umlsterm, Kollagenstoffwechsels is an umlsterm, HPLC is an umlsterm, Hydroxyprolinspiegel is an umlsterm, Marker is an umlsterm, Urin is an umlsterm, Urin is an umlsterm, Ausbildung is an umlsterm, Kollagenablagerungen is an umlsterm, Nervenfasern is an umlsterm, Haut is an umlsterm, Schmerzschwelle is an umlsterm, Analyse is an umlsterm, Urin is an umlsterm, Fibromyalgie is an umlsterm	ZfuerRheumatologie.8057s052.ger.abstr_task1	Sentence: Einleitung : Das Fehlen von Daten zur Pathophysiologie der Fibromyalgie sowie von kranheitsspezifischen Laborparametern bereitet Schwierigkeiten , die Erkrankung als Entitaet anzuerkennen . Auf der Suche nach charakteristischen Merkmalen der Fibromyalgie bestimmten wir die Konzentration der Kollagen-Crosslinks im Urin und im Serum der Patienten . Methoden : Die Patienten mit Fibromyalgie wurden entsprechend den American College of Rheumatology-Klassifikationskriterien in die Studie eingeschlossen . Von 39 Fibromyalgie-Patienten und von 55 gesunden Kontrollpersonen wurden unter standardisierten Bedingungen Urin- und Serumproben genommen . Pyridinolin Pyd ) und Desoxypyridinolin ( ( Dpyd ) , lysyloxidasevermittelte Produkte und bindegewebs- und knochenumbaudeterminierende Marker des Kollagenstoffwechsels , wurden mittels HPLC detektiert . Hydroxyprolinspiegel ( Hyp ) , ein Marker des Kollagen-Turnover , wurden ebenfalls gemessen . Die Ergebnisse wurden auf den Kreatininspiegel normiert und der Pyd/Dpyd-Quotient gebildet . Ergebnisse : Die Pyd/Dpyd-Ratio in Urin und Serum und der Hyp-Spiegel im Urin waren bei den Fibromyalgie-Patienten im Vergleich zu den Kontrollpersonen signifikant vermindert . Schlussfolgerung : Die gefundenen , verminderten Kollagen-Crosslinks-Spiegel sind moeglicherweise auf ein Remodelling der extrazellulaeren Matrix und der Ausbildung von Kollagenablagerungen um preterminale Nervenfasern in der Haut von Fibromyalgie-Patienten ( abgesenkte Schmerzschwelle ? ) zurueckzufuehren . Die Analyse eines gestoerten Kollagenmetabolismus durch histologische Untersuchungen oder , besser , durch HPLC-Analyse der Kollagen-Crosslinks im Urin oder Serum kann moeglicherweise zum weiteren Verstaendnis der Pathogenese der Fibromyalgie beitragen . Instructions: please typing these entity words according to sentence: Pathophysiologie, Fibromyalgie, Fibromyalgie, Konzentration, Urin, Patienten, Methoden, Patienten, Fibromyalgie, Urin-, knochenumbaudeterminierende, Marker, Kollagenstoffwechsels, HPLC, Hydroxyprolinspiegel, Marker, Urin, Urin, Ausbildung, Kollagenablagerungen, Nervenfasern, Haut, Schmerzschwelle, Analyse, Urin, Fibromyalgie Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]	Einleitung : Das Fehlen von Daten zur Pathophysiologie der Fibromyalgie sowie von kranheitsspezifischen Laborparametern bereitet Schwierigkeiten , die Erkrankung als Entitaet anzuerkennen . Auf der Suche nach charakteristischen Merkmalen der Fibromyalgie bestimmten wir die Konzentration der Kollagen-Crosslinks im Urin und im Serum der Patienten . Methoden : Die Patienten mit Fibromyalgie wurden entsprechend den American College of Rheumatology-Klassifikationskriterien in die Studie eingeschlossen . Von 39 Fibromyalgie-Patienten und von 55 gesunden Kontrollpersonen wurden unter standardisierten Bedingungen Urin- und Serumproben genommen . Pyridinolin Pyd ) und Desoxypyridinolin ( ( Dpyd ) , lysyloxidasevermittelte Produkte und bindegewebs- und knochenumbaudeterminierende Marker des Kollagenstoffwechsels , wurden mittels HPLC detektiert . Hydroxyprolinspiegel ( Hyp ) , ein Marker des Kollagen-Turnover , wurden ebenfalls gemessen . Die Ergebnisse wurden auf den Kreatininspiegel normiert und der Pyd/Dpyd-Quotient gebildet . Ergebnisse : Die Pyd/Dpyd-Ratio in Urin und Serum und der Hyp-Spiegel im Urin waren bei den Fibromyalgie-Patienten im Vergleich zu den Kontrollpersonen signifikant vermindert . Schlussfolgerung : Die gefundenen , verminderten Kollagen-Crosslinks-Spiegel sind moeglicherweise auf ein Remodelling der extrazellulaeren Matrix und der Ausbildung von Kollagenablagerungen um preterminale Nervenfasern in der Haut von Fibromyalgie-Patienten ( abgesenkte Schmerzschwelle ? ) zurueckzufuehren . Die Analyse eines gestoerten Kollagenmetabolismus durch histologische Untersuchungen oder , besser , durch HPLC-Analyse der Kollagen-Crosslinks im Urin oder Serum kann moeglicherweise zum weiteren Verstaendnis der Pathogenese der Fibromyalgie beitragen .	[ "Einleitung", ":", "Das", "Fehlen", "von", "Daten", "zur", "Pathophysiologie", "der", "Fibromyalgie", "sowie", "von", "kranheitsspezifischen", "Laborparametern", "bereitet", "Schwierigkeiten", ",", "die", "Erkrankung", "als", "Entitaet", "anzuerkennen", ".", "Auf", "der", "Suche", "nach", "charakteristischen", "Merkmalen", "der", "Fibromyalgie", "bestimmten", "wir", "die", "Konzentration", "der", "Kollagen", "-", "Crosslinks", "im", "Urin", "und", "im", "Serum", "der", "Patienten", ".", "Methoden", ":", "Die", "Patienten", "mit", "Fibromyalgie", "wurden", "entsprechend", "den", "American", "College", "of", "Rheumatology", "-", "Klassifikationskriterien", "in", "die", "Studie", "eingeschlossen", ".", "Von", "39", "Fibromyalgie", "-", "Patienten", "und", "von", "55", "gesunden", "Kontrollpersonen", "wurden", "unter", "standardisierten", "Bedingungen", "Urin-", "und", "Serumproben", "genommen", ".", "Pyridinolin", "Pyd", ")", "und", "Desoxypyridinolin", "(", "(", "Dpyd", ")", ",", "lysyloxidasevermittelte", "Produkte", "und", "bindegewebs-", "und", "knochenumbaudeterminierende", "Marker", "des", "Kollagenstoffwechsels", ",", "wurden", "mittels", "HPLC", "detektiert", ".", "Hydroxyprolinspiegel", "(", "Hyp", ")", ",", "ein", "Marker", "des", "Kollagen", "-", "Turnover", ",", "wurden", "ebenfalls", "gemessen", ".", "Die", "Ergebnisse", "wurden", "auf", "den", "Kreatininspiegel", "normiert", "und", "der", "Pyd", "/", "Dpyd", "-", "Quotient", "gebildet", ".", "Ergebnisse", ":", "Die", "Pyd", "/", "Dpyd", "-", "Ratio", "in", "Urin", "und", "Serum", "und", "der", "Hyp", "-", "Spiegel", "im", "Urin", "waren", "bei", "den", "Fibromyalgie", "-", "Patienten", "im", "Vergleich", "zu", "den", "Kontrollpersonen", "signifikant", "vermindert", ".", "Schlussfolgerung", ":", "Die", "gefundenen", ",", "verminderten", "Kollagen", "-", "Crosslinks", "-", "Spiegel", "sind", "moeglicherweise", "auf", "ein", "Remodelling", "der", "extrazellulaeren", "Matrix", "und", "der", "Ausbildung", "von", "Kollagenablagerungen", "um", "preterminale", "Nervenfasern", "in", "der", "Haut", "von", "Fibromyalgie", "-", "Patienten", "(", "abgesenkte", "Schmerzschwelle", "?", ")", "zurueckzufuehren", ".", "Die", "Analyse", "eines", "gestoerten", "Kollagenmetabolismus", "durch", "histologische", "Untersuchungen", "oder", ",", "besser", ",", "durch", "HPLC", "-", "Analyse", "der", "Kollagen", "-", "Crosslinks", "im", "Urin", "oder", "Serum", "kann", "moeglicherweise", "zum", "weiteren", "Verstaendnis", "der", "Pathogenese", "der", "Fibromyalgie", "beitragen", "." ]	[ "umlsterm" ]
Pathophysiologie, Fibromyalgie, Fibromyalgie, Konzentration, Urin, Patienten, Methoden, Patienten, Fibromyalgie, Urin-, knochenumbaudeterminierende, Marker, Kollagenstoffwechsels, HPLC, Hydroxyprolinspiegel, Marker, Urin, Urin, Ausbildung, Kollagenablagerungen, Nervenfasern, Haut, Schmerzschwelle, Analyse, Urin, Fibromyalgie	ZfuerRheumatologie.8057s052.ger.abstr_task2	Sentence: Einleitung : Das Fehlen von Daten zur Pathophysiologie der Fibromyalgie sowie von kranheitsspezifischen Laborparametern bereitet Schwierigkeiten , die Erkrankung als Entitaet anzuerkennen . Auf der Suche nach charakteristischen Merkmalen der Fibromyalgie bestimmten wir die Konzentration der Kollagen-Crosslinks im Urin und im Serum der Patienten . Methoden : Die Patienten mit Fibromyalgie wurden entsprechend den American College of Rheumatology-Klassifikationskriterien in die Studie eingeschlossen . Von 39 Fibromyalgie-Patienten und von 55 gesunden Kontrollpersonen wurden unter standardisierten Bedingungen Urin- und Serumproben genommen . Pyridinolin Pyd ) und Desoxypyridinolin ( ( Dpyd ) , lysyloxidasevermittelte Produkte und bindegewebs- und knochenumbaudeterminierende Marker des Kollagenstoffwechsels , wurden mittels HPLC detektiert . Hydroxyprolinspiegel ( Hyp ) , ein Marker des Kollagen-Turnover , wurden ebenfalls gemessen . Die Ergebnisse wurden auf den Kreatininspiegel normiert und der Pyd/Dpyd-Quotient gebildet . Ergebnisse : Die Pyd/Dpyd-Ratio in Urin und Serum und der Hyp-Spiegel im Urin waren bei den Fibromyalgie-Patienten im Vergleich zu den Kontrollpersonen signifikant vermindert . Schlussfolgerung : Die gefundenen , verminderten Kollagen-Crosslinks-Spiegel sind moeglicherweise auf ein Remodelling der extrazellulaeren Matrix und der Ausbildung von Kollagenablagerungen um preterminale Nervenfasern in der Haut von Fibromyalgie-Patienten ( abgesenkte Schmerzschwelle ? ) zurueckzufuehren . Die Analyse eines gestoerten Kollagenmetabolismus durch histologische Untersuchungen oder , besser , durch HPLC-Analyse der Kollagen-Crosslinks im Urin oder Serum kann moeglicherweise zum weiteren Verstaendnis der Pathogenese der Fibromyalgie beitragen . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]	Einleitung : Das Fehlen von Daten zur Pathophysiologie der Fibromyalgie sowie von kranheitsspezifischen Laborparametern bereitet Schwierigkeiten , die Erkrankung als Entitaet anzuerkennen . Auf der Suche nach charakteristischen Merkmalen der Fibromyalgie bestimmten wir die Konzentration der Kollagen-Crosslinks im Urin und im Serum der Patienten . Methoden : Die Patienten mit Fibromyalgie wurden entsprechend den American College of Rheumatology-Klassifikationskriterien in die Studie eingeschlossen . Von 39 Fibromyalgie-Patienten und von 55 gesunden Kontrollpersonen wurden unter standardisierten Bedingungen Urin- und Serumproben genommen . Pyridinolin Pyd ) und Desoxypyridinolin ( ( Dpyd ) , lysyloxidasevermittelte Produkte und bindegewebs- und knochenumbaudeterminierende Marker des Kollagenstoffwechsels , wurden mittels HPLC detektiert . Hydroxyprolinspiegel ( Hyp ) , ein Marker des Kollagen-Turnover , wurden ebenfalls gemessen . Die Ergebnisse wurden auf den Kreatininspiegel normiert und der Pyd/Dpyd-Quotient gebildet . Ergebnisse : Die Pyd/Dpyd-Ratio in Urin und Serum und der Hyp-Spiegel im Urin waren bei den Fibromyalgie-Patienten im Vergleich zu den Kontrollpersonen signifikant vermindert . Schlussfolgerung : Die gefundenen , verminderten Kollagen-Crosslinks-Spiegel sind moeglicherweise auf ein Remodelling der extrazellulaeren Matrix und der Ausbildung von Kollagenablagerungen um preterminale Nervenfasern in der Haut von Fibromyalgie-Patienten ( abgesenkte Schmerzschwelle ? ) zurueckzufuehren . Die Analyse eines gestoerten Kollagenmetabolismus durch histologische Untersuchungen oder , besser , durch HPLC-Analyse der Kollagen-Crosslinks im Urin oder Serum kann moeglicherweise zum weiteren Verstaendnis der Pathogenese der Fibromyalgie beitragen .	[ "Einleitung", ":", "Das", "Fehlen", "von", "Daten", "zur", "Pathophysiologie", "der", "Fibromyalgie", "sowie", "von", "kranheitsspezifischen", "Laborparametern", "bereitet", "Schwierigkeiten", ",", "die", "Erkrankung", "als", "Entitaet", "anzuerkennen", ".", "Auf", "der", "Suche", "nach", "charakteristischen", "Merkmalen", "der", "Fibromyalgie", "bestimmten", "wir", "die", "Konzentration", "der", "Kollagen", "-", "Crosslinks", "im", "Urin", "und", "im", "Serum", "der", "Patienten", ".", "Methoden", ":", "Die", "Patienten", "mit", "Fibromyalgie", "wurden", "entsprechend", "den", "American", "College", "of", "Rheumatology", "-", "Klassifikationskriterien", "in", "die", "Studie", "eingeschlossen", ".", "Von", "39", "Fibromyalgie", "-", "Patienten", "und", "von", "55", "gesunden", "Kontrollpersonen", "wurden", "unter", "standardisierten", "Bedingungen", "Urin-", "und", "Serumproben", "genommen", ".", "Pyridinolin", "Pyd", ")", "und", "Desoxypyridinolin", "(", "(", "Dpyd", ")", ",", "lysyloxidasevermittelte", "Produkte", "und", "bindegewebs-", "und", "knochenumbaudeterminierende", "Marker", "des", "Kollagenstoffwechsels", ",", "wurden", "mittels", "HPLC", "detektiert", ".", "Hydroxyprolinspiegel", "(", "Hyp", ")", ",", "ein", "Marker", "des", "Kollagen", "-", "Turnover", ",", "wurden", "ebenfalls", "gemessen", ".", "Die", "Ergebnisse", "wurden", "auf", "den", "Kreatininspiegel", "normiert", "und", "der", "Pyd", "/", "Dpyd", "-", "Quotient", "gebildet", ".", "Ergebnisse", ":", "Die", "Pyd", "/", "Dpyd", "-", "Ratio", "in", "Urin", "und", "Serum", "und", "der", "Hyp", "-", "Spiegel", "im", "Urin", "waren", "bei", "den", "Fibromyalgie", "-", "Patienten", "im", "Vergleich", "zu", "den", "Kontrollpersonen", "signifikant", "vermindert", ".", "Schlussfolgerung", ":", "Die", "gefundenen", ",", "verminderten", "Kollagen", "-", "Crosslinks", "-", "Spiegel", "sind", "moeglicherweise", "auf", "ein", "Remodelling", "der", "extrazellulaeren", "Matrix", "und", "der", "Ausbildung", "von", "Kollagenablagerungen", "um", "preterminale", "Nervenfasern", "in", "der", "Haut", "von", "Fibromyalgie", "-", "Patienten", "(", "abgesenkte", "Schmerzschwelle", "?", ")", "zurueckzufuehren", ".", "Die", "Analyse", "eines", "gestoerten", "Kollagenmetabolismus", "durch", "histologische", "Untersuchungen", "oder", ",", "besser", ",", "durch", "HPLC", "-", "Analyse", "der", "Kollagen", "-", "Crosslinks", "im", "Urin", "oder", "Serum", "kann", "moeglicherweise", "zum", "weiteren", "Verstaendnis", "der", "Pathogenese", "der", "Fibromyalgie", "beitragen", "." ]	[ "umlsterm" ]
chronically is a Temporal, HCV is a Condition, Genotype 1 is a Qualifier, HCV RNA viral load is a Measurement, ≥ 10 * 5 * IU / mL is a Value, 100,000 IU / mL is a Value, at screening is a Temporal	NCT01051414_inc_task0	Sentence: Subjects chronically infected with HCV Genotype 1 HCV RNA viral load of ≥ 105 IU/mL (100,000 IU/mL) at screening Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Temporal, Condition, Qualifier, Value, Measurement	[ "O", "B-Temporal", "O", "O", "B-Condition", "B-Qualifier", "I-Qualifier", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "O", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "B-Value", "I-Value", "I-Value", "I-Value", "O", "B-Temporal", "I-Temporal", "O" ]	Subjects chronically infected with HCV Genotype 1 HCV RNA viral load of ≥ 105 IU/mL (100,000 IU/mL) at screening	[ "Subjects", "chronically", "infected", "with", "HCV", "Genotype", "1", "\n", "HCV", "RNA", "viral", "load", "of", "≥", "10", "", "5", "", "IU", "/", "mL", "(", "100,000", "IU", "/", "mL", ")", "at", "screening", "\n" ]	[ "Measurement", "Value", "Temporal", "Multiplier", "Qualifier", "Reference_point", "Condition" ]
chronically is a Temporal, HCV is a Condition, Genotype 1 is a Qualifier, HCV RNA viral load is a Measurement, ≥ 10 * 5 * IU / mL is a Value, 100,000 IU / mL is a Value, at screening is a Temporal	NCT01051414_inc_task1	Sentence: Subjects chronically infected with HCV Genotype 1 HCV RNA viral load of ≥ 105 IU/mL (100,000 IU/mL) at screening Instructions: please typing these entity words according to sentence: chronically, HCV, Genotype 1, HCV RNA viral load, ≥ 10 * 5 * IU / mL, 100,000 IU / mL, at screening Options: Temporal, Condition, Qualifier, Value, Measurement	[ "O", "B-Temporal", "O", "O", "B-Condition", "B-Qualifier", "I-Qualifier", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "O", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "B-Value", "I-Value", "I-Value", "I-Value", "O", "B-Temporal", "I-Temporal", "O" ]	Subjects chronically infected with HCV Genotype 1 HCV RNA viral load of ≥ 105 IU/mL (100,000 IU/mL) at screening	[ "Subjects", "chronically", "infected", "with", "HCV", "Genotype", "1", "\n", "HCV", "RNA", "viral", "load", "of", "≥", "10", "", "5", "", "IU", "/", "mL", "(", "100,000", "IU", "/", "mL", ")", "at", "screening", "\n" ]	[ "Measurement", "Value", "Temporal", "Multiplier", "Qualifier", "Reference_point", "Condition" ]
chronically, HCV, Genotype 1, HCV RNA viral load, ≥ 10 * 5 * IU / mL, 100,000 IU / mL, at screening	NCT01051414_inc_task2	Sentence: Subjects chronically infected with HCV Genotype 1 HCV RNA viral load of ≥ 105 IU/mL (100,000 IU/mL) at screening Instructions: please extract entity words from the input sentence	[ "O", "B-Temporal", "O", "O", "B-Condition", "B-Qualifier", "I-Qualifier", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "O", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "B-Value", "I-Value", "I-Value", "I-Value", "O", "B-Temporal", "I-Temporal", "O" ]	Subjects chronically infected with HCV Genotype 1 HCV RNA viral load of ≥ 105 IU/mL (100,000 IU/mL) at screening	[ "Subjects", "chronically", "infected", "with", "HCV", "Genotype", "1", "\n", "HCV", "RNA", "viral", "load", "of", "≥", "10", "", "5", "", "IU", "/", "mL", "(", "100,000", "IU", "/", "mL", ")", "at", "screening", "\n" ]	[ "Measurement", "Value", "Temporal", "Multiplier", "Qualifier", "Reference_point", "Condition" ]

Angioplasty, syndromes, vessel, stent - like, angioplasty, PTCA, vessel, syndromes, prospective study, patients, myocardial infarction, unstable angina, PTCA, patients, angiography, All, angiograms, measurements, vessel, patients, patients, analysis, risk factors, diabetes mellitus, relative risk, hypertension, stenosis, stents, multivariate analysis, hypertension, risk factors, Diabetes, risk factor, patients, PTCA, occurrence, vessel, patients, PTCA, stents, stenosis, procedure, diabetes, hypertension

ZfuerKardiologie.00890485.eng.abstr_task2

Sentence: Angioplasty in acute coronary syndromes is complicated by a high rate of early vessel reocclusion and restenosis . Therefore , it is recommended to achieve a " stent-like " result by percutaneous transluminal coronary angioplasty ( PTCA ) or otherwise use coronary stenting ( provisional stenting ) . This study sought to determine angiographic and patient-related factors that are associated with early target vessel reocclusion or luminal renarrowing after coronary intervention in acute coronary syndromes ( ACS ) . In an observational prospective study we investigated 161 patients with ACS ( acute myocardial infarction and unstable angina ) submitted to PTCA . In 140 patients a follow-up angiography after 10 days was obtained . All angiograms were quantitatively evaluated by computerized measurements . Target vessel reocclusion and early luminal renarrowing was observed in 10 patients ( 7.1% ) and 19 patients ( 13.6% ) , respectively . Using univariate analysis , significant risk factors ( P 0.05 ) for early reocclusion and renarrowing were diabetes mellitus ( relative risk [ RR ] 6.1 and 5.0 ) , arterial hypertension ( RR 7.7 and 3.3 ) , postprocedural lesion length > =2 . 5mm ( RR 6.8 and 7.1 ) , postprocedural minimal lumen diameter =2 . 5 mm ( RR9.0 and 5.8 ) , residual stenosis > =25% ( RR 4.8 and 3.5 ) and absence of stents ( RR 4.1 and 3.2 ) . Moreover , in multivariate analysis hypertension and postprocedural lesion length could be identified as independent risk factors for reocclusion and renarrowing . Diabetes mellitus was found to be an independent risk factor for renarrowing . Conclusions : In a consecutive series of patients with ACS undergoing PTCA with provisional stenting the occurrence of early target vessel reocclusion and luminal renarrowing is lower than previously reported for this subset of patients treated by PTCA alone . Adverse outcome is related to absence of stents , angiographic factors ( residual stenosis , lesion length , minimal lumen diameter after procedure ) and patient-related factors such as diabetes and hypertension . Instructions: please extract entity words from the input sentence

[ "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O" ]

Angioplasty in acute coronary syndromes is complicated by a high rate of early vessel reocclusion and restenosis . Therefore , it is recommended to achieve a " stent-like " result by percutaneous transluminal coronary angioplasty ( PTCA ) or otherwise use coronary stenting ( provisional stenting ) . This study sought to determine angiographic and patient-related factors that are associated with early target vessel reocclusion or luminal renarrowing after coronary intervention in acute coronary syndromes ( ACS ) . In an observational prospective study we investigated 161 patients with ACS ( acute myocardial infarction and unstable angina ) submitted to PTCA . In 140 patients a follow-up angiography after 10 days was obtained . All angiograms were quantitatively evaluated by computerized measurements . Target vessel reocclusion and early luminal renarrowing was observed in 10 patients ( 7.1% ) and 19 patients ( 13.6% ) , respectively . Using univariate analysis , significant risk factors ( P 0.05 ) for early reocclusion and renarrowing were diabetes mellitus ( relative risk [ RR ] 6.1 and 5.0 ) , arterial hypertension ( RR 7.7 and 3.3 ) , postprocedural lesion length > =2 . 5mm ( RR 6.8 and 7.1 ) , postprocedural minimal lumen diameter =2 . 5 mm ( RR9.0 and 5.8 ) , residual stenosis > =25% ( RR 4.8 and 3.5 ) and absence of stents ( RR 4.1 and 3.2 ) . Moreover , in multivariate analysis hypertension and postprocedural lesion length could be identified as independent risk factors for reocclusion and renarrowing . Diabetes mellitus was found to be an independent risk factor for renarrowing . Conclusions : In a consecutive series of patients with ACS undergoing PTCA with provisional stenting the occurrence of early target vessel reocclusion and luminal renarrowing is lower than previously reported for this subset of patients treated by PTCA alone . Adverse outcome is related to absence of stents , angiographic factors ( residual stenosis , lesion length , minimal lumen diameter after procedure ) and patient-related factors such as diabetes and hypertension .

[ "Angioplasty", "in", "acute", "coronary", "syndromes", "is", "complicated", "by", "a", "high", "rate", "of", "early", "vessel", "reocclusion", "and", "restenosis", ".", "Therefore", ",", "it", "is", "recommended", "to", "achieve", "a", "\"", "stent", "-", "like", "\"", "result", "by", "percutaneous", "transluminal", "coronary", "angioplasty", "(", "PTCA", ")", "or", "otherwise", "use", "coronary", "stenting", "(", "provisional", "stenting", ")", ".", "This", "study", "sought", "to", "determine", "angiographic", "and", "patient", "-", "related", "factors", "that", "are", "associated", "with", "early", "target", "vessel", "reocclusion", "or", "luminal", "renarrowing", "after", "coronary", "intervention", "in", "acute", "coronary", "syndromes", "(", "ACS", ")", ".", "In", "an", "observational", "prospective", "study", "we", "investigated", "161", "patients", "with", "ACS", "(", "acute", "myocardial", "infarction", "and", "unstable", "angina", ")", "submitted", "to", "PTCA", ".", "In", "140", "patients", "a", "follow", "-", "up", "angiography", "after", "10", "days", "was", "obtained", ".", "All", "angiograms", "were", "quantitatively", "evaluated", "by", "computerized", "measurements", ".", "Target", "vessel", "reocclusion", "and", "early", "luminal", "renarrowing", "was", "observed", "in", "10", "patients", "(", "7.1", "%", ")", "and", "19", "patients", "(", "13.6", "%", ")", ",", "respectively", ".", "Using", "univariate", "analysis", ",", "significant", "risk", "factors", "(", "P", "0.05", ")", "for", "early", "reocclusion", "and", "renarrowing", "were", "diabetes", "mellitus", "(", "relative", "risk", "[", "RR", "]", "6.1", "and", "5.0", ")", ",", "arterial", "hypertension", "(", "RR", "7.7", "and", "3.3", ")", ",", "postprocedural", "lesion", "length", ">", "=", "2", ".", "5", "mm", "(", "RR", "6.8", "and", "7.1", ")", ",", "postprocedural", "minimal", "lumen", "diameter", "=", "2", ".", "5", "mm", "(", "RR9.0", "and", "5.8", ")", ",", "residual", "stenosis", ">", "=", "25", "%", "(", "RR", "4.8", "and", "3.5", ")", "and", "absence", "of", "stents", "(", "RR", "4.1", "and", "3.2", ")", ".", "Moreover", ",", "in", "multivariate", "analysis", "hypertension", "and", "postprocedural", "lesion", "length", "could", "be", "identified", "as", "independent", "risk", "factors", "for", "reocclusion", "and", "renarrowing", ".", "Diabetes", "mellitus", "was", "found", "to", "be", "an", "independent", "risk", "factor", "for", "renarrowing", ".", "Conclusions", ":", "In", "a", "consecutive", "series", "of", "patients", "with", "ACS", "undergoing", "PTCA", "with", "provisional", "stenting", "the", "occurrence", "of", "early", "target", "vessel", "reocclusion", "and", "luminal", "renarrowing", "is", "lower", "than", "previously", "reported", "for", "this", "subset", "of", "patients", "treated", "by", "PTCA", "alone", ".", "Adverse", "outcome", "is", "related", "to", "absence", "of", "stents", ",", "angiographic", "factors", "(", "residual", "stenosis", ",", "lesion", "length", ",", "minimal", "lumen", "diameter", "after", "procedure", ")", "and", "patient", "-", "related", "factors", "such", "as", "diabetes", "and", "hypertension", "." ]

[ "umlsterm" ]

U937 cells is a cell_line, antisense RXR - alpha cDNA is a DNA_family_or_group, retinoic acid is an other_organic_compound

54212_task0

Sentence: Stable transfection of U937 cells with sense or antisense RXR-alpha cDNA suggests a role for RXR-alpha in the control of monoblastic differentiation induced by retinoic acid and vitamin D. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: other_organic_compound, DNA_family_or_group, cell_line

[ "O", "O", "O", "B-cell_line", "I-cell_line", "O", "O", "O", "B-DNA_family_or_group", "I-DNA_family_or_group", "I-DNA_family_or_group", "I-DNA_family_or_group", "I-DNA_family_or_group", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-other_organic_compound", "I-other_organic_compound", "O", "O", "O" ]

Stable transfection of U937 cells with sense or antisense RXR-alpha cDNA suggests a role for RXR-alpha in the control of monoblastic differentiation induced by retinoic acid and vitamin D.

[ "Stable", "transfection", "of", "U937", "cells", "with", "sense", "or", "antisense", "RXR", "-", "alpha", "cDNA", "suggests", "a", "role", "for", "RXR", "-", "alpha", "in", "the", "control", "of", "monoblastic", "differentiation", "induced", "by", "retinoic", "acid", "and", "vitamin", "D." ]

[ "protein_family_or_group", "cell_line", "other_organic_compound", "other_name", "DNA_family_or_group", "DNA_domain_or_region", "cell_type", "RNA_molecule", "protein_molecule", "lipid" ]

U937 cells is a cell_line, antisense RXR - alpha cDNA is a DNA_family_or_group, retinoic acid is an other_organic_compound

54212_task1

Sentence: Stable transfection of U937 cells with sense or antisense RXR-alpha cDNA suggests a role for RXR-alpha in the control of monoblastic differentiation induced by retinoic acid and vitamin D. Instructions: please typing these entity words according to sentence: U937 cells, antisense RXR - alpha cDNA, retinoic acid Options: other_organic_compound, DNA_family_or_group, cell_line

[ "O", "O", "O", "B-cell_line", "I-cell_line", "O", "O", "O", "B-DNA_family_or_group", "I-DNA_family_or_group", "I-DNA_family_or_group", "I-DNA_family_or_group", "I-DNA_family_or_group", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-other_organic_compound", "I-other_organic_compound", "O", "O", "O" ]

Stable transfection of U937 cells with sense or antisense RXR-alpha cDNA suggests a role for RXR-alpha in the control of monoblastic differentiation induced by retinoic acid and vitamin D.

[ "Stable", "transfection", "of", "U937", "cells", "with", "sense", "or", "antisense", "RXR", "-", "alpha", "cDNA", "suggests", "a", "role", "for", "RXR", "-", "alpha", "in", "the", "control", "of", "monoblastic", "differentiation", "induced", "by", "retinoic", "acid", "and", "vitamin", "D." ]

[ "protein_family_or_group", "cell_line", "other_organic_compound", "other_name", "DNA_family_or_group", "DNA_domain_or_region", "cell_type", "RNA_molecule", "protein_molecule", "lipid" ]

U937 cells, antisense RXR - alpha cDNA, retinoic acid

54212_task2

Sentence: Stable transfection of U937 cells with sense or antisense RXR-alpha cDNA suggests a role for RXR-alpha in the control of monoblastic differentiation induced by retinoic acid and vitamin D. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "B-cell_line", "I-cell_line", "O", "O", "O", "B-DNA_family_or_group", "I-DNA_family_or_group", "I-DNA_family_or_group", "I-DNA_family_or_group", "I-DNA_family_or_group", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-other_organic_compound", "I-other_organic_compound", "O", "O", "O" ]

Stable transfection of U937 cells with sense or antisense RXR-alpha cDNA suggests a role for RXR-alpha in the control of monoblastic differentiation induced by retinoic acid and vitamin D.

[ "Stable", "transfection", "of", "U937", "cells", "with", "sense", "or", "antisense", "RXR", "-", "alpha", "cDNA", "suggests", "a", "role", "for", "RXR", "-", "alpha", "in", "the", "control", "of", "monoblastic", "differentiation", "induced", "by", "retinoic", "acid", "and", "vitamin", "D." ]

[ "protein_family_or_group", "cell_line", "other_organic_compound", "other_name", "DNA_family_or_group", "DNA_domain_or_region", "cell_type", "RNA_molecule", "protein_molecule", "lipid" ]

schizophrenia : is a Participant_Condition, antipsychotics is a Intervention_Pharmacological, quality of life is a Outcome_Other, symptoms is a Outcome_Other, people with schizophrenia is a Participant_Condition, antipsychotic medications is a Intervention_Pharmacological, more favorable health states is a Outcome_Physical, side effect characteristics is a Outcome_Adverse-effects, quality of life measures is a Outcome_Other, 1,049 patients is a Participant_Sample-size, depression is a Outcome_Physical, akathisia is a Outcome_Physical, perphenazine , olanzapine , risperidone is a Intervention_Pharmacological, quetiapine is a Intervention_Pharmacological, worst health state is a Outcome_Mental

68249_task0

Sentence: Comparing antipsychotic treatments for schizophrenia : a health state approach . The overall impact of first and second generation antipsychotics on quality of life and symptoms of people with schizophrenia remains controversial . We applied health state modeling to data from the Clinical Antipsychotic Trials of Intervention Effectiveness ( CATIE ) Schizophrenia study , a randomized trial of antipsychotic medications , and evaluated the likelihood of patients moving to more favorable health states over time . We applied K-means clustering to the data to create discrete groupings of patients with symptom and side effect characteristics that were then validated using quality of life measures . We compared cluster distributions across medications at baseline and 6 months after randomization . 1,049 patients were included in the initial cluster analysis . Five health states were identified : ( 1 ) low symptoms and low side effects ( LS + LSE ) ( 2 ) low symptoms and obesity ( LS + Ob ) ( 3 ) high symptoms and low side effects ( HS + LSE ) ( 4 ) high symptoms with depression and akathisia ( HS + Dp + Ak ) and ( 5 ) moderate symptoms and high side effects ( MS + HSE ) . Six-month outcomes among patients randomly assigned to perphenazine , olanzapine , risperidone and quetiapine were compared . At baseline , almost 20 % of patients were in the worst health state ( HS + Dp + Ak ) , with greater decreases at 6 months in this health state for perphenazine ( 9.2 % decrease ) and olanzapine ( 11.1 % ) groups compared to risperidone ( 4.7 % ) and quetiapine ( 6.7 % ) . This study demonstrated that health state analysis can provide insight into the overall clinical state of patients beyond the mere comparison of average scores and largely confirmed original CATIE findings . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Outcome_Adverse-effects, Participant_Condition, Outcome_Physical, Participant_Sample-size, Outcome_Other, Outcome_Mental

[ "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "B-Outcome_Other", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Comparing antipsychotic treatments for schizophrenia : a health state approach . The overall impact of first and second generation antipsychotics on quality of life and symptoms of people with schizophrenia remains controversial . We applied health state modeling to data from the Clinical Antipsychotic Trials of Intervention Effectiveness ( CATIE ) Schizophrenia study , a randomized trial of antipsychotic medications , and evaluated the likelihood of patients moving to more favorable health states over time . We applied K-means clustering to the data to create discrete groupings of patients with symptom and side effect characteristics that were then validated using quality of life measures . We compared cluster distributions across medications at baseline and 6 months after randomization . 1,049 patients were included in the initial cluster analysis . Five health states were identified : ( 1 ) low symptoms and low side effects ( LS + LSE ) ( 2 ) low symptoms and obesity ( LS + Ob ) ( 3 ) high symptoms and low side effects ( HS + LSE ) ( 4 ) high symptoms with depression and akathisia ( HS + Dp + Ak ) and ( 5 ) moderate symptoms and high side effects ( MS + HSE ) . Six-month outcomes among patients randomly assigned to perphenazine , olanzapine , risperidone and quetiapine were compared . At baseline , almost 20 % of patients were in the worst health state ( HS + Dp + Ak ) , with greater decreases at 6 months in this health state for perphenazine ( 9.2 % decrease ) and olanzapine ( 11.1 % ) groups compared to risperidone ( 4.7 % ) and quetiapine ( 6.7 % ) . This study demonstrated that health state analysis can provide insight into the overall clinical state of patients beyond the mere comparison of average scores and largely confirmed original CATIE findings .

[ "Comparing", "antipsychotic", "treatments", "for", "schizophrenia", ":", "a", "health", "state", "approach", ".", "The", "overall", "impact", "of", "first", "and", "second", "generation", "antipsychotics", "on", "quality", "of", "life", "and", "symptoms", "of", "people", "with", "schizophrenia", "remains", "controversial", ".", "We", "applied", "health", "state", "modeling", "to", "data", "from", "the", "Clinical", "Antipsychotic", "Trials", "of", "Intervention", "Effectiveness", "(", "CATIE", ")", "Schizophrenia", "study", ",", "a", "randomized", "trial", "of", "antipsychotic", "medications", ",", "and", "evaluated", "the", "likelihood", "of", "patients", "moving", "to", "more", "favorable", "health", "states", "over", "time", ".", "We", "applied", "K", "-", "means", "clustering", "to", "the", "data", "to", "create", "discrete", "groupings", "of", "patients", "with", "symptom", "and", "side", "effect", "characteristics", "that", "were", "then", "validated", "using", "quality", "of", "life", "measures", ".", "We", "compared", "cluster", "distributions", "across", "medications", "at", "baseline", "and", "6", "months", "after", "randomization", ".", "1,049", "patients", "were", "included", "in", "the", "initial", "cluster", "analysis", ".", "Five", "health", "states", "were", "identified", ":", "(", "1", ")", "low", "symptoms", "and", "low", "side", "effects", "(", "LS", "+", "LSE", ")", "(", "2", ")", "low", "symptoms", "and", "obesity", "(", "LS", "+", "Ob", ")", "(", "3", ")", "high", "symptoms", "and", "low", "side", "effects", "(", "HS", "+", "LSE", ")", "(", "4", ")", "high", "symptoms", "with", "depression", "and", "akathisia", "(", "HS", "+", "Dp", "+", "Ak", ")", "and", "(", "5", ")", "moderate", "symptoms", "and", "high", "side", "effects", "(", "MS", "+", "HSE", ")", ".", "Six", "-", "month", "outcomes", "among", "patients", "randomly", "assigned", "to", "perphenazine", ",", "olanzapine", ",", "risperidone", "and", "quetiapine", "were", "compared", ".", "At", "baseline", ",", "almost", "20", "%", "of", "patients", "were", "in", "the", "worst", "health", "state", "(", "HS", "+", "Dp", "+", "Ak", ")", ",", "with", "greater", "decreases", "at", "6", "months", "in", "this", "health", "state", "for", "perphenazine", "(", "9.2", "%", "decrease", ")", "and", "olanzapine", "(", "11.1", "%", ")", "groups", "compared", "to", "risperidone", "(", "4.7", "%", ")", "and", "quetiapine", "(", "6.7", "%", ")", ".", "This", "study", "demonstrated", "that", "health", "state", "analysis", "can", "provide", "insight", "into", "the", "overall", "clinical", "state", "of", "patients", "beyond", "the", "mere", "comparison", "of", "average", "scores", "and", "largely", "confirmed", "original", "CATIE", "findings", "." ]

[ "Intervention_Pharmacological", "Outcome_Physical", "Outcome_Adverse-effects", "Participant_Condition", "Outcome_Other", "Outcome_Mental", "Participant_Sample-size" ]

schizophrenia : is a Participant_Condition, antipsychotics is a Intervention_Pharmacological, quality of life is a Outcome_Other, symptoms is a Outcome_Other, people with schizophrenia is a Participant_Condition, antipsychotic medications is a Intervention_Pharmacological, more favorable health states is a Outcome_Physical, side effect characteristics is a Outcome_Adverse-effects, quality of life measures is a Outcome_Other, 1,049 patients is a Participant_Sample-size, depression is a Outcome_Physical, akathisia is a Outcome_Physical, perphenazine , olanzapine , risperidone is a Intervention_Pharmacological, quetiapine is a Intervention_Pharmacological, worst health state is a Outcome_Mental

68249_task1

Sentence: Comparing antipsychotic treatments for schizophrenia : a health state approach . The overall impact of first and second generation antipsychotics on quality of life and symptoms of people with schizophrenia remains controversial . We applied health state modeling to data from the Clinical Antipsychotic Trials of Intervention Effectiveness ( CATIE ) Schizophrenia study , a randomized trial of antipsychotic medications , and evaluated the likelihood of patients moving to more favorable health states over time . We applied K-means clustering to the data to create discrete groupings of patients with symptom and side effect characteristics that were then validated using quality of life measures . We compared cluster distributions across medications at baseline and 6 months after randomization . 1,049 patients were included in the initial cluster analysis . Five health states were identified : ( 1 ) low symptoms and low side effects ( LS + LSE ) ( 2 ) low symptoms and obesity ( LS + Ob ) ( 3 ) high symptoms and low side effects ( HS + LSE ) ( 4 ) high symptoms with depression and akathisia ( HS + Dp + Ak ) and ( 5 ) moderate symptoms and high side effects ( MS + HSE ) . Six-month outcomes among patients randomly assigned to perphenazine , olanzapine , risperidone and quetiapine were compared . At baseline , almost 20 % of patients were in the worst health state ( HS + Dp + Ak ) , with greater decreases at 6 months in this health state for perphenazine ( 9.2 % decrease ) and olanzapine ( 11.1 % ) groups compared to risperidone ( 4.7 % ) and quetiapine ( 6.7 % ) . This study demonstrated that health state analysis can provide insight into the overall clinical state of patients beyond the mere comparison of average scores and largely confirmed original CATIE findings . Instructions: please typing these entity words according to sentence: schizophrenia :, antipsychotics, quality of life, symptoms, people with schizophrenia, antipsychotic medications, more favorable health states, side effect characteristics, quality of life measures, 1,049 patients, depression, akathisia, perphenazine , olanzapine , risperidone, quetiapine, worst health state Options: Intervention_Pharmacological, Outcome_Adverse-effects, Participant_Condition, Outcome_Physical, Participant_Sample-size, Outcome_Other, Outcome_Mental

[ "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "B-Outcome_Other", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Comparing antipsychotic treatments for schizophrenia : a health state approach . The overall impact of first and second generation antipsychotics on quality of life and symptoms of people with schizophrenia remains controversial . We applied health state modeling to data from the Clinical Antipsychotic Trials of Intervention Effectiveness ( CATIE ) Schizophrenia study , a randomized trial of antipsychotic medications , and evaluated the likelihood of patients moving to more favorable health states over time . We applied K-means clustering to the data to create discrete groupings of patients with symptom and side effect characteristics that were then validated using quality of life measures . We compared cluster distributions across medications at baseline and 6 months after randomization . 1,049 patients were included in the initial cluster analysis . Five health states were identified : ( 1 ) low symptoms and low side effects ( LS + LSE ) ( 2 ) low symptoms and obesity ( LS + Ob ) ( 3 ) high symptoms and low side effects ( HS + LSE ) ( 4 ) high symptoms with depression and akathisia ( HS + Dp + Ak ) and ( 5 ) moderate symptoms and high side effects ( MS + HSE ) . Six-month outcomes among patients randomly assigned to perphenazine , olanzapine , risperidone and quetiapine were compared . At baseline , almost 20 % of patients were in the worst health state ( HS + Dp + Ak ) , with greater decreases at 6 months in this health state for perphenazine ( 9.2 % decrease ) and olanzapine ( 11.1 % ) groups compared to risperidone ( 4.7 % ) and quetiapine ( 6.7 % ) . This study demonstrated that health state analysis can provide insight into the overall clinical state of patients beyond the mere comparison of average scores and largely confirmed original CATIE findings .

[ "Comparing", "antipsychotic", "treatments", "for", "schizophrenia", ":", "a", "health", "state", "approach", ".", "The", "overall", "impact", "of", "first", "and", "second", "generation", "antipsychotics", "on", "quality", "of", "life", "and", "symptoms", "of", "people", "with", "schizophrenia", "remains", "controversial", ".", "We", "applied", "health", "state", "modeling", "to", "data", "from", "the", "Clinical", "Antipsychotic", "Trials", "of", "Intervention", "Effectiveness", "(", "CATIE", ")", "Schizophrenia", "study", ",", "a", "randomized", "trial", "of", "antipsychotic", "medications", ",", "and", "evaluated", "the", "likelihood", "of", "patients", "moving", "to", "more", "favorable", "health", "states", "over", "time", ".", "We", "applied", "K", "-", "means", "clustering", "to", "the", "data", "to", "create", "discrete", "groupings", "of", "patients", "with", "symptom", "and", "side", "effect", "characteristics", "that", "were", "then", "validated", "using", "quality", "of", "life", "measures", ".", "We", "compared", "cluster", "distributions", "across", "medications", "at", "baseline", "and", "6", "months", "after", "randomization", ".", "1,049", "patients", "were", "included", "in", "the", "initial", "cluster", "analysis", ".", "Five", "health", "states", "were", "identified", ":", "(", "1", ")", "low", "symptoms", "and", "low", "side", "effects", "(", "LS", "+", "LSE", ")", "(", "2", ")", "low", "symptoms", "and", "obesity", "(", "LS", "+", "Ob", ")", "(", "3", ")", "high", "symptoms", "and", "low", "side", "effects", "(", "HS", "+", "LSE", ")", "(", "4", ")", "high", "symptoms", "with", "depression", "and", "akathisia", "(", "HS", "+", "Dp", "+", "Ak", ")", "and", "(", "5", ")", "moderate", "symptoms", "and", "high", "side", "effects", "(", "MS", "+", "HSE", ")", ".", "Six", "-", "month", "outcomes", "among", "patients", "randomly", "assigned", "to", "perphenazine", ",", "olanzapine", ",", "risperidone", "and", "quetiapine", "were", "compared", ".", "At", "baseline", ",", "almost", "20", "%", "of", "patients", "were", "in", "the", "worst", "health", "state", "(", "HS", "+", "Dp", "+", "Ak", ")", ",", "with", "greater", "decreases", "at", "6", "months", "in", "this", "health", "state", "for", "perphenazine", "(", "9.2", "%", "decrease", ")", "and", "olanzapine", "(", "11.1", "%", ")", "groups", "compared", "to", "risperidone", "(", "4.7", "%", ")", "and", "quetiapine", "(", "6.7", "%", ")", ".", "This", "study", "demonstrated", "that", "health", "state", "analysis", "can", "provide", "insight", "into", "the", "overall", "clinical", "state", "of", "patients", "beyond", "the", "mere", "comparison", "of", "average", "scores", "and", "largely", "confirmed", "original", "CATIE", "findings", "." ]

[ "Intervention_Pharmacological", "Outcome_Physical", "Outcome_Adverse-effects", "Participant_Condition", "Outcome_Other", "Outcome_Mental", "Participant_Sample-size" ]

schizophrenia :, antipsychotics, quality of life, symptoms, people with schizophrenia, antipsychotic medications, more favorable health states, side effect characteristics, quality of life measures, 1,049 patients, depression, akathisia, perphenazine , olanzapine , risperidone, quetiapine, worst health state

68249_task2

Sentence: Comparing antipsychotic treatments for schizophrenia : a health state approach . The overall impact of first and second generation antipsychotics on quality of life and symptoms of people with schizophrenia remains controversial . We applied health state modeling to data from the Clinical Antipsychotic Trials of Intervention Effectiveness ( CATIE ) Schizophrenia study , a randomized trial of antipsychotic medications , and evaluated the likelihood of patients moving to more favorable health states over time . We applied K-means clustering to the data to create discrete groupings of patients with symptom and side effect characteristics that were then validated using quality of life measures . We compared cluster distributions across medications at baseline and 6 months after randomization . 1,049 patients were included in the initial cluster analysis . Five health states were identified : ( 1 ) low symptoms and low side effects ( LS + LSE ) ( 2 ) low symptoms and obesity ( LS + Ob ) ( 3 ) high symptoms and low side effects ( HS + LSE ) ( 4 ) high symptoms with depression and akathisia ( HS + Dp + Ak ) and ( 5 ) moderate symptoms and high side effects ( MS + HSE ) . Six-month outcomes among patients randomly assigned to perphenazine , olanzapine , risperidone and quetiapine were compared . At baseline , almost 20 % of patients were in the worst health state ( HS + Dp + Ak ) , with greater decreases at 6 months in this health state for perphenazine ( 9.2 % decrease ) and olanzapine ( 11.1 % ) groups compared to risperidone ( 4.7 % ) and quetiapine ( 6.7 % ) . This study demonstrated that health state analysis can provide insight into the overall clinical state of patients beyond the mere comparison of average scores and largely confirmed original CATIE findings . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "B-Outcome_Other", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Comparing antipsychotic treatments for schizophrenia : a health state approach . The overall impact of first and second generation antipsychotics on quality of life and symptoms of people with schizophrenia remains controversial . We applied health state modeling to data from the Clinical Antipsychotic Trials of Intervention Effectiveness ( CATIE ) Schizophrenia study , a randomized trial of antipsychotic medications , and evaluated the likelihood of patients moving to more favorable health states over time . We applied K-means clustering to the data to create discrete groupings of patients with symptom and side effect characteristics that were then validated using quality of life measures . We compared cluster distributions across medications at baseline and 6 months after randomization . 1,049 patients were included in the initial cluster analysis . Five health states were identified : ( 1 ) low symptoms and low side effects ( LS + LSE ) ( 2 ) low symptoms and obesity ( LS + Ob ) ( 3 ) high symptoms and low side effects ( HS + LSE ) ( 4 ) high symptoms with depression and akathisia ( HS + Dp + Ak ) and ( 5 ) moderate symptoms and high side effects ( MS + HSE ) . Six-month outcomes among patients randomly assigned to perphenazine , olanzapine , risperidone and quetiapine were compared . At baseline , almost 20 % of patients were in the worst health state ( HS + Dp + Ak ) , with greater decreases at 6 months in this health state for perphenazine ( 9.2 % decrease ) and olanzapine ( 11.1 % ) groups compared to risperidone ( 4.7 % ) and quetiapine ( 6.7 % ) . This study demonstrated that health state analysis can provide insight into the overall clinical state of patients beyond the mere comparison of average scores and largely confirmed original CATIE findings .

[ "Comparing", "antipsychotic", "treatments", "for", "schizophrenia", ":", "a", "health", "state", "approach", ".", "The", "overall", "impact", "of", "first", "and", "second", "generation", "antipsychotics", "on", "quality", "of", "life", "and", "symptoms", "of", "people", "with", "schizophrenia", "remains", "controversial", ".", "We", "applied", "health", "state", "modeling", "to", "data", "from", "the", "Clinical", "Antipsychotic", "Trials", "of", "Intervention", "Effectiveness", "(", "CATIE", ")", "Schizophrenia", "study", ",", "a", "randomized", "trial", "of", "antipsychotic", "medications", ",", "and", "evaluated", "the", "likelihood", "of", "patients", "moving", "to", "more", "favorable", "health", "states", "over", "time", ".", "We", "applied", "K", "-", "means", "clustering", "to", "the", "data", "to", "create", "discrete", "groupings", "of", "patients", "with", "symptom", "and", "side", "effect", "characteristics", "that", "were", "then", "validated", "using", "quality", "of", "life", "measures", ".", "We", "compared", "cluster", "distributions", "across", "medications", "at", "baseline", "and", "6", "months", "after", "randomization", ".", "1,049", "patients", "were", "included", "in", "the", "initial", "cluster", "analysis", ".", "Five", "health", "states", "were", "identified", ":", "(", "1", ")", "low", "symptoms", "and", "low", "side", "effects", "(", "LS", "+", "LSE", ")", "(", "2", ")", "low", "symptoms", "and", "obesity", "(", "LS", "+", "Ob", ")", "(", "3", ")", "high", "symptoms", "and", "low", "side", "effects", "(", "HS", "+", "LSE", ")", "(", "4", ")", "high", "symptoms", "with", "depression", "and", "akathisia", "(", "HS", "+", "Dp", "+", "Ak", ")", "and", "(", "5", ")", "moderate", "symptoms", "and", "high", "side", "effects", "(", "MS", "+", "HSE", ")", ".", "Six", "-", "month", "outcomes", "among", "patients", "randomly", "assigned", "to", "perphenazine", ",", "olanzapine", ",", "risperidone", "and", "quetiapine", "were", "compared", ".", "At", "baseline", ",", "almost", "20", "%", "of", "patients", "were", "in", "the", "worst", "health", "state", "(", "HS", "+", "Dp", "+", "Ak", ")", ",", "with", "greater", "decreases", "at", "6", "months", "in", "this", "health", "state", "for", "perphenazine", "(", "9.2", "%", "decrease", ")", "and", "olanzapine", "(", "11.1", "%", ")", "groups", "compared", "to", "risperidone", "(", "4.7", "%", ")", "and", "quetiapine", "(", "6.7", "%", ")", ".", "This", "study", "demonstrated", "that", "health", "state", "analysis", "can", "provide", "insight", "into", "the", "overall", "clinical", "state", "of", "patients", "beyond", "the", "mere", "comparison", "of", "average", "scores", "and", "largely", "confirmed", "original", "CATIE", "findings", "." ]

[ "Intervention_Pharmacological", "Outcome_Physical", "Outcome_Adverse-effects", "Participant_Condition", "Outcome_Other", "Outcome_Mental", "Participant_Sample-size" ]

Zic2 is a protein, Sp1 is a protein, Sp3 is a protein, AR1 is a DNA

1.0alpha7.train.1318_task0

Sentence: C, Zic2 competes with Sp1 and Sp3 binding to AR1. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: DNA, protein

[ "O", "O", "O", "B-protein", "O", "O", "O", "B-protein", "O", "O", "B-protein", "O", "O", "O", "B-DNA", "O" ]

C, Zic2 competes with Sp1 and Sp3 binding to AR1.

[ "C", ",", " ", "Zic2", "competes", "with", " ", "Sp1", "and", " ", "Sp3", "binding", "to", " ", "AR1", "." ]

[ "protein", "DNA" ]

Zic2 is a protein, Sp1 is a protein, Sp3 is a protein, AR1 is a DNA

1.0alpha7.train.1318_task1

Sentence: C, Zic2 competes with Sp1 and Sp3 binding to AR1. Instructions: please typing these entity words according to sentence: Zic2, Sp1, Sp3, AR1 Options: DNA, protein

[ "O", "O", "O", "B-protein", "O", "O", "O", "B-protein", "O", "O", "B-protein", "O", "O", "O", "B-DNA", "O" ]

C, Zic2 competes with Sp1 and Sp3 binding to AR1.

[ "C", ",", " ", "Zic2", "competes", "with", " ", "Sp1", "and", " ", "Sp3", "binding", "to", " ", "AR1", "." ]

[ "protein", "DNA" ]

Zic2, Sp1, Sp3, AR1

1.0alpha7.train.1318_task2

Sentence: C, Zic2 competes with Sp1 and Sp3 binding to AR1. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "B-protein", "O", "O", "O", "B-protein", "O", "O", "B-protein", "O", "O", "O", "B-DNA", "O" ]

C, Zic2 competes with Sp1 and Sp3 binding to AR1.

[ "C", ",", " ", "Zic2", "competes", "with", " ", "Sp1", "and", " ", "Sp3", "binding", "to", " ", "AR1", "." ]

[ "protein", "DNA" ]

estradiol is a lipid, polymorphonuclear leukocyte chemotaxis is an other_name

7976_task0

Sentence: Physiological concentration of estradiol inhibits polymorphonuclear leukocyte chemotaxis via a receptor mediated system. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: lipid, other_name

[ "O", "O", "O", "B-lipid", "O", "B-other_name", "I-other_name", "I-other_name", "O", "O", "O", "O", "O", "O" ]

Physiological concentration of estradiol inhibits polymorphonuclear leukocyte chemotaxis via a receptor mediated system.

[ "Physiological", "concentration", "of", "estradiol", "inhibits", "polymorphonuclear", "leukocyte", "chemotaxis", "via", "a", "receptor", "mediated", "system", "." ]

[ "other_name", "cell_type", "lipid", "other_organic_compound" ]

estradiol is a lipid, polymorphonuclear leukocyte chemotaxis is an other_name

7976_task1

Sentence: Physiological concentration of estradiol inhibits polymorphonuclear leukocyte chemotaxis via a receptor mediated system. Instructions: please typing these entity words according to sentence: estradiol, polymorphonuclear leukocyte chemotaxis Options: lipid, other_name

[ "O", "O", "O", "B-lipid", "O", "B-other_name", "I-other_name", "I-other_name", "O", "O", "O", "O", "O", "O" ]

Physiological concentration of estradiol inhibits polymorphonuclear leukocyte chemotaxis via a receptor mediated system.

[ "Physiological", "concentration", "of", "estradiol", "inhibits", "polymorphonuclear", "leukocyte", "chemotaxis", "via", "a", "receptor", "mediated", "system", "." ]

[ "other_name", "cell_type", "lipid", "other_organic_compound" ]

estradiol, polymorphonuclear leukocyte chemotaxis

7976_task2

Sentence: Physiological concentration of estradiol inhibits polymorphonuclear leukocyte chemotaxis via a receptor mediated system. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "B-lipid", "O", "B-other_name", "I-other_name", "I-other_name", "O", "O", "O", "O", "O", "O" ]

Physiological concentration of estradiol inhibits polymorphonuclear leukocyte chemotaxis via a receptor mediated system.

[ "Physiological", "concentration", "of", "estradiol", "inhibits", "polymorphonuclear", "leukocyte", "chemotaxis", "via", "a", "receptor", "mediated", "system", "." ]

[ "other_name", "cell_type", "lipid", "other_organic_compound" ]

Krankenhauspatienten is an umlsterm, Arzneimittel is an umlsterm, Schwindel is an umlsterm, Schwindelbeschwerden is an umlsterm

ZfuerGerontologie+Geriatrie.80310286.ger.abstr_task0

Sentence: Im Rahmen der Sturzpraevention wird u.a. eine routinemaessige Ueberpruefung der Medikation gefordert . In einer Zufallsstichprobe von 276 ueber 75jaehrigen Krankenhauspatienten wurde untersucht , wie haeufig Arzneimittel verordnet werden , die ueber die moegliche Ausloesung von Schwindel das Sturzrisiko erhoehen koennen . Schwindelbeschwerden und Sturzereignisse wurden standardisiert erhoben . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O" ]

Im Rahmen der Sturzpraevention wird u.a. eine routinemaessige Ueberpruefung der Medikation gefordert . In einer Zufallsstichprobe von 276 ueber 75jaehrigen Krankenhauspatienten wurde untersucht , wie haeufig Arzneimittel verordnet werden , die ueber die moegliche Ausloesung von Schwindel das Sturzrisiko erhoehen koennen . Schwindelbeschwerden und Sturzereignisse wurden standardisiert erhoben .

[ "Im", "Rahmen", "der", "Sturzpraevention", "wird", "u.a", ".", "eine", "routinemaessige", "Ueberpruefung", "der", "Medikation", "gefordert", ".", "In", "einer", "Zufallsstichprobe", "von", "276", "ueber", "75jaehrigen", "Krankenhauspatienten", "wurde", "untersucht", ",", "wie", "haeufig", "Arzneimittel", "verordnet", "werden", ",", "die", "ueber", "die", "moegliche", "Ausloesung", "von", "Schwindel", "das", "Sturzrisiko", "erhoehen", "koennen", ".", "Schwindelbeschwerden", "und", "Sturzereignisse", "wurden", "standardisiert", "erhoben", "." ]

[ "umlsterm" ]

Krankenhauspatienten is an umlsterm, Arzneimittel is an umlsterm, Schwindel is an umlsterm, Schwindelbeschwerden is an umlsterm

ZfuerGerontologie+Geriatrie.80310286.ger.abstr_task1

Sentence: Im Rahmen der Sturzpraevention wird u.a. eine routinemaessige Ueberpruefung der Medikation gefordert . In einer Zufallsstichprobe von 276 ueber 75jaehrigen Krankenhauspatienten wurde untersucht , wie haeufig Arzneimittel verordnet werden , die ueber die moegliche Ausloesung von Schwindel das Sturzrisiko erhoehen koennen . Schwindelbeschwerden und Sturzereignisse wurden standardisiert erhoben . Instructions: please typing these entity words according to sentence: Krankenhauspatienten, Arzneimittel, Schwindel, Schwindelbeschwerden Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O" ]

Im Rahmen der Sturzpraevention wird u.a. eine routinemaessige Ueberpruefung der Medikation gefordert . In einer Zufallsstichprobe von 276 ueber 75jaehrigen Krankenhauspatienten wurde untersucht , wie haeufig Arzneimittel verordnet werden , die ueber die moegliche Ausloesung von Schwindel das Sturzrisiko erhoehen koennen . Schwindelbeschwerden und Sturzereignisse wurden standardisiert erhoben .

[ "Im", "Rahmen", "der", "Sturzpraevention", "wird", "u.a", ".", "eine", "routinemaessige", "Ueberpruefung", "der", "Medikation", "gefordert", ".", "In", "einer", "Zufallsstichprobe", "von", "276", "ueber", "75jaehrigen", "Krankenhauspatienten", "wurde", "untersucht", ",", "wie", "haeufig", "Arzneimittel", "verordnet", "werden", ",", "die", "ueber", "die", "moegliche", "Ausloesung", "von", "Schwindel", "das", "Sturzrisiko", "erhoehen", "koennen", ".", "Schwindelbeschwerden", "und", "Sturzereignisse", "wurden", "standardisiert", "erhoben", "." ]

[ "umlsterm" ]

Krankenhauspatienten, Arzneimittel, Schwindel, Schwindelbeschwerden

ZfuerGerontologie+Geriatrie.80310286.ger.abstr_task2

Sentence: Im Rahmen der Sturzpraevention wird u.a. eine routinemaessige Ueberpruefung der Medikation gefordert . In einer Zufallsstichprobe von 276 ueber 75jaehrigen Krankenhauspatienten wurde untersucht , wie haeufig Arzneimittel verordnet werden , die ueber die moegliche Ausloesung von Schwindel das Sturzrisiko erhoehen koennen . Schwindelbeschwerden und Sturzereignisse wurden standardisiert erhoben . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O" ]

Im Rahmen der Sturzpraevention wird u.a. eine routinemaessige Ueberpruefung der Medikation gefordert . In einer Zufallsstichprobe von 276 ueber 75jaehrigen Krankenhauspatienten wurde untersucht , wie haeufig Arzneimittel verordnet werden , die ueber die moegliche Ausloesung von Schwindel das Sturzrisiko erhoehen koennen . Schwindelbeschwerden und Sturzereignisse wurden standardisiert erhoben .

[ "Im", "Rahmen", "der", "Sturzpraevention", "wird", "u.a", ".", "eine", "routinemaessige", "Ueberpruefung", "der", "Medikation", "gefordert", ".", "In", "einer", "Zufallsstichprobe", "von", "276", "ueber", "75jaehrigen", "Krankenhauspatienten", "wurde", "untersucht", ",", "wie", "haeufig", "Arzneimittel", "verordnet", "werden", ",", "die", "ueber", "die", "moegliche", "Ausloesung", "von", "Schwindel", "das", "Sturzrisiko", "erhoehen", "koennen", ".", "Schwindelbeschwerden", "und", "Sturzereignisse", "wurden", "standardisiert", "erhoben", "." ]

[ "umlsterm" ]

drugs is an umlsterm, form is an umlsterm, ventricular tachycardia is an umlsterm, torsade de pointes is an umlsterm, drugs is an umlsterm, antibiotics is an umlsterm, antifungals is an umlsterm, hypokalaemia is an umlsterm, bradycardia is an umlsterm, potassium channel is an umlsterm, review is an umlsterm, knowledge is an umlsterm, risk is an umlsterm, therapy is an umlsterm, syndrome is an umlsterm

IntensiveMedizin.80350557.eng.abstr_task0

Sentence: In recent years a multitude of reports has been published on the effects of various antiarrhythmic and non-antiarrhythmic drugs causing QT-intervall prolongation and thus triggering a characteristic form of polymorphic ventricular tachycardia known as torsade de pointes . These drugs included antiarrhythmics , antibiotics , antifungals , prokinetics and various other substances which often cause QT-prolongation and torsades only in combination with other riskfactors such as hypokalaemia or bradycardia . Most of these substances block the delayed rectifier potassium channel in myocytes . In this review we summarized the current knowledge on electrophysiologic mechanisms , riskfactors , arrhythmogenic risk and therapy of the acquired long-QT syndrome . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]

In recent years a multitude of reports has been published on the effects of various antiarrhythmic and non-antiarrhythmic drugs causing QT-intervall prolongation and thus triggering a characteristic form of polymorphic ventricular tachycardia known as torsade de pointes . These drugs included antiarrhythmics , antibiotics , antifungals , prokinetics and various other substances which often cause QT-prolongation and torsades only in combination with other riskfactors such as hypokalaemia or bradycardia . Most of these substances block the delayed rectifier potassium channel in myocytes . In this review we summarized the current knowledge on electrophysiologic mechanisms , riskfactors , arrhythmogenic risk and therapy of the acquired long-QT syndrome .

[ "In", "recent", "years", "a", "multitude", "of", "reports", "has", "been", "published", "on", "the", "effects", "of", "various", "antiarrhythmic", "and", "non", "-", "antiarrhythmic", "drugs", "causing", "QT", "-", "intervall", "prolongation", "and", "thus", "triggering", "a", "characteristic", "form", "of", "polymorphic", "ventricular", "tachycardia", "known", "as", "torsade", "de", "pointes", ".", "These", "drugs", "included", "antiarrhythmics", ",", "antibiotics", ",", "antifungals", ",", "prokinetics", "and", "various", "other", "substances", "which", "often", "cause", "QT", "-", "prolongation", "and", "torsades", "only", "in", "combination", "with", "other", "riskfactors", "such", "as", "hypokalaemia", "or", "bradycardia", ".", "Most", "of", "these", "substances", "block", "the", "delayed", "rectifier", "potassium", "channel", "in", "myocytes", ".", "In", "this", "review", "we", "summarized", "the", "current", "knowledge", "on", "electrophysiologic", "mechanisms", ",", "riskfactors", ",", "arrhythmogenic", "risk", "and", "therapy", "of", "the", "acquired", "long", "-", "QT", "syndrome", "." ]

[ "umlsterm" ]

drugs is an umlsterm, form is an umlsterm, ventricular tachycardia is an umlsterm, torsade de pointes is an umlsterm, drugs is an umlsterm, antibiotics is an umlsterm, antifungals is an umlsterm, hypokalaemia is an umlsterm, bradycardia is an umlsterm, potassium channel is an umlsterm, review is an umlsterm, knowledge is an umlsterm, risk is an umlsterm, therapy is an umlsterm, syndrome is an umlsterm

IntensiveMedizin.80350557.eng.abstr_task1

Sentence: In recent years a multitude of reports has been published on the effects of various antiarrhythmic and non-antiarrhythmic drugs causing QT-intervall prolongation and thus triggering a characteristic form of polymorphic ventricular tachycardia known as torsade de pointes . These drugs included antiarrhythmics , antibiotics , antifungals , prokinetics and various other substances which often cause QT-prolongation and torsades only in combination with other riskfactors such as hypokalaemia or bradycardia . Most of these substances block the delayed rectifier potassium channel in myocytes . In this review we summarized the current knowledge on electrophysiologic mechanisms , riskfactors , arrhythmogenic risk and therapy of the acquired long-QT syndrome . Instructions: please typing these entity words according to sentence: drugs, form, ventricular tachycardia, torsade de pointes, drugs, antibiotics, antifungals, hypokalaemia, bradycardia, potassium channel, review, knowledge, risk, therapy, syndrome Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]

In recent years a multitude of reports has been published on the effects of various antiarrhythmic and non-antiarrhythmic drugs causing QT-intervall prolongation and thus triggering a characteristic form of polymorphic ventricular tachycardia known as torsade de pointes . These drugs included antiarrhythmics , antibiotics , antifungals , prokinetics and various other substances which often cause QT-prolongation and torsades only in combination with other riskfactors such as hypokalaemia or bradycardia . Most of these substances block the delayed rectifier potassium channel in myocytes . In this review we summarized the current knowledge on electrophysiologic mechanisms , riskfactors , arrhythmogenic risk and therapy of the acquired long-QT syndrome .

[ "In", "recent", "years", "a", "multitude", "of", "reports", "has", "been", "published", "on", "the", "effects", "of", "various", "antiarrhythmic", "and", "non", "-", "antiarrhythmic", "drugs", "causing", "QT", "-", "intervall", "prolongation", "and", "thus", "triggering", "a", "characteristic", "form", "of", "polymorphic", "ventricular", "tachycardia", "known", "as", "torsade", "de", "pointes", ".", "These", "drugs", "included", "antiarrhythmics", ",", "antibiotics", ",", "antifungals", ",", "prokinetics", "and", "various", "other", "substances", "which", "often", "cause", "QT", "-", "prolongation", "and", "torsades", "only", "in", "combination", "with", "other", "riskfactors", "such", "as", "hypokalaemia", "or", "bradycardia", ".", "Most", "of", "these", "substances", "block", "the", "delayed", "rectifier", "potassium", "channel", "in", "myocytes", ".", "In", "this", "review", "we", "summarized", "the", "current", "knowledge", "on", "electrophysiologic", "mechanisms", ",", "riskfactors", ",", "arrhythmogenic", "risk", "and", "therapy", "of", "the", "acquired", "long", "-", "QT", "syndrome", "." ]

[ "umlsterm" ]

drugs, form, ventricular tachycardia, torsade de pointes, drugs, antibiotics, antifungals, hypokalaemia, bradycardia, potassium channel, review, knowledge, risk, therapy, syndrome

IntensiveMedizin.80350557.eng.abstr_task2

Sentence: In recent years a multitude of reports has been published on the effects of various antiarrhythmic and non-antiarrhythmic drugs causing QT-intervall prolongation and thus triggering a characteristic form of polymorphic ventricular tachycardia known as torsade de pointes . These drugs included antiarrhythmics , antibiotics , antifungals , prokinetics and various other substances which often cause QT-prolongation and torsades only in combination with other riskfactors such as hypokalaemia or bradycardia . Most of these substances block the delayed rectifier potassium channel in myocytes . In this review we summarized the current knowledge on electrophysiologic mechanisms , riskfactors , arrhythmogenic risk and therapy of the acquired long-QT syndrome . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]

In recent years a multitude of reports has been published on the effects of various antiarrhythmic and non-antiarrhythmic drugs causing QT-intervall prolongation and thus triggering a characteristic form of polymorphic ventricular tachycardia known as torsade de pointes . These drugs included antiarrhythmics , antibiotics , antifungals , prokinetics and various other substances which often cause QT-prolongation and torsades only in combination with other riskfactors such as hypokalaemia or bradycardia . Most of these substances block the delayed rectifier potassium channel in myocytes . In this review we summarized the current knowledge on electrophysiologic mechanisms , riskfactors , arrhythmogenic risk and therapy of the acquired long-QT syndrome .

[ "In", "recent", "years", "a", "multitude", "of", "reports", "has", "been", "published", "on", "the", "effects", "of", "various", "antiarrhythmic", "and", "non", "-", "antiarrhythmic", "drugs", "causing", "QT", "-", "intervall", "prolongation", "and", "thus", "triggering", "a", "characteristic", "form", "of", "polymorphic", "ventricular", "tachycardia", "known", "as", "torsade", "de", "pointes", ".", "These", "drugs", "included", "antiarrhythmics", ",", "antibiotics", ",", "antifungals", ",", "prokinetics", "and", "various", "other", "substances", "which", "often", "cause", "QT", "-", "prolongation", "and", "torsades", "only", "in", "combination", "with", "other", "riskfactors", "such", "as", "hypokalaemia", "or", "bradycardia", ".", "Most", "of", "these", "substances", "block", "the", "delayed", "rectifier", "potassium", "channel", "in", "myocytes", ".", "In", "this", "review", "we", "summarized", "the", "current", "knowledge", "on", "electrophysiologic", "mechanisms", ",", "riskfactors", ",", "arrhythmogenic", "risk", "and", "therapy", "of", "the", "acquired", "long", "-", "QT", "syndrome", "." ]

[ "umlsterm" ]

serous is a Organism_substance, Serous is a Organism_substance, eyes is a Organ, eyes is a Organ, Choroidal is a Multi-tissue_structure, retinal is a Multi-tissue_structure, eye is a Organ, choroidal is a Multi-tissue_structure, Retinal Pigment Epithelium is a Tissue, RPE is a Tissue, choroidal is a Multi-tissue_structure, retinal is a Multi-tissue_structure, RPE is a Tissue

PMID-18188789_task0

Sentence: [Photodynamic therapy in severe chronic central serous chorioretinopaty] OBJECTIVE: To determine the efficacy of Photodynamic Therapy (PDT) in chronic Central Serous Chorioretinopathy (CSC). METHODS: Patients diagnosed with chronic CSC, with clinical evidence of activity and treated with Photodynamic Therapy, are included in this report. All were assessed by a complete ophthalmological examination, including assessment of the best corrected visual acuity (BCVA) using an ETDRS chart, fluorescein and indocyanine angiography and optical coherence tomography (OCT). The main objective of the study was to determine the mean visual acuity change. RESULTS: 11 eyes of 11 patients were included in the study, which had a mean follow-up period of 11 months. The mean BCVA increased from 20/76 to 20/64. 35% of eyes improved their BCVA by 2 lines or more, 45% remained stable and 18% lost 2 lines or more. Choroidal hyperpermeability was reduced in every case. Neurosensorial retinal detachment decreased in 80% of cases. Only one eye received a second PDT treatment due to choroidal neovascularization. An increase of atrophy over the Retinal Pigment Epithelium (RPE) was observed in another patient. CONCLUSIONS: PDT can reduce the clinical signs of activity, such as choroidal hyperpermeability or neurosensorial retinal detachment, in patients affected by chronic CSC. However, the increase in visual acuity is variable, probably due to the extent of RPE damage. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Multi-tissue_structure, Tissue, Organ, Organism_substance

[ "O", "O", "O", "O", "O", "O", "O", "B-Organism_substance", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism_substance", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organ", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organ", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organ", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "O", "B-Tissue", "I-Tissue", "I-Tissue", "O", "B-Tissue", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "O", "O", "B-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Tissue", "O", "O", "O" ]

[Photodynamic therapy in severe chronic central serous chorioretinopaty] OBJECTIVE: To determine the efficacy of Photodynamic Therapy (PDT) in chronic Central Serous Chorioretinopathy (CSC). METHODS: Patients diagnosed with chronic CSC, with clinical evidence of activity and treated with Photodynamic Therapy, are included in this report. All were assessed by a complete ophthalmological examination, including assessment of the best corrected visual acuity (BCVA) using an ETDRS chart, fluorescein and indocyanine angiography and optical coherence tomography (OCT). The main objective of the study was to determine the mean visual acuity change. RESULTS: 11 eyes of 11 patients were included in the study, which had a mean follow-up period of 11 months. The mean BCVA increased from 20/76 to 20/64. 35% of eyes improved their BCVA by 2 lines or more, 45% remained stable and 18% lost 2 lines or more. Choroidal hyperpermeability was reduced in every case. Neurosensorial retinal detachment decreased in 80% of cases. Only one eye received a second PDT treatment due to choroidal neovascularization. An increase of atrophy over the Retinal Pigment Epithelium (RPE) was observed in another patient. CONCLUSIONS: PDT can reduce the clinical signs of activity, such as choroidal hyperpermeability or neurosensorial retinal detachment, in patients affected by chronic CSC. However, the increase in visual acuity is variable, probably due to the extent of RPE damage.

[ "[", "Photodynamic", "therapy", "in", "severe", "chronic", "central", "serous", "chorioretinopaty", "]", "\n", "OBJECTIVE", ":", "To", "determine", "the", "efficacy", "of", "Photodynamic", "Therapy", "(", "PDT", ")", "in", "chronic", "Central", "Serous", "Chorioretinopathy", "(", "CSC", ")", ".", "METHODS", ":", "Patients", "diagnosed", "with", "chronic", "CSC", ",", "with", "clinical", "evidence", "of", "activity", "and", "treated", "with", "Photodynamic", "Therapy", ",", "are", "included", "in", "this", "report", ".", "All", "were", "assessed", "by", "a", "complete", "ophthalmological", "examination", ",", "including", "assessment", "of", "the", "best", "corrected", "visual", "acuity", "(", "BCVA", ")", "using", "an", "ETDRS", "chart", ",", "fluorescein", "and", "indocyanine", "angiography", "and", "optical", "coherence", "tomography", "(", "OCT", ")", ".", "The", "main", "objective", "of", "the", "study", "was", "to", "determine", "the", "mean", "visual", "acuity", "change", ".", "RESULTS", ":", "11", "eyes", "of", "11", "patients", "were", "included", "in", "the", "study", ",", "which", "had", "a", "mean", "follow", "-", "up", "period", "of", "11", "months", ".", "The", "mean", "BCVA", "increased", "from", "20/76", "to", "20/64", ".", "35", "%", "of", "eyes", "improved", "their", "BCVA", "by", "2", "lines", "or", "more", ",", "45", "%", "remained", "stable", "and", "18", "%", "lost", "2", "lines", "or", "more", ".", "Choroidal", "hyperpermeability", "was", "reduced", "in", "every", "case", ".", "Neurosensorial", "retinal", "detachment", "decreased", "in", "80", "%", "of", "cases", ".", "Only", "one", "eye", "received", "a", "second", "PDT", "treatment", "due", "to", "choroidal", "neovascularization", ".", "An", "increase", "of", "atrophy", "over", "the", "Retinal", "Pigment", "Epithelium", "(", "RPE", ")", "was", "observed", "in", "another", "patient", ".", "CONCLUSIONS", ":", "PDT", "can", "reduce", "the", "clinical", "signs", "of", "activity", ",", "such", "as", "choroidal", "hyperpermeability", "or", "neurosensorial", "retinal", "detachment", ",", "in", "patients", "affected", "by", "chronic", "CSC", ".", "However", ",", "the", "increase", "in", "visual", "acuity", "is", "variable", ",", "probably", "due", "to", "the", "extent", "of", "RPE", "damage", ".", "\n" ]

[ "Tissue", "Multi-tissue_structure", "Organism_substance", "Organ" ]

serous is a Organism_substance, Serous is a Organism_substance, eyes is a Organ, eyes is a Organ, Choroidal is a Multi-tissue_structure, retinal is a Multi-tissue_structure, eye is a Organ, choroidal is a Multi-tissue_structure, Retinal Pigment Epithelium is a Tissue, RPE is a Tissue, choroidal is a Multi-tissue_structure, retinal is a Multi-tissue_structure, RPE is a Tissue

PMID-18188789_task1

Sentence: [Photodynamic therapy in severe chronic central serous chorioretinopaty] OBJECTIVE: To determine the efficacy of Photodynamic Therapy (PDT) in chronic Central Serous Chorioretinopathy (CSC). METHODS: Patients diagnosed with chronic CSC, with clinical evidence of activity and treated with Photodynamic Therapy, are included in this report. All were assessed by a complete ophthalmological examination, including assessment of the best corrected visual acuity (BCVA) using an ETDRS chart, fluorescein and indocyanine angiography and optical coherence tomography (OCT). The main objective of the study was to determine the mean visual acuity change. RESULTS: 11 eyes of 11 patients were included in the study, which had a mean follow-up period of 11 months. The mean BCVA increased from 20/76 to 20/64. 35% of eyes improved their BCVA by 2 lines or more, 45% remained stable and 18% lost 2 lines or more. Choroidal hyperpermeability was reduced in every case. Neurosensorial retinal detachment decreased in 80% of cases. Only one eye received a second PDT treatment due to choroidal neovascularization. An increase of atrophy over the Retinal Pigment Epithelium (RPE) was observed in another patient. CONCLUSIONS: PDT can reduce the clinical signs of activity, such as choroidal hyperpermeability or neurosensorial retinal detachment, in patients affected by chronic CSC. However, the increase in visual acuity is variable, probably due to the extent of RPE damage. Instructions: please typing these entity words according to sentence: serous, Serous, eyes, eyes, Choroidal, retinal, eye, choroidal, Retinal Pigment Epithelium, RPE, choroidal, retinal, RPE Options: Multi-tissue_structure, Tissue, Organ, Organism_substance

[ "O", "O", "O", "O", "O", "O", "O", "B-Organism_substance", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism_substance", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organ", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organ", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organ", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "O", "B-Tissue", "I-Tissue", "I-Tissue", "O", "B-Tissue", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "O", "O", "B-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Tissue", "O", "O", "O" ]

[Photodynamic therapy in severe chronic central serous chorioretinopaty] OBJECTIVE: To determine the efficacy of Photodynamic Therapy (PDT) in chronic Central Serous Chorioretinopathy (CSC). METHODS: Patients diagnosed with chronic CSC, with clinical evidence of activity and treated with Photodynamic Therapy, are included in this report. All were assessed by a complete ophthalmological examination, including assessment of the best corrected visual acuity (BCVA) using an ETDRS chart, fluorescein and indocyanine angiography and optical coherence tomography (OCT). The main objective of the study was to determine the mean visual acuity change. RESULTS: 11 eyes of 11 patients were included in the study, which had a mean follow-up period of 11 months. The mean BCVA increased from 20/76 to 20/64. 35% of eyes improved their BCVA by 2 lines or more, 45% remained stable and 18% lost 2 lines or more. Choroidal hyperpermeability was reduced in every case. Neurosensorial retinal detachment decreased in 80% of cases. Only one eye received a second PDT treatment due to choroidal neovascularization. An increase of atrophy over the Retinal Pigment Epithelium (RPE) was observed in another patient. CONCLUSIONS: PDT can reduce the clinical signs of activity, such as choroidal hyperpermeability or neurosensorial retinal detachment, in patients affected by chronic CSC. However, the increase in visual acuity is variable, probably due to the extent of RPE damage.

[ "[", "Photodynamic", "therapy", "in", "severe", "chronic", "central", "serous", "chorioretinopaty", "]", "\n", "OBJECTIVE", ":", "To", "determine", "the", "efficacy", "of", "Photodynamic", "Therapy", "(", "PDT", ")", "in", "chronic", "Central", "Serous", "Chorioretinopathy", "(", "CSC", ")", ".", "METHODS", ":", "Patients", "diagnosed", "with", "chronic", "CSC", ",", "with", "clinical", "evidence", "of", "activity", "and", "treated", "with", "Photodynamic", "Therapy", ",", "are", "included", "in", "this", "report", ".", "All", "were", "assessed", "by", "a", "complete", "ophthalmological", "examination", ",", "including", "assessment", "of", "the", "best", "corrected", "visual", "acuity", "(", "BCVA", ")", "using", "an", "ETDRS", "chart", ",", "fluorescein", "and", "indocyanine", "angiography", "and", "optical", "coherence", "tomography", "(", "OCT", ")", ".", "The", "main", "objective", "of", "the", "study", "was", "to", "determine", "the", "mean", "visual", "acuity", "change", ".", "RESULTS", ":", "11", "eyes", "of", "11", "patients", "were", "included", "in", "the", "study", ",", "which", "had", "a", "mean", "follow", "-", "up", "period", "of", "11", "months", ".", "The", "mean", "BCVA", "increased", "from", "20/76", "to", "20/64", ".", "35", "%", "of", "eyes", "improved", "their", "BCVA", "by", "2", "lines", "or", "more", ",", "45", "%", "remained", "stable", "and", "18", "%", "lost", "2", "lines", "or", "more", ".", "Choroidal", "hyperpermeability", "was", "reduced", "in", "every", "case", ".", "Neurosensorial", "retinal", "detachment", "decreased", "in", "80", "%", "of", "cases", ".", "Only", "one", "eye", "received", "a", "second", "PDT", "treatment", "due", "to", "choroidal", "neovascularization", ".", "An", "increase", "of", "atrophy", "over", "the", "Retinal", "Pigment", "Epithelium", "(", "RPE", ")", "was", "observed", "in", "another", "patient", ".", "CONCLUSIONS", ":", "PDT", "can", "reduce", "the", "clinical", "signs", "of", "activity", ",", "such", "as", "choroidal", "hyperpermeability", "or", "neurosensorial", "retinal", "detachment", ",", "in", "patients", "affected", "by", "chronic", "CSC", ".", "However", ",", "the", "increase", "in", "visual", "acuity", "is", "variable", ",", "probably", "due", "to", "the", "extent", "of", "RPE", "damage", ".", "\n" ]

[ "Tissue", "Multi-tissue_structure", "Organism_substance", "Organ" ]

serous, Serous, eyes, eyes, Choroidal, retinal, eye, choroidal, Retinal Pigment Epithelium, RPE, choroidal, retinal, RPE

PMID-18188789_task2

Sentence: [Photodynamic therapy in severe chronic central serous chorioretinopaty] OBJECTIVE: To determine the efficacy of Photodynamic Therapy (PDT) in chronic Central Serous Chorioretinopathy (CSC). METHODS: Patients diagnosed with chronic CSC, with clinical evidence of activity and treated with Photodynamic Therapy, are included in this report. All were assessed by a complete ophthalmological examination, including assessment of the best corrected visual acuity (BCVA) using an ETDRS chart, fluorescein and indocyanine angiography and optical coherence tomography (OCT). The main objective of the study was to determine the mean visual acuity change. RESULTS: 11 eyes of 11 patients were included in the study, which had a mean follow-up period of 11 months. The mean BCVA increased from 20/76 to 20/64. 35% of eyes improved their BCVA by 2 lines or more, 45% remained stable and 18% lost 2 lines or more. Choroidal hyperpermeability was reduced in every case. Neurosensorial retinal detachment decreased in 80% of cases. Only one eye received a second PDT treatment due to choroidal neovascularization. An increase of atrophy over the Retinal Pigment Epithelium (RPE) was observed in another patient. CONCLUSIONS: PDT can reduce the clinical signs of activity, such as choroidal hyperpermeability or neurosensorial retinal detachment, in patients affected by chronic CSC. However, the increase in visual acuity is variable, probably due to the extent of RPE damage. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "B-Organism_substance", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism_substance", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organ", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organ", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organ", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "O", "B-Tissue", "I-Tissue", "I-Tissue", "O", "B-Tissue", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "O", "O", "B-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Tissue", "O", "O", "O" ]

[Photodynamic therapy in severe chronic central serous chorioretinopaty] OBJECTIVE: To determine the efficacy of Photodynamic Therapy (PDT) in chronic Central Serous Chorioretinopathy (CSC). METHODS: Patients diagnosed with chronic CSC, with clinical evidence of activity and treated with Photodynamic Therapy, are included in this report. All were assessed by a complete ophthalmological examination, including assessment of the best corrected visual acuity (BCVA) using an ETDRS chart, fluorescein and indocyanine angiography and optical coherence tomography (OCT). The main objective of the study was to determine the mean visual acuity change. RESULTS: 11 eyes of 11 patients were included in the study, which had a mean follow-up period of 11 months. The mean BCVA increased from 20/76 to 20/64. 35% of eyes improved their BCVA by 2 lines or more, 45% remained stable and 18% lost 2 lines or more. Choroidal hyperpermeability was reduced in every case. Neurosensorial retinal detachment decreased in 80% of cases. Only one eye received a second PDT treatment due to choroidal neovascularization. An increase of atrophy over the Retinal Pigment Epithelium (RPE) was observed in another patient. CONCLUSIONS: PDT can reduce the clinical signs of activity, such as choroidal hyperpermeability or neurosensorial retinal detachment, in patients affected by chronic CSC. However, the increase in visual acuity is variable, probably due to the extent of RPE damage.

[ "[", "Photodynamic", "therapy", "in", "severe", "chronic", "central", "serous", "chorioretinopaty", "]", "\n", "OBJECTIVE", ":", "To", "determine", "the", "efficacy", "of", "Photodynamic", "Therapy", "(", "PDT", ")", "in", "chronic", "Central", "Serous", "Chorioretinopathy", "(", "CSC", ")", ".", "METHODS", ":", "Patients", "diagnosed", "with", "chronic", "CSC", ",", "with", "clinical", "evidence", "of", "activity", "and", "treated", "with", "Photodynamic", "Therapy", ",", "are", "included", "in", "this", "report", ".", "All", "were", "assessed", "by", "a", "complete", "ophthalmological", "examination", ",", "including", "assessment", "of", "the", "best", "corrected", "visual", "acuity", "(", "BCVA", ")", "using", "an", "ETDRS", "chart", ",", "fluorescein", "and", "indocyanine", "angiography", "and", "optical", "coherence", "tomography", "(", "OCT", ")", ".", "The", "main", "objective", "of", "the", "study", "was", "to", "determine", "the", "mean", "visual", "acuity", "change", ".", "RESULTS", ":", "11", "eyes", "of", "11", "patients", "were", "included", "in", "the", "study", ",", "which", "had", "a", "mean", "follow", "-", "up", "period", "of", "11", "months", ".", "The", "mean", "BCVA", "increased", "from", "20/76", "to", "20/64", ".", "35", "%", "of", "eyes", "improved", "their", "BCVA", "by", "2", "lines", "or", "more", ",", "45", "%", "remained", "stable", "and", "18", "%", "lost", "2", "lines", "or", "more", ".", "Choroidal", "hyperpermeability", "was", "reduced", "in", "every", "case", ".", "Neurosensorial", "retinal", "detachment", "decreased", "in", "80", "%", "of", "cases", ".", "Only", "one", "eye", "received", "a", "second", "PDT", "treatment", "due", "to", "choroidal", "neovascularization", ".", "An", "increase", "of", "atrophy", "over", "the", "Retinal", "Pigment", "Epithelium", "(", "RPE", ")", "was", "observed", "in", "another", "patient", ".", "CONCLUSIONS", ":", "PDT", "can", "reduce", "the", "clinical", "signs", "of", "activity", ",", "such", "as", "choroidal", "hyperpermeability", "or", "neurosensorial", "retinal", "detachment", ",", "in", "patients", "affected", "by", "chronic", "CSC", ".", "However", ",", "the", "increase", "in", "visual", "acuity", "is", "variable", ",", "probably", "due", "to", "the", "extent", "of", "RPE", "damage", ".", "\n" ]

[ "Tissue", "Multi-tissue_structure", "Organism_substance", "Organ" ]

gunshot injuries is an umlsterm, tissue is an umlsterm, direct is an umlsterm, trauma is an umlsterm, eye is an umlsterm, ear is an umlsterm, rupture is an umlsterm, neck is an umlsterm, vessels is an umlsterm, endoscopy is an umlsterm, imaging is an umlsterm, tissue is an umlsterm, risk of is an umlsterm, wound infection is an umlsterm, gunshot wound is an umlsterm

HNO.70450643.eng.abstr_task0

Sentence: Different types of gunshot injuries caused by warning weapons are demonstrated . Most important are contact shots , causing major tissue damage that can differ from that caused by classical projectiles . Possible consequences , besides direct trauma to the eye and ear , are airway distress because of extensive swelling and rupture of major neck vessels . The detailed examination includes endoscopy and radiologic imaging . Any major permanent cavity in the tissue bears a high risk of wound infection . For different reasons the fact of a gunshot wound may be kept secret by the victims . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O" ]

Different types of gunshot injuries caused by warning weapons are demonstrated . Most important are contact shots , causing major tissue damage that can differ from that caused by classical projectiles . Possible consequences , besides direct trauma to the eye and ear , are airway distress because of extensive swelling and rupture of major neck vessels . The detailed examination includes endoscopy and radiologic imaging . Any major permanent cavity in the tissue bears a high risk of wound infection . For different reasons the fact of a gunshot wound may be kept secret by the victims .

[ "Different", "types", "of", "gunshot", "injuries", "caused", "by", "warning", "weapons", "are", "demonstrated", ".", "Most", "important", "are", "contact", "shots", ",", "causing", "major", "tissue", "damage", "that", "can", "differ", "from", "that", "caused", "by", "classical", "projectiles", ".", "Possible", "consequences", ",", "besides", "direct", "trauma", "to", "the", "eye", "and", "ear", ",", "are", "airway", "distress", "because", "of", "extensive", "swelling", "and", "rupture", "of", "major", "neck", "vessels", ".", "The", "detailed", "examination", "includes", "endoscopy", "and", "radiologic", "imaging", ".", "Any", "major", "permanent", "cavity", "in", "the", "tissue", "bears", "a", "high", "risk", "of", "wound", "infection", ".", "For", "different", "reasons", "the", "fact", "of", "a", "gunshot", "wound", "may", "be", "kept", "secret", "by", "the", "victims", "." ]

[ "umlsterm" ]

gunshot injuries is an umlsterm, tissue is an umlsterm, direct is an umlsterm, trauma is an umlsterm, eye is an umlsterm, ear is an umlsterm, rupture is an umlsterm, neck is an umlsterm, vessels is an umlsterm, endoscopy is an umlsterm, imaging is an umlsterm, tissue is an umlsterm, risk of is an umlsterm, wound infection is an umlsterm, gunshot wound is an umlsterm

HNO.70450643.eng.abstr_task1

Sentence: Different types of gunshot injuries caused by warning weapons are demonstrated . Most important are contact shots , causing major tissue damage that can differ from that caused by classical projectiles . Possible consequences , besides direct trauma to the eye and ear , are airway distress because of extensive swelling and rupture of major neck vessels . The detailed examination includes endoscopy and radiologic imaging . Any major permanent cavity in the tissue bears a high risk of wound infection . For different reasons the fact of a gunshot wound may be kept secret by the victims . Instructions: please typing these entity words according to sentence: gunshot injuries, tissue, direct, trauma, eye, ear, rupture, neck, vessels, endoscopy, imaging, tissue, risk of, wound infection, gunshot wound Options: umlsterm

[ "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O" ]

Different types of gunshot injuries caused by warning weapons are demonstrated . Most important are contact shots , causing major tissue damage that can differ from that caused by classical projectiles . Possible consequences , besides direct trauma to the eye and ear , are airway distress because of extensive swelling and rupture of major neck vessels . The detailed examination includes endoscopy and radiologic imaging . Any major permanent cavity in the tissue bears a high risk of wound infection . For different reasons the fact of a gunshot wound may be kept secret by the victims .

[ "Different", "types", "of", "gunshot", "injuries", "caused", "by", "warning", "weapons", "are", "demonstrated", ".", "Most", "important", "are", "contact", "shots", ",", "causing", "major", "tissue", "damage", "that", "can", "differ", "from", "that", "caused", "by", "classical", "projectiles", ".", "Possible", "consequences", ",", "besides", "direct", "trauma", "to", "the", "eye", "and", "ear", ",", "are", "airway", "distress", "because", "of", "extensive", "swelling", "and", "rupture", "of", "major", "neck", "vessels", ".", "The", "detailed", "examination", "includes", "endoscopy", "and", "radiologic", "imaging", ".", "Any", "major", "permanent", "cavity", "in", "the", "tissue", "bears", "a", "high", "risk", "of", "wound", "infection", ".", "For", "different", "reasons", "the", "fact", "of", "a", "gunshot", "wound", "may", "be", "kept", "secret", "by", "the", "victims", "." ]

[ "umlsterm" ]

gunshot injuries, tissue, direct, trauma, eye, ear, rupture, neck, vessels, endoscopy, imaging, tissue, risk of, wound infection, gunshot wound

HNO.70450643.eng.abstr_task2

Sentence: Different types of gunshot injuries caused by warning weapons are demonstrated . Most important are contact shots , causing major tissue damage that can differ from that caused by classical projectiles . Possible consequences , besides direct trauma to the eye and ear , are airway distress because of extensive swelling and rupture of major neck vessels . The detailed examination includes endoscopy and radiologic imaging . Any major permanent cavity in the tissue bears a high risk of wound infection . For different reasons the fact of a gunshot wound may be kept secret by the victims . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O" ]

Different types of gunshot injuries caused by warning weapons are demonstrated . Most important are contact shots , causing major tissue damage that can differ from that caused by classical projectiles . Possible consequences , besides direct trauma to the eye and ear , are airway distress because of extensive swelling and rupture of major neck vessels . The detailed examination includes endoscopy and radiologic imaging . Any major permanent cavity in the tissue bears a high risk of wound infection . For different reasons the fact of a gunshot wound may be kept secret by the victims .

[ "Different", "types", "of", "gunshot", "injuries", "caused", "by", "warning", "weapons", "are", "demonstrated", ".", "Most", "important", "are", "contact", "shots", ",", "causing", "major", "tissue", "damage", "that", "can", "differ", "from", "that", "caused", "by", "classical", "projectiles", ".", "Possible", "consequences", ",", "besides", "direct", "trauma", "to", "the", "eye", "and", "ear", ",", "are", "airway", "distress", "because", "of", "extensive", "swelling", "and", "rupture", "of", "major", "neck", "vessels", ".", "The", "detailed", "examination", "includes", "endoscopy", "and", "radiologic", "imaging", ".", "Any", "major", "permanent", "cavity", "in", "the", "tissue", "bears", "a", "high", "risk", "of", "wound", "infection", ".", "For", "different", "reasons", "the", "fact", "of", "a", "gunshot", "wound", "may", "be", "kept", "secret", "by", "the", "victims", "." ]

[ "umlsterm" ]

síndrome mieloproliferativo crónico is a MORFOLOGIA_NEOPLASIA, trombocitemia esencial is a MORFOLOGIA_NEOPLASIA, carcinoma adenoide quístico grado 2 is a MORFOLOGIA_NEOPLASIA, micrometástasis is a MORFOLOGIA_NEOPLASIA, pT2N1miM0 is a MORFOLOGIA_NEOPLASIA, nódulos pulmonares is a MORFOLOGIA_NEOPLASIA, metástasis is a MORFOLOGIA_NEOPLASIA, nódulos diafragmáticos is a MORFOLOGIA_NEOPLASIA, implantes tumorales is a MORFOLOGIA_NEOPLASIA, pleura visceral y parietal con lesiones is a MORFOLOGIA_NEOPLASIA, metástasis is a MORFOLOGIA_NEOPLASIA, neoplasia is a MORFOLOGIA_NEOPLASIA, adenoide quístico is a MORFOLOGIA_NEOPLASIA, carcinoma adenoide quístico metastásico is a MORFOLOGIA_NEOPLASIA, afectación pulmonar is a MORFOLOGIA_NEOPLASIA, tumor is a MORFOLOGIA_NEOPLASIA, tumor is a MORFOLOGIA_NEOPLASIA, metástasis is a MORFOLOGIA_NEOPLASIA, recaída sistémica is a MORFOLOGIA_NEOPLASIA, carcinoma adenoide quístico is a MORFOLOGIA_NEOPLASIA

569_task0

Sentence: Anamnesis En este caso se presenta una mujer de 79 años, no fumadora ni bebedora, que, como antecedente destacable, presenta síndrome mieloproliferativo crónico, probable trombocitemia esencial con aumento ligero-moderado de megacariocitos en médula ósea, no displásicos, de disposición anómala paratrabecular en acúmulos, con ligero aumento de trama reticulínica. En tratamiento con indapamida retard, ispágula, omeprazol, ácido ibandrónico, alopurinol, hidroxicarbamida, ácido acetil salicílico y lorazepam. Vive con su marido. La paciente debuta con un nódulo sospechoso de 15 mm en mama izquierda en enero de 2017, por el que se le estudia con las correspondientes pruebas de imagen (TC y gammagrafía ósea) y examen histopatológico (biopsia por tru-cut), decidiéndose realizar tumorectomía con biopsia selectiva del ganglio centinela más radioterapia tras la negatividad en el estudio de extensión previamente realizado. En la Anatomía Patológica se diagnostica de carcinoma adenoide quístico grado 2, bordes quirúrgicos libres, con un ganglio linfático de un total de dos con micrometástasis y en la inmunohistoquímica se cataloga como triple negativo (pT2N1miM0). Comienza revisiones. En febrero de 2019, acude a Urgencias por comenzar con disnea progresiva sobre todo con ortopnea o esfuerzo moderado. En Urgencias objetivan derrame pleural derecho, por lo que se ingresa para estudio. Exploración física Durante la exploración física, no se palpaban adenopatías periféricas, masas ni nódulos mamarios. Auscultación respiratoria con hipoventilación en base derecha hasta tercio superior, izquierda normal. El resto de la exploración física por aparatos no tiene alteraciones. ignos de TVP Pruebas complementarias En las pruebas de imagen realizadas (TC-TAP y gammagrafía ósea) se objetiva derrame pleural derecho, nódulos pulmonares y pleurales bilaterales sugestivos de metástasis y nódulos diafragmáticos derechos anteriores en probable relación con adenopatías versus implantes tumorales. Se le realizó drenaje del líquido pleural más talcaje con resultado de líquido negativo para celularidad. Se decide realizar toracoscopia en la que se observa pleura visceral y parietal con lesiones sospechosas de metástasis. Se procede a la aspiración de líquido pleural y biopsia de lesiones de pleura parietal, obteniendo como resultado en la anatomía patológica de infiltración pleural compatible con neoplasia de origen mamario previa (adenoide quístico). Diagnóstico Finalmente, la paciente es diagnosticada de carcinoma adenoide quístico metastásico de origen mamario, con afectación pulmonar y pleural. Tratamiento Revisada la literatura, no existe evidencia sobre la actitud terapéutica sobre este tipo de tumor. Normalmente es un tumor con un curso indolente con una SLE a 10 años del 90-100 %, y las metástasis a distancia son raras y lentamente progresivas, sólo reportadas en forma de casos clínicos. Sin embargo, en este caso se presenta una recaída sistémica sintomática a los 2 años del primario, lo que es extremadamente infrecuente. No existe evidencia sólida sobre el tratamiento de quimioterapia más adecuado, si bien la recomendación es tratarlo como un carcinoma adenoide quístico de glándulas salivares. El esquema con una evidencia más sólida es el CAP (ciclofosfamida [500 mg/m2], doxorrubicina [50 mg/m2], cisplatino [50 mg/m2]) con una tasa de respuestas del 28 %. Pero al tratarse de una paciente frágil, se opta por un esquema de tratamiento en monoterapia con una toxicidad más manejable. El esquema en monoterapia con una mayor tasa de respuestas (15-44 %) es la vinorelbina, por lo que la paciente inicia el primer ciclo de vinorelbina oral a 60 mg/m2 días 1 y 8 cada 21 días, el día 11 de marzo de 20193,4. Evolución La paciente hasta el día de hoy sigue en tratamiento, habiendo recibido cuatro ciclos con muy buena tolerancia al mismo y sin evidencia de progresión clínica, sólo destacando como toxicidad asociada al tratamiento astenia G1. Dentro de unos días, antes del quinto ciclo, se realizará TC de valoración de respuesta. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: MORFOLOGIA_NEOPLASIA

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Anamnesis En este caso se presenta una mujer de 79 años, no fumadora ni bebedora, que, como antecedente destacable, presenta síndrome mieloproliferativo crónico, probable trombocitemia esencial con aumento ligero-moderado de megacariocitos en médula ósea, no displásicos, de disposición anómala paratrabecular en acúmulos, con ligero aumento de trama reticulínica. En tratamiento con indapamida retard, ispágula, omeprazol, ácido ibandrónico, alopurinol, hidroxicarbamida, ácido acetil salicílico y lorazepam. Vive con su marido. La paciente debuta con un nódulo sospechoso de 15 mm en mama izquierda en enero de 2017, por el que se le estudia con las correspondientes pruebas de imagen (TC y gammagrafía ósea) y examen histopatológico (biopsia por tru-cut), decidiéndose realizar tumorectomía con biopsia selectiva del ganglio centinela más radioterapia tras la negatividad en el estudio de extensión previamente realizado. En la Anatomía Patológica se diagnostica de carcinoma adenoide quístico grado 2, bordes quirúrgicos libres, con un ganglio linfático de un total de dos con micrometástasis y en la inmunohistoquímica se cataloga como triple negativo (pT2N1miM0). Comienza revisiones. En febrero de 2019, acude a Urgencias por comenzar con disnea progresiva sobre todo con ortopnea o esfuerzo moderado. En Urgencias objetivan derrame pleural derecho, por lo que se ingresa para estudio. Exploración física Durante la exploración física, no se palpaban adenopatías periféricas, masas ni nódulos mamarios. Auscultación respiratoria con hipoventilación en base derecha hasta tercio superior, izquierda normal. El resto de la exploración física por aparatos no tiene alteraciones. ignos de TVP Pruebas complementarias En las pruebas de imagen realizadas (TC-TAP y gammagrafía ósea) se objetiva derrame pleural derecho, nódulos pulmonares y pleurales bilaterales sugestivos de metástasis y nódulos diafragmáticos derechos anteriores en probable relación con adenopatías versus implantes tumorales. Se le realizó drenaje del líquido pleural más talcaje con resultado de líquido negativo para celularidad. Se decide realizar toracoscopia en la que se observa pleura visceral y parietal con lesiones sospechosas de metástasis. Se procede a la aspiración de líquido pleural y biopsia de lesiones de pleura parietal, obteniendo como resultado en la anatomía patológica de infiltración pleural compatible con neoplasia de origen mamario previa (adenoide quístico). Diagnóstico Finalmente, la paciente es diagnosticada de carcinoma adenoide quístico metastásico de origen mamario, con afectación pulmonar y pleural. Tratamiento Revisada la literatura, no existe evidencia sobre la actitud terapéutica sobre este tipo de tumor. Normalmente es un tumor con un curso indolente con una SLE a 10 años del 90-100 %, y las metástasis a distancia son raras y lentamente progresivas, sólo reportadas en forma de casos clínicos. Sin embargo, en este caso se presenta una recaída sistémica sintomática a los 2 años del primario, lo que es extremadamente infrecuente. No existe evidencia sólida sobre el tratamiento de quimioterapia más adecuado, si bien la recomendación es tratarlo como un carcinoma adenoide quístico de glándulas salivares. El esquema con una evidencia más sólida es el CAP (ciclofosfamida [500 mg/m2], doxorrubicina [50 mg/m2], cisplatino [50 mg/m2]) con una tasa de respuestas del 28 %. Pero al tratarse de una paciente frágil, se opta por un esquema de tratamiento en monoterapia con una toxicidad más manejable. El esquema en monoterapia con una mayor tasa de respuestas (15-44 %) es la vinorelbina, por lo que la paciente inicia el primer ciclo de vinorelbina oral a 60 mg/m2 días 1 y 8 cada 21 días, el día 11 de marzo de 20193,4. Evolución La paciente hasta el día de hoy sigue en tratamiento, habiendo recibido cuatro ciclos con muy buena tolerancia al mismo y sin evidencia de progresión clínica, sólo destacando como toxicidad asociada al tratamiento astenia G1. Dentro de unos días, antes del quinto ciclo, se realizará TC de valoración de respuesta.

[ "Anamnesis", "\n", "En", "este", "caso", "se", "presenta", "una", "mujer", "de", "79", "años", ",", "no", "fumadora", "ni", "bebedora", ",", "que", ",", "como", "antecedente", "destacable", ",", "presenta", "síndrome", "mieloproliferativo", "crónico", ",", "probable", "trombocitemia", "esencial", "con", "aumento", "ligero", "-", "moderado", "de", "megacariocitos", "en", "médula", "ósea", ",", "no", "displásicos", ",", "de", "disposición", "anómala", "paratrabecular", "en", "acúmulos", ",", "con", "ligero", "aumento", "de", "trama", "reticulínica", ".", "En", "tratamiento", "con", "indapamida", "retard", ",", "ispágula", ",", "omeprazol", ",", "ácido", "ibandrónico", ",", "alopurinol", ",", "hidroxicarbamida", ",", "ácido", "acetil", "salicílico", "y", "lorazepam", ".", "Vive", "con", "su", "marido", ".", "\n", "La", "paciente", "debuta", "con", "un", "nódulo", "sospechoso", "de", "15", "mm", "en", "mama", "izquierda", "en", "enero", "de", "2017", ",", "por", "el", "que", "se", "le", "estudia", "con", "las", "correspondientes", "pruebas", "de", "imagen", "(", "TC", "y", "gammagrafía", "ósea", ")", "y", "examen", "histopatológico", "(", "biopsia", "por", "tru", "-", "cut", ")", ",", "decidiéndose", "realizar", "tumorectomía", "con", "biopsia", "selectiva", "del", "ganglio", "centinela", "más", "radioterapia", "tras", "la", "negatividad", "en", "el", "estudio", "de", "extensión", "previamente", "realizado", ".", "En", "la", "Anatomía", "Patológica", "se", "diagnostica", "de", "carcinoma", "adenoide", "quístico", "grado", "2", ",", "bordes", "quirúrgicos", "libres", ",", "con", "un", "ganglio", "linfático", "de", "un", "total", "de", "dos", "con", "micrometástasis", "y", "en", "la", "inmunohistoquímica", "se", "cataloga", "como", "triple", "negativo", "(", "pT2N1miM0", ")", ".", "Comienza", "revisiones", ".", "\n", "En", "febrero", "de", "2019", ",", "acude", "a", "Urgencias", "por", "comenzar", "con", "disnea", "progresiva", "sobre", "todo", "con", "ortopnea", "o", "esfuerzo", "moderado", ".", "En", "Urgencias", "objetivan", "derrame", "pleural", "derecho", ",", "por", "lo", "que", "se", "ingresa", "para", "estudio", ".", "\n\n", "Exploración", "física", "\n", "Durante", "la", "exploración", "física", ",", "no", "se", "palpaban", "adenopatías", "periféricas", ",", "masas", "ni", "nódulos", "mamarios", ".", "Auscultación", "respiratoria", "con", "hipoventilación", "en", "base", "derecha", "hasta", "tercio", "superior", ",", "izquierda", "normal", ".", "El", "resto", "de", "la", "exploración", "física", "por", "aparatos", "no", "tiene", "alteraciones", ".", "\n", "ignos", "de", "TVP", "\n\n", "Pruebas", "complementarias", "\n", "En", "las", "pruebas", "de", "imagen", "realizadas", "(", "TC", "-", "TAP", "y", "gammagrafía", "ósea", ")", "se", "objetiva", "derrame", "pleural", "derecho", ",", "nódulos", "pulmonares", "y", "pleurales", "bilaterales", "sugestivos", "de", "metástasis", "y", "nódulos", "diafragmáticos", "derechos", "anteriores", "en", "probable", "relación", "con", "adenopatías", "versus", "implantes", "tumorales", ".", "Se", "le", "realizó", "drenaje", "del", "líquido", "pleural", "más", "talcaje", "con", "resultado", "de", "líquido", "negativo", "para", "celularidad", ".", "Se", "decide", "realizar", "toracoscopia", "en", "la", "que", "se", "observa", "pleura", "visceral", "y", "parietal", "con", "lesiones", "sospechosas", "de", "metástasis", ".", "Se", "procede", "a", "la", "aspiración", "de", "líquido", "pleural", "y", "biopsia", "de", "lesiones", "de", "pleura", "parietal", ",", "obteniendo", "como", "resultado", "en", "la", "anatomía", "patológica", "de", "infiltración", "pleural", "compatible", "con", "neoplasia", "de", "origen", "mamario", "previa", "(", "adenoide", "quístico", ")", ".", "\n\n", "Diagnóstico", "\n", "Finalmente", ",", "la", "paciente", "es", "diagnosticada", "de", "carcinoma", "adenoide", "quístico", "metastásico", "de", "origen", "mamario", ",", "con", "afectación", "pulmonar", "y", "pleural", ".", "\n\n", "Tratamiento", "\n", "Revisada", "la", "literatura", ",", "no", "existe", "evidencia", "sobre", "la", "actitud", "terapéutica", "sobre", "este", "tipo", "de", "tumor", ".", "Normalmente", "es", "un", "tumor", "con", "un", "curso", "indolente", "con", "una", "SLE", "a", "10", "años", "del", "90", "-", "100", "%", ",", "y", "las", "metástasis", "a", "distancia", "son", "raras", "y", "lentamente", "progresivas", ",", "sólo", "reportadas", "en", "forma", "de", "casos", "clínicos", ".", "Sin", "embargo", ",", "en", "este", "caso", "se", "presenta", "una", "recaída", "sistémica", "sintomática", "a", "los", "2", "años", "del", "primario", ",", "lo", "que", "es", "extremadamente", "infrecuente", ".", "\n", "No", "existe", "evidencia", "sólida", "sobre", "el", "tratamiento", "de", "quimioterapia", "más", "adecuado", ",", "si", "bien", "la", "recomendación", "es", "tratarlo", "como", "un", "carcinoma", "adenoide", "quístico", "de", "glándulas", "salivares", ".", "El", "esquema", "con", "una", "evidencia", "más", "sólida", "es", "el", "CAP", "(", "ciclofosfamida", "[", "500", "mg", "/", "m2", "]", ",", "doxorrubicina", "[", "50", "mg", "/", "m2", "]", ",", "cisplatino", "[", "50", "mg", "/", "m2", "]", ")", "con", "una", "tasa", "de", "respuestas", "del", "28", "%", ".", "Pero", "al", "tratarse", "de", "una", "paciente", "frágil", ",", "se", "opta", "por", "un", "esquema", "de", "tratamiento", "en", "monoterapia", "con", "una", "toxicidad", "más", "manejable", ".", "El", "esquema", "en", "monoterapia", "con", "una", "mayor", "tasa", "de", "respuestas", "(", "15", "-", "44", "%", ")", "es", "la", "vinorelbina", ",", "por", "lo", "que", "la", "paciente", "inicia", "el", "primer", "ciclo", "de", "vinorelbina", "oral", "a", "60", "mg", "/", "m2", "días", "1", "y", "8", "cada", "21", "días", ",", "el", "día", "11", "de", "marzo", "de", "20193,4", ".", "\n\n", "Evolución", "\n", "La", "paciente", "hasta", "el", "día", "de", "hoy", "sigue", "en", "tratamiento", ",", "habiendo", "recibido", "cuatro", "ciclos", "con", "muy", "buena", "tolerancia", "al", "mismo", "y", "sin", "evidencia", "de", "progresión", "clínica", ",", "sólo", "destacando", "como", "toxicidad", "asociada", "al", "tratamiento", "astenia", "G1", ".", "Dentro", "de", "unos", "días", ",", "antes", "del", "quinto", "ciclo", ",", "se", "realizará", "TC", "de", "valoración", "de", "respuesta", "." ]

[ "MORFOLOGIA_NEOPLASIA" ]

síndrome mieloproliferativo crónico is a MORFOLOGIA_NEOPLASIA, trombocitemia esencial is a MORFOLOGIA_NEOPLASIA, carcinoma adenoide quístico grado 2 is a MORFOLOGIA_NEOPLASIA, micrometástasis is a MORFOLOGIA_NEOPLASIA, pT2N1miM0 is a MORFOLOGIA_NEOPLASIA, nódulos pulmonares is a MORFOLOGIA_NEOPLASIA, metástasis is a MORFOLOGIA_NEOPLASIA, nódulos diafragmáticos is a MORFOLOGIA_NEOPLASIA, implantes tumorales is a MORFOLOGIA_NEOPLASIA, pleura visceral y parietal con lesiones is a MORFOLOGIA_NEOPLASIA, metástasis is a MORFOLOGIA_NEOPLASIA, neoplasia is a MORFOLOGIA_NEOPLASIA, adenoide quístico is a MORFOLOGIA_NEOPLASIA, carcinoma adenoide quístico metastásico is a MORFOLOGIA_NEOPLASIA, afectación pulmonar is a MORFOLOGIA_NEOPLASIA, tumor is a MORFOLOGIA_NEOPLASIA, tumor is a MORFOLOGIA_NEOPLASIA, metástasis is a MORFOLOGIA_NEOPLASIA, recaída sistémica is a MORFOLOGIA_NEOPLASIA, carcinoma adenoide quístico is a MORFOLOGIA_NEOPLASIA

569_task1

Sentence: Anamnesis En este caso se presenta una mujer de 79 años, no fumadora ni bebedora, que, como antecedente destacable, presenta síndrome mieloproliferativo crónico, probable trombocitemia esencial con aumento ligero-moderado de megacariocitos en médula ósea, no displásicos, de disposición anómala paratrabecular en acúmulos, con ligero aumento de trama reticulínica. En tratamiento con indapamida retard, ispágula, omeprazol, ácido ibandrónico, alopurinol, hidroxicarbamida, ácido acetil salicílico y lorazepam. Vive con su marido. La paciente debuta con un nódulo sospechoso de 15 mm en mama izquierda en enero de 2017, por el que se le estudia con las correspondientes pruebas de imagen (TC y gammagrafía ósea) y examen histopatológico (biopsia por tru-cut), decidiéndose realizar tumorectomía con biopsia selectiva del ganglio centinela más radioterapia tras la negatividad en el estudio de extensión previamente realizado. En la Anatomía Patológica se diagnostica de carcinoma adenoide quístico grado 2, bordes quirúrgicos libres, con un ganglio linfático de un total de dos con micrometástasis y en la inmunohistoquímica se cataloga como triple negativo (pT2N1miM0). Comienza revisiones. En febrero de 2019, acude a Urgencias por comenzar con disnea progresiva sobre todo con ortopnea o esfuerzo moderado. En Urgencias objetivan derrame pleural derecho, por lo que se ingresa para estudio. Exploración física Durante la exploración física, no se palpaban adenopatías periféricas, masas ni nódulos mamarios. Auscultación respiratoria con hipoventilación en base derecha hasta tercio superior, izquierda normal. El resto de la exploración física por aparatos no tiene alteraciones. ignos de TVP Pruebas complementarias En las pruebas de imagen realizadas (TC-TAP y gammagrafía ósea) se objetiva derrame pleural derecho, nódulos pulmonares y pleurales bilaterales sugestivos de metástasis y nódulos diafragmáticos derechos anteriores en probable relación con adenopatías versus implantes tumorales. Se le realizó drenaje del líquido pleural más talcaje con resultado de líquido negativo para celularidad. Se decide realizar toracoscopia en la que se observa pleura visceral y parietal con lesiones sospechosas de metástasis. Se procede a la aspiración de líquido pleural y biopsia de lesiones de pleura parietal, obteniendo como resultado en la anatomía patológica de infiltración pleural compatible con neoplasia de origen mamario previa (adenoide quístico). Diagnóstico Finalmente, la paciente es diagnosticada de carcinoma adenoide quístico metastásico de origen mamario, con afectación pulmonar y pleural. Tratamiento Revisada la literatura, no existe evidencia sobre la actitud terapéutica sobre este tipo de tumor. Normalmente es un tumor con un curso indolente con una SLE a 10 años del 90-100 %, y las metástasis a distancia son raras y lentamente progresivas, sólo reportadas en forma de casos clínicos. Sin embargo, en este caso se presenta una recaída sistémica sintomática a los 2 años del primario, lo que es extremadamente infrecuente. No existe evidencia sólida sobre el tratamiento de quimioterapia más adecuado, si bien la recomendación es tratarlo como un carcinoma adenoide quístico de glándulas salivares. El esquema con una evidencia más sólida es el CAP (ciclofosfamida [500 mg/m2], doxorrubicina [50 mg/m2], cisplatino [50 mg/m2]) con una tasa de respuestas del 28 %. Pero al tratarse de una paciente frágil, se opta por un esquema de tratamiento en monoterapia con una toxicidad más manejable. El esquema en monoterapia con una mayor tasa de respuestas (15-44 %) es la vinorelbina, por lo que la paciente inicia el primer ciclo de vinorelbina oral a 60 mg/m2 días 1 y 8 cada 21 días, el día 11 de marzo de 20193,4. Evolución La paciente hasta el día de hoy sigue en tratamiento, habiendo recibido cuatro ciclos con muy buena tolerancia al mismo y sin evidencia de progresión clínica, sólo destacando como toxicidad asociada al tratamiento astenia G1. Dentro de unos días, antes del quinto ciclo, se realizará TC de valoración de respuesta. Instructions: please typing these entity words according to sentence: síndrome mieloproliferativo crónico, trombocitemia esencial, carcinoma adenoide quístico grado 2, micrometástasis, pT2N1miM0, nódulos pulmonares, metástasis, nódulos diafragmáticos, implantes tumorales, pleura visceral y parietal con lesiones, metástasis, neoplasia, adenoide quístico, carcinoma adenoide quístico metastásico, afectación pulmonar, tumor, tumor, metástasis, recaída sistémica, carcinoma adenoide quístico Options: MORFOLOGIA_NEOPLASIA

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Anamnesis En este caso se presenta una mujer de 79 años, no fumadora ni bebedora, que, como antecedente destacable, presenta síndrome mieloproliferativo crónico, probable trombocitemia esencial con aumento ligero-moderado de megacariocitos en médula ósea, no displásicos, de disposición anómala paratrabecular en acúmulos, con ligero aumento de trama reticulínica. En tratamiento con indapamida retard, ispágula, omeprazol, ácido ibandrónico, alopurinol, hidroxicarbamida, ácido acetil salicílico y lorazepam. Vive con su marido. La paciente debuta con un nódulo sospechoso de 15 mm en mama izquierda en enero de 2017, por el que se le estudia con las correspondientes pruebas de imagen (TC y gammagrafía ósea) y examen histopatológico (biopsia por tru-cut), decidiéndose realizar tumorectomía con biopsia selectiva del ganglio centinela más radioterapia tras la negatividad en el estudio de extensión previamente realizado. En la Anatomía Patológica se diagnostica de carcinoma adenoide quístico grado 2, bordes quirúrgicos libres, con un ganglio linfático de un total de dos con micrometástasis y en la inmunohistoquímica se cataloga como triple negativo (pT2N1miM0). Comienza revisiones. En febrero de 2019, acude a Urgencias por comenzar con disnea progresiva sobre todo con ortopnea o esfuerzo moderado. En Urgencias objetivan derrame pleural derecho, por lo que se ingresa para estudio. Exploración física Durante la exploración física, no se palpaban adenopatías periféricas, masas ni nódulos mamarios. Auscultación respiratoria con hipoventilación en base derecha hasta tercio superior, izquierda normal. El resto de la exploración física por aparatos no tiene alteraciones. ignos de TVP Pruebas complementarias En las pruebas de imagen realizadas (TC-TAP y gammagrafía ósea) se objetiva derrame pleural derecho, nódulos pulmonares y pleurales bilaterales sugestivos de metástasis y nódulos diafragmáticos derechos anteriores en probable relación con adenopatías versus implantes tumorales. Se le realizó drenaje del líquido pleural más talcaje con resultado de líquido negativo para celularidad. Se decide realizar toracoscopia en la que se observa pleura visceral y parietal con lesiones sospechosas de metástasis. Se procede a la aspiración de líquido pleural y biopsia de lesiones de pleura parietal, obteniendo como resultado en la anatomía patológica de infiltración pleural compatible con neoplasia de origen mamario previa (adenoide quístico). Diagnóstico Finalmente, la paciente es diagnosticada de carcinoma adenoide quístico metastásico de origen mamario, con afectación pulmonar y pleural. Tratamiento Revisada la literatura, no existe evidencia sobre la actitud terapéutica sobre este tipo de tumor. Normalmente es un tumor con un curso indolente con una SLE a 10 años del 90-100 %, y las metástasis a distancia son raras y lentamente progresivas, sólo reportadas en forma de casos clínicos. Sin embargo, en este caso se presenta una recaída sistémica sintomática a los 2 años del primario, lo que es extremadamente infrecuente. No existe evidencia sólida sobre el tratamiento de quimioterapia más adecuado, si bien la recomendación es tratarlo como un carcinoma adenoide quístico de glándulas salivares. El esquema con una evidencia más sólida es el CAP (ciclofosfamida [500 mg/m2], doxorrubicina [50 mg/m2], cisplatino [50 mg/m2]) con una tasa de respuestas del 28 %. Pero al tratarse de una paciente frágil, se opta por un esquema de tratamiento en monoterapia con una toxicidad más manejable. El esquema en monoterapia con una mayor tasa de respuestas (15-44 %) es la vinorelbina, por lo que la paciente inicia el primer ciclo de vinorelbina oral a 60 mg/m2 días 1 y 8 cada 21 días, el día 11 de marzo de 20193,4. Evolución La paciente hasta el día de hoy sigue en tratamiento, habiendo recibido cuatro ciclos con muy buena tolerancia al mismo y sin evidencia de progresión clínica, sólo destacando como toxicidad asociada al tratamiento astenia G1. Dentro de unos días, antes del quinto ciclo, se realizará TC de valoración de respuesta.

[ "Anamnesis", "\n", "En", "este", "caso", "se", "presenta", "una", "mujer", "de", "79", "años", ",", "no", "fumadora", "ni", "bebedora", ",", "que", ",", "como", "antecedente", "destacable", ",", "presenta", "síndrome", "mieloproliferativo", "crónico", ",", "probable", "trombocitemia", "esencial", "con", "aumento", "ligero", "-", "moderado", "de", "megacariocitos", "en", "médula", "ósea", ",", "no", "displásicos", ",", "de", "disposición", "anómala", "paratrabecular", "en", "acúmulos", ",", "con", "ligero", "aumento", "de", "trama", "reticulínica", ".", "En", "tratamiento", "con", "indapamida", "retard", ",", "ispágula", ",", "omeprazol", ",", "ácido", "ibandrónico", ",", "alopurinol", ",", "hidroxicarbamida", ",", "ácido", "acetil", "salicílico", "y", "lorazepam", ".", "Vive", "con", "su", "marido", ".", "\n", "La", "paciente", "debuta", "con", "un", "nódulo", "sospechoso", "de", "15", "mm", "en", "mama", "izquierda", "en", "enero", "de", "2017", ",", "por", "el", "que", "se", "le", "estudia", "con", "las", "correspondientes", "pruebas", "de", "imagen", "(", "TC", "y", "gammagrafía", "ósea", ")", "y", "examen", "histopatológico", "(", "biopsia", "por", "tru", "-", "cut", ")", ",", "decidiéndose", "realizar", "tumorectomía", "con", "biopsia", "selectiva", "del", "ganglio", "centinela", "más", "radioterapia", "tras", "la", "negatividad", "en", "el", "estudio", "de", "extensión", "previamente", "realizado", ".", "En", "la", "Anatomía", "Patológica", "se", "diagnostica", "de", "carcinoma", "adenoide", "quístico", "grado", "2", ",", "bordes", "quirúrgicos", "libres", ",", "con", "un", "ganglio", "linfático", "de", "un", "total", "de", "dos", "con", "micrometástasis", "y", "en", "la", "inmunohistoquímica", "se", "cataloga", "como", "triple", "negativo", "(", "pT2N1miM0", ")", ".", "Comienza", "revisiones", ".", "\n", "En", "febrero", "de", "2019", ",", "acude", "a", "Urgencias", "por", "comenzar", "con", "disnea", "progresiva", "sobre", "todo", "con", "ortopnea", "o", "esfuerzo", "moderado", ".", "En", "Urgencias", "objetivan", "derrame", "pleural", "derecho", ",", "por", "lo", "que", "se", "ingresa", "para", "estudio", ".", "\n\n", "Exploración", "física", "\n", "Durante", "la", "exploración", "física", ",", "no", "se", "palpaban", "adenopatías", "periféricas", ",", "masas", "ni", "nódulos", "mamarios", ".", "Auscultación", "respiratoria", "con", "hipoventilación", "en", "base", "derecha", "hasta", "tercio", "superior", ",", "izquierda", "normal", ".", "El", "resto", "de", "la", "exploración", "física", "por", "aparatos", "no", "tiene", "alteraciones", ".", "\n", "ignos", "de", "TVP", "\n\n", "Pruebas", "complementarias", "\n", "En", "las", "pruebas", "de", "imagen", "realizadas", "(", "TC", "-", "TAP", "y", "gammagrafía", "ósea", ")", "se", "objetiva", "derrame", "pleural", "derecho", ",", "nódulos", "pulmonares", "y", "pleurales", "bilaterales", "sugestivos", "de", "metástasis", "y", "nódulos", "diafragmáticos", "derechos", "anteriores", "en", "probable", "relación", "con", "adenopatías", "versus", "implantes", "tumorales", ".", "Se", "le", "realizó", "drenaje", "del", "líquido", "pleural", "más", "talcaje", "con", "resultado", "de", "líquido", "negativo", "para", "celularidad", ".", "Se", "decide", "realizar", "toracoscopia", "en", "la", "que", "se", "observa", "pleura", "visceral", "y", "parietal", "con", "lesiones", "sospechosas", "de", "metástasis", ".", "Se", "procede", "a", "la", "aspiración", "de", "líquido", "pleural", "y", "biopsia", "de", "lesiones", "de", "pleura", "parietal", ",", "obteniendo", "como", "resultado", "en", "la", "anatomía", "patológica", "de", "infiltración", "pleural", "compatible", "con", "neoplasia", "de", "origen", "mamario", "previa", "(", "adenoide", "quístico", ")", ".", "\n\n", "Diagnóstico", "\n", "Finalmente", ",", "la", "paciente", "es", "diagnosticada", "de", "carcinoma", "adenoide", "quístico", "metastásico", "de", "origen", "mamario", ",", "con", "afectación", "pulmonar", "y", "pleural", ".", "\n\n", "Tratamiento", "\n", "Revisada", "la", "literatura", ",", "no", "existe", "evidencia", "sobre", "la", "actitud", "terapéutica", "sobre", "este", "tipo", "de", "tumor", ".", "Normalmente", "es", "un", "tumor", "con", "un", "curso", "indolente", "con", "una", "SLE", "a", "10", "años", "del", "90", "-", "100", "%", ",", "y", "las", "metástasis", "a", "distancia", "son", "raras", "y", "lentamente", "progresivas", ",", "sólo", "reportadas", "en", "forma", "de", "casos", "clínicos", ".", "Sin", "embargo", ",", "en", "este", "caso", "se", "presenta", "una", "recaída", "sistémica", "sintomática", "a", "los", "2", "años", "del", "primario", ",", "lo", "que", "es", "extremadamente", "infrecuente", ".", "\n", "No", "existe", "evidencia", "sólida", "sobre", "el", "tratamiento", "de", "quimioterapia", "más", "adecuado", ",", "si", "bien", "la", "recomendación", "es", "tratarlo", "como", "un", "carcinoma", "adenoide", "quístico", "de", "glándulas", "salivares", ".", "El", "esquema", "con", "una", "evidencia", "más", "sólida", "es", "el", "CAP", "(", "ciclofosfamida", "[", "500", "mg", "/", "m2", "]", ",", "doxorrubicina", "[", "50", "mg", "/", "m2", "]", ",", "cisplatino", "[", "50", "mg", "/", "m2", "]", ")", "con", "una", "tasa", "de", "respuestas", "del", "28", "%", ".", "Pero", "al", "tratarse", "de", "una", "paciente", "frágil", ",", "se", "opta", "por", "un", "esquema", "de", "tratamiento", "en", "monoterapia", "con", "una", "toxicidad", "más", "manejable", ".", "El", "esquema", "en", "monoterapia", "con", "una", "mayor", "tasa", "de", "respuestas", "(", "15", "-", "44", "%", ")", "es", "la", "vinorelbina", ",", "por", "lo", "que", "la", "paciente", "inicia", "el", "primer", "ciclo", "de", "vinorelbina", "oral", "a", "60", "mg", "/", "m2", "días", "1", "y", "8", "cada", "21", "días", ",", "el", "día", "11", "de", "marzo", "de", "20193,4", ".", "\n\n", "Evolución", "\n", "La", "paciente", "hasta", "el", "día", "de", "hoy", "sigue", "en", "tratamiento", ",", "habiendo", "recibido", "cuatro", "ciclos", "con", "muy", "buena", "tolerancia", "al", "mismo", "y", "sin", "evidencia", "de", "progresión", "clínica", ",", "sólo", "destacando", "como", "toxicidad", "asociada", "al", "tratamiento", "astenia", "G1", ".", "Dentro", "de", "unos", "días", ",", "antes", "del", "quinto", "ciclo", ",", "se", "realizará", "TC", "de", "valoración", "de", "respuesta", "." ]

[ "MORFOLOGIA_NEOPLASIA" ]

síndrome mieloproliferativo crónico, trombocitemia esencial, carcinoma adenoide quístico grado 2, micrometástasis, pT2N1miM0, nódulos pulmonares, metástasis, nódulos diafragmáticos, implantes tumorales, pleura visceral y parietal con lesiones, metástasis, neoplasia, adenoide quístico, carcinoma adenoide quístico metastásico, afectación pulmonar, tumor, tumor, metástasis, recaída sistémica, carcinoma adenoide quístico

569_task2

Sentence: Anamnesis En este caso se presenta una mujer de 79 años, no fumadora ni bebedora, que, como antecedente destacable, presenta síndrome mieloproliferativo crónico, probable trombocitemia esencial con aumento ligero-moderado de megacariocitos en médula ósea, no displásicos, de disposición anómala paratrabecular en acúmulos, con ligero aumento de trama reticulínica. En tratamiento con indapamida retard, ispágula, omeprazol, ácido ibandrónico, alopurinol, hidroxicarbamida, ácido acetil salicílico y lorazepam. Vive con su marido. La paciente debuta con un nódulo sospechoso de 15 mm en mama izquierda en enero de 2017, por el que se le estudia con las correspondientes pruebas de imagen (TC y gammagrafía ósea) y examen histopatológico (biopsia por tru-cut), decidiéndose realizar tumorectomía con biopsia selectiva del ganglio centinela más radioterapia tras la negatividad en el estudio de extensión previamente realizado. En la Anatomía Patológica se diagnostica de carcinoma adenoide quístico grado 2, bordes quirúrgicos libres, con un ganglio linfático de un total de dos con micrometástasis y en la inmunohistoquímica se cataloga como triple negativo (pT2N1miM0). Comienza revisiones. En febrero de 2019, acude a Urgencias por comenzar con disnea progresiva sobre todo con ortopnea o esfuerzo moderado. En Urgencias objetivan derrame pleural derecho, por lo que se ingresa para estudio. Exploración física Durante la exploración física, no se palpaban adenopatías periféricas, masas ni nódulos mamarios. Auscultación respiratoria con hipoventilación en base derecha hasta tercio superior, izquierda normal. El resto de la exploración física por aparatos no tiene alteraciones. ignos de TVP Pruebas complementarias En las pruebas de imagen realizadas (TC-TAP y gammagrafía ósea) se objetiva derrame pleural derecho, nódulos pulmonares y pleurales bilaterales sugestivos de metástasis y nódulos diafragmáticos derechos anteriores en probable relación con adenopatías versus implantes tumorales. Se le realizó drenaje del líquido pleural más talcaje con resultado de líquido negativo para celularidad. Se decide realizar toracoscopia en la que se observa pleura visceral y parietal con lesiones sospechosas de metástasis. Se procede a la aspiración de líquido pleural y biopsia de lesiones de pleura parietal, obteniendo como resultado en la anatomía patológica de infiltración pleural compatible con neoplasia de origen mamario previa (adenoide quístico). Diagnóstico Finalmente, la paciente es diagnosticada de carcinoma adenoide quístico metastásico de origen mamario, con afectación pulmonar y pleural. Tratamiento Revisada la literatura, no existe evidencia sobre la actitud terapéutica sobre este tipo de tumor. Normalmente es un tumor con un curso indolente con una SLE a 10 años del 90-100 %, y las metástasis a distancia son raras y lentamente progresivas, sólo reportadas en forma de casos clínicos. Sin embargo, en este caso se presenta una recaída sistémica sintomática a los 2 años del primario, lo que es extremadamente infrecuente. No existe evidencia sólida sobre el tratamiento de quimioterapia más adecuado, si bien la recomendación es tratarlo como un carcinoma adenoide quístico de glándulas salivares. El esquema con una evidencia más sólida es el CAP (ciclofosfamida [500 mg/m2], doxorrubicina [50 mg/m2], cisplatino [50 mg/m2]) con una tasa de respuestas del 28 %. Pero al tratarse de una paciente frágil, se opta por un esquema de tratamiento en monoterapia con una toxicidad más manejable. El esquema en monoterapia con una mayor tasa de respuestas (15-44 %) es la vinorelbina, por lo que la paciente inicia el primer ciclo de vinorelbina oral a 60 mg/m2 días 1 y 8 cada 21 días, el día 11 de marzo de 20193,4. Evolución La paciente hasta el día de hoy sigue en tratamiento, habiendo recibido cuatro ciclos con muy buena tolerancia al mismo y sin evidencia de progresión clínica, sólo destacando como toxicidad asociada al tratamiento astenia G1. Dentro de unos días, antes del quinto ciclo, se realizará TC de valoración de respuesta. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Anamnesis En este caso se presenta una mujer de 79 años, no fumadora ni bebedora, que, como antecedente destacable, presenta síndrome mieloproliferativo crónico, probable trombocitemia esencial con aumento ligero-moderado de megacariocitos en médula ósea, no displásicos, de disposición anómala paratrabecular en acúmulos, con ligero aumento de trama reticulínica. En tratamiento con indapamida retard, ispágula, omeprazol, ácido ibandrónico, alopurinol, hidroxicarbamida, ácido acetil salicílico y lorazepam. Vive con su marido. La paciente debuta con un nódulo sospechoso de 15 mm en mama izquierda en enero de 2017, por el que se le estudia con las correspondientes pruebas de imagen (TC y gammagrafía ósea) y examen histopatológico (biopsia por tru-cut), decidiéndose realizar tumorectomía con biopsia selectiva del ganglio centinela más radioterapia tras la negatividad en el estudio de extensión previamente realizado. En la Anatomía Patológica se diagnostica de carcinoma adenoide quístico grado 2, bordes quirúrgicos libres, con un ganglio linfático de un total de dos con micrometástasis y en la inmunohistoquímica se cataloga como triple negativo (pT2N1miM0). Comienza revisiones. En febrero de 2019, acude a Urgencias por comenzar con disnea progresiva sobre todo con ortopnea o esfuerzo moderado. En Urgencias objetivan derrame pleural derecho, por lo que se ingresa para estudio. Exploración física Durante la exploración física, no se palpaban adenopatías periféricas, masas ni nódulos mamarios. Auscultación respiratoria con hipoventilación en base derecha hasta tercio superior, izquierda normal. El resto de la exploración física por aparatos no tiene alteraciones. ignos de TVP Pruebas complementarias En las pruebas de imagen realizadas (TC-TAP y gammagrafía ósea) se objetiva derrame pleural derecho, nódulos pulmonares y pleurales bilaterales sugestivos de metástasis y nódulos diafragmáticos derechos anteriores en probable relación con adenopatías versus implantes tumorales. Se le realizó drenaje del líquido pleural más talcaje con resultado de líquido negativo para celularidad. Se decide realizar toracoscopia en la que se observa pleura visceral y parietal con lesiones sospechosas de metástasis. Se procede a la aspiración de líquido pleural y biopsia de lesiones de pleura parietal, obteniendo como resultado en la anatomía patológica de infiltración pleural compatible con neoplasia de origen mamario previa (adenoide quístico). Diagnóstico Finalmente, la paciente es diagnosticada de carcinoma adenoide quístico metastásico de origen mamario, con afectación pulmonar y pleural. Tratamiento Revisada la literatura, no existe evidencia sobre la actitud terapéutica sobre este tipo de tumor. Normalmente es un tumor con un curso indolente con una SLE a 10 años del 90-100 %, y las metástasis a distancia son raras y lentamente progresivas, sólo reportadas en forma de casos clínicos. Sin embargo, en este caso se presenta una recaída sistémica sintomática a los 2 años del primario, lo que es extremadamente infrecuente. No existe evidencia sólida sobre el tratamiento de quimioterapia más adecuado, si bien la recomendación es tratarlo como un carcinoma adenoide quístico de glándulas salivares. El esquema con una evidencia más sólida es el CAP (ciclofosfamida [500 mg/m2], doxorrubicina [50 mg/m2], cisplatino [50 mg/m2]) con una tasa de respuestas del 28 %. Pero al tratarse de una paciente frágil, se opta por un esquema de tratamiento en monoterapia con una toxicidad más manejable. El esquema en monoterapia con una mayor tasa de respuestas (15-44 %) es la vinorelbina, por lo que la paciente inicia el primer ciclo de vinorelbina oral a 60 mg/m2 días 1 y 8 cada 21 días, el día 11 de marzo de 20193,4. Evolución La paciente hasta el día de hoy sigue en tratamiento, habiendo recibido cuatro ciclos con muy buena tolerancia al mismo y sin evidencia de progresión clínica, sólo destacando como toxicidad asociada al tratamiento astenia G1. Dentro de unos días, antes del quinto ciclo, se realizará TC de valoración de respuesta.

[ "Anamnesis", "\n", "En", "este", "caso", "se", "presenta", "una", "mujer", "de", "79", "años", ",", "no", "fumadora", "ni", "bebedora", ",", "que", ",", "como", "antecedente", "destacable", ",", "presenta", "síndrome", "mieloproliferativo", "crónico", ",", "probable", "trombocitemia", "esencial", "con", "aumento", "ligero", "-", "moderado", "de", "megacariocitos", "en", "médula", "ósea", ",", "no", "displásicos", ",", "de", "disposición", "anómala", "paratrabecular", "en", "acúmulos", ",", "con", "ligero", "aumento", "de", "trama", "reticulínica", ".", "En", "tratamiento", "con", "indapamida", "retard", ",", "ispágula", ",", "omeprazol", ",", "ácido", "ibandrónico", ",", "alopurinol", ",", "hidroxicarbamida", ",", "ácido", "acetil", "salicílico", "y", "lorazepam", ".", "Vive", "con", "su", "marido", ".", "\n", "La", "paciente", "debuta", "con", "un", "nódulo", "sospechoso", "de", "15", "mm", "en", "mama", "izquierda", "en", "enero", "de", "2017", ",", "por", "el", "que", "se", "le", "estudia", "con", "las", "correspondientes", "pruebas", "de", "imagen", "(", "TC", "y", "gammagrafía", "ósea", ")", "y", "examen", "histopatológico", "(", "biopsia", "por", "tru", "-", "cut", ")", ",", "decidiéndose", "realizar", "tumorectomía", "con", "biopsia", "selectiva", "del", "ganglio", "centinela", "más", "radioterapia", "tras", "la", "negatividad", "en", "el", "estudio", "de", "extensión", "previamente", "realizado", ".", "En", "la", "Anatomía", "Patológica", "se", "diagnostica", "de", "carcinoma", "adenoide", "quístico", "grado", "2", ",", "bordes", "quirúrgicos", "libres", ",", "con", "un", "ganglio", "linfático", "de", "un", "total", "de", "dos", "con", "micrometástasis", "y", "en", "la", "inmunohistoquímica", "se", "cataloga", "como", "triple", "negativo", "(", "pT2N1miM0", ")", ".", "Comienza", "revisiones", ".", "\n", "En", "febrero", "de", "2019", ",", "acude", "a", "Urgencias", "por", "comenzar", "con", "disnea", "progresiva", "sobre", "todo", "con", "ortopnea", "o", "esfuerzo", "moderado", ".", "En", "Urgencias", "objetivan", "derrame", "pleural", "derecho", ",", "por", "lo", "que", "se", "ingresa", "para", "estudio", ".", "\n\n", "Exploración", "física", "\n", "Durante", "la", "exploración", "física", ",", "no", "se", "palpaban", "adenopatías", "periféricas", ",", "masas", "ni", "nódulos", "mamarios", ".", "Auscultación", "respiratoria", "con", "hipoventilación", "en", "base", "derecha", "hasta", "tercio", "superior", ",", "izquierda", "normal", ".", "El", "resto", "de", "la", "exploración", "física", "por", "aparatos", "no", "tiene", "alteraciones", ".", "\n", "ignos", "de", "TVP", "\n\n", "Pruebas", "complementarias", "\n", "En", "las", "pruebas", "de", "imagen", "realizadas", "(", "TC", "-", "TAP", "y", "gammagrafía", "ósea", ")", "se", "objetiva", "derrame", "pleural", "derecho", ",", "nódulos", "pulmonares", "y", "pleurales", "bilaterales", "sugestivos", "de", "metástasis", "y", "nódulos", "diafragmáticos", "derechos", "anteriores", "en", "probable", "relación", "con", "adenopatías", "versus", "implantes", "tumorales", ".", "Se", "le", "realizó", "drenaje", "del", "líquido", "pleural", "más", "talcaje", "con", "resultado", "de", "líquido", "negativo", "para", "celularidad", ".", "Se", "decide", "realizar", "toracoscopia", "en", "la", "que", "se", "observa", "pleura", "visceral", "y", "parietal", "con", "lesiones", "sospechosas", "de", "metástasis", ".", "Se", "procede", "a", "la", "aspiración", "de", "líquido", "pleural", "y", "biopsia", "de", "lesiones", "de", "pleura", "parietal", ",", "obteniendo", "como", "resultado", "en", "la", "anatomía", "patológica", "de", "infiltración", "pleural", "compatible", "con", "neoplasia", "de", "origen", "mamario", "previa", "(", "adenoide", "quístico", ")", ".", "\n\n", "Diagnóstico", "\n", "Finalmente", ",", "la", "paciente", "es", "diagnosticada", "de", "carcinoma", "adenoide", "quístico", "metastásico", "de", "origen", "mamario", ",", "con", "afectación", "pulmonar", "y", "pleural", ".", "\n\n", "Tratamiento", "\n", "Revisada", "la", "literatura", ",", "no", "existe", "evidencia", "sobre", "la", "actitud", "terapéutica", "sobre", "este", "tipo", "de", "tumor", ".", "Normalmente", "es", "un", "tumor", "con", "un", "curso", "indolente", "con", "una", "SLE", "a", "10", "años", "del", "90", "-", "100", "%", ",", "y", "las", "metástasis", "a", "distancia", "son", "raras", "y", "lentamente", "progresivas", ",", "sólo", "reportadas", "en", "forma", "de", "casos", "clínicos", ".", "Sin", "embargo", ",", "en", "este", "caso", "se", "presenta", "una", "recaída", "sistémica", "sintomática", "a", "los", "2", "años", "del", "primario", ",", "lo", "que", "es", "extremadamente", "infrecuente", ".", "\n", "No", "existe", "evidencia", "sólida", "sobre", "el", "tratamiento", "de", "quimioterapia", "más", "adecuado", ",", "si", "bien", "la", "recomendación", "es", "tratarlo", "como", "un", "carcinoma", "adenoide", "quístico", "de", "glándulas", "salivares", ".", "El", "esquema", "con", "una", "evidencia", "más", "sólida", "es", "el", "CAP", "(", "ciclofosfamida", "[", "500", "mg", "/", "m2", "]", ",", "doxorrubicina", "[", "50", "mg", "/", "m2", "]", ",", "cisplatino", "[", "50", "mg", "/", "m2", "]", ")", "con", "una", "tasa", "de", "respuestas", "del", "28", "%", ".", "Pero", "al", "tratarse", "de", "una", "paciente", "frágil", ",", "se", "opta", "por", "un", "esquema", "de", "tratamiento", "en", "monoterapia", "con", "una", "toxicidad", "más", "manejable", ".", "El", "esquema", "en", "monoterapia", "con", "una", "mayor", "tasa", "de", "respuestas", "(", "15", "-", "44", "%", ")", "es", "la", "vinorelbina", ",", "por", "lo", "que", "la", "paciente", "inicia", "el", "primer", "ciclo", "de", "vinorelbina", "oral", "a", "60", "mg", "/", "m2", "días", "1", "y", "8", "cada", "21", "días", ",", "el", "día", "11", "de", "marzo", "de", "20193,4", ".", "\n\n", "Evolución", "\n", "La", "paciente", "hasta", "el", "día", "de", "hoy", "sigue", "en", "tratamiento", ",", "habiendo", "recibido", "cuatro", "ciclos", "con", "muy", "buena", "tolerancia", "al", "mismo", "y", "sin", "evidencia", "de", "progresión", "clínica", ",", "sólo", "destacando", "como", "toxicidad", "asociada", "al", "tratamiento", "astenia", "G1", ".", "Dentro", "de", "unos", "días", ",", "antes", "del", "quinto", "ciclo", ",", "se", "realizará", "TC", "de", "valoración", "de", "respuesta", "." ]

[ "MORFOLOGIA_NEOPLASIA" ]

Erytheme is an umlsterm, Hautveraenderungen is an umlsterm, Kind is an umlsterm, Hautveraenderungen is an umlsterm, Extremitaeten is an umlsterm, Streptokokken is an umlsterm, Dermatitis is an umlsterm, Kinder is an umlsterm, Kandidose is an umlsterm, Ekzem is an umlsterm, Behandlung is an umlsterm, Hautveraenderungen is an umlsterm, Therapie is an umlsterm

DerHautarzt.00510086.ger.abstr_task0

Sentence: Bei 2 Jungen im Alter von 6 und 9 Jahren liessen sich ueber einen langen Zeitraum bestehende scharf begrenzte perianale Erytheme , die bei einem Jungen die alleinigen Hautveraenderungen darstellen , bei dem anderen Kind mit zusaetzlichen Hautveraenderungen am Genitale sowie den Extremitaeten einhergingen , durch den kulturellen Nachweis von Streptokokken dem Krankheitsbild der perianalen streptogenen Dermatitis " " zuordnen . Diese v.a. Kinder , betreffende Erkrankung muss differendialdiagnostisch v.a. gegenueber der Kandidose und dem perianalen atopischen Ekzem abgegrenzt werden . Wie auch im Fall der beiden hier beschriebenen Jungen fuehrt eine topische Behandlung in der Regel nicht zur Abheilung der Hautveraenderungen . Die orale Penzillingabe stellt die Therapie der Wahl dar . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]

Bei 2 Jungen im Alter von 6 und 9 Jahren liessen sich ueber einen langen Zeitraum bestehende scharf begrenzte perianale Erytheme , die bei einem Jungen die alleinigen Hautveraenderungen darstellen , bei dem anderen Kind mit zusaetzlichen Hautveraenderungen am Genitale sowie den Extremitaeten einhergingen , durch den kulturellen Nachweis von Streptokokken dem Krankheitsbild der perianalen streptogenen Dermatitis " " zuordnen . Diese v.a. Kinder , betreffende Erkrankung muss differendialdiagnostisch v.a. gegenueber der Kandidose und dem perianalen atopischen Ekzem abgegrenzt werden . Wie auch im Fall der beiden hier beschriebenen Jungen fuehrt eine topische Behandlung in der Regel nicht zur Abheilung der Hautveraenderungen . Die orale Penzillingabe stellt die Therapie der Wahl dar .

[ "Bei", "2", "Jungen", "im", "Alter", "von", "6", "und", "9", "Jahren", "liessen", "sich", "ueber", "einen", "langen", "Zeitraum", "bestehende", "scharf", "begrenzte", "perianale", "Erytheme", ",", "die", "bei", "einem", "Jungen", "die", "alleinigen", "Hautveraenderungen", "darstellen", ",", "bei", "dem", "anderen", "Kind", "mit", "zusaetzlichen", "Hautveraenderungen", "am", "Genitale", "sowie", "den", "Extremitaeten", "einhergingen", ",", "durch", "den", "kulturellen", "Nachweis", "von", "Streptokokken", "dem", "Krankheitsbild", "der", "perianalen", "streptogenen", "Dermatitis", "\"", "\"", "zuordnen", ".", "Diese", "v.a", ".", "Kinder", ",", "betreffende", "Erkrankung", "muss", "differendialdiagnostisch", "v.a", ".", "gegenueber", "der", "Kandidose", "und", "dem", "perianalen", "atopischen", "Ekzem", "abgegrenzt", "werden", ".", "Wie", "auch", "im", "Fall", "der", "beiden", "hier", "beschriebenen", "Jungen", "fuehrt", "eine", "topische", "Behandlung", "in", "der", "Regel", "nicht", "zur", "Abheilung", "der", "Hautveraenderungen", ".", "Die", "orale", "Penzillingabe", "stellt", "die", "Therapie", "der", "Wahl", "dar", "." ]

[ "umlsterm" ]

Erytheme is an umlsterm, Hautveraenderungen is an umlsterm, Kind is an umlsterm, Hautveraenderungen is an umlsterm, Extremitaeten is an umlsterm, Streptokokken is an umlsterm, Dermatitis is an umlsterm, Kinder is an umlsterm, Kandidose is an umlsterm, Ekzem is an umlsterm, Behandlung is an umlsterm, Hautveraenderungen is an umlsterm, Therapie is an umlsterm

DerHautarzt.00510086.ger.abstr_task1

Sentence: Bei 2 Jungen im Alter von 6 und 9 Jahren liessen sich ueber einen langen Zeitraum bestehende scharf begrenzte perianale Erytheme , die bei einem Jungen die alleinigen Hautveraenderungen darstellen , bei dem anderen Kind mit zusaetzlichen Hautveraenderungen am Genitale sowie den Extremitaeten einhergingen , durch den kulturellen Nachweis von Streptokokken dem Krankheitsbild der perianalen streptogenen Dermatitis " " zuordnen . Diese v.a. Kinder , betreffende Erkrankung muss differendialdiagnostisch v.a. gegenueber der Kandidose und dem perianalen atopischen Ekzem abgegrenzt werden . Wie auch im Fall der beiden hier beschriebenen Jungen fuehrt eine topische Behandlung in der Regel nicht zur Abheilung der Hautveraenderungen . Die orale Penzillingabe stellt die Therapie der Wahl dar . Instructions: please typing these entity words according to sentence: Erytheme, Hautveraenderungen, Kind, Hautveraenderungen, Extremitaeten, Streptokokken, Dermatitis, Kinder, Kandidose, Ekzem, Behandlung, Hautveraenderungen, Therapie Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]

Bei 2 Jungen im Alter von 6 und 9 Jahren liessen sich ueber einen langen Zeitraum bestehende scharf begrenzte perianale Erytheme , die bei einem Jungen die alleinigen Hautveraenderungen darstellen , bei dem anderen Kind mit zusaetzlichen Hautveraenderungen am Genitale sowie den Extremitaeten einhergingen , durch den kulturellen Nachweis von Streptokokken dem Krankheitsbild der perianalen streptogenen Dermatitis " " zuordnen . Diese v.a. Kinder , betreffende Erkrankung muss differendialdiagnostisch v.a. gegenueber der Kandidose und dem perianalen atopischen Ekzem abgegrenzt werden . Wie auch im Fall der beiden hier beschriebenen Jungen fuehrt eine topische Behandlung in der Regel nicht zur Abheilung der Hautveraenderungen . Die orale Penzillingabe stellt die Therapie der Wahl dar .

[ "Bei", "2", "Jungen", "im", "Alter", "von", "6", "und", "9", "Jahren", "liessen", "sich", "ueber", "einen", "langen", "Zeitraum", "bestehende", "scharf", "begrenzte", "perianale", "Erytheme", ",", "die", "bei", "einem", "Jungen", "die", "alleinigen", "Hautveraenderungen", "darstellen", ",", "bei", "dem", "anderen", "Kind", "mit", "zusaetzlichen", "Hautveraenderungen", "am", "Genitale", "sowie", "den", "Extremitaeten", "einhergingen", ",", "durch", "den", "kulturellen", "Nachweis", "von", "Streptokokken", "dem", "Krankheitsbild", "der", "perianalen", "streptogenen", "Dermatitis", "\"", "\"", "zuordnen", ".", "Diese", "v.a", ".", "Kinder", ",", "betreffende", "Erkrankung", "muss", "differendialdiagnostisch", "v.a", ".", "gegenueber", "der", "Kandidose", "und", "dem", "perianalen", "atopischen", "Ekzem", "abgegrenzt", "werden", ".", "Wie", "auch", "im", "Fall", "der", "beiden", "hier", "beschriebenen", "Jungen", "fuehrt", "eine", "topische", "Behandlung", "in", "der", "Regel", "nicht", "zur", "Abheilung", "der", "Hautveraenderungen", ".", "Die", "orale", "Penzillingabe", "stellt", "die", "Therapie", "der", "Wahl", "dar", "." ]

[ "umlsterm" ]

Erytheme, Hautveraenderungen, Kind, Hautveraenderungen, Extremitaeten, Streptokokken, Dermatitis, Kinder, Kandidose, Ekzem, Behandlung, Hautveraenderungen, Therapie

DerHautarzt.00510086.ger.abstr_task2

Sentence: Bei 2 Jungen im Alter von 6 und 9 Jahren liessen sich ueber einen langen Zeitraum bestehende scharf begrenzte perianale Erytheme , die bei einem Jungen die alleinigen Hautveraenderungen darstellen , bei dem anderen Kind mit zusaetzlichen Hautveraenderungen am Genitale sowie den Extremitaeten einhergingen , durch den kulturellen Nachweis von Streptokokken dem Krankheitsbild der perianalen streptogenen Dermatitis " " zuordnen . Diese v.a. Kinder , betreffende Erkrankung muss differendialdiagnostisch v.a. gegenueber der Kandidose und dem perianalen atopischen Ekzem abgegrenzt werden . Wie auch im Fall der beiden hier beschriebenen Jungen fuehrt eine topische Behandlung in der Regel nicht zur Abheilung der Hautveraenderungen . Die orale Penzillingabe stellt die Therapie der Wahl dar . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]

Bei 2 Jungen im Alter von 6 und 9 Jahren liessen sich ueber einen langen Zeitraum bestehende scharf begrenzte perianale Erytheme , die bei einem Jungen die alleinigen Hautveraenderungen darstellen , bei dem anderen Kind mit zusaetzlichen Hautveraenderungen am Genitale sowie den Extremitaeten einhergingen , durch den kulturellen Nachweis von Streptokokken dem Krankheitsbild der perianalen streptogenen Dermatitis " " zuordnen . Diese v.a. Kinder , betreffende Erkrankung muss differendialdiagnostisch v.a. gegenueber der Kandidose und dem perianalen atopischen Ekzem abgegrenzt werden . Wie auch im Fall der beiden hier beschriebenen Jungen fuehrt eine topische Behandlung in der Regel nicht zur Abheilung der Hautveraenderungen . Die orale Penzillingabe stellt die Therapie der Wahl dar .

[ "Bei", "2", "Jungen", "im", "Alter", "von", "6", "und", "9", "Jahren", "liessen", "sich", "ueber", "einen", "langen", "Zeitraum", "bestehende", "scharf", "begrenzte", "perianale", "Erytheme", ",", "die", "bei", "einem", "Jungen", "die", "alleinigen", "Hautveraenderungen", "darstellen", ",", "bei", "dem", "anderen", "Kind", "mit", "zusaetzlichen", "Hautveraenderungen", "am", "Genitale", "sowie", "den", "Extremitaeten", "einhergingen", ",", "durch", "den", "kulturellen", "Nachweis", "von", "Streptokokken", "dem", "Krankheitsbild", "der", "perianalen", "streptogenen", "Dermatitis", "\"", "\"", "zuordnen", ".", "Diese", "v.a", ".", "Kinder", ",", "betreffende", "Erkrankung", "muss", "differendialdiagnostisch", "v.a", ".", "gegenueber", "der", "Kandidose", "und", "dem", "perianalen", "atopischen", "Ekzem", "abgegrenzt", "werden", ".", "Wie", "auch", "im", "Fall", "der", "beiden", "hier", "beschriebenen", "Jungen", "fuehrt", "eine", "topische", "Behandlung", "in", "der", "Regel", "nicht", "zur", "Abheilung", "der", "Hautveraenderungen", ".", "Die", "orale", "Penzillingabe", "stellt", "die", "Therapie", "der", "Wahl", "dar", "." ]

[ "umlsterm" ]

Atherosklerose is an umlsterm, T - Lymphozyten is an umlsterm, Makrophagen is an umlsterm, Risikofaktoren is an umlsterm, Marker is an umlsterm, Entzuendung is an umlsterm, Leukozyten is an umlsterm, Protein is an umlsterm, Serumamyloid is an umlsterm, Interleukin is an umlsterm, Lipoproteine is an umlsterm, Lipoproteine is an umlsterm, Elemente is an umlsterm, Makrophagen is an umlsterm

Herz.00250117.ger.abstr_task0

Sentence: Die Atherosklerose besitzt viele Merkmale einer chronisch entzuendlichen Erkrankung . Atherosklerotische Laesionen enthalten Entzuendungszellen , aktivierte T-Lymphozyten und Makrophagen . Auch nach Korrektur fuer etablierte kardiovaskulaere Risikofaktoren koennen systemische Marker einer Entzuendung , wie Leukozyten , C-reaktives Protein , Serumamyloid A , Interleukin 6 und loesliche Adhaesionsmolekuele , zur Abschaetzung des Risikos fuer kuenftige kardiovaskulaere Ereignisse beitragen . Atherogene Lipoproteine , insbesondere modifizierte Lipoproteine niedriger Dichte ( LDL ) , verursachen entzuendliche Reaktionen zellulaerer Elemente der Gefaesswand , zum Beispiel Stoerungen den Endothelzellfunktion oder die Aktivierung von Makrophagen . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]

Die Atherosklerose besitzt viele Merkmale einer chronisch entzuendlichen Erkrankung . Atherosklerotische Laesionen enthalten Entzuendungszellen , aktivierte T-Lymphozyten und Makrophagen . Auch nach Korrektur fuer etablierte kardiovaskulaere Risikofaktoren koennen systemische Marker einer Entzuendung , wie Leukozyten , C-reaktives Protein , Serumamyloid A , Interleukin 6 und loesliche Adhaesionsmolekuele , zur Abschaetzung des Risikos fuer kuenftige kardiovaskulaere Ereignisse beitragen . Atherogene Lipoproteine , insbesondere modifizierte Lipoproteine niedriger Dichte ( LDL ) , verursachen entzuendliche Reaktionen zellulaerer Elemente der Gefaesswand , zum Beispiel Stoerungen den Endothelzellfunktion oder die Aktivierung von Makrophagen .

[ "Die", "Atherosklerose", "besitzt", "viele", "Merkmale", "einer", "chronisch", "entzuendlichen", "Erkrankung", ".", "Atherosklerotische", "Laesionen", "enthalten", "Entzuendungszellen", ",", "aktivierte", "T", "-", "Lymphozyten", "und", "Makrophagen", ".", "Auch", "nach", "Korrektur", "fuer", "etablierte", "kardiovaskulaere", "Risikofaktoren", "koennen", "systemische", "Marker", "einer", "Entzuendung", ",", "wie", "Leukozyten", ",", "C", "-", "reaktives", "Protein", ",", "Serumamyloid", "A", ",", "Interleukin", "6", "und", "loesliche", "Adhaesionsmolekuele", ",", "zur", "Abschaetzung", "des", "Risikos", "fuer", "kuenftige", "kardiovaskulaere", "Ereignisse", "beitragen", ".", "Atherogene", "Lipoproteine", ",", "insbesondere", "modifizierte", "Lipoproteine", "niedriger", "Dichte", "(", "LDL", ")", ",", "verursachen", "entzuendliche", "Reaktionen", "zellulaerer", "Elemente", "der", "Gefaesswand", ",", "zum", "Beispiel", "Stoerungen", "den", "Endothelzellfunktion", "oder", "die", "Aktivierung", "von", "Makrophagen", "." ]

[ "umlsterm" ]

Atherosklerose is an umlsterm, T - Lymphozyten is an umlsterm, Makrophagen is an umlsterm, Risikofaktoren is an umlsterm, Marker is an umlsterm, Entzuendung is an umlsterm, Leukozyten is an umlsterm, Protein is an umlsterm, Serumamyloid is an umlsterm, Interleukin is an umlsterm, Lipoproteine is an umlsterm, Lipoproteine is an umlsterm, Elemente is an umlsterm, Makrophagen is an umlsterm

Herz.00250117.ger.abstr_task1

Sentence: Die Atherosklerose besitzt viele Merkmale einer chronisch entzuendlichen Erkrankung . Atherosklerotische Laesionen enthalten Entzuendungszellen , aktivierte T-Lymphozyten und Makrophagen . Auch nach Korrektur fuer etablierte kardiovaskulaere Risikofaktoren koennen systemische Marker einer Entzuendung , wie Leukozyten , C-reaktives Protein , Serumamyloid A , Interleukin 6 und loesliche Adhaesionsmolekuele , zur Abschaetzung des Risikos fuer kuenftige kardiovaskulaere Ereignisse beitragen . Atherogene Lipoproteine , insbesondere modifizierte Lipoproteine niedriger Dichte ( LDL ) , verursachen entzuendliche Reaktionen zellulaerer Elemente der Gefaesswand , zum Beispiel Stoerungen den Endothelzellfunktion oder die Aktivierung von Makrophagen . Instructions: please typing these entity words according to sentence: Atherosklerose, T - Lymphozyten, Makrophagen, Risikofaktoren, Marker, Entzuendung, Leukozyten, Protein, Serumamyloid, Interleukin, Lipoproteine, Lipoproteine, Elemente, Makrophagen Options: umlsterm

[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]

Die Atherosklerose besitzt viele Merkmale einer chronisch entzuendlichen Erkrankung . Atherosklerotische Laesionen enthalten Entzuendungszellen , aktivierte T-Lymphozyten und Makrophagen . Auch nach Korrektur fuer etablierte kardiovaskulaere Risikofaktoren koennen systemische Marker einer Entzuendung , wie Leukozyten , C-reaktives Protein , Serumamyloid A , Interleukin 6 und loesliche Adhaesionsmolekuele , zur Abschaetzung des Risikos fuer kuenftige kardiovaskulaere Ereignisse beitragen . Atherogene Lipoproteine , insbesondere modifizierte Lipoproteine niedriger Dichte ( LDL ) , verursachen entzuendliche Reaktionen zellulaerer Elemente der Gefaesswand , zum Beispiel Stoerungen den Endothelzellfunktion oder die Aktivierung von Makrophagen .

[ "Die", "Atherosklerose", "besitzt", "viele", "Merkmale", "einer", "chronisch", "entzuendlichen", "Erkrankung", ".", "Atherosklerotische", "Laesionen", "enthalten", "Entzuendungszellen", ",", "aktivierte", "T", "-", "Lymphozyten", "und", "Makrophagen", ".", "Auch", "nach", "Korrektur", "fuer", "etablierte", "kardiovaskulaere", "Risikofaktoren", "koennen", "systemische", "Marker", "einer", "Entzuendung", ",", "wie", "Leukozyten", ",", "C", "-", "reaktives", "Protein", ",", "Serumamyloid", "A", ",", "Interleukin", "6", "und", "loesliche", "Adhaesionsmolekuele", ",", "zur", "Abschaetzung", "des", "Risikos", "fuer", "kuenftige", "kardiovaskulaere", "Ereignisse", "beitragen", ".", "Atherogene", "Lipoproteine", ",", "insbesondere", "modifizierte", "Lipoproteine", "niedriger", "Dichte", "(", "LDL", ")", ",", "verursachen", "entzuendliche", "Reaktionen", "zellulaerer", "Elemente", "der", "Gefaesswand", ",", "zum", "Beispiel", "Stoerungen", "den", "Endothelzellfunktion", "oder", "die", "Aktivierung", "von", "Makrophagen", "." ]

[ "umlsterm" ]

Atherosklerose, T - Lymphozyten, Makrophagen, Risikofaktoren, Marker, Entzuendung, Leukozyten, Protein, Serumamyloid, Interleukin, Lipoproteine, Lipoproteine, Elemente, Makrophagen

Herz.00250117.ger.abstr_task2

Sentence: Die Atherosklerose besitzt viele Merkmale einer chronisch entzuendlichen Erkrankung . Atherosklerotische Laesionen enthalten Entzuendungszellen , aktivierte T-Lymphozyten und Makrophagen . Auch nach Korrektur fuer etablierte kardiovaskulaere Risikofaktoren koennen systemische Marker einer Entzuendung , wie Leukozyten , C-reaktives Protein , Serumamyloid A , Interleukin 6 und loesliche Adhaesionsmolekuele , zur Abschaetzung des Risikos fuer kuenftige kardiovaskulaere Ereignisse beitragen . Atherogene Lipoproteine , insbesondere modifizierte Lipoproteine niedriger Dichte ( LDL ) , verursachen entzuendliche Reaktionen zellulaerer Elemente der Gefaesswand , zum Beispiel Stoerungen den Endothelzellfunktion oder die Aktivierung von Makrophagen . Instructions: please extract entity words from the input sentence

[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]

Die Atherosklerose besitzt viele Merkmale einer chronisch entzuendlichen Erkrankung . Atherosklerotische Laesionen enthalten Entzuendungszellen , aktivierte T-Lymphozyten und Makrophagen . Auch nach Korrektur fuer etablierte kardiovaskulaere Risikofaktoren koennen systemische Marker einer Entzuendung , wie Leukozyten , C-reaktives Protein , Serumamyloid A , Interleukin 6 und loesliche Adhaesionsmolekuele , zur Abschaetzung des Risikos fuer kuenftige kardiovaskulaere Ereignisse beitragen . Atherogene Lipoproteine , insbesondere modifizierte Lipoproteine niedriger Dichte ( LDL ) , verursachen entzuendliche Reaktionen zellulaerer Elemente der Gefaesswand , zum Beispiel Stoerungen den Endothelzellfunktion oder die Aktivierung von Makrophagen .

[ "Die", "Atherosklerose", "besitzt", "viele", "Merkmale", "einer", "chronisch", "entzuendlichen", "Erkrankung", ".", "Atherosklerotische", "Laesionen", "enthalten", "Entzuendungszellen", ",", "aktivierte", "T", "-", "Lymphozyten", "und", "Makrophagen", ".", "Auch", "nach", "Korrektur", "fuer", "etablierte", "kardiovaskulaere", "Risikofaktoren", "koennen", "systemische", "Marker", "einer", "Entzuendung", ",", "wie", "Leukozyten", ",", "C", "-", "reaktives", "Protein", ",", "Serumamyloid", "A", ",", "Interleukin", "6", "und", "loesliche", "Adhaesionsmolekuele", ",", "zur", "Abschaetzung", "des", "Risikos", "fuer", "kuenftige", "kardiovaskulaere", "Ereignisse", "beitragen", ".", "Atherogene", "Lipoproteine", ",", "insbesondere", "modifizierte", "Lipoproteine", "niedriger", "Dichte", "(", "LDL", ")", ",", "verursachen", "entzuendliche", "Reaktionen", "zellulaerer", "Elemente", "der", "Gefaesswand", ",", "zum", "Beispiel", "Stoerungen", "den", "Endothelzellfunktion", "oder", "die", "Aktivierung", "von", "Makrophagen", "." ]

[ "umlsterm" ]

research is an umlsterm, development is an umlsterm, treatment is an umlsterm, atrial fibrillation is an umlsterm, therapies is an umlsterm, clinical research is an umlsterm, development is an umlsterm, electrode is an umlsterm, cardioversion is an umlsterm, devices is an umlsterm

Herzschrittmachertherapie.80090076.eng.abstr_task0

Sentence: Over the past 5-7 years , there has been a renewed research interest into the mechanism as well as the development of newer " emerging " treatment modalities for atrial fibrillation . One of these novel therapies is the implantable atrial defibrillator . In this article we will review the basic and clinical research which has been used in the development of electrode systems and shock waveforms utilized by commercially-available implantable atrial cardioversion devices . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O" ]

Over the past 5-7 years , there has been a renewed research interest into the mechanism as well as the development of newer " emerging " treatment modalities for atrial fibrillation . One of these novel therapies is the implantable atrial defibrillator . In this article we will review the basic and clinical research which has been used in the development of electrode systems and shock waveforms utilized by commercially-available implantable atrial cardioversion devices .

[ "Over", "the", "past", "5", "-", "7", "years", ",", "there", "has", "been", "a", "renewed", "research", "interest", "into", "the", "mechanism", "as", "well", "as", "the", "development", "of", "newer", "\"", "emerging", "\"", "treatment", "modalities", "for", "atrial", "fibrillation", ".", "One", "of", "these", "novel", "therapies", "is", "the", "implantable", "atrial", "defibrillator", ".", "In", "this", "article", "we", "will", "review", "the", "basic", "and", "clinical", "research", "which", "has", "been", "used", "in", "the", "development", "of", "electrode", "systems", "and", "shock", "waveforms", "utilized", "by", "commercially", "-", "available", "implantable", "atrial", "cardioversion", "devices", "." ]

[ "umlsterm" ]

research is an umlsterm, development is an umlsterm, treatment is an umlsterm, atrial fibrillation is an umlsterm, therapies is an umlsterm, clinical research is an umlsterm, development is an umlsterm, electrode is an umlsterm, cardioversion is an umlsterm, devices is an umlsterm

Herzschrittmachertherapie.80090076.eng.abstr_task1

Sentence: Over the past 5-7 years , there has been a renewed research interest into the mechanism as well as the development of newer " emerging " treatment modalities for atrial fibrillation . One of these novel therapies is the implantable atrial defibrillator . In this article we will review the basic and clinical research which has been used in the development of electrode systems and shock waveforms utilized by commercially-available implantable atrial cardioversion devices . Instructions: please typing these entity words according to sentence: research, development, treatment, atrial fibrillation, therapies, clinical research, development, electrode, cardioversion, devices Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O" ]

Over the past 5-7 years , there has been a renewed research interest into the mechanism as well as the development of newer " emerging " treatment modalities for atrial fibrillation . One of these novel therapies is the implantable atrial defibrillator . In this article we will review the basic and clinical research which has been used in the development of electrode systems and shock waveforms utilized by commercially-available implantable atrial cardioversion devices .

[ "Over", "the", "past", "5", "-", "7", "years", ",", "there", "has", "been", "a", "renewed", "research", "interest", "into", "the", "mechanism", "as", "well", "as", "the", "development", "of", "newer", "\"", "emerging", "\"", "treatment", "modalities", "for", "atrial", "fibrillation", ".", "One", "of", "these", "novel", "therapies", "is", "the", "implantable", "atrial", "defibrillator", ".", "In", "this", "article", "we", "will", "review", "the", "basic", "and", "clinical", "research", "which", "has", "been", "used", "in", "the", "development", "of", "electrode", "systems", "and", "shock", "waveforms", "utilized", "by", "commercially", "-", "available", "implantable", "atrial", "cardioversion", "devices", "." ]

[ "umlsterm" ]

research, development, treatment, atrial fibrillation, therapies, clinical research, development, electrode, cardioversion, devices

Herzschrittmachertherapie.80090076.eng.abstr_task2

Sentence: Over the past 5-7 years , there has been a renewed research interest into the mechanism as well as the development of newer " emerging " treatment modalities for atrial fibrillation . One of these novel therapies is the implantable atrial defibrillator . In this article we will review the basic and clinical research which has been used in the development of electrode systems and shock waveforms utilized by commercially-available implantable atrial cardioversion devices . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O" ]

Over the past 5-7 years , there has been a renewed research interest into the mechanism as well as the development of newer " emerging " treatment modalities for atrial fibrillation . One of these novel therapies is the implantable atrial defibrillator . In this article we will review the basic and clinical research which has been used in the development of electrode systems and shock waveforms utilized by commercially-available implantable atrial cardioversion devices .

[ "Over", "the", "past", "5", "-", "7", "years", ",", "there", "has", "been", "a", "renewed", "research", "interest", "into", "the", "mechanism", "as", "well", "as", "the", "development", "of", "newer", "\"", "emerging", "\"", "treatment", "modalities", "for", "atrial", "fibrillation", ".", "One", "of", "these", "novel", "therapies", "is", "the", "implantable", "atrial", "defibrillator", ".", "In", "this", "article", "we", "will", "review", "the", "basic", "and", "clinical", "research", "which", "has", "been", "used", "in", "the", "development", "of", "electrode", "systems", "and", "shock", "waveforms", "utilized", "by", "commercially", "-", "available", "implantable", "atrial", "cardioversion", "devices", "." ]

[ "umlsterm" ]

administration is an umlsterm, GP IIb / IIIa is an umlsterm, antagonists is an umlsterm, myocardial infarction is an umlsterm, death is an umlsterm, PTCA is an umlsterm, prospective study is an umlsterm, abciximab is an umlsterm, vessel is an umlsterm, Methods is an umlsterm, vessel is an umlsterm, patients is an umlsterm, PTCA is an umlsterm, patients is an umlsterm, unstable angina is an umlsterm, Abciximab is an umlsterm, intravenous infusion is an umlsterm, PTCA is an umlsterm, administration is an umlsterm, abciximab is an umlsterm, procedure is an umlsterm, control is an umlsterm, angiography is an umlsterm, patients is an umlsterm, abciximab is an umlsterm, therapy is an umlsterm, patients is an umlsterm, stent is an umlsterm, implantation is an umlsterm, PTCA is an umlsterm, angiography is an umlsterm, vessels is an umlsterm, patients is an umlsterm, patients is an umlsterm, emergency is an umlsterm, vessel is an umlsterm, PTCA is an umlsterm, surgery is an umlsterm, control is an umlsterm, angiography is an umlsterm, vessel is an umlsterm, MACE is an umlsterm, patients is an umlsterm, abciximab is an umlsterm, therapy is an umlsterm, PTCA is an umlsterm, use is an umlsterm, abciximab is an umlsterm, prophylactic is an umlsterm, abciximab is an umlsterm, treatment is an umlsterm

ZfuerKardiologie.00890722.eng.abstr_task0

Sentence: The administration of GP IIb/IIIa antagonists has been shown to be effective in reducing myocardial infarction and cardial death when given before PTCA . This prospective study was performed to determine the efficacy of abciximab in a bail-out situation to manage threatened or acute vessel closure . Methods : Acute or threatened vessel closure was observed in 104 ( 5.5% ) out of 1903 consecutive patients treated with PTCA in our institution . Of the 104 patients 46 ( 44% ) were treated for unstable angina ( CCS IV ) . Abciximab was administered in bail-out situations in a dosage of 0.25mg/kg given as a bolus , which was followed by an intravenous infusion of 10µg/min over 12 hours . Repeat PTCA was performed shortly after the administration of the abciximab bolus . After the procedure , the sheathe was left in place and control angiography was carried out 24 h later . Results : In 100 of the 104 patients TIMI flow III could be restored by abciximab therapy and RePTCA . In 4 patients an additional stent implantation was necessary due to persistent flow limitation . One day post PTCA , early follow-up angiography demonstrated patency of all vessels except two . In-hospital events occurred in 4 patients . Three of these patients underwent emergency CABG due to subacute vessel closure a few hours after PTCA and died during or directly after surgery . Follow-up after one year included clinical status and control angiography of the target vessel . During long-term follow-up , MACE occured in 15 patients ( 2 MI , 8 CABG and 5 RePTCA ) . Conclusion : The results of this prospective trial demonstrate the efficacy of abciximab therapy in bail-out situations occurring during or early after PTCA . The use of abciximab in bail-out situations appears clinically beneficial . Further studies have to compare the efficacy of this approach with prophylactic abciximab treatment . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O" ]

The administration of GP IIb/IIIa antagonists has been shown to be effective in reducing myocardial infarction and cardial death when given before PTCA . This prospective study was performed to determine the efficacy of abciximab in a bail-out situation to manage threatened or acute vessel closure . Methods : Acute or threatened vessel closure was observed in 104 ( 5.5% ) out of 1903 consecutive patients treated with PTCA in our institution . Of the 104 patients 46 ( 44% ) were treated for unstable angina ( CCS IV ) . Abciximab was administered in bail-out situations in a dosage of 0.25mg/kg given as a bolus , which was followed by an intravenous infusion of 10µg/min over 12 hours . Repeat PTCA was performed shortly after the administration of the abciximab bolus . After the procedure , the sheathe was left in place and control angiography was carried out 24 h later . Results : In 100 of the 104 patients TIMI flow III could be restored by abciximab therapy and RePTCA . In 4 patients an additional stent implantation was necessary due to persistent flow limitation . One day post PTCA , early follow-up angiography demonstrated patency of all vessels except two . In-hospital events occurred in 4 patients . Three of these patients underwent emergency CABG due to subacute vessel closure a few hours after PTCA and died during or directly after surgery . Follow-up after one year included clinical status and control angiography of the target vessel . During long-term follow-up , MACE occured in 15 patients ( 2 MI , 8 CABG and 5 RePTCA ) . Conclusion : The results of this prospective trial demonstrate the efficacy of abciximab therapy in bail-out situations occurring during or early after PTCA . The use of abciximab in bail-out situations appears clinically beneficial . Further studies have to compare the efficacy of this approach with prophylactic abciximab treatment .

[ "The", "administration", "of", "GP", "IIb", "/", "IIIa", "antagonists", "has", "been", "shown", "to", "be", "effective", "in", "reducing", "myocardial", "infarction", "and", "cardial", "death", "when", "given", "before", "PTCA", ".", "This", "prospective", "study", "was", "performed", "to", "determine", "the", "efficacy", "of", "abciximab", "in", "a", "bail", "-", "out", "situation", "to", "manage", "threatened", "or", "acute", "vessel", "closure", ".", "Methods", ":", "Acute", "or", "threatened", "vessel", "closure", "was", "observed", "in", "104", "(", "5.5", "%", ")", "out", "of", "1903", "consecutive", "patients", "treated", "with", "PTCA", "in", "our", "institution", ".", "Of", "the", "104", "patients", "46", "(", "44", "%", ")", "were", "treated", "for", "unstable", "angina", "(", "CCS", "IV", ")", ".", "Abciximab", "was", "administered", "in", "bail", "-", "out", "situations", "in", "a", "dosage", "of", "0.25mg", "/", "kg", "given", "as", "a", "bolus", ",", "which", "was", "followed", "by", "an", "intravenous", "infusion", "of", "10µg", "/", "min", "over", "12", "hours", ".", "Repeat", "PTCA", "was", "performed", "shortly", "after", "the", "administration", "of", "the", "abciximab", "bolus", ".", "After", "the", "procedure", ",", "the", "sheathe", "was", "left", "in", "place", "and", "control", "angiography", "was", "carried", "out", "24", "h", "later", ".", "Results", ":", "In", "100", "of", "the", "104", "patients", "TIMI", "flow", "III", "could", "be", "restored", "by", "abciximab", "therapy", "and", "RePTCA", ".", "In", "4", "patients", "an", "additional", "stent", "implantation", "was", "necessary", "due", "to", "persistent", "flow", "limitation", ".", "One", "day", "post", "PTCA", ",", "early", "follow", "-", "up", "angiography", "demonstrated", "patency", "of", "all", "vessels", "except", "two", ".", "In", "-", "hospital", "events", "occurred", "in", "4", "patients", ".", "Three", "of", "these", "patients", "underwent", "emergency", "CABG", "due", "to", "subacute", "vessel", "closure", "a", "few", "hours", "after", "PTCA", "and", "died", "during", "or", "directly", "after", "surgery", ".", "Follow", "-", "up", "after", "one", "year", "included", "clinical", "status", "and", "control", "angiography", "of", "the", "target", "vessel", ".", "During", "long", "-", "term", "follow", "-", "up", ",", "MACE", "occured", "in", "15", "patients", "(", "2", "MI", ",", "8", "CABG", "and", "5", "RePTCA", ")", ".", "Conclusion", ":", "The", "results", "of", "this", "prospective", "trial", "demonstrate", "the", "efficacy", "of", "abciximab", "therapy", "in", "bail", "-", "out", "situations", "occurring", "during", "or", "early", "after", "PTCA", ".", "The", "use", "of", "abciximab", "in", "bail", "-", "out", "situations", "appears", "clinically", "beneficial", ".", "Further", "studies", "have", "to", "compare", "the", "efficacy", "of", "this", "approach", "with", "prophylactic", "abciximab", "treatment", "." ]

[ "umlsterm" ]

administration is an umlsterm, GP IIb / IIIa is an umlsterm, antagonists is an umlsterm, myocardial infarction is an umlsterm, death is an umlsterm, PTCA is an umlsterm, prospective study is an umlsterm, abciximab is an umlsterm, vessel is an umlsterm, Methods is an umlsterm, vessel is an umlsterm, patients is an umlsterm, PTCA is an umlsterm, patients is an umlsterm, unstable angina is an umlsterm, Abciximab is an umlsterm, intravenous infusion is an umlsterm, PTCA is an umlsterm, administration is an umlsterm, abciximab is an umlsterm, procedure is an umlsterm, control is an umlsterm, angiography is an umlsterm, patients is an umlsterm, abciximab is an umlsterm, therapy is an umlsterm, patients is an umlsterm, stent is an umlsterm, implantation is an umlsterm, PTCA is an umlsterm, angiography is an umlsterm, vessels is an umlsterm, patients is an umlsterm, patients is an umlsterm, emergency is an umlsterm, vessel is an umlsterm, PTCA is an umlsterm, surgery is an umlsterm, control is an umlsterm, angiography is an umlsterm, vessel is an umlsterm, MACE is an umlsterm, patients is an umlsterm, abciximab is an umlsterm, therapy is an umlsterm, PTCA is an umlsterm, use is an umlsterm, abciximab is an umlsterm, prophylactic is an umlsterm, abciximab is an umlsterm, treatment is an umlsterm

ZfuerKardiologie.00890722.eng.abstr_task1

Sentence: The administration of GP IIb/IIIa antagonists has been shown to be effective in reducing myocardial infarction and cardial death when given before PTCA . This prospective study was performed to determine the efficacy of abciximab in a bail-out situation to manage threatened or acute vessel closure . Methods : Acute or threatened vessel closure was observed in 104 ( 5.5% ) out of 1903 consecutive patients treated with PTCA in our institution . Of the 104 patients 46 ( 44% ) were treated for unstable angina ( CCS IV ) . Abciximab was administered in bail-out situations in a dosage of 0.25mg/kg given as a bolus , which was followed by an intravenous infusion of 10µg/min over 12 hours . Repeat PTCA was performed shortly after the administration of the abciximab bolus . After the procedure , the sheathe was left in place and control angiography was carried out 24 h later . Results : In 100 of the 104 patients TIMI flow III could be restored by abciximab therapy and RePTCA . In 4 patients an additional stent implantation was necessary due to persistent flow limitation . One day post PTCA , early follow-up angiography demonstrated patency of all vessels except two . In-hospital events occurred in 4 patients . Three of these patients underwent emergency CABG due to subacute vessel closure a few hours after PTCA and died during or directly after surgery . Follow-up after one year included clinical status and control angiography of the target vessel . During long-term follow-up , MACE occured in 15 patients ( 2 MI , 8 CABG and 5 RePTCA ) . Conclusion : The results of this prospective trial demonstrate the efficacy of abciximab therapy in bail-out situations occurring during or early after PTCA . The use of abciximab in bail-out situations appears clinically beneficial . Further studies have to compare the efficacy of this approach with prophylactic abciximab treatment . Instructions: please typing these entity words according to sentence: administration, GP IIb / IIIa, antagonists, myocardial infarction, death, PTCA, prospective study, abciximab, vessel, Methods, vessel, patients, PTCA, patients, unstable angina, Abciximab, intravenous infusion, PTCA, administration, abciximab, procedure, control, angiography, patients, abciximab, therapy, patients, stent, implantation, PTCA, angiography, vessels, patients, patients, emergency, vessel, PTCA, surgery, control, angiography, vessel, MACE, patients, abciximab, therapy, PTCA, use, abciximab, prophylactic, abciximab, treatment Options: umlsterm

[ "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O" ]

The administration of GP IIb/IIIa antagonists has been shown to be effective in reducing myocardial infarction and cardial death when given before PTCA . This prospective study was performed to determine the efficacy of abciximab in a bail-out situation to manage threatened or acute vessel closure . Methods : Acute or threatened vessel closure was observed in 104 ( 5.5% ) out of 1903 consecutive patients treated with PTCA in our institution . Of the 104 patients 46 ( 44% ) were treated for unstable angina ( CCS IV ) . Abciximab was administered in bail-out situations in a dosage of 0.25mg/kg given as a bolus , which was followed by an intravenous infusion of 10µg/min over 12 hours . Repeat PTCA was performed shortly after the administration of the abciximab bolus . After the procedure , the sheathe was left in place and control angiography was carried out 24 h later . Results : In 100 of the 104 patients TIMI flow III could be restored by abciximab therapy and RePTCA . In 4 patients an additional stent implantation was necessary due to persistent flow limitation . One day post PTCA , early follow-up angiography demonstrated patency of all vessels except two . In-hospital events occurred in 4 patients . Three of these patients underwent emergency CABG due to subacute vessel closure a few hours after PTCA and died during or directly after surgery . Follow-up after one year included clinical status and control angiography of the target vessel . During long-term follow-up , MACE occured in 15 patients ( 2 MI , 8 CABG and 5 RePTCA ) . Conclusion : The results of this prospective trial demonstrate the efficacy of abciximab therapy in bail-out situations occurring during or early after PTCA . The use of abciximab in bail-out situations appears clinically beneficial . Further studies have to compare the efficacy of this approach with prophylactic abciximab treatment .

[ "The", "administration", "of", "GP", "IIb", "/", "IIIa", "antagonists", "has", "been", "shown", "to", "be", "effective", "in", "reducing", "myocardial", "infarction", "and", "cardial", "death", "when", "given", "before", "PTCA", ".", "This", "prospective", "study", "was", "performed", "to", "determine", "the", "efficacy", "of", "abciximab", "in", "a", "bail", "-", "out", "situation", "to", "manage", "threatened", "or", "acute", "vessel", "closure", ".", "Methods", ":", "Acute", "or", "threatened", "vessel", "closure", "was", "observed", "in", "104", "(", "5.5", "%", ")", "out", "of", "1903", "consecutive", "patients", "treated", "with", "PTCA", "in", "our", "institution", ".", "Of", "the", "104", "patients", "46", "(", "44", "%", ")", "were", "treated", "for", "unstable", "angina", "(", "CCS", "IV", ")", ".", "Abciximab", "was", "administered", "in", "bail", "-", "out", "situations", "in", "a", "dosage", "of", "0.25mg", "/", "kg", "given", "as", "a", "bolus", ",", "which", "was", "followed", "by", "an", "intravenous", "infusion", "of", "10µg", "/", "min", "over", "12", "hours", ".", "Repeat", "PTCA", "was", "performed", "shortly", "after", "the", "administration", "of", "the", "abciximab", "bolus", ".", "After", "the", "procedure", ",", "the", "sheathe", "was", "left", "in", "place", "and", "control", "angiography", "was", "carried", "out", "24", "h", "later", ".", "Results", ":", "In", "100", "of", "the", "104", "patients", "TIMI", "flow", "III", "could", "be", "restored", "by", "abciximab", "therapy", "and", "RePTCA", ".", "In", "4", "patients", "an", "additional", "stent", "implantation", "was", "necessary", "due", "to", "persistent", "flow", "limitation", ".", "One", "day", "post", "PTCA", ",", "early", "follow", "-", "up", "angiography", "demonstrated", "patency", "of", "all", "vessels", "except", "two", ".", "In", "-", "hospital", "events", "occurred", "in", "4", "patients", ".", "Three", "of", "these", "patients", "underwent", "emergency", "CABG", "due", "to", "subacute", "vessel", "closure", "a", "few", "hours", "after", "PTCA", "and", "died", "during", "or", "directly", "after", "surgery", ".", "Follow", "-", "up", "after", "one", "year", "included", "clinical", "status", "and", "control", "angiography", "of", "the", "target", "vessel", ".", "During", "long", "-", "term", "follow", "-", "up", ",", "MACE", "occured", "in", "15", "patients", "(", "2", "MI", ",", "8", "CABG", "and", "5", "RePTCA", ")", ".", "Conclusion", ":", "The", "results", "of", "this", "prospective", "trial", "demonstrate", "the", "efficacy", "of", "abciximab", "therapy", "in", "bail", "-", "out", "situations", "occurring", "during", "or", "early", "after", "PTCA", ".", "The", "use", "of", "abciximab", "in", "bail", "-", "out", "situations", "appears", "clinically", "beneficial", ".", "Further", "studies", "have", "to", "compare", "the", "efficacy", "of", "this", "approach", "with", "prophylactic", "abciximab", "treatment", "." ]

[ "umlsterm" ]

administration, GP IIb / IIIa, antagonists, myocardial infarction, death, PTCA, prospective study, abciximab, vessel, Methods, vessel, patients, PTCA, patients, unstable angina, Abciximab, intravenous infusion, PTCA, administration, abciximab, procedure, control, angiography, patients, abciximab, therapy, patients, stent, implantation, PTCA, angiography, vessels, patients, patients, emergency, vessel, PTCA, surgery, control, angiography, vessel, MACE, patients, abciximab, therapy, PTCA, use, abciximab, prophylactic, abciximab, treatment

ZfuerKardiologie.00890722.eng.abstr_task2

Sentence: The administration of GP IIb/IIIa antagonists has been shown to be effective in reducing myocardial infarction and cardial death when given before PTCA . This prospective study was performed to determine the efficacy of abciximab in a bail-out situation to manage threatened or acute vessel closure . Methods : Acute or threatened vessel closure was observed in 104 ( 5.5% ) out of 1903 consecutive patients treated with PTCA in our institution . Of the 104 patients 46 ( 44% ) were treated for unstable angina ( CCS IV ) . Abciximab was administered in bail-out situations in a dosage of 0.25mg/kg given as a bolus , which was followed by an intravenous infusion of 10µg/min over 12 hours . Repeat PTCA was performed shortly after the administration of the abciximab bolus . After the procedure , the sheathe was left in place and control angiography was carried out 24 h later . Results : In 100 of the 104 patients TIMI flow III could be restored by abciximab therapy and RePTCA . In 4 patients an additional stent implantation was necessary due to persistent flow limitation . One day post PTCA , early follow-up angiography demonstrated patency of all vessels except two . In-hospital events occurred in 4 patients . Three of these patients underwent emergency CABG due to subacute vessel closure a few hours after PTCA and died during or directly after surgery . Follow-up after one year included clinical status and control angiography of the target vessel . During long-term follow-up , MACE occured in 15 patients ( 2 MI , 8 CABG and 5 RePTCA ) . Conclusion : The results of this prospective trial demonstrate the efficacy of abciximab therapy in bail-out situations occurring during or early after PTCA . The use of abciximab in bail-out situations appears clinically beneficial . Further studies have to compare the efficacy of this approach with prophylactic abciximab treatment . Instructions: please extract entity words from the input sentence

[ "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O" ]

The administration of GP IIb/IIIa antagonists has been shown to be effective in reducing myocardial infarction and cardial death when given before PTCA . This prospective study was performed to determine the efficacy of abciximab in a bail-out situation to manage threatened or acute vessel closure . Methods : Acute or threatened vessel closure was observed in 104 ( 5.5% ) out of 1903 consecutive patients treated with PTCA in our institution . Of the 104 patients 46 ( 44% ) were treated for unstable angina ( CCS IV ) . Abciximab was administered in bail-out situations in a dosage of 0.25mg/kg given as a bolus , which was followed by an intravenous infusion of 10µg/min over 12 hours . Repeat PTCA was performed shortly after the administration of the abciximab bolus . After the procedure , the sheathe was left in place and control angiography was carried out 24 h later . Results : In 100 of the 104 patients TIMI flow III could be restored by abciximab therapy and RePTCA . In 4 patients an additional stent implantation was necessary due to persistent flow limitation . One day post PTCA , early follow-up angiography demonstrated patency of all vessels except two . In-hospital events occurred in 4 patients . Three of these patients underwent emergency CABG due to subacute vessel closure a few hours after PTCA and died during or directly after surgery . Follow-up after one year included clinical status and control angiography of the target vessel . During long-term follow-up , MACE occured in 15 patients ( 2 MI , 8 CABG and 5 RePTCA ) . Conclusion : The results of this prospective trial demonstrate the efficacy of abciximab therapy in bail-out situations occurring during or early after PTCA . The use of abciximab in bail-out situations appears clinically beneficial . Further studies have to compare the efficacy of this approach with prophylactic abciximab treatment .

[ "The", "administration", "of", "GP", "IIb", "/", "IIIa", "antagonists", "has", "been", "shown", "to", "be", "effective", "in", "reducing", "myocardial", "infarction", "and", "cardial", "death", "when", "given", "before", "PTCA", ".", "This", "prospective", "study", "was", "performed", "to", "determine", "the", "efficacy", "of", "abciximab", "in", "a", "bail", "-", "out", "situation", "to", "manage", "threatened", "or", "acute", "vessel", "closure", ".", "Methods", ":", "Acute", "or", "threatened", "vessel", "closure", "was", "observed", "in", "104", "(", "5.5", "%", ")", "out", "of", "1903", "consecutive", "patients", "treated", "with", "PTCA", "in", "our", "institution", ".", "Of", "the", "104", "patients", "46", "(", "44", "%", ")", "were", "treated", "for", "unstable", "angina", "(", "CCS", "IV", ")", ".", "Abciximab", "was", "administered", "in", "bail", "-", "out", "situations", "in", "a", "dosage", "of", "0.25mg", "/", "kg", "given", "as", "a", "bolus", ",", "which", "was", "followed", "by", "an", "intravenous", "infusion", "of", "10µg", "/", "min", "over", "12", "hours", ".", "Repeat", "PTCA", "was", "performed", "shortly", "after", "the", "administration", "of", "the", "abciximab", "bolus", ".", "After", "the", "procedure", ",", "the", "sheathe", "was", "left", "in", "place", "and", "control", "angiography", "was", "carried", "out", "24", "h", "later", ".", "Results", ":", "In", "100", "of", "the", "104", "patients", "TIMI", "flow", "III", "could", "be", "restored", "by", "abciximab", "therapy", "and", "RePTCA", ".", "In", "4", "patients", "an", "additional", "stent", "implantation", "was", "necessary", "due", "to", "persistent", "flow", "limitation", ".", "One", "day", "post", "PTCA", ",", "early", "follow", "-", "up", "angiography", "demonstrated", "patency", "of", "all", "vessels", "except", "two", ".", "In", "-", "hospital", "events", "occurred", "in", "4", "patients", ".", "Three", "of", "these", "patients", "underwent", "emergency", "CABG", "due", "to", "subacute", "vessel", "closure", "a", "few", "hours", "after", "PTCA", "and", "died", "during", "or", "directly", "after", "surgery", ".", "Follow", "-", "up", "after", "one", "year", "included", "clinical", "status", "and", "control", "angiography", "of", "the", "target", "vessel", ".", "During", "long", "-", "term", "follow", "-", "up", ",", "MACE", "occured", "in", "15", "patients", "(", "2", "MI", ",", "8", "CABG", "and", "5", "RePTCA", ")", ".", "Conclusion", ":", "The", "results", "of", "this", "prospective", "trial", "demonstrate", "the", "efficacy", "of", "abciximab", "therapy", "in", "bail", "-", "out", "situations", "occurring", "during", "or", "early", "after", "PTCA", ".", "The", "use", "of", "abciximab", "in", "bail", "-", "out", "situations", "appears", "clinically", "beneficial", ".", "Further", "studies", "have", "to", "compare", "the", "efficacy", "of", "this", "approach", "with", "prophylactic", "abciximab", "treatment", "." ]

[ "umlsterm" ]

epidermal growth factor receptor is a Intervention_Pharmacological, tumor differentiation is a Outcome_Physical, radiotherapy is a Intervention_Physical, squamous cell carcinomas of the head and neck is a Participant_Condition, disease specific survival is a Outcome_Mortality, squamous cell carcinomas of the head and neck ( HNSCC is a Participant_Condition, Eight hundred and three patients is a Participant_Sample-size, prominent separation of response is a Outcome_Other, expression of EGFr is a Outcome_Physical

21199_task0

Sentence: The influence of epidermal growth factor receptor and tumor differentiation on the response to accelerated radiotherapy of squamous cell carcinomas of the head and neck in the randomized DAHANCA 6 and 7 study . BACKGROUND AND PURPOSE Reduction of the overall treatment time of radiotherapy has increased locoregional control and disease specific survival in squamous cell carcinomas of the head and neck ( HNSCC ) , but the response is heterogeneous . EGFr is often overexpressed in HNSCC and has been related to the repopulation taking place during radiotherapy . The aim of the current study was to address the influence of EGFr and histopathological differentiation when the overall treatment time of radiotherapy was moderately reduced . PATIENTS AND METHODS Eight hundred and three patients with representative pretreatment tissue samples from the randomized DAHANCA 6 and 7 study of 5 vs. 6 fx/wk of radiotherapy . EGFr was visualized using immunohistochemistry and separated into high and low expression before correlation with clinical data . RESULTS Tumors with high EGFr ( 84 % ) responded better to moderately accelerated radiotherapy , than carcinomas with low EGFr , using locoregional control as endpoint and a similar pattern was seen , stratifying by well/moderate vs. poor tumor differentiation . Therefore , a combined parameter was constructed showing a more prominent separation of response : tumors with high EGFr and well/moderate differentiation did benefit from moderate acceleration of treatment regarding locoregional control , HR 0.54 ( 0.37-0.78 ) , whereas such an effect was not seen in tumors with low EGFr and/or poor differentiation , HR 0.8 ( 0.51-1.25 ) . These results reflected the disease specific survival as well and were confirmed in multivariable analyses . CONCLUSIONS Moderately accelerated fractionation is superior to conventional treatment in HNSCC but the response is heterogeneous and may be predicted by high expression of EGFr and well/moderate tumor differentiation . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Intervention_Physical, Participant_Condition, Outcome_Mortality, Outcome_Physical, Participant_Sample-size, Outcome_Other

[ "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "B-Intervention_Physical", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O" ]

The influence of epidermal growth factor receptor and tumor differentiation on the response to accelerated radiotherapy of squamous cell carcinomas of the head and neck in the randomized DAHANCA 6 and 7 study . BACKGROUND AND PURPOSE Reduction of the overall treatment time of radiotherapy has increased locoregional control and disease specific survival in squamous cell carcinomas of the head and neck ( HNSCC ) , but the response is heterogeneous . EGFr is often overexpressed in HNSCC and has been related to the repopulation taking place during radiotherapy . The aim of the current study was to address the influence of EGFr and histopathological differentiation when the overall treatment time of radiotherapy was moderately reduced . PATIENTS AND METHODS Eight hundred and three patients with representative pretreatment tissue samples from the randomized DAHANCA 6 and 7 study of 5 vs. 6 fx/wk of radiotherapy . EGFr was visualized using immunohistochemistry and separated into high and low expression before correlation with clinical data . RESULTS Tumors with high EGFr ( 84 % ) responded better to moderately accelerated radiotherapy , than carcinomas with low EGFr , using locoregional control as endpoint and a similar pattern was seen , stratifying by well/moderate vs. poor tumor differentiation . Therefore , a combined parameter was constructed showing a more prominent separation of response : tumors with high EGFr and well/moderate differentiation did benefit from moderate acceleration of treatment regarding locoregional control , HR 0.54 ( 0.37-0.78 ) , whereas such an effect was not seen in tumors with low EGFr and/or poor differentiation , HR 0.8 ( 0.51-1.25 ) . These results reflected the disease specific survival as well and were confirmed in multivariable analyses . CONCLUSIONS Moderately accelerated fractionation is superior to conventional treatment in HNSCC but the response is heterogeneous and may be predicted by high expression of EGFr and well/moderate tumor differentiation .

[ "The", "influence", "of", "epidermal", "growth", "factor", "receptor", "and", "tumor", "differentiation", "on", "the", "response", "to", "accelerated", "radiotherapy", "of", "squamous", "cell", "carcinomas", "of", "the", "head", "and", "neck", "in", "the", "randomized", "DAHANCA", "6", "and", "7", "study", ".", "BACKGROUND", "AND", "PURPOSE", "Reduction", "of", "the", "overall", "treatment", "time", "of", "radiotherapy", "has", "increased", "locoregional", "control", "and", "disease", "specific", "survival", "in", "squamous", "cell", "carcinomas", "of", "the", "head", "and", "neck", "(", "HNSCC", ")", ",", "but", "the", "response", "is", "heterogeneous", ".", "EGFr", "is", "often", "overexpressed", "in", "HNSCC", "and", "has", "been", "related", "to", "the", "repopulation", "taking", "place", "during", "radiotherapy", ".", "The", "aim", "of", "the", "current", "study", "was", "to", "address", "the", "influence", "of", "EGFr", "and", "histopathological", "differentiation", "when", "the", "overall", "treatment", "time", "of", "radiotherapy", "was", "moderately", "reduced", ".", "PATIENTS", "AND", "METHODS", "Eight", "hundred", "and", "three", "patients", "with", "representative", "pretreatment", "tissue", "samples", "from", "the", "randomized", "DAHANCA", "6", "and", "7", "study", "of", "5", "vs", ".", "6", "fx", "/", "wk", "of", "radiotherapy", ".", "EGFr", "was", "visualized", "using", "immunohistochemistry", "and", "separated", "into", "high", "and", "low", "expression", "before", "correlation", "with", "clinical", "data", ".", "RESULTS", "Tumors", "with", "high", "EGFr", "(", "84", "%", ")", "responded", "better", "to", "moderately", "accelerated", "radiotherapy", ",", "than", "carcinomas", "with", "low", "EGFr", ",", "using", "locoregional", "control", "as", "endpoint", "and", "a", "similar", "pattern", "was", "seen", ",", "stratifying", "by", "well", "/", "moderate", "vs", ".", "poor", "tumor", "differentiation", ".", "Therefore", ",", "a", "combined", "parameter", "was", "constructed", "showing", "a", "more", "prominent", "separation", "of", "response", ":", "tumors", "with", "high", "EGFr", "and", "well", "/", "moderate", "differentiation", "did", "benefit", "from", "moderate", "acceleration", "of", "treatment", "regarding", "locoregional", "control", ",", "HR", "0.54", "(", "0.37", "-", "0.78", ")", ",", "whereas", "such", "an", "effect", "was", "not", "seen", "in", "tumors", "with", "low", "EGFr", "and", "/", "or", "poor", "differentiation", ",", "HR", "0.8", "(", "0.51", "-", "1.25", ")", ".", "These", "results", "reflected", "the", "disease", "specific", "survival", "as", "well", "and", "were", "confirmed", "in", "multivariable", "analyses", ".", "CONCLUSIONS", "Moderately", "accelerated", "fractionation", "is", "superior", "to", "conventional", "treatment", "in", "HNSCC", "but", "the", "response", "is", "heterogeneous", "and", "may", "be", "predicted", "by", "high", "expression", "of", "EGFr", "and", "well", "/", "moderate", "tumor", "differentiation", "." ]

[ "Participant_Condition", "Intervention_Pharmacological", "Outcome_Other", "Participant_Sample-size", "Outcome_Mortality", "Outcome_Physical", "Intervention_Physical" ]

epidermal growth factor receptor is a Intervention_Pharmacological, tumor differentiation is a Outcome_Physical, radiotherapy is a Intervention_Physical, squamous cell carcinomas of the head and neck is a Participant_Condition, disease specific survival is a Outcome_Mortality, squamous cell carcinomas of the head and neck ( HNSCC is a Participant_Condition, Eight hundred and three patients is a Participant_Sample-size, prominent separation of response is a Outcome_Other, expression of EGFr is a Outcome_Physical

21199_task1

Sentence: The influence of epidermal growth factor receptor and tumor differentiation on the response to accelerated radiotherapy of squamous cell carcinomas of the head and neck in the randomized DAHANCA 6 and 7 study . BACKGROUND AND PURPOSE Reduction of the overall treatment time of radiotherapy has increased locoregional control and disease specific survival in squamous cell carcinomas of the head and neck ( HNSCC ) , but the response is heterogeneous . EGFr is often overexpressed in HNSCC and has been related to the repopulation taking place during radiotherapy . The aim of the current study was to address the influence of EGFr and histopathological differentiation when the overall treatment time of radiotherapy was moderately reduced . PATIENTS AND METHODS Eight hundred and three patients with representative pretreatment tissue samples from the randomized DAHANCA 6 and 7 study of 5 vs. 6 fx/wk of radiotherapy . EGFr was visualized using immunohistochemistry and separated into high and low expression before correlation with clinical data . RESULTS Tumors with high EGFr ( 84 % ) responded better to moderately accelerated radiotherapy , than carcinomas with low EGFr , using locoregional control as endpoint and a similar pattern was seen , stratifying by well/moderate vs. poor tumor differentiation . Therefore , a combined parameter was constructed showing a more prominent separation of response : tumors with high EGFr and well/moderate differentiation did benefit from moderate acceleration of treatment regarding locoregional control , HR 0.54 ( 0.37-0.78 ) , whereas such an effect was not seen in tumors with low EGFr and/or poor differentiation , HR 0.8 ( 0.51-1.25 ) . These results reflected the disease specific survival as well and were confirmed in multivariable analyses . CONCLUSIONS Moderately accelerated fractionation is superior to conventional treatment in HNSCC but the response is heterogeneous and may be predicted by high expression of EGFr and well/moderate tumor differentiation . Instructions: please typing these entity words according to sentence: epidermal growth factor receptor, tumor differentiation, radiotherapy, squamous cell carcinomas of the head and neck, disease specific survival, squamous cell carcinomas of the head and neck ( HNSCC, Eight hundred and three patients, prominent separation of response, expression of EGFr Options: Intervention_Pharmacological, Intervention_Physical, Participant_Condition, Outcome_Mortality, Outcome_Physical, Participant_Sample-size, Outcome_Other

[ "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "B-Intervention_Physical", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O" ]

The influence of epidermal growth factor receptor and tumor differentiation on the response to accelerated radiotherapy of squamous cell carcinomas of the head and neck in the randomized DAHANCA 6 and 7 study . BACKGROUND AND PURPOSE Reduction of the overall treatment time of radiotherapy has increased locoregional control and disease specific survival in squamous cell carcinomas of the head and neck ( HNSCC ) , but the response is heterogeneous . EGFr is often overexpressed in HNSCC and has been related to the repopulation taking place during radiotherapy . The aim of the current study was to address the influence of EGFr and histopathological differentiation when the overall treatment time of radiotherapy was moderately reduced . PATIENTS AND METHODS Eight hundred and three patients with representative pretreatment tissue samples from the randomized DAHANCA 6 and 7 study of 5 vs. 6 fx/wk of radiotherapy . EGFr was visualized using immunohistochemistry and separated into high and low expression before correlation with clinical data . RESULTS Tumors with high EGFr ( 84 % ) responded better to moderately accelerated radiotherapy , than carcinomas with low EGFr , using locoregional control as endpoint and a similar pattern was seen , stratifying by well/moderate vs. poor tumor differentiation . Therefore , a combined parameter was constructed showing a more prominent separation of response : tumors with high EGFr and well/moderate differentiation did benefit from moderate acceleration of treatment regarding locoregional control , HR 0.54 ( 0.37-0.78 ) , whereas such an effect was not seen in tumors with low EGFr and/or poor differentiation , HR 0.8 ( 0.51-1.25 ) . These results reflected the disease specific survival as well and were confirmed in multivariable analyses . CONCLUSIONS Moderately accelerated fractionation is superior to conventional treatment in HNSCC but the response is heterogeneous and may be predicted by high expression of EGFr and well/moderate tumor differentiation .

[ "The", "influence", "of", "epidermal", "growth", "factor", "receptor", "and", "tumor", "differentiation", "on", "the", "response", "to", "accelerated", "radiotherapy", "of", "squamous", "cell", "carcinomas", "of", "the", "head", "and", "neck", "in", "the", "randomized", "DAHANCA", "6", "and", "7", "study", ".", "BACKGROUND", "AND", "PURPOSE", "Reduction", "of", "the", "overall", "treatment", "time", "of", "radiotherapy", "has", "increased", "locoregional", "control", "and", "disease", "specific", "survival", "in", "squamous", "cell", "carcinomas", "of", "the", "head", "and", "neck", "(", "HNSCC", ")", ",", "but", "the", "response", "is", "heterogeneous", ".", "EGFr", "is", "often", "overexpressed", "in", "HNSCC", "and", "has", "been", "related", "to", "the", "repopulation", "taking", "place", "during", "radiotherapy", ".", "The", "aim", "of", "the", "current", "study", "was", "to", "address", "the", "influence", "of", "EGFr", "and", "histopathological", "differentiation", "when", "the", "overall", "treatment", "time", "of", "radiotherapy", "was", "moderately", "reduced", ".", "PATIENTS", "AND", "METHODS", "Eight", "hundred", "and", "three", "patients", "with", "representative", "pretreatment", "tissue", "samples", "from", "the", "randomized", "DAHANCA", "6", "and", "7", "study", "of", "5", "vs", ".", "6", "fx", "/", "wk", "of", "radiotherapy", ".", "EGFr", "was", "visualized", "using", "immunohistochemistry", "and", "separated", "into", "high", "and", "low", "expression", "before", "correlation", "with", "clinical", "data", ".", "RESULTS", "Tumors", "with", "high", "EGFr", "(", "84", "%", ")", "responded", "better", "to", "moderately", "accelerated", "radiotherapy", ",", "than", "carcinomas", "with", "low", "EGFr", ",", "using", "locoregional", "control", "as", "endpoint", "and", "a", "similar", "pattern", "was", "seen", ",", "stratifying", "by", "well", "/", "moderate", "vs", ".", "poor", "tumor", "differentiation", ".", "Therefore", ",", "a", "combined", "parameter", "was", "constructed", "showing", "a", "more", "prominent", "separation", "of", "response", ":", "tumors", "with", "high", "EGFr", "and", "well", "/", "moderate", "differentiation", "did", "benefit", "from", "moderate", "acceleration", "of", "treatment", "regarding", "locoregional", "control", ",", "HR", "0.54", "(", "0.37", "-", "0.78", ")", ",", "whereas", "such", "an", "effect", "was", "not", "seen", "in", "tumors", "with", "low", "EGFr", "and", "/", "or", "poor", "differentiation", ",", "HR", "0.8", "(", "0.51", "-", "1.25", ")", ".", "These", "results", "reflected", "the", "disease", "specific", "survival", "as", "well", "and", "were", "confirmed", "in", "multivariable", "analyses", ".", "CONCLUSIONS", "Moderately", "accelerated", "fractionation", "is", "superior", "to", "conventional", "treatment", "in", "HNSCC", "but", "the", "response", "is", "heterogeneous", "and", "may", "be", "predicted", "by", "high", "expression", "of", "EGFr", "and", "well", "/", "moderate", "tumor", "differentiation", "." ]

[ "Participant_Condition", "Intervention_Pharmacological", "Outcome_Other", "Participant_Sample-size", "Outcome_Mortality", "Outcome_Physical", "Intervention_Physical" ]

epidermal growth factor receptor, tumor differentiation, radiotherapy, squamous cell carcinomas of the head and neck, disease specific survival, squamous cell carcinomas of the head and neck ( HNSCC, Eight hundred and three patients, prominent separation of response, expression of EGFr

21199_task2

Sentence: The influence of epidermal growth factor receptor and tumor differentiation on the response to accelerated radiotherapy of squamous cell carcinomas of the head and neck in the randomized DAHANCA 6 and 7 study . BACKGROUND AND PURPOSE Reduction of the overall treatment time of radiotherapy has increased locoregional control and disease specific survival in squamous cell carcinomas of the head and neck ( HNSCC ) , but the response is heterogeneous . EGFr is often overexpressed in HNSCC and has been related to the repopulation taking place during radiotherapy . The aim of the current study was to address the influence of EGFr and histopathological differentiation when the overall treatment time of radiotherapy was moderately reduced . PATIENTS AND METHODS Eight hundred and three patients with representative pretreatment tissue samples from the randomized DAHANCA 6 and 7 study of 5 vs. 6 fx/wk of radiotherapy . EGFr was visualized using immunohistochemistry and separated into high and low expression before correlation with clinical data . RESULTS Tumors with high EGFr ( 84 % ) responded better to moderately accelerated radiotherapy , than carcinomas with low EGFr , using locoregional control as endpoint and a similar pattern was seen , stratifying by well/moderate vs. poor tumor differentiation . Therefore , a combined parameter was constructed showing a more prominent separation of response : tumors with high EGFr and well/moderate differentiation did benefit from moderate acceleration of treatment regarding locoregional control , HR 0.54 ( 0.37-0.78 ) , whereas such an effect was not seen in tumors with low EGFr and/or poor differentiation , HR 0.8 ( 0.51-1.25 ) . These results reflected the disease specific survival as well and were confirmed in multivariable analyses . CONCLUSIONS Moderately accelerated fractionation is superior to conventional treatment in HNSCC but the response is heterogeneous and may be predicted by high expression of EGFr and well/moderate tumor differentiation . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "B-Intervention_Physical", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O" ]

The influence of epidermal growth factor receptor and tumor differentiation on the response to accelerated radiotherapy of squamous cell carcinomas of the head and neck in the randomized DAHANCA 6 and 7 study . BACKGROUND AND PURPOSE Reduction of the overall treatment time of radiotherapy has increased locoregional control and disease specific survival in squamous cell carcinomas of the head and neck ( HNSCC ) , but the response is heterogeneous . EGFr is often overexpressed in HNSCC and has been related to the repopulation taking place during radiotherapy . The aim of the current study was to address the influence of EGFr and histopathological differentiation when the overall treatment time of radiotherapy was moderately reduced . PATIENTS AND METHODS Eight hundred and three patients with representative pretreatment tissue samples from the randomized DAHANCA 6 and 7 study of 5 vs. 6 fx/wk of radiotherapy . EGFr was visualized using immunohistochemistry and separated into high and low expression before correlation with clinical data . RESULTS Tumors with high EGFr ( 84 % ) responded better to moderately accelerated radiotherapy , than carcinomas with low EGFr , using locoregional control as endpoint and a similar pattern was seen , stratifying by well/moderate vs. poor tumor differentiation . Therefore , a combined parameter was constructed showing a more prominent separation of response : tumors with high EGFr and well/moderate differentiation did benefit from moderate acceleration of treatment regarding locoregional control , HR 0.54 ( 0.37-0.78 ) , whereas such an effect was not seen in tumors with low EGFr and/or poor differentiation , HR 0.8 ( 0.51-1.25 ) . These results reflected the disease specific survival as well and were confirmed in multivariable analyses . CONCLUSIONS Moderately accelerated fractionation is superior to conventional treatment in HNSCC but the response is heterogeneous and may be predicted by high expression of EGFr and well/moderate tumor differentiation .

[ "The", "influence", "of", "epidermal", "growth", "factor", "receptor", "and", "tumor", "differentiation", "on", "the", "response", "to", "accelerated", "radiotherapy", "of", "squamous", "cell", "carcinomas", "of", "the", "head", "and", "neck", "in", "the", "randomized", "DAHANCA", "6", "and", "7", "study", ".", "BACKGROUND", "AND", "PURPOSE", "Reduction", "of", "the", "overall", "treatment", "time", "of", "radiotherapy", "has", "increased", "locoregional", "control", "and", "disease", "specific", "survival", "in", "squamous", "cell", "carcinomas", "of", "the", "head", "and", "neck", "(", "HNSCC", ")", ",", "but", "the", "response", "is", "heterogeneous", ".", "EGFr", "is", "often", "overexpressed", "in", "HNSCC", "and", "has", "been", "related", "to", "the", "repopulation", "taking", "place", "during", "radiotherapy", ".", "The", "aim", "of", "the", "current", "study", "was", "to", "address", "the", "influence", "of", "EGFr", "and", "histopathological", "differentiation", "when", "the", "overall", "treatment", "time", "of", "radiotherapy", "was", "moderately", "reduced", ".", "PATIENTS", "AND", "METHODS", "Eight", "hundred", "and", "three", "patients", "with", "representative", "pretreatment", "tissue", "samples", "from", "the", "randomized", "DAHANCA", "6", "and", "7", "study", "of", "5", "vs", ".", "6", "fx", "/", "wk", "of", "radiotherapy", ".", "EGFr", "was", "visualized", "using", "immunohistochemistry", "and", "separated", "into", "high", "and", "low", "expression", "before", "correlation", "with", "clinical", "data", ".", "RESULTS", "Tumors", "with", "high", "EGFr", "(", "84", "%", ")", "responded", "better", "to", "moderately", "accelerated", "radiotherapy", ",", "than", "carcinomas", "with", "low", "EGFr", ",", "using", "locoregional", "control", "as", "endpoint", "and", "a", "similar", "pattern", "was", "seen", ",", "stratifying", "by", "well", "/", "moderate", "vs", ".", "poor", "tumor", "differentiation", ".", "Therefore", ",", "a", "combined", "parameter", "was", "constructed", "showing", "a", "more", "prominent", "separation", "of", "response", ":", "tumors", "with", "high", "EGFr", "and", "well", "/", "moderate", "differentiation", "did", "benefit", "from", "moderate", "acceleration", "of", "treatment", "regarding", "locoregional", "control", ",", "HR", "0.54", "(", "0.37", "-", "0.78", ")", ",", "whereas", "such", "an", "effect", "was", "not", "seen", "in", "tumors", "with", "low", "EGFr", "and", "/", "or", "poor", "differentiation", ",", "HR", "0.8", "(", "0.51", "-", "1.25", ")", ".", "These", "results", "reflected", "the", "disease", "specific", "survival", "as", "well", "and", "were", "confirmed", "in", "multivariable", "analyses", ".", "CONCLUSIONS", "Moderately", "accelerated", "fractionation", "is", "superior", "to", "conventional", "treatment", "in", "HNSCC", "but", "the", "response", "is", "heterogeneous", "and", "may", "be", "predicted", "by", "high", "expression", "of", "EGFr", "and", "well", "/", "moderate", "tumor", "differentiation", "." ]

[ "Participant_Condition", "Intervention_Pharmacological", "Outcome_Other", "Participant_Sample-size", "Outcome_Mortality", "Outcome_Physical", "Intervention_Physical" ]

Renal replacement therapy is an umlsterm, treatment is an umlsterm, acute renal failure is an umlsterm, renal replacement therapy is an umlsterm, intensive care unit is an umlsterm, patients is an umlsterm, renal replacement therapy is an umlsterm

IntensiveMedizin.70340040.eng.abstr_task0

Sentence: Renal replacement therapy is of primary importance for the treatment of acute renal failure associated with multiple system organ failure . If renal replacement therapy is not available in the intensive care unit , patients must be transferred to specialized units , where renal replacement therapy can be applied . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O" ]

Renal replacement therapy is of primary importance for the treatment of acute renal failure associated with multiple system organ failure . If renal replacement therapy is not available in the intensive care unit , patients must be transferred to specialized units , where renal replacement therapy can be applied .

[ "Renal", "replacement", "therapy", "is", "of", "primary", "importance", "for", "the", "treatment", "of", "acute", "renal", "failure", "associated", "with", "multiple", "system", "organ", "failure", ".", "If", "renal", "replacement", "therapy", "is", "not", "available", "in", "the", "intensive", "care", "unit", ",", "patients", "must", "be", "transferred", "to", "specialized", "units", ",", "where", "renal", "replacement", "therapy", "can", "be", "applied", "." ]

[ "umlsterm" ]

Renal replacement therapy is an umlsterm, treatment is an umlsterm, acute renal failure is an umlsterm, renal replacement therapy is an umlsterm, intensive care unit is an umlsterm, patients is an umlsterm, renal replacement therapy is an umlsterm

IntensiveMedizin.70340040.eng.abstr_task1

Sentence: Renal replacement therapy is of primary importance for the treatment of acute renal failure associated with multiple system organ failure . If renal replacement therapy is not available in the intensive care unit , patients must be transferred to specialized units , where renal replacement therapy can be applied . Instructions: please typing these entity words according to sentence: Renal replacement therapy, treatment, acute renal failure, renal replacement therapy, intensive care unit, patients, renal replacement therapy Options: umlsterm

[ "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O" ]

Renal replacement therapy is of primary importance for the treatment of acute renal failure associated with multiple system organ failure . If renal replacement therapy is not available in the intensive care unit , patients must be transferred to specialized units , where renal replacement therapy can be applied .

[ "Renal", "replacement", "therapy", "is", "of", "primary", "importance", "for", "the", "treatment", "of", "acute", "renal", "failure", "associated", "with", "multiple", "system", "organ", "failure", ".", "If", "renal", "replacement", "therapy", "is", "not", "available", "in", "the", "intensive", "care", "unit", ",", "patients", "must", "be", "transferred", "to", "specialized", "units", ",", "where", "renal", "replacement", "therapy", "can", "be", "applied", "." ]

[ "umlsterm" ]

Renal replacement therapy, treatment, acute renal failure, renal replacement therapy, intensive care unit, patients, renal replacement therapy

IntensiveMedizin.70340040.eng.abstr_task2

Sentence: Renal replacement therapy is of primary importance for the treatment of acute renal failure associated with multiple system organ failure . If renal replacement therapy is not available in the intensive care unit , patients must be transferred to specialized units , where renal replacement therapy can be applied . Instructions: please extract entity words from the input sentence

[ "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O" ]

Renal replacement therapy is of primary importance for the treatment of acute renal failure associated with multiple system organ failure . If renal replacement therapy is not available in the intensive care unit , patients must be transferred to specialized units , where renal replacement therapy can be applied .

[ "Renal", "replacement", "therapy", "is", "of", "primary", "importance", "for", "the", "treatment", "of", "acute", "renal", "failure", "associated", "with", "multiple", "system", "organ", "failure", ".", "If", "renal", "replacement", "therapy", "is", "not", "available", "in", "the", "intensive", "care", "unit", ",", "patients", "must", "be", "transferred", "to", "specialized", "units", ",", "where", "renal", "replacement", "therapy", "can", "be", "applied", "." ]

[ "umlsterm" ]

paper is an umlsterm, contrast is an umlsterm, injection is an umlsterm, techniques is an umlsterm, vessel is an umlsterm, contrast is an umlsterm, angiography is an umlsterm, vessel is an umlsterm, contrast is an umlsterm, contrast is an umlsterm, injection is an umlsterm, injection is an umlsterm, techniques is an umlsterm, standard is an umlsterm, technique is an umlsterm, contrast is an umlsterm, patients is an umlsterm, adjustment is an umlsterm, individual differences is an umlsterm, use is an umlsterm, contrast agent is an umlsterm, patient is an umlsterm, mathematical models is an umlsterm, contrast is an umlsterm, patient is an umlsterm, contrast is an umlsterm, techniques is an umlsterm

DerRadiologe.90390093.eng.abstr_task0

Sentence: This paper compares different contrast injection techniques for optimizing vessel contrast in CT angiography ( CTA ) . The optimal vessel contrast shall be defined as constant strong enhancement confined to the scanning interval . This " plateau enhancement " guarantees high-quality CTA images and should therefore be approximated during every CTA examination by an appropriate contrast injection protocol . With well-established injection techniques such as the standard bolus technique ( constant uniphasic contrast bolus for all patients ) or adjustment of the scan delay , considerable individual differences in the arterial enhancement can be observed , and a nondiagnostic examination or an inefficient use of contrast agent might be the result in a particular patient . Therefore , two sophisticated mathematical models have recently been developed for analyzing the individual enhancement characteristics . These models can be exploited to predict the arterial enhancement for any given intravenous contrast bolus in any patient and to optimize the contrast bolus in order to approach the ideal " plateau enhancement " . These techniques have to prove their effectiveness in larger clinical series . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

This paper compares different contrast injection techniques for optimizing vessel contrast in CT angiography ( CTA ) . The optimal vessel contrast shall be defined as constant strong enhancement confined to the scanning interval . This " plateau enhancement " guarantees high-quality CTA images and should therefore be approximated during every CTA examination by an appropriate contrast injection protocol . With well-established injection techniques such as the standard bolus technique ( constant uniphasic contrast bolus for all patients ) or adjustment of the scan delay , considerable individual differences in the arterial enhancement can be observed , and a nondiagnostic examination or an inefficient use of contrast agent might be the result in a particular patient . Therefore , two sophisticated mathematical models have recently been developed for analyzing the individual enhancement characteristics . These models can be exploited to predict the arterial enhancement for any given intravenous contrast bolus in any patient and to optimize the contrast bolus in order to approach the ideal " plateau enhancement " . These techniques have to prove their effectiveness in larger clinical series .

[ "This", "paper", "compares", "different", "contrast", "injection", "techniques", "for", "optimizing", "vessel", "contrast", "in", "CT", "angiography", "(", "CTA", ")", ".", "The", "optimal", "vessel", "contrast", "shall", "be", "defined", "as", "constant", "strong", "enhancement", "confined", "to", "the", "scanning", "interval", ".", "This", "\"", "plateau", "enhancement", "\"", "guarantees", "high", "-", "quality", "CTA", "images", "and", "should", "therefore", "be", "approximated", "during", "every", "CTA", "examination", "by", "an", "appropriate", "contrast", "injection", "protocol", ".", "With", "well", "-", "established", "injection", "techniques", "such", "as", "the", "standard", "bolus", "technique", "(", "constant", "uniphasic", "contrast", "bolus", "for", "all", "patients", ")", "or", "adjustment", "of", "the", "scan", "delay", ",", "considerable", "individual", "differences", "in", "the", "arterial", "enhancement", "can", "be", "observed", ",", "and", "a", "nondiagnostic", "examination", "or", "an", "inefficient", "use", "of", "contrast", "agent", "might", "be", "the", "result", "in", "a", "particular", "patient", ".", "Therefore", ",", "two", "sophisticated", "mathematical", "models", "have", "recently", "been", "developed", "for", "analyzing", "the", "individual", "enhancement", "characteristics", ".", "These", "models", "can", "be", "exploited", "to", "predict", "the", "arterial", "enhancement", "for", "any", "given", "intravenous", "contrast", "bolus", "in", "any", "patient", "and", "to", "optimize", "the", "contrast", "bolus", "in", "order", "to", "approach", "the", "ideal", "\"", "plateau", "enhancement", "\"", ".", "These", "techniques", "have", "to", "prove", "their", "effectiveness", "in", "larger", "clinical", "series", "." ]

[ "umlsterm" ]

paper is an umlsterm, contrast is an umlsterm, injection is an umlsterm, techniques is an umlsterm, vessel is an umlsterm, contrast is an umlsterm, angiography is an umlsterm, vessel is an umlsterm, contrast is an umlsterm, contrast is an umlsterm, injection is an umlsterm, injection is an umlsterm, techniques is an umlsterm, standard is an umlsterm, technique is an umlsterm, contrast is an umlsterm, patients is an umlsterm, adjustment is an umlsterm, individual differences is an umlsterm, use is an umlsterm, contrast agent is an umlsterm, patient is an umlsterm, mathematical models is an umlsterm, contrast is an umlsterm, patient is an umlsterm, contrast is an umlsterm, techniques is an umlsterm

DerRadiologe.90390093.eng.abstr_task1

Sentence: This paper compares different contrast injection techniques for optimizing vessel contrast in CT angiography ( CTA ) . The optimal vessel contrast shall be defined as constant strong enhancement confined to the scanning interval . This " plateau enhancement " guarantees high-quality CTA images and should therefore be approximated during every CTA examination by an appropriate contrast injection protocol . With well-established injection techniques such as the standard bolus technique ( constant uniphasic contrast bolus for all patients ) or adjustment of the scan delay , considerable individual differences in the arterial enhancement can be observed , and a nondiagnostic examination or an inefficient use of contrast agent might be the result in a particular patient . Therefore , two sophisticated mathematical models have recently been developed for analyzing the individual enhancement characteristics . These models can be exploited to predict the arterial enhancement for any given intravenous contrast bolus in any patient and to optimize the contrast bolus in order to approach the ideal " plateau enhancement " . These techniques have to prove their effectiveness in larger clinical series . Instructions: please typing these entity words according to sentence: paper, contrast, injection, techniques, vessel, contrast, angiography, vessel, contrast, contrast, injection, injection, techniques, standard, technique, contrast, patients, adjustment, individual differences, use, contrast agent, patient, mathematical models, contrast, patient, contrast, techniques Options: umlsterm

[ "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

This paper compares different contrast injection techniques for optimizing vessel contrast in CT angiography ( CTA ) . The optimal vessel contrast shall be defined as constant strong enhancement confined to the scanning interval . This " plateau enhancement " guarantees high-quality CTA images and should therefore be approximated during every CTA examination by an appropriate contrast injection protocol . With well-established injection techniques such as the standard bolus technique ( constant uniphasic contrast bolus for all patients ) or adjustment of the scan delay , considerable individual differences in the arterial enhancement can be observed , and a nondiagnostic examination or an inefficient use of contrast agent might be the result in a particular patient . Therefore , two sophisticated mathematical models have recently been developed for analyzing the individual enhancement characteristics . These models can be exploited to predict the arterial enhancement for any given intravenous contrast bolus in any patient and to optimize the contrast bolus in order to approach the ideal " plateau enhancement " . These techniques have to prove their effectiveness in larger clinical series .

[ "This", "paper", "compares", "different", "contrast", "injection", "techniques", "for", "optimizing", "vessel", "contrast", "in", "CT", "angiography", "(", "CTA", ")", ".", "The", "optimal", "vessel", "contrast", "shall", "be", "defined", "as", "constant", "strong", "enhancement", "confined", "to", "the", "scanning", "interval", ".", "This", "\"", "plateau", "enhancement", "\"", "guarantees", "high", "-", "quality", "CTA", "images", "and", "should", "therefore", "be", "approximated", "during", "every", "CTA", "examination", "by", "an", "appropriate", "contrast", "injection", "protocol", ".", "With", "well", "-", "established", "injection", "techniques", "such", "as", "the", "standard", "bolus", "technique", "(", "constant", "uniphasic", "contrast", "bolus", "for", "all", "patients", ")", "or", "adjustment", "of", "the", "scan", "delay", ",", "considerable", "individual", "differences", "in", "the", "arterial", "enhancement", "can", "be", "observed", ",", "and", "a", "nondiagnostic", "examination", "or", "an", "inefficient", "use", "of", "contrast", "agent", "might", "be", "the", "result", "in", "a", "particular", "patient", ".", "Therefore", ",", "two", "sophisticated", "mathematical", "models", "have", "recently", "been", "developed", "for", "analyzing", "the", "individual", "enhancement", "characteristics", ".", "These", "models", "can", "be", "exploited", "to", "predict", "the", "arterial", "enhancement", "for", "any", "given", "intravenous", "contrast", "bolus", "in", "any", "patient", "and", "to", "optimize", "the", "contrast", "bolus", "in", "order", "to", "approach", "the", "ideal", "\"", "plateau", "enhancement", "\"", ".", "These", "techniques", "have", "to", "prove", "their", "effectiveness", "in", "larger", "clinical", "series", "." ]

[ "umlsterm" ]

paper, contrast, injection, techniques, vessel, contrast, angiography, vessel, contrast, contrast, injection, injection, techniques, standard, technique, contrast, patients, adjustment, individual differences, use, contrast agent, patient, mathematical models, contrast, patient, contrast, techniques

DerRadiologe.90390093.eng.abstr_task2

Sentence: This paper compares different contrast injection techniques for optimizing vessel contrast in CT angiography ( CTA ) . The optimal vessel contrast shall be defined as constant strong enhancement confined to the scanning interval . This " plateau enhancement " guarantees high-quality CTA images and should therefore be approximated during every CTA examination by an appropriate contrast injection protocol . With well-established injection techniques such as the standard bolus technique ( constant uniphasic contrast bolus for all patients ) or adjustment of the scan delay , considerable individual differences in the arterial enhancement can be observed , and a nondiagnostic examination or an inefficient use of contrast agent might be the result in a particular patient . Therefore , two sophisticated mathematical models have recently been developed for analyzing the individual enhancement characteristics . These models can be exploited to predict the arterial enhancement for any given intravenous contrast bolus in any patient and to optimize the contrast bolus in order to approach the ideal " plateau enhancement " . These techniques have to prove their effectiveness in larger clinical series . Instructions: please extract entity words from the input sentence

[ "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

This paper compares different contrast injection techniques for optimizing vessel contrast in CT angiography ( CTA ) . The optimal vessel contrast shall be defined as constant strong enhancement confined to the scanning interval . This " plateau enhancement " guarantees high-quality CTA images and should therefore be approximated during every CTA examination by an appropriate contrast injection protocol . With well-established injection techniques such as the standard bolus technique ( constant uniphasic contrast bolus for all patients ) or adjustment of the scan delay , considerable individual differences in the arterial enhancement can be observed , and a nondiagnostic examination or an inefficient use of contrast agent might be the result in a particular patient . Therefore , two sophisticated mathematical models have recently been developed for analyzing the individual enhancement characteristics . These models can be exploited to predict the arterial enhancement for any given intravenous contrast bolus in any patient and to optimize the contrast bolus in order to approach the ideal " plateau enhancement " . These techniques have to prove their effectiveness in larger clinical series .

[ "This", "paper", "compares", "different", "contrast", "injection", "techniques", "for", "optimizing", "vessel", "contrast", "in", "CT", "angiography", "(", "CTA", ")", ".", "The", "optimal", "vessel", "contrast", "shall", "be", "defined", "as", "constant", "strong", "enhancement", "confined", "to", "the", "scanning", "interval", ".", "This", "\"", "plateau", "enhancement", "\"", "guarantees", "high", "-", "quality", "CTA", "images", "and", "should", "therefore", "be", "approximated", "during", "every", "CTA", "examination", "by", "an", "appropriate", "contrast", "injection", "protocol", ".", "With", "well", "-", "established", "injection", "techniques", "such", "as", "the", "standard", "bolus", "technique", "(", "constant", "uniphasic", "contrast", "bolus", "for", "all", "patients", ")", "or", "adjustment", "of", "the", "scan", "delay", ",", "considerable", "individual", "differences", "in", "the", "arterial", "enhancement", "can", "be", "observed", ",", "and", "a", "nondiagnostic", "examination", "or", "an", "inefficient", "use", "of", "contrast", "agent", "might", "be", "the", "result", "in", "a", "particular", "patient", ".", "Therefore", ",", "two", "sophisticated", "mathematical", "models", "have", "recently", "been", "developed", "for", "analyzing", "the", "individual", "enhancement", "characteristics", ".", "These", "models", "can", "be", "exploited", "to", "predict", "the", "arterial", "enhancement", "for", "any", "given", "intravenous", "contrast", "bolus", "in", "any", "patient", "and", "to", "optimize", "the", "contrast", "bolus", "in", "order", "to", "approach", "the", "ideal", "\"", "plateau", "enhancement", "\"", ".", "These", "techniques", "have", "to", "prove", "their", "effectiveness", "in", "larger", "clinical", "series", "." ]

[ "umlsterm" ]

Efficacy is a Outcome_Other, tolerability is a Outcome_Other, donepezil is a Intervention_Pharmacological, vascular dementia is a Participant_Condition, placebo - controlled is a Intervention_Control, cholinesterase inhibitors is a Intervention_Pharmacological, efficacy is a Outcome_Other, safety is a Outcome_Other, mean age , 73.9 years is a Participant_Age, improvement in cognition is a Outcome_Mental, Alzheimer ' s Disease Assessment Scale - cognitive subscale is a Outcome_Mental, patients ' global function is a Outcome_Physical, Clinician ' s Interview - Based Impression of Change - Plus version is a Outcome_Mental, Sum of the Boxes of the Clinical Dementia Rating is a Outcome_Physical, activities of daily living is a Outcome_Physical, Alzheimer ' s Disease Functional Assessment and Change Scale is a Outcome_Mental, Withdrawal rates is a Outcome_Other, adverse events is a Outcome_Adverse-effects

13897_task0

Sentence: Efficacy and tolerability of donepezil in vascular dementia : positive results of a 24-week , multicenter , international , randomized , placebo-controlled clinical trial . BACKGROUND AND PURPOSE Clinical observations suggest that patients with vascular dementia ( VaD ) may benefit from treatment with cholinesterase inhibitors . This study evaluated the efficacy and safety of donepezil for relieving symptoms of dementia in VaD . METHODS Patients ( n=603 ; mean age , 73.9 years ; 55.2 % men ) with probable ( 70.5 % ) or possible ( 29.5 % ) VaD , according to criteria of the National Institute of Neurological Disorders and Stroke ( NINDS ) and the Association Internationale pour la Recherche et l'Enseignement en Neurosciences ( AIREN ) , were randomized to 24 weeks of treatment with donepezil 5 mg/d ( n=198 ) , donepezil 10 mg/d ( 5 mg/d for first 28 days ; n=206 ) , or placebo ( n=199 ) . Analyses were based on the intent-to-treat population . RESULTS At week 24 , both donepezil groups showed significant improvement in cognition versus placebo on the Alzheimer 's Disease Assessment Scale-cognitive subscale ( mean change from baseline score effect size : donepezil 5 mg/d , -1.90 ; P=0.001 ; donepezil 10 mg/d , -2.33 ; P < 0.001 ) . Significant improvements in patients ' global function were seen versus placebo at week 24 ( observed cases ) , on the Clinician 's Interview-Based Impression of Change-Plus version only for patients on donepezil 5 mg/d ( P=0.014 ) , and on the Sum of the Boxes of the Clinical Dementia Rating only for patients on 10 mg/d ( P=0.007 ) . Donepezil-treated patients showed significant benefits in activities of daily living over placebo on the Alzheimer 's Disease Functional Assessment and Change Scale ( mean change from baseline score effect size at week 24 : donepezil 5 mg/d , -1.31 , P=0.02 ; donepezil 10 mg/d , -1.31 , P=0.02 ) . Donepezil was well tolerated . Withdrawal rates due to adverse events were relatively low ( placebo , 11.1 % ; donepezil 5 mg/d , 11.1 % ; donepezil 10 mg/d , 21.8 % ; P=0.005 versus placebo ) . CONCLUSIONS These data demonstrate that donepezil is an effective and well-tolerated treatment for VaD and show it may have an important place in the management of this condition . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Outcome_Adverse-effects, Intervention_Control, Participant_Condition, Participant_Age, Outcome_Physical, Outcome_Other, Outcome_Mental

[ "B-Outcome_Other", "O", "B-Outcome_Other", "O", "B-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Efficacy and tolerability of donepezil in vascular dementia : positive results of a 24-week , multicenter , international , randomized , placebo-controlled clinical trial . BACKGROUND AND PURPOSE Clinical observations suggest that patients with vascular dementia ( VaD ) may benefit from treatment with cholinesterase inhibitors . This study evaluated the efficacy and safety of donepezil for relieving symptoms of dementia in VaD . METHODS Patients ( n=603 ; mean age , 73.9 years ; 55.2 % men ) with probable ( 70.5 % ) or possible ( 29.5 % ) VaD , according to criteria of the National Institute of Neurological Disorders and Stroke ( NINDS ) and the Association Internationale pour la Recherche et l'Enseignement en Neurosciences ( AIREN ) , were randomized to 24 weeks of treatment with donepezil 5 mg/d ( n=198 ) , donepezil 10 mg/d ( 5 mg/d for first 28 days ; n=206 ) , or placebo ( n=199 ) . Analyses were based on the intent-to-treat population . RESULTS At week 24 , both donepezil groups showed significant improvement in cognition versus placebo on the Alzheimer 's Disease Assessment Scale-cognitive subscale ( mean change from baseline score effect size : donepezil 5 mg/d , -1.90 ; P=0.001 ; donepezil 10 mg/d , -2.33 ; P < 0.001 ) . Significant improvements in patients ' global function were seen versus placebo at week 24 ( observed cases ) , on the Clinician 's Interview-Based Impression of Change-Plus version only for patients on donepezil 5 mg/d ( P=0.014 ) , and on the Sum of the Boxes of the Clinical Dementia Rating only for patients on 10 mg/d ( P=0.007 ) . Donepezil-treated patients showed significant benefits in activities of daily living over placebo on the Alzheimer 's Disease Functional Assessment and Change Scale ( mean change from baseline score effect size at week 24 : donepezil 5 mg/d , -1.31 , P=0.02 ; donepezil 10 mg/d , -1.31 , P=0.02 ) . Donepezil was well tolerated . Withdrawal rates due to adverse events were relatively low ( placebo , 11.1 % ; donepezil 5 mg/d , 11.1 % ; donepezil 10 mg/d , 21.8 % ; P=0.005 versus placebo ) . CONCLUSIONS These data demonstrate that donepezil is an effective and well-tolerated treatment for VaD and show it may have an important place in the management of this condition .

[ "Efficacy", "and", "tolerability", "of", "donepezil", "in", "vascular", "dementia", ":", "positive", "results", "of", "a", "24-week", ",", "multicenter", ",", "international", ",", "randomized", ",", "placebo", "-", "controlled", "clinical", "trial", ".", "BACKGROUND", "AND", "PURPOSE", "Clinical", "observations", "suggest", "that", "patients", "with", "vascular", "dementia", "(", "VaD", ")", "may", "benefit", "from", "treatment", "with", "cholinesterase", "inhibitors", ".", "This", "study", "evaluated", "the", "efficacy", "and", "safety", "of", "donepezil", "for", "relieving", "symptoms", "of", "dementia", "in", "VaD", ".", "METHODS", "Patients", "(", "n=603", ";", "mean", "age", ",", "73.9", "years", ";", "55.2", "%", "men", ")", "with", "probable", "(", "70.5", "%", ")", "or", "possible", "(", "29.5", "%", ")", "VaD", ",", "according", "to", "criteria", "of", "the", "National", "Institute", "of", "Neurological", "Disorders", "and", "Stroke", "(", "NINDS", ")", "and", "the", "Association", "Internationale", "pour", "la", "Recherche", "et", "l'Enseignement", "en", "Neurosciences", "(", "AIREN", ")", ",", "were", "randomized", "to", "24", "weeks", "of", "treatment", "with", "donepezil", "5", "mg", "/", "d", "(", "n=198", ")", ",", "donepezil", "10", "mg", "/", "d", "(", "5", "mg", "/", "d", "for", "first", "28", "days", ";", "n=206", ")", ",", "or", "placebo", "(", "n=199", ")", ".", "Analyses", "were", "based", "on", "the", "intent", "-", "to", "-", "treat", "population", ".", "RESULTS", "At", "week", "24", ",", "both", "donepezil", "groups", "showed", "significant", "improvement", "in", "cognition", "versus", "placebo", "on", "the", "Alzheimer", "'", "s", "Disease", "Assessment", "Scale", "-", "cognitive", "subscale", "(", "mean", "change", "from", "baseline", "score", "effect", "size", ":", "donepezil", "5", "mg", "/", "d", ",", "-1.90", ";", "P=0.001", ";", "donepezil", "10", "mg", "/", "d", ",", "-2.33", ";", "P", "<", "0.001", ")", ".", "Significant", "improvements", "in", "patients", "'", "global", "function", "were", "seen", "versus", "placebo", "at", "week", "24", "(", "observed", "cases", ")", ",", "on", "the", "Clinician", "'", "s", "Interview", "-", "Based", "Impression", "of", "Change", "-", "Plus", "version", "only", "for", "patients", "on", "donepezil", "5", "mg", "/", "d", "(", "P=0.014", ")", ",", "and", "on", "the", "Sum", "of", "the", "Boxes", "of", "the", "Clinical", "Dementia", "Rating", "only", "for", "patients", "on", "10", "mg", "/", "d", "(", "P=0.007", ")", ".", "Donepezil", "-", "treated", "patients", "showed", "significant", "benefits", "in", "activities", "of", "daily", "living", "over", "placebo", "on", "the", "Alzheimer", "'", "s", "Disease", "Functional", "Assessment", "and", "Change", "Scale", "(", "mean", "change", "from", "baseline", "score", "effect", "size", "at", "week", "24", ":", "donepezil", "5", "mg", "/", "d", ",", "-1.31", ",", "P=0.02", ";", "donepezil", "10", "mg", "/", "d", ",", "-1.31", ",", "P=0.02", ")", ".", "Donepezil", "was", "well", "tolerated", ".", "Withdrawal", "rates", "due", "to", "adverse", "events", "were", "relatively", "low", "(", "placebo", ",", "11.1", "%", ";", "donepezil", "5", "mg", "/", "d", ",", "11.1", "%", ";", "donepezil", "10", "mg", "/", "d", ",", "21.8", "%", ";", "P=0.005", "versus", "placebo", ")", ".", "CONCLUSIONS", "These", "data", "demonstrate", "that", "donepezil", "is", "an", "effective", "and", "well", "-", "tolerated", "treatment", "for", "VaD", "and", "show", "it", "may", "have", "an", "important", "place", "in", "the", "management", "of", "this", "condition", "." ]

[ "Outcome_Mental", "Outcome_Physical", "Intervention_Pharmacological", "Participant_Age", "Intervention_Control", "Participant_Condition", "Outcome_Other", "Outcome_Adverse-effects", "Participant_Sex" ]

Efficacy is a Outcome_Other, tolerability is a Outcome_Other, donepezil is a Intervention_Pharmacological, vascular dementia is a Participant_Condition, placebo - controlled is a Intervention_Control, cholinesterase inhibitors is a Intervention_Pharmacological, efficacy is a Outcome_Other, safety is a Outcome_Other, mean age , 73.9 years is a Participant_Age, improvement in cognition is a Outcome_Mental, Alzheimer ' s Disease Assessment Scale - cognitive subscale is a Outcome_Mental, patients ' global function is a Outcome_Physical, Clinician ' s Interview - Based Impression of Change - Plus version is a Outcome_Mental, Sum of the Boxes of the Clinical Dementia Rating is a Outcome_Physical, activities of daily living is a Outcome_Physical, Alzheimer ' s Disease Functional Assessment and Change Scale is a Outcome_Mental, Withdrawal rates is a Outcome_Other, adverse events is a Outcome_Adverse-effects

13897_task1

Sentence: Efficacy and tolerability of donepezil in vascular dementia : positive results of a 24-week , multicenter , international , randomized , placebo-controlled clinical trial . BACKGROUND AND PURPOSE Clinical observations suggest that patients with vascular dementia ( VaD ) may benefit from treatment with cholinesterase inhibitors . This study evaluated the efficacy and safety of donepezil for relieving symptoms of dementia in VaD . METHODS Patients ( n=603 ; mean age , 73.9 years ; 55.2 % men ) with probable ( 70.5 % ) or possible ( 29.5 % ) VaD , according to criteria of the National Institute of Neurological Disorders and Stroke ( NINDS ) and the Association Internationale pour la Recherche et l'Enseignement en Neurosciences ( AIREN ) , were randomized to 24 weeks of treatment with donepezil 5 mg/d ( n=198 ) , donepezil 10 mg/d ( 5 mg/d for first 28 days ; n=206 ) , or placebo ( n=199 ) . Analyses were based on the intent-to-treat population . RESULTS At week 24 , both donepezil groups showed significant improvement in cognition versus placebo on the Alzheimer 's Disease Assessment Scale-cognitive subscale ( mean change from baseline score effect size : donepezil 5 mg/d , -1.90 ; P=0.001 ; donepezil 10 mg/d , -2.33 ; P < 0.001 ) . Significant improvements in patients ' global function were seen versus placebo at week 24 ( observed cases ) , on the Clinician 's Interview-Based Impression of Change-Plus version only for patients on donepezil 5 mg/d ( P=0.014 ) , and on the Sum of the Boxes of the Clinical Dementia Rating only for patients on 10 mg/d ( P=0.007 ) . Donepezil-treated patients showed significant benefits in activities of daily living over placebo on the Alzheimer 's Disease Functional Assessment and Change Scale ( mean change from baseline score effect size at week 24 : donepezil 5 mg/d , -1.31 , P=0.02 ; donepezil 10 mg/d , -1.31 , P=0.02 ) . Donepezil was well tolerated . Withdrawal rates due to adverse events were relatively low ( placebo , 11.1 % ; donepezil 5 mg/d , 11.1 % ; donepezil 10 mg/d , 21.8 % ; P=0.005 versus placebo ) . CONCLUSIONS These data demonstrate that donepezil is an effective and well-tolerated treatment for VaD and show it may have an important place in the management of this condition . Instructions: please typing these entity words according to sentence: Efficacy, tolerability, donepezil, vascular dementia, placebo - controlled, cholinesterase inhibitors, efficacy, safety, mean age , 73.9 years, improvement in cognition, Alzheimer ' s Disease Assessment Scale - cognitive subscale, patients ' global function, Clinician ' s Interview - Based Impression of Change - Plus version, Sum of the Boxes of the Clinical Dementia Rating, activities of daily living, Alzheimer ' s Disease Functional Assessment and Change Scale, Withdrawal rates, adverse events Options: Intervention_Pharmacological, Outcome_Adverse-effects, Intervention_Control, Participant_Condition, Participant_Age, Outcome_Physical, Outcome_Other, Outcome_Mental

[ "B-Outcome_Other", "O", "B-Outcome_Other", "O", "B-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Efficacy and tolerability of donepezil in vascular dementia : positive results of a 24-week , multicenter , international , randomized , placebo-controlled clinical trial . BACKGROUND AND PURPOSE Clinical observations suggest that patients with vascular dementia ( VaD ) may benefit from treatment with cholinesterase inhibitors . This study evaluated the efficacy and safety of donepezil for relieving symptoms of dementia in VaD . METHODS Patients ( n=603 ; mean age , 73.9 years ; 55.2 % men ) with probable ( 70.5 % ) or possible ( 29.5 % ) VaD , according to criteria of the National Institute of Neurological Disorders and Stroke ( NINDS ) and the Association Internationale pour la Recherche et l'Enseignement en Neurosciences ( AIREN ) , were randomized to 24 weeks of treatment with donepezil 5 mg/d ( n=198 ) , donepezil 10 mg/d ( 5 mg/d for first 28 days ; n=206 ) , or placebo ( n=199 ) . Analyses were based on the intent-to-treat population . RESULTS At week 24 , both donepezil groups showed significant improvement in cognition versus placebo on the Alzheimer 's Disease Assessment Scale-cognitive subscale ( mean change from baseline score effect size : donepezil 5 mg/d , -1.90 ; P=0.001 ; donepezil 10 mg/d , -2.33 ; P < 0.001 ) . Significant improvements in patients ' global function were seen versus placebo at week 24 ( observed cases ) , on the Clinician 's Interview-Based Impression of Change-Plus version only for patients on donepezil 5 mg/d ( P=0.014 ) , and on the Sum of the Boxes of the Clinical Dementia Rating only for patients on 10 mg/d ( P=0.007 ) . Donepezil-treated patients showed significant benefits in activities of daily living over placebo on the Alzheimer 's Disease Functional Assessment and Change Scale ( mean change from baseline score effect size at week 24 : donepezil 5 mg/d , -1.31 , P=0.02 ; donepezil 10 mg/d , -1.31 , P=0.02 ) . Donepezil was well tolerated . Withdrawal rates due to adverse events were relatively low ( placebo , 11.1 % ; donepezil 5 mg/d , 11.1 % ; donepezil 10 mg/d , 21.8 % ; P=0.005 versus placebo ) . CONCLUSIONS These data demonstrate that donepezil is an effective and well-tolerated treatment for VaD and show it may have an important place in the management of this condition .

[ "Efficacy", "and", "tolerability", "of", "donepezil", "in", "vascular", "dementia", ":", "positive", "results", "of", "a", "24-week", ",", "multicenter", ",", "international", ",", "randomized", ",", "placebo", "-", "controlled", "clinical", "trial", ".", "BACKGROUND", "AND", "PURPOSE", "Clinical", "observations", "suggest", "that", "patients", "with", "vascular", "dementia", "(", "VaD", ")", "may", "benefit", "from", "treatment", "with", "cholinesterase", "inhibitors", ".", "This", "study", "evaluated", "the", "efficacy", "and", "safety", "of", "donepezil", "for", "relieving", "symptoms", "of", "dementia", "in", "VaD", ".", "METHODS", "Patients", "(", "n=603", ";", "mean", "age", ",", "73.9", "years", ";", "55.2", "%", "men", ")", "with", "probable", "(", "70.5", "%", ")", "or", "possible", "(", "29.5", "%", ")", "VaD", ",", "according", "to", "criteria", "of", "the", "National", "Institute", "of", "Neurological", "Disorders", "and", "Stroke", "(", "NINDS", ")", "and", "the", "Association", "Internationale", "pour", "la", "Recherche", "et", "l'Enseignement", "en", "Neurosciences", "(", "AIREN", ")", ",", "were", "randomized", "to", "24", "weeks", "of", "treatment", "with", "donepezil", "5", "mg", "/", "d", "(", "n=198", ")", ",", "donepezil", "10", "mg", "/", "d", "(", "5", "mg", "/", "d", "for", "first", "28", "days", ";", "n=206", ")", ",", "or", "placebo", "(", "n=199", ")", ".", "Analyses", "were", "based", "on", "the", "intent", "-", "to", "-", "treat", "population", ".", "RESULTS", "At", "week", "24", ",", "both", "donepezil", "groups", "showed", "significant", "improvement", "in", "cognition", "versus", "placebo", "on", "the", "Alzheimer", "'", "s", "Disease", "Assessment", "Scale", "-", "cognitive", "subscale", "(", "mean", "change", "from", "baseline", "score", "effect", "size", ":", "donepezil", "5", "mg", "/", "d", ",", "-1.90", ";", "P=0.001", ";", "donepezil", "10", "mg", "/", "d", ",", "-2.33", ";", "P", "<", "0.001", ")", ".", "Significant", "improvements", "in", "patients", "'", "global", "function", "were", "seen", "versus", "placebo", "at", "week", "24", "(", "observed", "cases", ")", ",", "on", "the", "Clinician", "'", "s", "Interview", "-", "Based", "Impression", "of", "Change", "-", "Plus", "version", "only", "for", "patients", "on", "donepezil", "5", "mg", "/", "d", "(", "P=0.014", ")", ",", "and", "on", "the", "Sum", "of", "the", "Boxes", "of", "the", "Clinical", "Dementia", "Rating", "only", "for", "patients", "on", "10", "mg", "/", "d", "(", "P=0.007", ")", ".", "Donepezil", "-", "treated", "patients", "showed", "significant", "benefits", "in", "activities", "of", "daily", "living", "over", "placebo", "on", "the", "Alzheimer", "'", "s", "Disease", "Functional", "Assessment", "and", "Change", "Scale", "(", "mean", "change", "from", "baseline", "score", "effect", "size", "at", "week", "24", ":", "donepezil", "5", "mg", "/", "d", ",", "-1.31", ",", "P=0.02", ";", "donepezil", "10", "mg", "/", "d", ",", "-1.31", ",", "P=0.02", ")", ".", "Donepezil", "was", "well", "tolerated", ".", "Withdrawal", "rates", "due", "to", "adverse", "events", "were", "relatively", "low", "(", "placebo", ",", "11.1", "%", ";", "donepezil", "5", "mg", "/", "d", ",", "11.1", "%", ";", "donepezil", "10", "mg", "/", "d", ",", "21.8", "%", ";", "P=0.005", "versus", "placebo", ")", ".", "CONCLUSIONS", "These", "data", "demonstrate", "that", "donepezil", "is", "an", "effective", "and", "well", "-", "tolerated", "treatment", "for", "VaD", "and", "show", "it", "may", "have", "an", "important", "place", "in", "the", "management", "of", "this", "condition", "." ]

[ "Outcome_Mental", "Outcome_Physical", "Intervention_Pharmacological", "Participant_Age", "Intervention_Control", "Participant_Condition", "Outcome_Other", "Outcome_Adverse-effects", "Participant_Sex" ]

Efficacy, tolerability, donepezil, vascular dementia, placebo - controlled, cholinesterase inhibitors, efficacy, safety, mean age , 73.9 years, improvement in cognition, Alzheimer ' s Disease Assessment Scale - cognitive subscale, patients ' global function, Clinician ' s Interview - Based Impression of Change - Plus version, Sum of the Boxes of the Clinical Dementia Rating, activities of daily living, Alzheimer ' s Disease Functional Assessment and Change Scale, Withdrawal rates, adverse events

13897_task2

Sentence: Efficacy and tolerability of donepezil in vascular dementia : positive results of a 24-week , multicenter , international , randomized , placebo-controlled clinical trial . BACKGROUND AND PURPOSE Clinical observations suggest that patients with vascular dementia ( VaD ) may benefit from treatment with cholinesterase inhibitors . This study evaluated the efficacy and safety of donepezil for relieving symptoms of dementia in VaD . METHODS Patients ( n=603 ; mean age , 73.9 years ; 55.2 % men ) with probable ( 70.5 % ) or possible ( 29.5 % ) VaD , according to criteria of the National Institute of Neurological Disorders and Stroke ( NINDS ) and the Association Internationale pour la Recherche et l'Enseignement en Neurosciences ( AIREN ) , were randomized to 24 weeks of treatment with donepezil 5 mg/d ( n=198 ) , donepezil 10 mg/d ( 5 mg/d for first 28 days ; n=206 ) , or placebo ( n=199 ) . Analyses were based on the intent-to-treat population . RESULTS At week 24 , both donepezil groups showed significant improvement in cognition versus placebo on the Alzheimer 's Disease Assessment Scale-cognitive subscale ( mean change from baseline score effect size : donepezil 5 mg/d , -1.90 ; P=0.001 ; donepezil 10 mg/d , -2.33 ; P < 0.001 ) . Significant improvements in patients ' global function were seen versus placebo at week 24 ( observed cases ) , on the Clinician 's Interview-Based Impression of Change-Plus version only for patients on donepezil 5 mg/d ( P=0.014 ) , and on the Sum of the Boxes of the Clinical Dementia Rating only for patients on 10 mg/d ( P=0.007 ) . Donepezil-treated patients showed significant benefits in activities of daily living over placebo on the Alzheimer 's Disease Functional Assessment and Change Scale ( mean change from baseline score effect size at week 24 : donepezil 5 mg/d , -1.31 , P=0.02 ; donepezil 10 mg/d , -1.31 , P=0.02 ) . Donepezil was well tolerated . Withdrawal rates due to adverse events were relatively low ( placebo , 11.1 % ; donepezil 5 mg/d , 11.1 % ; donepezil 10 mg/d , 21.8 % ; P=0.005 versus placebo ) . CONCLUSIONS These data demonstrate that donepezil is an effective and well-tolerated treatment for VaD and show it may have an important place in the management of this condition . Instructions: please extract entity words from the input sentence

[ "B-Outcome_Other", "O", "B-Outcome_Other", "O", "B-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "I-Participant_Age", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Efficacy and tolerability of donepezil in vascular dementia : positive results of a 24-week , multicenter , international , randomized , placebo-controlled clinical trial . BACKGROUND AND PURPOSE Clinical observations suggest that patients with vascular dementia ( VaD ) may benefit from treatment with cholinesterase inhibitors . This study evaluated the efficacy and safety of donepezil for relieving symptoms of dementia in VaD . METHODS Patients ( n=603 ; mean age , 73.9 years ; 55.2 % men ) with probable ( 70.5 % ) or possible ( 29.5 % ) VaD , according to criteria of the National Institute of Neurological Disorders and Stroke ( NINDS ) and the Association Internationale pour la Recherche et l'Enseignement en Neurosciences ( AIREN ) , were randomized to 24 weeks of treatment with donepezil 5 mg/d ( n=198 ) , donepezil 10 mg/d ( 5 mg/d for first 28 days ; n=206 ) , or placebo ( n=199 ) . Analyses were based on the intent-to-treat population . RESULTS At week 24 , both donepezil groups showed significant improvement in cognition versus placebo on the Alzheimer 's Disease Assessment Scale-cognitive subscale ( mean change from baseline score effect size : donepezil 5 mg/d , -1.90 ; P=0.001 ; donepezil 10 mg/d , -2.33 ; P < 0.001 ) . Significant improvements in patients ' global function were seen versus placebo at week 24 ( observed cases ) , on the Clinician 's Interview-Based Impression of Change-Plus version only for patients on donepezil 5 mg/d ( P=0.014 ) , and on the Sum of the Boxes of the Clinical Dementia Rating only for patients on 10 mg/d ( P=0.007 ) . Donepezil-treated patients showed significant benefits in activities of daily living over placebo on the Alzheimer 's Disease Functional Assessment and Change Scale ( mean change from baseline score effect size at week 24 : donepezil 5 mg/d , -1.31 , P=0.02 ; donepezil 10 mg/d , -1.31 , P=0.02 ) . Donepezil was well tolerated . Withdrawal rates due to adverse events were relatively low ( placebo , 11.1 % ; donepezil 5 mg/d , 11.1 % ; donepezil 10 mg/d , 21.8 % ; P=0.005 versus placebo ) . CONCLUSIONS These data demonstrate that donepezil is an effective and well-tolerated treatment for VaD and show it may have an important place in the management of this condition .

[ "Efficacy", "and", "tolerability", "of", "donepezil", "in", "vascular", "dementia", ":", "positive", "results", "of", "a", "24-week", ",", "multicenter", ",", "international", ",", "randomized", ",", "placebo", "-", "controlled", "clinical", "trial", ".", "BACKGROUND", "AND", "PURPOSE", "Clinical", "observations", "suggest", "that", "patients", "with", "vascular", "dementia", "(", "VaD", ")", "may", "benefit", "from", "treatment", "with", "cholinesterase", "inhibitors", ".", "This", "study", "evaluated", "the", "efficacy", "and", "safety", "of", "donepezil", "for", "relieving", "symptoms", "of", "dementia", "in", "VaD", ".", "METHODS", "Patients", "(", "n=603", ";", "mean", "age", ",", "73.9", "years", ";", "55.2", "%", "men", ")", "with", "probable", "(", "70.5", "%", ")", "or", "possible", "(", "29.5", "%", ")", "VaD", ",", "according", "to", "criteria", "of", "the", "National", "Institute", "of", "Neurological", "Disorders", "and", "Stroke", "(", "NINDS", ")", "and", "the", "Association", "Internationale", "pour", "la", "Recherche", "et", "l'Enseignement", "en", "Neurosciences", "(", "AIREN", ")", ",", "were", "randomized", "to", "24", "weeks", "of", "treatment", "with", "donepezil", "5", "mg", "/", "d", "(", "n=198", ")", ",", "donepezil", "10", "mg", "/", "d", "(", "5", "mg", "/", "d", "for", "first", "28", "days", ";", "n=206", ")", ",", "or", "placebo", "(", "n=199", ")", ".", "Analyses", "were", "based", "on", "the", "intent", "-", "to", "-", "treat", "population", ".", "RESULTS", "At", "week", "24", ",", "both", "donepezil", "groups", "showed", "significant", "improvement", "in", "cognition", "versus", "placebo", "on", "the", "Alzheimer", "'", "s", "Disease", "Assessment", "Scale", "-", "cognitive", "subscale", "(", "mean", "change", "from", "baseline", "score", "effect", "size", ":", "donepezil", "5", "mg", "/", "d", ",", "-1.90", ";", "P=0.001", ";", "donepezil", "10", "mg", "/", "d", ",", "-2.33", ";", "P", "<", "0.001", ")", ".", "Significant", "improvements", "in", "patients", "'", "global", "function", "were", "seen", "versus", "placebo", "at", "week", "24", "(", "observed", "cases", ")", ",", "on", "the", "Clinician", "'", "s", "Interview", "-", "Based", "Impression", "of", "Change", "-", "Plus", "version", "only", "for", "patients", "on", "donepezil", "5", "mg", "/", "d", "(", "P=0.014", ")", ",", "and", "on", "the", "Sum", "of", "the", "Boxes", "of", "the", "Clinical", "Dementia", "Rating", "only", "for", "patients", "on", "10", "mg", "/", "d", "(", "P=0.007", ")", ".", "Donepezil", "-", "treated", "patients", "showed", "significant", "benefits", "in", "activities", "of", "daily", "living", "over", "placebo", "on", "the", "Alzheimer", "'", "s", "Disease", "Functional", "Assessment", "and", "Change", "Scale", "(", "mean", "change", "from", "baseline", "score", "effect", "size", "at", "week", "24", ":", "donepezil", "5", "mg", "/", "d", ",", "-1.31", ",", "P=0.02", ";", "donepezil", "10", "mg", "/", "d", ",", "-1.31", ",", "P=0.02", ")", ".", "Donepezil", "was", "well", "tolerated", ".", "Withdrawal", "rates", "due", "to", "adverse", "events", "were", "relatively", "low", "(", "placebo", ",", "11.1", "%", ";", "donepezil", "5", "mg", "/", "d", ",", "11.1", "%", ";", "donepezil", "10", "mg", "/", "d", ",", "21.8", "%", ";", "P=0.005", "versus", "placebo", ")", ".", "CONCLUSIONS", "These", "data", "demonstrate", "that", "donepezil", "is", "an", "effective", "and", "well", "-", "tolerated", "treatment", "for", "VaD", "and", "show", "it", "may", "have", "an", "important", "place", "in", "the", "management", "of", "this", "condition", "." ]

[ "Outcome_Mental", "Outcome_Physical", "Intervention_Pharmacological", "Participant_Age", "Intervention_Control", "Participant_Condition", "Outcome_Other", "Outcome_Adverse-effects", "Participant_Sex" ]

dermatomyositis - like is an umlsterm, maintenance is an umlsterm, therapy is an umlsterm, hydroxyurea is an umlsterm, patients is an umlsterm, chronic myelogenous leukaemia is an umlsterm, CML is an umlsterm, side effects is an umlsterm, pruritus is an umlsterm, hyperpigmentation is an umlsterm, patients is an umlsterm, skin is an umlsterm, hands is an umlsterm, fingers is an umlsterm, erythema is an umlsterm, face is an umlsterm, patients is an umlsterm, oedema is an umlsterm, eyelids is an umlsterm, patient is an umlsterm, dermatomyositis - like is an umlsterm, signs is an umlsterm, muscle - specific is an umlsterm, enzymes is an umlsterm, normal ranges is an umlsterm, Skin is an umlsterm, biopsy is an umlsterm, dermatitis is an umlsterm, cell is an umlsterm, cells is an umlsterm, keratinocytes is an umlsterm, telangiectases is an umlsterm, dermis is an umlsterm, histopathological is an umlsterm, findings is an umlsterm, lichen is an umlsterm, planus - like is an umlsterm, skin is an umlsterm, hands is an umlsterm, hydroxyurea is an umlsterm, therapy is an umlsterm, skin is an umlsterm, dermatomyositis - like is an umlsterm, lichen is an umlsterm, planus - like is an umlsterm, patients is an umlsterm, hydroxyurea is an umlsterm, therapy is an umlsterm

DerHautarzt.50460717.eng.abstr_task0

Sentence: We report on dermatomyositis-like adverse cutaneous reactions following long-term maintenance therapy with hydroxyurea in two patients suffering from chronic myelogenous leukaemia ( CML ) . In addition to non-specific side effects , such as xerosis , pruritus and hyperpigmentation , both patients presented with more specific skin changes , i.e. erythematous lesions , scaling , and partially atrophic areas distributed in a linear fashion on the dorsal aspects of the hands and fingers . In addition , teleangiectatic erythema of the face was present in both patients , and this was associated with oedema of the eyelids in one patient . Despite these dermatomyositis-like features there were no clinical signs of muscular involvement , and muscle-specific enzymes were within normal ranges . Skin biopsy specimens revealed an interface dermatitis characterized by a lichenoid cell infiltrate , vacuolar alteration of basal cells , necrotic keratinocytes within the spinous zone , focal hypergranulosis , orthohyperkeratosis and telangiectases in the upper part of the dermis . Analogous histopathological findings have been documented in lichen planus-like skin changes on the hands following hydroxyurea therapy . It seems doubtful whether there are actually any major differences between those skin changes described as dermatomyositis-like and those interpreted as lichen planus-like in patients receiving long-term hydroxyurea therapy . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O" ]

We report on dermatomyositis-like adverse cutaneous reactions following long-term maintenance therapy with hydroxyurea in two patients suffering from chronic myelogenous leukaemia ( CML ) . In addition to non-specific side effects , such as xerosis , pruritus and hyperpigmentation , both patients presented with more specific skin changes , i.e. erythematous lesions , scaling , and partially atrophic areas distributed in a linear fashion on the dorsal aspects of the hands and fingers . In addition , teleangiectatic erythema of the face was present in both patients , and this was associated with oedema of the eyelids in one patient . Despite these dermatomyositis-like features there were no clinical signs of muscular involvement , and muscle-specific enzymes were within normal ranges . Skin biopsy specimens revealed an interface dermatitis characterized by a lichenoid cell infiltrate , vacuolar alteration of basal cells , necrotic keratinocytes within the spinous zone , focal hypergranulosis , orthohyperkeratosis and telangiectases in the upper part of the dermis . Analogous histopathological findings have been documented in lichen planus-like skin changes on the hands following hydroxyurea therapy . It seems doubtful whether there are actually any major differences between those skin changes described as dermatomyositis-like and those interpreted as lichen planus-like in patients receiving long-term hydroxyurea therapy .

[ "We", "report", "on", "dermatomyositis", "-", "like", "adverse", "cutaneous", "reactions", "following", "long", "-", "term", "maintenance", "therapy", "with", "hydroxyurea", "in", "two", "patients", "suffering", "from", "chronic", "myelogenous", "leukaemia", "(", "CML", ")", ".", "In", "addition", "to", "non", "-", "specific", "side", "effects", ",", "such", "as", "xerosis", ",", "pruritus", "and", "hyperpigmentation", ",", "both", "patients", "presented", "with", "more", "specific", "skin", "changes", ",", "i.e", ".", "erythematous", "lesions", ",", "scaling", ",", "and", "partially", "atrophic", "areas", "distributed", "in", "a", "linear", "fashion", "on", "the", "dorsal", "aspects", "of", "the", "hands", "and", "fingers", ".", "In", "addition", ",", "teleangiectatic", "erythema", "of", "the", "face", "was", "present", "in", "both", "patients", ",", "and", "this", "was", "associated", "with", "oedema", "of", "the", "eyelids", "in", "one", "patient", ".", "Despite", "these", "dermatomyositis", "-", "like", "features", "there", "were", "no", "clinical", "signs", "of", "muscular", "involvement", ",", "and", "muscle", "-", "specific", "enzymes", "were", "within", "normal", "ranges", ".", "Skin", "biopsy", "specimens", "revealed", "an", "interface", "dermatitis", "characterized", "by", "a", "lichenoid", "cell", "infiltrate", ",", "vacuolar", "alteration", "of", "basal", "cells", ",", "necrotic", "keratinocytes", "within", "the", "spinous", "zone", ",", "focal", "hypergranulosis", ",", "orthohyperkeratosis", "and", "telangiectases", "in", "the", "upper", "part", "of", "the", "dermis", ".", "Analogous", "histopathological", "findings", "have", "been", "documented", "in", "lichen", "planus", "-", "like", "skin", "changes", "on", "the", "hands", "following", "hydroxyurea", "therapy", ".", "It", "seems", "doubtful", "whether", "there", "are", "actually", "any", "major", "differences", "between", "those", "skin", "changes", "described", "as", "dermatomyositis", "-", "like", "and", "those", "interpreted", "as", "lichen", "planus", "-", "like", "in", "patients", "receiving", "long", "-", "term", "hydroxyurea", "therapy", "." ]

[ "umlsterm" ]

dermatomyositis - like is an umlsterm, maintenance is an umlsterm, therapy is an umlsterm, hydroxyurea is an umlsterm, patients is an umlsterm, chronic myelogenous leukaemia is an umlsterm, CML is an umlsterm, side effects is an umlsterm, pruritus is an umlsterm, hyperpigmentation is an umlsterm, patients is an umlsterm, skin is an umlsterm, hands is an umlsterm, fingers is an umlsterm, erythema is an umlsterm, face is an umlsterm, patients is an umlsterm, oedema is an umlsterm, eyelids is an umlsterm, patient is an umlsterm, dermatomyositis - like is an umlsterm, signs is an umlsterm, muscle - specific is an umlsterm, enzymes is an umlsterm, normal ranges is an umlsterm, Skin is an umlsterm, biopsy is an umlsterm, dermatitis is an umlsterm, cell is an umlsterm, cells is an umlsterm, keratinocytes is an umlsterm, telangiectases is an umlsterm, dermis is an umlsterm, histopathological is an umlsterm, findings is an umlsterm, lichen is an umlsterm, planus - like is an umlsterm, skin is an umlsterm, hands is an umlsterm, hydroxyurea is an umlsterm, therapy is an umlsterm, skin is an umlsterm, dermatomyositis - like is an umlsterm, lichen is an umlsterm, planus - like is an umlsterm, patients is an umlsterm, hydroxyurea is an umlsterm, therapy is an umlsterm

DerHautarzt.50460717.eng.abstr_task1

Sentence: We report on dermatomyositis-like adverse cutaneous reactions following long-term maintenance therapy with hydroxyurea in two patients suffering from chronic myelogenous leukaemia ( CML ) . In addition to non-specific side effects , such as xerosis , pruritus and hyperpigmentation , both patients presented with more specific skin changes , i.e. erythematous lesions , scaling , and partially atrophic areas distributed in a linear fashion on the dorsal aspects of the hands and fingers . In addition , teleangiectatic erythema of the face was present in both patients , and this was associated with oedema of the eyelids in one patient . Despite these dermatomyositis-like features there were no clinical signs of muscular involvement , and muscle-specific enzymes were within normal ranges . Skin biopsy specimens revealed an interface dermatitis characterized by a lichenoid cell infiltrate , vacuolar alteration of basal cells , necrotic keratinocytes within the spinous zone , focal hypergranulosis , orthohyperkeratosis and telangiectases in the upper part of the dermis . Analogous histopathological findings have been documented in lichen planus-like skin changes on the hands following hydroxyurea therapy . It seems doubtful whether there are actually any major differences between those skin changes described as dermatomyositis-like and those interpreted as lichen planus-like in patients receiving long-term hydroxyurea therapy . Instructions: please typing these entity words according to sentence: dermatomyositis - like, maintenance, therapy, hydroxyurea, patients, chronic myelogenous leukaemia, CML, side effects, pruritus, hyperpigmentation, patients, skin, hands, fingers, erythema, face, patients, oedema, eyelids, patient, dermatomyositis - like, signs, muscle - specific, enzymes, normal ranges, Skin, biopsy, dermatitis, cell, cells, keratinocytes, telangiectases, dermis, histopathological, findings, lichen, planus - like, skin, hands, hydroxyurea, therapy, skin, dermatomyositis - like, lichen, planus - like, patients, hydroxyurea, therapy Options: umlsterm

[ "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O" ]

We report on dermatomyositis-like adverse cutaneous reactions following long-term maintenance therapy with hydroxyurea in two patients suffering from chronic myelogenous leukaemia ( CML ) . In addition to non-specific side effects , such as xerosis , pruritus and hyperpigmentation , both patients presented with more specific skin changes , i.e. erythematous lesions , scaling , and partially atrophic areas distributed in a linear fashion on the dorsal aspects of the hands and fingers . In addition , teleangiectatic erythema of the face was present in both patients , and this was associated with oedema of the eyelids in one patient . Despite these dermatomyositis-like features there were no clinical signs of muscular involvement , and muscle-specific enzymes were within normal ranges . Skin biopsy specimens revealed an interface dermatitis characterized by a lichenoid cell infiltrate , vacuolar alteration of basal cells , necrotic keratinocytes within the spinous zone , focal hypergranulosis , orthohyperkeratosis and telangiectases in the upper part of the dermis . Analogous histopathological findings have been documented in lichen planus-like skin changes on the hands following hydroxyurea therapy . It seems doubtful whether there are actually any major differences between those skin changes described as dermatomyositis-like and those interpreted as lichen planus-like in patients receiving long-term hydroxyurea therapy .

[ "We", "report", "on", "dermatomyositis", "-", "like", "adverse", "cutaneous", "reactions", "following", "long", "-", "term", "maintenance", "therapy", "with", "hydroxyurea", "in", "two", "patients", "suffering", "from", "chronic", "myelogenous", "leukaemia", "(", "CML", ")", ".", "In", "addition", "to", "non", "-", "specific", "side", "effects", ",", "such", "as", "xerosis", ",", "pruritus", "and", "hyperpigmentation", ",", "both", "patients", "presented", "with", "more", "specific", "skin", "changes", ",", "i.e", ".", "erythematous", "lesions", ",", "scaling", ",", "and", "partially", "atrophic", "areas", "distributed", "in", "a", "linear", "fashion", "on", "the", "dorsal", "aspects", "of", "the", "hands", "and", "fingers", ".", "In", "addition", ",", "teleangiectatic", "erythema", "of", "the", "face", "was", "present", "in", "both", "patients", ",", "and", "this", "was", "associated", "with", "oedema", "of", "the", "eyelids", "in", "one", "patient", ".", "Despite", "these", "dermatomyositis", "-", "like", "features", "there", "were", "no", "clinical", "signs", "of", "muscular", "involvement", ",", "and", "muscle", "-", "specific", "enzymes", "were", "within", "normal", "ranges", ".", "Skin", "biopsy", "specimens", "revealed", "an", "interface", "dermatitis", "characterized", "by", "a", "lichenoid", "cell", "infiltrate", ",", "vacuolar", "alteration", "of", "basal", "cells", ",", "necrotic", "keratinocytes", "within", "the", "spinous", "zone", ",", "focal", "hypergranulosis", ",", "orthohyperkeratosis", "and", "telangiectases", "in", "the", "upper", "part", "of", "the", "dermis", ".", "Analogous", "histopathological", "findings", "have", "been", "documented", "in", "lichen", "planus", "-", "like", "skin", "changes", "on", "the", "hands", "following", "hydroxyurea", "therapy", ".", "It", "seems", "doubtful", "whether", "there", "are", "actually", "any", "major", "differences", "between", "those", "skin", "changes", "described", "as", "dermatomyositis", "-", "like", "and", "those", "interpreted", "as", "lichen", "planus", "-", "like", "in", "patients", "receiving", "long", "-", "term", "hydroxyurea", "therapy", "." ]

[ "umlsterm" ]

dermatomyositis - like, maintenance, therapy, hydroxyurea, patients, chronic myelogenous leukaemia, CML, side effects, pruritus, hyperpigmentation, patients, skin, hands, fingers, erythema, face, patients, oedema, eyelids, patient, dermatomyositis - like, signs, muscle - specific, enzymes, normal ranges, Skin, biopsy, dermatitis, cell, cells, keratinocytes, telangiectases, dermis, histopathological, findings, lichen, planus - like, skin, hands, hydroxyurea, therapy, skin, dermatomyositis - like, lichen, planus - like, patients, hydroxyurea, therapy

DerHautarzt.50460717.eng.abstr_task2

Sentence: We report on dermatomyositis-like adverse cutaneous reactions following long-term maintenance therapy with hydroxyurea in two patients suffering from chronic myelogenous leukaemia ( CML ) . In addition to non-specific side effects , such as xerosis , pruritus and hyperpigmentation , both patients presented with more specific skin changes , i.e. erythematous lesions , scaling , and partially atrophic areas distributed in a linear fashion on the dorsal aspects of the hands and fingers . In addition , teleangiectatic erythema of the face was present in both patients , and this was associated with oedema of the eyelids in one patient . Despite these dermatomyositis-like features there were no clinical signs of muscular involvement , and muscle-specific enzymes were within normal ranges . Skin biopsy specimens revealed an interface dermatitis characterized by a lichenoid cell infiltrate , vacuolar alteration of basal cells , necrotic keratinocytes within the spinous zone , focal hypergranulosis , orthohyperkeratosis and telangiectases in the upper part of the dermis . Analogous histopathological findings have been documented in lichen planus-like skin changes on the hands following hydroxyurea therapy . It seems doubtful whether there are actually any major differences between those skin changes described as dermatomyositis-like and those interpreted as lichen planus-like in patients receiving long-term hydroxyurea therapy . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O" ]

We report on dermatomyositis-like adverse cutaneous reactions following long-term maintenance therapy with hydroxyurea in two patients suffering from chronic myelogenous leukaemia ( CML ) . In addition to non-specific side effects , such as xerosis , pruritus and hyperpigmentation , both patients presented with more specific skin changes , i.e. erythematous lesions , scaling , and partially atrophic areas distributed in a linear fashion on the dorsal aspects of the hands and fingers . In addition , teleangiectatic erythema of the face was present in both patients , and this was associated with oedema of the eyelids in one patient . Despite these dermatomyositis-like features there were no clinical signs of muscular involvement , and muscle-specific enzymes were within normal ranges . Skin biopsy specimens revealed an interface dermatitis characterized by a lichenoid cell infiltrate , vacuolar alteration of basal cells , necrotic keratinocytes within the spinous zone , focal hypergranulosis , orthohyperkeratosis and telangiectases in the upper part of the dermis . Analogous histopathological findings have been documented in lichen planus-like skin changes on the hands following hydroxyurea therapy . It seems doubtful whether there are actually any major differences between those skin changes described as dermatomyositis-like and those interpreted as lichen planus-like in patients receiving long-term hydroxyurea therapy .

[ "We", "report", "on", "dermatomyositis", "-", "like", "adverse", "cutaneous", "reactions", "following", "long", "-", "term", "maintenance", "therapy", "with", "hydroxyurea", "in", "two", "patients", "suffering", "from", "chronic", "myelogenous", "leukaemia", "(", "CML", ")", ".", "In", "addition", "to", "non", "-", "specific", "side", "effects", ",", "such", "as", "xerosis", ",", "pruritus", "and", "hyperpigmentation", ",", "both", "patients", "presented", "with", "more", "specific", "skin", "changes", ",", "i.e", ".", "erythematous", "lesions", ",", "scaling", ",", "and", "partially", "atrophic", "areas", "distributed", "in", "a", "linear", "fashion", "on", "the", "dorsal", "aspects", "of", "the", "hands", "and", "fingers", ".", "In", "addition", ",", "teleangiectatic", "erythema", "of", "the", "face", "was", "present", "in", "both", "patients", ",", "and", "this", "was", "associated", "with", "oedema", "of", "the", "eyelids", "in", "one", "patient", ".", "Despite", "these", "dermatomyositis", "-", "like", "features", "there", "were", "no", "clinical", "signs", "of", "muscular", "involvement", ",", "and", "muscle", "-", "specific", "enzymes", "were", "within", "normal", "ranges", ".", "Skin", "biopsy", "specimens", "revealed", "an", "interface", "dermatitis", "characterized", "by", "a", "lichenoid", "cell", "infiltrate", ",", "vacuolar", "alteration", "of", "basal", "cells", ",", "necrotic", "keratinocytes", "within", "the", "spinous", "zone", ",", "focal", "hypergranulosis", ",", "orthohyperkeratosis", "and", "telangiectases", "in", "the", "upper", "part", "of", "the", "dermis", ".", "Analogous", "histopathological", "findings", "have", "been", "documented", "in", "lichen", "planus", "-", "like", "skin", "changes", "on", "the", "hands", "following", "hydroxyurea", "therapy", ".", "It", "seems", "doubtful", "whether", "there", "are", "actually", "any", "major", "differences", "between", "those", "skin", "changes", "described", "as", "dermatomyositis", "-", "like", "and", "those", "interpreted", "as", "lichen", "planus", "-", "like", "in", "patients", "receiving", "long", "-", "term", "hydroxyurea", "therapy", "." ]

[ "umlsterm" ]

sequence alterations is an other_name, upstream regulatory region is a DNA_domain_or_region, estrogen receptor gene is a DNA_domain_or_region, ER - negative breast cancer cell line is a cell_line

64115_task0

Sentence: Identification of sequence alterations in the upstream regulatory region of the estrogen receptor gene in an ER-negative breast cancer cell line. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: DNA_domain_or_region, cell_line, other_name

[ "O", "O", "B-other_name", "I-other_name", "O", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "O", "B-cell_line", "I-cell_line", "I-cell_line", "I-cell_line", "I-cell_line", "I-cell_line", "I-cell_line", "O" ]

Identification of sequence alterations in the upstream regulatory region of the estrogen receptor gene in an ER-negative breast cancer cell line.

[ "Identification", "of", "sequence", "alterations", "in", "the", "upstream", "regulatory", "region", "of", "the", "estrogen", "receptor", "gene", "in", "an", "ER", "-", "negative", "breast", "cancer", "cell", "line", "." ]

[ "cell_line", "other_name", "DNA_domain_or_region", "protein_molecule", "tissue", "body_part" ]

sequence alterations is an other_name, upstream regulatory region is a DNA_domain_or_region, estrogen receptor gene is a DNA_domain_or_region, ER - negative breast cancer cell line is a cell_line

64115_task1

Sentence: Identification of sequence alterations in the upstream regulatory region of the estrogen receptor gene in an ER-negative breast cancer cell line. Instructions: please typing these entity words according to sentence: sequence alterations, upstream regulatory region, estrogen receptor gene, ER - negative breast cancer cell line Options: DNA_domain_or_region, cell_line, other_name

[ "O", "O", "B-other_name", "I-other_name", "O", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "O", "B-cell_line", "I-cell_line", "I-cell_line", "I-cell_line", "I-cell_line", "I-cell_line", "I-cell_line", "O" ]

Identification of sequence alterations in the upstream regulatory region of the estrogen receptor gene in an ER-negative breast cancer cell line.

[ "Identification", "of", "sequence", "alterations", "in", "the", "upstream", "regulatory", "region", "of", "the", "estrogen", "receptor", "gene", "in", "an", "ER", "-", "negative", "breast", "cancer", "cell", "line", "." ]

[ "cell_line", "other_name", "DNA_domain_or_region", "protein_molecule", "tissue", "body_part" ]

sequence alterations, upstream regulatory region, estrogen receptor gene, ER - negative breast cancer cell line

64115_task2

Sentence: Identification of sequence alterations in the upstream regulatory region of the estrogen receptor gene in an ER-negative breast cancer cell line. Instructions: please extract entity words from the input sentence

[ "O", "O", "B-other_name", "I-other_name", "O", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "O", "B-cell_line", "I-cell_line", "I-cell_line", "I-cell_line", "I-cell_line", "I-cell_line", "I-cell_line", "O" ]

Identification of sequence alterations in the upstream regulatory region of the estrogen receptor gene in an ER-negative breast cancer cell line.

[ "Identification", "of", "sequence", "alterations", "in", "the", "upstream", "regulatory", "region", "of", "the", "estrogen", "receptor", "gene", "in", "an", "ER", "-", "negative", "breast", "cancer", "cell", "line", "." ]

[ "cell_line", "other_name", "DNA_domain_or_region", "protein_molecule", "tissue", "body_part" ]

cellular networks is a Multi-tissue_structure

PMID-21596785_task0

Sentence: mirAct: a web tool for evaluating microRNA activity based on gene expression data. MicroRNAs (miRNAs) are critical regulators in the complex cellular networks. The mirAct web server (http://sysbio.ustc.edu.cn/software/mirAct) is a tool designed to investigate miRNA activity based on gene-expression data by using the negative regulation relationship between miRNAs and their target genes. mirAct supports multiple-class data and enables clustering analysis based on computationally determined miRNA activity. Here, we describe the framework of mirAct, demonstrate its performance by comparing with other similar programs and exemplify its applications using case studies. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Multi-tissue_structure

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

mirAct: a web tool for evaluating microRNA activity based on gene expression data. MicroRNAs (miRNAs) are critical regulators in the complex cellular networks. The mirAct web server (http://sysbio.ustc.edu.cn/software/mirAct) is a tool designed to investigate miRNA activity based on gene-expression data by using the negative regulation relationship between miRNAs and their target genes. mirAct supports multiple-class data and enables clustering analysis based on computationally determined miRNA activity. Here, we describe the framework of mirAct, demonstrate its performance by comparing with other similar programs and exemplify its applications using case studies.

[ "mirAct", ":", "a", "web", "tool", "for", "evaluating", "microRNA", "activity", "based", "on", "gene", "expression", "data", ".", "\n", "MicroRNAs", "(", "miRNAs", ")", "are", "critical", "regulators", "in", "the", "complex", "cellular", "networks", ".", "The", "mirAct", "web", "server", "(", "http://sysbio.ustc.edu.cn/software/mirAct", ")", "is", "a", "tool", "designed", "to", "investigate", "miRNA", "activity", "based", "on", "gene", "-", "expression", "data", "by", "using", "the", "negative", "regulation", "relationship", "between", "miRNAs", "and", "their", "target", "genes", ".", "mirAct", "supports", "multiple", "-", "class", "data", "and", "enables", "clustering", "analysis", "based", "on", "computationally", "determined", "miRNA", "activity", ".", "Here", ",", "we", "describe", "the", "framework", "of", "mirAct", ",", "demonstrate", "its", "performance", "by", "comparing", "with", "other", "similar", "programs", "and", "exemplify", "its", "applications", "using", "case", "studies", ".", "\n" ]

[ "Multi-tissue_structure" ]

cellular networks is a Multi-tissue_structure

PMID-21596785_task1

Sentence: mirAct: a web tool for evaluating microRNA activity based on gene expression data. MicroRNAs (miRNAs) are critical regulators in the complex cellular networks. The mirAct web server (http://sysbio.ustc.edu.cn/software/mirAct) is a tool designed to investigate miRNA activity based on gene-expression data by using the negative regulation relationship between miRNAs and their target genes. mirAct supports multiple-class data and enables clustering analysis based on computationally determined miRNA activity. Here, we describe the framework of mirAct, demonstrate its performance by comparing with other similar programs and exemplify its applications using case studies. Instructions: please typing these entity words according to sentence: cellular networks Options: Multi-tissue_structure

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

mirAct: a web tool for evaluating microRNA activity based on gene expression data. MicroRNAs (miRNAs) are critical regulators in the complex cellular networks. The mirAct web server (http://sysbio.ustc.edu.cn/software/mirAct) is a tool designed to investigate miRNA activity based on gene-expression data by using the negative regulation relationship between miRNAs and their target genes. mirAct supports multiple-class data and enables clustering analysis based on computationally determined miRNA activity. Here, we describe the framework of mirAct, demonstrate its performance by comparing with other similar programs and exemplify its applications using case studies.

[ "mirAct", ":", "a", "web", "tool", "for", "evaluating", "microRNA", "activity", "based", "on", "gene", "expression", "data", ".", "\n", "MicroRNAs", "(", "miRNAs", ")", "are", "critical", "regulators", "in", "the", "complex", "cellular", "networks", ".", "The", "mirAct", "web", "server", "(", "http://sysbio.ustc.edu.cn/software/mirAct", ")", "is", "a", "tool", "designed", "to", "investigate", "miRNA", "activity", "based", "on", "gene", "-", "expression", "data", "by", "using", "the", "negative", "regulation", "relationship", "between", "miRNAs", "and", "their", "target", "genes", ".", "mirAct", "supports", "multiple", "-", "class", "data", "and", "enables", "clustering", "analysis", "based", "on", "computationally", "determined", "miRNA", "activity", ".", "Here", ",", "we", "describe", "the", "framework", "of", "mirAct", ",", "demonstrate", "its", "performance", "by", "comparing", "with", "other", "similar", "programs", "and", "exemplify", "its", "applications", "using", "case", "studies", ".", "\n" ]

[ "Multi-tissue_structure" ]

cellular networks

PMID-21596785_task2

Sentence: mirAct: a web tool for evaluating microRNA activity based on gene expression data. MicroRNAs (miRNAs) are critical regulators in the complex cellular networks. The mirAct web server (http://sysbio.ustc.edu.cn/software/mirAct) is a tool designed to investigate miRNA activity based on gene-expression data by using the negative regulation relationship between miRNAs and their target genes. mirAct supports multiple-class data and enables clustering analysis based on computationally determined miRNA activity. Here, we describe the framework of mirAct, demonstrate its performance by comparing with other similar programs and exemplify its applications using case studies. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

mirAct: a web tool for evaluating microRNA activity based on gene expression data. MicroRNAs (miRNAs) are critical regulators in the complex cellular networks. The mirAct web server (http://sysbio.ustc.edu.cn/software/mirAct) is a tool designed to investigate miRNA activity based on gene-expression data by using the negative regulation relationship between miRNAs and their target genes. mirAct supports multiple-class data and enables clustering analysis based on computationally determined miRNA activity. Here, we describe the framework of mirAct, demonstrate its performance by comparing with other similar programs and exemplify its applications using case studies.

[ "mirAct", ":", "a", "web", "tool", "for", "evaluating", "microRNA", "activity", "based", "on", "gene", "expression", "data", ".", "\n", "MicroRNAs", "(", "miRNAs", ")", "are", "critical", "regulators", "in", "the", "complex", "cellular", "networks", ".", "The", "mirAct", "web", "server", "(", "http://sysbio.ustc.edu.cn/software/mirAct", ")", "is", "a", "tool", "designed", "to", "investigate", "miRNA", "activity", "based", "on", "gene", "-", "expression", "data", "by", "using", "the", "negative", "regulation", "relationship", "between", "miRNAs", "and", "their", "target", "genes", ".", "mirAct", "supports", "multiple", "-", "class", "data", "and", "enables", "clustering", "analysis", "based", "on", "computationally", "determined", "miRNA", "activity", ".", "Here", ",", "we", "describe", "the", "framework", "of", "mirAct", ",", "demonstrate", "its", "performance", "by", "comparing", "with", "other", "similar", "programs", "and", "exemplify", "its", "applications", "using", "case", "studies", ".", "\n" ]

[ "Multi-tissue_structure" ]

Munc18 - 2 is a Individual_protein, Sec1 is a Individual_protein, syntaxin 3 is a Individual_protein, t - SNARE is a Protein_family_or_group

78_task0

Sentence: Munc18-2 is a Sec1 homologue enriched in epithelial cells and forms a complex with syntaxin 3, a t-SNARE localized to the apical plasma membrane. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Individual_protein, Protein_family_or_group

[ "B-Individual_protein", "I-Individual_protein", "I-Individual_protein", "O", "O", "B-Individual_protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "I-Individual_protein", "O", "O", "B-Protein_family_or_group", "I-Protein_family_or_group", "I-Protein_family_or_group", "O", "O", "O", "O", "O", "O", "O" ]

Munc18-2 is a Sec1 homologue enriched in epithelial cells and forms a complex with syntaxin 3, a t-SNARE localized to the apical plasma membrane.

[ "Munc18", "-", "2", "is", "a", "Sec1", "homologue", "enriched", "in", "epithelial", "cells", "and", "forms", "a", "complex", "with", "syntaxin", "3", ",", "a", "t", "-", "SNARE", "localized", "to", "the", "apical", "plasma", "membrane", "." ]

[ "Individual_protein", "Protein_family_or_group" ]

Munc18 - 2 is a Individual_protein, Sec1 is a Individual_protein, syntaxin 3 is a Individual_protein, t - SNARE is a Protein_family_or_group

78_task1

Sentence: Munc18-2 is a Sec1 homologue enriched in epithelial cells and forms a complex with syntaxin 3, a t-SNARE localized to the apical plasma membrane. Instructions: please typing these entity words according to sentence: Munc18 - 2, Sec1, syntaxin 3, t - SNARE Options: Individual_protein, Protein_family_or_group

[ "B-Individual_protein", "I-Individual_protein", "I-Individual_protein", "O", "O", "B-Individual_protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "I-Individual_protein", "O", "O", "B-Protein_family_or_group", "I-Protein_family_or_group", "I-Protein_family_or_group", "O", "O", "O", "O", "O", "O", "O" ]

Munc18-2 is a Sec1 homologue enriched in epithelial cells and forms a complex with syntaxin 3, a t-SNARE localized to the apical plasma membrane.

[ "Munc18", "-", "2", "is", "a", "Sec1", "homologue", "enriched", "in", "epithelial", "cells", "and", "forms", "a", "complex", "with", "syntaxin", "3", ",", "a", "t", "-", "SNARE", "localized", "to", "the", "apical", "plasma", "membrane", "." ]

[ "Individual_protein", "Protein_family_or_group" ]

Munc18 - 2, Sec1, syntaxin 3, t - SNARE

78_task2

Sentence: Munc18-2 is a Sec1 homologue enriched in epithelial cells and forms a complex with syntaxin 3, a t-SNARE localized to the apical plasma membrane. Instructions: please extract entity words from the input sentence

[ "B-Individual_protein", "I-Individual_protein", "I-Individual_protein", "O", "O", "B-Individual_protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "I-Individual_protein", "O", "O", "B-Protein_family_or_group", "I-Protein_family_or_group", "I-Protein_family_or_group", "O", "O", "O", "O", "O", "O", "O" ]

Munc18-2 is a Sec1 homologue enriched in epithelial cells and forms a complex with syntaxin 3, a t-SNARE localized to the apical plasma membrane.

[ "Munc18", "-", "2", "is", "a", "Sec1", "homologue", "enriched", "in", "epithelial", "cells", "and", "forms", "a", "complex", "with", "syntaxin", "3", ",", "a", "t", "-", "SNARE", "localized", "to", "the", "apical", "plasma", "membrane", "." ]

[ "Individual_protein", "Protein_family_or_group" ]

chicken ovalbumin upstream promoter - transcription factor II is a Gene_or_gene_product, human is a Organism, colorectal cancer is a Cancer, Chicken ovalbumin upstream promoter - transcription factor II is a Gene_or_gene_product, COUP - TFII is a Gene_or_gene_product, COUP - TFII is a Gene_or_gene_product, human is a Organism, lung carcinoma cells is a Cell, COUP - TFII is a Gene_or_gene_product, colorectal cancer is a Cancer, COUP - TFII is a Gene_or_gene_product, colorectal cancer is a Cancer, COUP - TFII is a Gene_or_gene_product, colorectal cancer is a Cancer, COUP - TFII is a Gene_or_gene_product, human is a Organism, colorectal cancer tissues is a Tissue, normal tissues is a Tissue, colorectal cancer is a Cancer, patients is a Organism, COUP - TFII is a Gene_or_gene_product, patients is a Organism, tumors is a Cancer, COUP - TFII is a Gene_or_gene_product, COUP - TFII is a Gene_or_gene_product, vessel is a Multi-tissue_structure, carcinoembryonic antigen is a Gene_or_gene_product, CEA is a Gene_or_gene_product, COUP - TFII is a Gene_or_gene_product, COUP - TFII is a Gene_or_gene_product, COUP - TFII is a Gene_or_gene_product, colorectal cancer is a Cancer

280_task0

Sentence: Clinical significance of chicken ovalbumin upstream promoter-transcription factor II expression in human colorectal cancer. Chicken ovalbumin upstream promoter-transcription factor II (COUP-TFII) plays an essential role in angiogenesis and development. A previous study showed that the expression of COUP-TFII enhanced invasiveness of human lung carcinoma cells. However, no published data are available concerning the biological and clinical significance of COUP-TFII expression in colorectal cancer. Thus, our objective was to explore the expression of COUP-TFII in colorectal cancer as well as its association with clinicopathological features, and to evaluate the role of COUP-TFII as a prognostic indicator in colorectal cancer. We investigated the presence of COUP-TFII in human colorectal cancer tissues and adjacent normal tissues from 95 primary colorectal cancer patients by immunohistochemistry. The correlation between the expression of COUP-TFII and clinicopathologic features was investigated. The 3-year disease-free survival (DFS) and overall survival (OS) of patients with tumors expressing different levels of COUP-TFII were evaluated by the Kaplan-Meier method. No significant correlation was found between COUP-TFII expression and age at surgery, gender, histopathologic differentiation, vessel invasion, carcinoembryonic antigen (CEA), or nodal involvement. However, survival analysis showed that the COUP-TFII-positive group had a significantly better OS compared to COUP-TFII-negative group (80.4% vs. 57.7%, P=0.0491). Based on our results, COUP-TFII may represent a biomarker for good prognosis in colorectal cancer. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Multi-tissue_structure, Tissue, Organism, Cancer, Gene_or_gene_product, Cell

[ "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "B-Organism", "B-Cancer", "I-Cancer", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "B-Organism", "B-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "B-Cancer", "I-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Cancer", "I-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Organism", "B-Tissue", "I-Tissue", "I-Tissue", "O", "O", "B-Tissue", "I-Tissue", "O", "O", "O", "B-Cancer", "I-Cancer", "B-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "O", "B-Cancer", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "O", "O" ]

Clinical significance of chicken ovalbumin upstream promoter-transcription factor II expression in human colorectal cancer. Chicken ovalbumin upstream promoter-transcription factor II (COUP-TFII) plays an essential role in angiogenesis and development. A previous study showed that the expression of COUP-TFII enhanced invasiveness of human lung carcinoma cells. However, no published data are available concerning the biological and clinical significance of COUP-TFII expression in colorectal cancer. Thus, our objective was to explore the expression of COUP-TFII in colorectal cancer as well as its association with clinicopathological features, and to evaluate the role of COUP-TFII as a prognostic indicator in colorectal cancer. We investigated the presence of COUP-TFII in human colorectal cancer tissues and adjacent normal tissues from 95 primary colorectal cancer patients by immunohistochemistry. The correlation between the expression of COUP-TFII and clinicopathologic features was investigated. The 3-year disease-free survival (DFS) and overall survival (OS) of patients with tumors expressing different levels of COUP-TFII were evaluated by the Kaplan-Meier method. No significant correlation was found between COUP-TFII expression and age at surgery, gender, histopathologic differentiation, vessel invasion, carcinoembryonic antigen (CEA), or nodal involvement. However, survival analysis showed that the COUP-TFII-positive group had a significantly better OS compared to COUP-TFII-negative group (80.4% vs. 57.7%, P=0.0491). Based on our results, COUP-TFII may represent a biomarker for good prognosis in colorectal cancer.

[ "Clinical", "significance", "of", "chicken", "ovalbumin", "upstream", "promoter", "-", "transcription", "factor", "II", "expression", "in", "human", "colorectal", "cancer", ".", "\n", "Chicken", "ovalbumin", "upstream", "promoter", "-", "transcription", "factor", "II", "(", "COUP", "-", "TFII", ")", "plays", "an", "essential", "role", "in", "angiogenesis", "and", "development", ".", "A", "previous", "study", "showed", "that", "the", "expression", "of", "COUP", "-", "TFII", "enhanced", "invasiveness", "of", "human", "lung", "carcinoma", "cells", ".", "However", ",", "no", "published", "data", "are", "available", "concerning", "the", "biological", "and", "clinical", "significance", "of", "COUP", "-", "TFII", "expression", "in", "colorectal", "cancer", ".", "Thus", ",", "our", "objective", "was", "to", "explore", "the", "expression", "of", "COUP", "-", "TFII", "in", "colorectal", "cancer", "as", "well", "as", "its", "association", "with", "clinicopathological", "features", ",", "and", "to", "evaluate", "the", "role", "of", "COUP", "-", "TFII", "as", "a", "prognostic", "indicator", "in", "colorectal", "cancer", ".", "We", "investigated", "the", "presence", "of", "COUP", "-", "TFII", "in", "human", "colorectal", "cancer", "tissues", "and", "adjacent", "normal", "tissues", "from", "95", "primary", "colorectal", "cancer", "patients", "by", "immunohistochemistry", ".", "The", "correlation", "between", "the", "expression", "of", "COUP", "-", "TFII", "and", "clinicopathologic", "features", "was", "investigated", ".", "The", "3-year", "disease", "-", "free", "survival", "(", "DFS", ")", "and", "overall", "survival", "(", "OS", ")", "of", "patients", "with", "tumors", "expressing", "different", "levels", "of", "COUP", "-", "TFII", "were", "evaluated", "by", "the", "Kaplan", "-", "Meier", "method", ".", "No", "significant", "correlation", "was", "found", "between", "COUP", "-", "TFII", "expression", "and", "age", "at", "surgery", ",", "gender", ",", "histopathologic", "differentiation", ",", "vessel", "invasion", ",", "carcinoembryonic", "antigen", "(", "CEA", ")", ",", "or", "nodal", "involvement", ".", "However", ",", "survival", "analysis", "showed", "that", "the", "COUP", "-", "TFII", "-", "positive", "group", "had", "a", "significantly", "better", "OS", "compared", "to", "COUP", "-", "TFII", "-", "negative", "group", "(", "80.4", "%", "vs", ".", "57.7", "%", ",", "P=0.0491", ")", ".", "Based", "on", "our", "results", ",", "COUP", "-", "TFII", "may", "represent", "a", "biomarker", "for", "good", "prognosis", "in", "colorectal", "cancer", ".", "\n" ]

[ "Gene_or_gene_product", "Tissue", "Cell", "Cancer", "Organism", "Multi-tissue_structure" ]

chicken ovalbumin upstream promoter - transcription factor II is a Gene_or_gene_product, human is a Organism, colorectal cancer is a Cancer, Chicken ovalbumin upstream promoter - transcription factor II is a Gene_or_gene_product, COUP - TFII is a Gene_or_gene_product, COUP - TFII is a Gene_or_gene_product, human is a Organism, lung carcinoma cells is a Cell, COUP - TFII is a Gene_or_gene_product, colorectal cancer is a Cancer, COUP - TFII is a Gene_or_gene_product, colorectal cancer is a Cancer, COUP - TFII is a Gene_or_gene_product, colorectal cancer is a Cancer, COUP - TFII is a Gene_or_gene_product, human is a Organism, colorectal cancer tissues is a Tissue, normal tissues is a Tissue, colorectal cancer is a Cancer, patients is a Organism, COUP - TFII is a Gene_or_gene_product, patients is a Organism, tumors is a Cancer, COUP - TFII is a Gene_or_gene_product, COUP - TFII is a Gene_or_gene_product, vessel is a Multi-tissue_structure, carcinoembryonic antigen is a Gene_or_gene_product, CEA is a Gene_or_gene_product, COUP - TFII is a Gene_or_gene_product, COUP - TFII is a Gene_or_gene_product, COUP - TFII is a Gene_or_gene_product, colorectal cancer is a Cancer

280_task1

Sentence: Clinical significance of chicken ovalbumin upstream promoter-transcription factor II expression in human colorectal cancer. Chicken ovalbumin upstream promoter-transcription factor II (COUP-TFII) plays an essential role in angiogenesis and development. A previous study showed that the expression of COUP-TFII enhanced invasiveness of human lung carcinoma cells. However, no published data are available concerning the biological and clinical significance of COUP-TFII expression in colorectal cancer. Thus, our objective was to explore the expression of COUP-TFII in colorectal cancer as well as its association with clinicopathological features, and to evaluate the role of COUP-TFII as a prognostic indicator in colorectal cancer. We investigated the presence of COUP-TFII in human colorectal cancer tissues and adjacent normal tissues from 95 primary colorectal cancer patients by immunohistochemistry. The correlation between the expression of COUP-TFII and clinicopathologic features was investigated. The 3-year disease-free survival (DFS) and overall survival (OS) of patients with tumors expressing different levels of COUP-TFII were evaluated by the Kaplan-Meier method. No significant correlation was found between COUP-TFII expression and age at surgery, gender, histopathologic differentiation, vessel invasion, carcinoembryonic antigen (CEA), or nodal involvement. However, survival analysis showed that the COUP-TFII-positive group had a significantly better OS compared to COUP-TFII-negative group (80.4% vs. 57.7%, P=0.0491). Based on our results, COUP-TFII may represent a biomarker for good prognosis in colorectal cancer. Instructions: please typing these entity words according to sentence: chicken ovalbumin upstream promoter - transcription factor II, human, colorectal cancer, Chicken ovalbumin upstream promoter - transcription factor II, COUP - TFII, COUP - TFII, human, lung carcinoma cells, COUP - TFII, colorectal cancer, COUP - TFII, colorectal cancer, COUP - TFII, colorectal cancer, COUP - TFII, human, colorectal cancer tissues, normal tissues, colorectal cancer, patients, COUP - TFII, patients, tumors, COUP - TFII, COUP - TFII, vessel, carcinoembryonic antigen, CEA, COUP - TFII, COUP - TFII, COUP - TFII, colorectal cancer Options: Multi-tissue_structure, Tissue, Organism, Cancer, Gene_or_gene_product, Cell

[ "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "B-Organism", "B-Cancer", "I-Cancer", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "B-Organism", "B-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "B-Cancer", "I-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Cancer", "I-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Organism", "B-Tissue", "I-Tissue", "I-Tissue", "O", "O", "B-Tissue", "I-Tissue", "O", "O", "O", "B-Cancer", "I-Cancer", "B-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "O", "B-Cancer", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "O", "O" ]

Clinical significance of chicken ovalbumin upstream promoter-transcription factor II expression in human colorectal cancer. Chicken ovalbumin upstream promoter-transcription factor II (COUP-TFII) plays an essential role in angiogenesis and development. A previous study showed that the expression of COUP-TFII enhanced invasiveness of human lung carcinoma cells. However, no published data are available concerning the biological and clinical significance of COUP-TFII expression in colorectal cancer. Thus, our objective was to explore the expression of COUP-TFII in colorectal cancer as well as its association with clinicopathological features, and to evaluate the role of COUP-TFII as a prognostic indicator in colorectal cancer. We investigated the presence of COUP-TFII in human colorectal cancer tissues and adjacent normal tissues from 95 primary colorectal cancer patients by immunohistochemistry. The correlation between the expression of COUP-TFII and clinicopathologic features was investigated. The 3-year disease-free survival (DFS) and overall survival (OS) of patients with tumors expressing different levels of COUP-TFII were evaluated by the Kaplan-Meier method. No significant correlation was found between COUP-TFII expression and age at surgery, gender, histopathologic differentiation, vessel invasion, carcinoembryonic antigen (CEA), or nodal involvement. However, survival analysis showed that the COUP-TFII-positive group had a significantly better OS compared to COUP-TFII-negative group (80.4% vs. 57.7%, P=0.0491). Based on our results, COUP-TFII may represent a biomarker for good prognosis in colorectal cancer.

[ "Clinical", "significance", "of", "chicken", "ovalbumin", "upstream", "promoter", "-", "transcription", "factor", "II", "expression", "in", "human", "colorectal", "cancer", ".", "\n", "Chicken", "ovalbumin", "upstream", "promoter", "-", "transcription", "factor", "II", "(", "COUP", "-", "TFII", ")", "plays", "an", "essential", "role", "in", "angiogenesis", "and", "development", ".", "A", "previous", "study", "showed", "that", "the", "expression", "of", "COUP", "-", "TFII", "enhanced", "invasiveness", "of", "human", "lung", "carcinoma", "cells", ".", "However", ",", "no", "published", "data", "are", "available", "concerning", "the", "biological", "and", "clinical", "significance", "of", "COUP", "-", "TFII", "expression", "in", "colorectal", "cancer", ".", "Thus", ",", "our", "objective", "was", "to", "explore", "the", "expression", "of", "COUP", "-", "TFII", "in", "colorectal", "cancer", "as", "well", "as", "its", "association", "with", "clinicopathological", "features", ",", "and", "to", "evaluate", "the", "role", "of", "COUP", "-", "TFII", "as", "a", "prognostic", "indicator", "in", "colorectal", "cancer", ".", "We", "investigated", "the", "presence", "of", "COUP", "-", "TFII", "in", "human", "colorectal", "cancer", "tissues", "and", "adjacent", "normal", "tissues", "from", "95", "primary", "colorectal", "cancer", "patients", "by", "immunohistochemistry", ".", "The", "correlation", "between", "the", "expression", "of", "COUP", "-", "TFII", "and", "clinicopathologic", "features", "was", "investigated", ".", "The", "3-year", "disease", "-", "free", "survival", "(", "DFS", ")", "and", "overall", "survival", "(", "OS", ")", "of", "patients", "with", "tumors", "expressing", "different", "levels", "of", "COUP", "-", "TFII", "were", "evaluated", "by", "the", "Kaplan", "-", "Meier", "method", ".", "No", "significant", "correlation", "was", "found", "between", "COUP", "-", "TFII", "expression", "and", "age", "at", "surgery", ",", "gender", ",", "histopathologic", "differentiation", ",", "vessel", "invasion", ",", "carcinoembryonic", "antigen", "(", "CEA", ")", ",", "or", "nodal", "involvement", ".", "However", ",", "survival", "analysis", "showed", "that", "the", "COUP", "-", "TFII", "-", "positive", "group", "had", "a", "significantly", "better", "OS", "compared", "to", "COUP", "-", "TFII", "-", "negative", "group", "(", "80.4", "%", "vs", ".", "57.7", "%", ",", "P=0.0491", ")", ".", "Based", "on", "our", "results", ",", "COUP", "-", "TFII", "may", "represent", "a", "biomarker", "for", "good", "prognosis", "in", "colorectal", "cancer", ".", "\n" ]

[ "Gene_or_gene_product", "Tissue", "Cell", "Cancer", "Organism", "Multi-tissue_structure" ]

chicken ovalbumin upstream promoter - transcription factor II, human, colorectal cancer, Chicken ovalbumin upstream promoter - transcription factor II, COUP - TFII, COUP - TFII, human, lung carcinoma cells, COUP - TFII, colorectal cancer, COUP - TFII, colorectal cancer, COUP - TFII, colorectal cancer, COUP - TFII, human, colorectal cancer tissues, normal tissues, colorectal cancer, patients, COUP - TFII, patients, tumors, COUP - TFII, COUP - TFII, vessel, carcinoembryonic antigen, CEA, COUP - TFII, COUP - TFII, COUP - TFII, colorectal cancer

280_task2

Sentence: Clinical significance of chicken ovalbumin upstream promoter-transcription factor II expression in human colorectal cancer. Chicken ovalbumin upstream promoter-transcription factor II (COUP-TFII) plays an essential role in angiogenesis and development. A previous study showed that the expression of COUP-TFII enhanced invasiveness of human lung carcinoma cells. However, no published data are available concerning the biological and clinical significance of COUP-TFII expression in colorectal cancer. Thus, our objective was to explore the expression of COUP-TFII in colorectal cancer as well as its association with clinicopathological features, and to evaluate the role of COUP-TFII as a prognostic indicator in colorectal cancer. We investigated the presence of COUP-TFII in human colorectal cancer tissues and adjacent normal tissues from 95 primary colorectal cancer patients by immunohistochemistry. The correlation between the expression of COUP-TFII and clinicopathologic features was investigated. The 3-year disease-free survival (DFS) and overall survival (OS) of patients with tumors expressing different levels of COUP-TFII were evaluated by the Kaplan-Meier method. No significant correlation was found between COUP-TFII expression and age at surgery, gender, histopathologic differentiation, vessel invasion, carcinoembryonic antigen (CEA), or nodal involvement. However, survival analysis showed that the COUP-TFII-positive group had a significantly better OS compared to COUP-TFII-negative group (80.4% vs. 57.7%, P=0.0491). Based on our results, COUP-TFII may represent a biomarker for good prognosis in colorectal cancer. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "B-Organism", "B-Cancer", "I-Cancer", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "B-Organism", "B-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "B-Cancer", "I-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Cancer", "I-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Organism", "B-Tissue", "I-Tissue", "I-Tissue", "O", "O", "B-Tissue", "I-Tissue", "O", "O", "O", "B-Cancer", "I-Cancer", "B-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "O", "B-Cancer", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "I-Cancer", "O", "O" ]

Clinical significance of chicken ovalbumin upstream promoter-transcription factor II expression in human colorectal cancer. Chicken ovalbumin upstream promoter-transcription factor II (COUP-TFII) plays an essential role in angiogenesis and development. A previous study showed that the expression of COUP-TFII enhanced invasiveness of human lung carcinoma cells. However, no published data are available concerning the biological and clinical significance of COUP-TFII expression in colorectal cancer. Thus, our objective was to explore the expression of COUP-TFII in colorectal cancer as well as its association with clinicopathological features, and to evaluate the role of COUP-TFII as a prognostic indicator in colorectal cancer. We investigated the presence of COUP-TFII in human colorectal cancer tissues and adjacent normal tissues from 95 primary colorectal cancer patients by immunohistochemistry. The correlation between the expression of COUP-TFII and clinicopathologic features was investigated. The 3-year disease-free survival (DFS) and overall survival (OS) of patients with tumors expressing different levels of COUP-TFII were evaluated by the Kaplan-Meier method. No significant correlation was found between COUP-TFII expression and age at surgery, gender, histopathologic differentiation, vessel invasion, carcinoembryonic antigen (CEA), or nodal involvement. However, survival analysis showed that the COUP-TFII-positive group had a significantly better OS compared to COUP-TFII-negative group (80.4% vs. 57.7%, P=0.0491). Based on our results, COUP-TFII may represent a biomarker for good prognosis in colorectal cancer.

[ "Clinical", "significance", "of", "chicken", "ovalbumin", "upstream", "promoter", "-", "transcription", "factor", "II", "expression", "in", "human", "colorectal", "cancer", ".", "\n", "Chicken", "ovalbumin", "upstream", "promoter", "-", "transcription", "factor", "II", "(", "COUP", "-", "TFII", ")", "plays", "an", "essential", "role", "in", "angiogenesis", "and", "development", ".", "A", "previous", "study", "showed", "that", "the", "expression", "of", "COUP", "-", "TFII", "enhanced", "invasiveness", "of", "human", "lung", "carcinoma", "cells", ".", "However", ",", "no", "published", "data", "are", "available", "concerning", "the", "biological", "and", "clinical", "significance", "of", "COUP", "-", "TFII", "expression", "in", "colorectal", "cancer", ".", "Thus", ",", "our", "objective", "was", "to", "explore", "the", "expression", "of", "COUP", "-", "TFII", "in", "colorectal", "cancer", "as", "well", "as", "its", "association", "with", "clinicopathological", "features", ",", "and", "to", "evaluate", "the", "role", "of", "COUP", "-", "TFII", "as", "a", "prognostic", "indicator", "in", "colorectal", "cancer", ".", "We", "investigated", "the", "presence", "of", "COUP", "-", "TFII", "in", "human", "colorectal", "cancer", "tissues", "and", "adjacent", "normal", "tissues", "from", "95", "primary", "colorectal", "cancer", "patients", "by", "immunohistochemistry", ".", "The", "correlation", "between", "the", "expression", "of", "COUP", "-", "TFII", "and", "clinicopathologic", "features", "was", "investigated", ".", "The", "3-year", "disease", "-", "free", "survival", "(", "DFS", ")", "and", "overall", "survival", "(", "OS", ")", "of", "patients", "with", "tumors", "expressing", "different", "levels", "of", "COUP", "-", "TFII", "were", "evaluated", "by", "the", "Kaplan", "-", "Meier", "method", ".", "No", "significant", "correlation", "was", "found", "between", "COUP", "-", "TFII", "expression", "and", "age", "at", "surgery", ",", "gender", ",", "histopathologic", "differentiation", ",", "vessel", "invasion", ",", "carcinoembryonic", "antigen", "(", "CEA", ")", ",", "or", "nodal", "involvement", ".", "However", ",", "survival", "analysis", "showed", "that", "the", "COUP", "-", "TFII", "-", "positive", "group", "had", "a", "significantly", "better", "OS", "compared", "to", "COUP", "-", "TFII", "-", "negative", "group", "(", "80.4", "%", "vs", ".", "57.7", "%", ",", "P=0.0491", ")", ".", "Based", "on", "our", "results", ",", "COUP", "-", "TFII", "may", "represent", "a", "biomarker", "for", "good", "prognosis", "in", "colorectal", "cancer", ".", "\n" ]

[ "Gene_or_gene_product", "Tissue", "Cell", "Cancer", "Organism", "Multi-tissue_structure" ]

Kind is an umlsterm, Hodentorsion is an umlsterm, Hydatidentorsion is an umlsterm, Oedem is an umlsterm, Haematom is an umlsterm, Haematoms is an umlsterm, Nebennierenblutung is an umlsterm, Hodentorsion is an umlsterm, Hodenfreilegung is an umlsterm, Hoden is an umlsterm, Nebennierenblutung is an umlsterm, Nebennierenblutung is an umlsterm, Nebennierenblutungen is an umlsterm, Geburtsgewicht is an umlsterm, Hypoxie is an umlsterm, Asphyxie is an umlsterm, Kindern is an umlsterm, Kindes is an umlsterm, Therapie is an umlsterm

DerUrologeA.00390048.ger.abstr_task0

Sentence: Die haeufigsten Ursachen des akuten Skrotums " " beim Kind sind Hodentorsion Hydatidentorsion , Epididymoorchitis , idiopathisches Oedem und Haematom . , Selten kann der Ursprung eines skrotalen Haematoms eine extra- oder intraperitoneale Nebennierenblutung sein . Bislang wurden 12 Faelle beschrieben . Wir berichten ueber 3 weitere Faelle , die zwischen 1992 und 1997 in unserer Klinik behandelt wurden . Im ersten Fall erfolgte bei Verdacht auf Hodentorsion die operative Hodenfreilegung , und es fand sich neben einem unauffaelligen Hoden nur blutig-seroese Fluessigkeit . Sonographisch konnte postoperativ eine ipsilaterale Nebennierenblutung nachgewiesen werden . In den uebrigen 2 Faellen wurde die Nebennierenblutung als Ursache der skrotalen Schwellung primaer erkannt und auf eine Operation verzichtet . Ursaechlich fuer Nebennierenblutungen beim Neugeborenen sind vor allem Geburtstrauma , grosses Geburtsgewicht , Hypoxie und Asphyxie . Dies war auch bei unseren Kindern der Fall . Kann die klinische Situation des Kindes beherrscht werden , so ist die vollstaendige Ausheilung unter konservativer Therapie zu erwarten . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]

Die haeufigsten Ursachen des akuten Skrotums " " beim Kind sind Hodentorsion Hydatidentorsion , Epididymoorchitis , idiopathisches Oedem und Haematom . , Selten kann der Ursprung eines skrotalen Haematoms eine extra- oder intraperitoneale Nebennierenblutung sein . Bislang wurden 12 Faelle beschrieben . Wir berichten ueber 3 weitere Faelle , die zwischen 1992 und 1997 in unserer Klinik behandelt wurden . Im ersten Fall erfolgte bei Verdacht auf Hodentorsion die operative Hodenfreilegung , und es fand sich neben einem unauffaelligen Hoden nur blutig-seroese Fluessigkeit . Sonographisch konnte postoperativ eine ipsilaterale Nebennierenblutung nachgewiesen werden . In den uebrigen 2 Faellen wurde die Nebennierenblutung als Ursache der skrotalen Schwellung primaer erkannt und auf eine Operation verzichtet . Ursaechlich fuer Nebennierenblutungen beim Neugeborenen sind vor allem Geburtstrauma , grosses Geburtsgewicht , Hypoxie und Asphyxie . Dies war auch bei unseren Kindern der Fall . Kann die klinische Situation des Kindes beherrscht werden , so ist die vollstaendige Ausheilung unter konservativer Therapie zu erwarten .

[ "Die", "haeufigsten", "Ursachen", "des", "akuten", "Skrotums", "\"", "\"", "beim", "Kind", "sind", "Hodentorsion", "Hydatidentorsion", ",", "Epididymoorchitis", ",", "idiopathisches", "Oedem", "und", "Haematom", ".", ",", "Selten", "kann", "der", "Ursprung", "eines", "skrotalen", "Haematoms", "eine", "extra-", "oder", "intraperitoneale", "Nebennierenblutung", "sein", ".", "Bislang", "wurden", "12", "Faelle", "beschrieben", ".", "Wir", "berichten", "ueber", "3", "weitere", "Faelle", ",", "die", "zwischen", "1992", "und", "1997", "in", "unserer", "Klinik", "behandelt", "wurden", ".", "Im", "ersten", "Fall", "erfolgte", "bei", "Verdacht", "auf", "Hodentorsion", "die", "operative", "Hodenfreilegung", ",", "und", "es", "fand", "sich", "neben", "einem", "unauffaelligen", "Hoden", "nur", "blutig", "-", "seroese", "Fluessigkeit", ".", "Sonographisch", "konnte", "postoperativ", "eine", "ipsilaterale", "Nebennierenblutung", "nachgewiesen", "werden", ".", "In", "den", "uebrigen", "2", "Faellen", "wurde", "die", "Nebennierenblutung", "als", "Ursache", "der", "skrotalen", "Schwellung", "primaer", "erkannt", "und", "auf", "eine", "Operation", "verzichtet", ".", "Ursaechlich", "fuer", "Nebennierenblutungen", "beim", "Neugeborenen", "sind", "vor", "allem", "Geburtstrauma", ",", "grosses", "Geburtsgewicht", ",", "Hypoxie", "und", "Asphyxie", ".", "Dies", "war", "auch", "bei", "unseren", "Kindern", "der", "Fall", ".", "Kann", "die", "klinische", "Situation", "des", "Kindes", "beherrscht", "werden", ",", "so", "ist", "die", "vollstaendige", "Ausheilung", "unter", "konservativer", "Therapie", "zu", "erwarten", "." ]

[ "umlsterm" ]

Kind is an umlsterm, Hodentorsion is an umlsterm, Hydatidentorsion is an umlsterm, Oedem is an umlsterm, Haematom is an umlsterm, Haematoms is an umlsterm, Nebennierenblutung is an umlsterm, Hodentorsion is an umlsterm, Hodenfreilegung is an umlsterm, Hoden is an umlsterm, Nebennierenblutung is an umlsterm, Nebennierenblutung is an umlsterm, Nebennierenblutungen is an umlsterm, Geburtsgewicht is an umlsterm, Hypoxie is an umlsterm, Asphyxie is an umlsterm, Kindern is an umlsterm, Kindes is an umlsterm, Therapie is an umlsterm

DerUrologeA.00390048.ger.abstr_task1

Sentence: Die haeufigsten Ursachen des akuten Skrotums " " beim Kind sind Hodentorsion Hydatidentorsion , Epididymoorchitis , idiopathisches Oedem und Haematom . , Selten kann der Ursprung eines skrotalen Haematoms eine extra- oder intraperitoneale Nebennierenblutung sein . Bislang wurden 12 Faelle beschrieben . Wir berichten ueber 3 weitere Faelle , die zwischen 1992 und 1997 in unserer Klinik behandelt wurden . Im ersten Fall erfolgte bei Verdacht auf Hodentorsion die operative Hodenfreilegung , und es fand sich neben einem unauffaelligen Hoden nur blutig-seroese Fluessigkeit . Sonographisch konnte postoperativ eine ipsilaterale Nebennierenblutung nachgewiesen werden . In den uebrigen 2 Faellen wurde die Nebennierenblutung als Ursache der skrotalen Schwellung primaer erkannt und auf eine Operation verzichtet . Ursaechlich fuer Nebennierenblutungen beim Neugeborenen sind vor allem Geburtstrauma , grosses Geburtsgewicht , Hypoxie und Asphyxie . Dies war auch bei unseren Kindern der Fall . Kann die klinische Situation des Kindes beherrscht werden , so ist die vollstaendige Ausheilung unter konservativer Therapie zu erwarten . Instructions: please typing these entity words according to sentence: Kind, Hodentorsion, Hydatidentorsion, Oedem, Haematom, Haematoms, Nebennierenblutung, Hodentorsion, Hodenfreilegung, Hoden, Nebennierenblutung, Nebennierenblutung, Nebennierenblutungen, Geburtsgewicht, Hypoxie, Asphyxie, Kindern, Kindes, Therapie Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]

Die haeufigsten Ursachen des akuten Skrotums " " beim Kind sind Hodentorsion Hydatidentorsion , Epididymoorchitis , idiopathisches Oedem und Haematom . , Selten kann der Ursprung eines skrotalen Haematoms eine extra- oder intraperitoneale Nebennierenblutung sein . Bislang wurden 12 Faelle beschrieben . Wir berichten ueber 3 weitere Faelle , die zwischen 1992 und 1997 in unserer Klinik behandelt wurden . Im ersten Fall erfolgte bei Verdacht auf Hodentorsion die operative Hodenfreilegung , und es fand sich neben einem unauffaelligen Hoden nur blutig-seroese Fluessigkeit . Sonographisch konnte postoperativ eine ipsilaterale Nebennierenblutung nachgewiesen werden . In den uebrigen 2 Faellen wurde die Nebennierenblutung als Ursache der skrotalen Schwellung primaer erkannt und auf eine Operation verzichtet . Ursaechlich fuer Nebennierenblutungen beim Neugeborenen sind vor allem Geburtstrauma , grosses Geburtsgewicht , Hypoxie und Asphyxie . Dies war auch bei unseren Kindern der Fall . Kann die klinische Situation des Kindes beherrscht werden , so ist die vollstaendige Ausheilung unter konservativer Therapie zu erwarten .

[ "Die", "haeufigsten", "Ursachen", "des", "akuten", "Skrotums", "\"", "\"", "beim", "Kind", "sind", "Hodentorsion", "Hydatidentorsion", ",", "Epididymoorchitis", ",", "idiopathisches", "Oedem", "und", "Haematom", ".", ",", "Selten", "kann", "der", "Ursprung", "eines", "skrotalen", "Haematoms", "eine", "extra-", "oder", "intraperitoneale", "Nebennierenblutung", "sein", ".", "Bislang", "wurden", "12", "Faelle", "beschrieben", ".", "Wir", "berichten", "ueber", "3", "weitere", "Faelle", ",", "die", "zwischen", "1992", "und", "1997", "in", "unserer", "Klinik", "behandelt", "wurden", ".", "Im", "ersten", "Fall", "erfolgte", "bei", "Verdacht", "auf", "Hodentorsion", "die", "operative", "Hodenfreilegung", ",", "und", "es", "fand", "sich", "neben", "einem", "unauffaelligen", "Hoden", "nur", "blutig", "-", "seroese", "Fluessigkeit", ".", "Sonographisch", "konnte", "postoperativ", "eine", "ipsilaterale", "Nebennierenblutung", "nachgewiesen", "werden", ".", "In", "den", "uebrigen", "2", "Faellen", "wurde", "die", "Nebennierenblutung", "als", "Ursache", "der", "skrotalen", "Schwellung", "primaer", "erkannt", "und", "auf", "eine", "Operation", "verzichtet", ".", "Ursaechlich", "fuer", "Nebennierenblutungen", "beim", "Neugeborenen", "sind", "vor", "allem", "Geburtstrauma", ",", "grosses", "Geburtsgewicht", ",", "Hypoxie", "und", "Asphyxie", ".", "Dies", "war", "auch", "bei", "unseren", "Kindern", "der", "Fall", ".", "Kann", "die", "klinische", "Situation", "des", "Kindes", "beherrscht", "werden", ",", "so", "ist", "die", "vollstaendige", "Ausheilung", "unter", "konservativer", "Therapie", "zu", "erwarten", "." ]

[ "umlsterm" ]

Kind, Hodentorsion, Hydatidentorsion, Oedem, Haematom, Haematoms, Nebennierenblutung, Hodentorsion, Hodenfreilegung, Hoden, Nebennierenblutung, Nebennierenblutung, Nebennierenblutungen, Geburtsgewicht, Hypoxie, Asphyxie, Kindern, Kindes, Therapie

DerUrologeA.00390048.ger.abstr_task2

Sentence: Die haeufigsten Ursachen des akuten Skrotums " " beim Kind sind Hodentorsion Hydatidentorsion , Epididymoorchitis , idiopathisches Oedem und Haematom . , Selten kann der Ursprung eines skrotalen Haematoms eine extra- oder intraperitoneale Nebennierenblutung sein . Bislang wurden 12 Faelle beschrieben . Wir berichten ueber 3 weitere Faelle , die zwischen 1992 und 1997 in unserer Klinik behandelt wurden . Im ersten Fall erfolgte bei Verdacht auf Hodentorsion die operative Hodenfreilegung , und es fand sich neben einem unauffaelligen Hoden nur blutig-seroese Fluessigkeit . Sonographisch konnte postoperativ eine ipsilaterale Nebennierenblutung nachgewiesen werden . In den uebrigen 2 Faellen wurde die Nebennierenblutung als Ursache der skrotalen Schwellung primaer erkannt und auf eine Operation verzichtet . Ursaechlich fuer Nebennierenblutungen beim Neugeborenen sind vor allem Geburtstrauma , grosses Geburtsgewicht , Hypoxie und Asphyxie . Dies war auch bei unseren Kindern der Fall . Kann die klinische Situation des Kindes beherrscht werden , so ist die vollstaendige Ausheilung unter konservativer Therapie zu erwarten . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]

Die haeufigsten Ursachen des akuten Skrotums " " beim Kind sind Hodentorsion Hydatidentorsion , Epididymoorchitis , idiopathisches Oedem und Haematom . , Selten kann der Ursprung eines skrotalen Haematoms eine extra- oder intraperitoneale Nebennierenblutung sein . Bislang wurden 12 Faelle beschrieben . Wir berichten ueber 3 weitere Faelle , die zwischen 1992 und 1997 in unserer Klinik behandelt wurden . Im ersten Fall erfolgte bei Verdacht auf Hodentorsion die operative Hodenfreilegung , und es fand sich neben einem unauffaelligen Hoden nur blutig-seroese Fluessigkeit . Sonographisch konnte postoperativ eine ipsilaterale Nebennierenblutung nachgewiesen werden . In den uebrigen 2 Faellen wurde die Nebennierenblutung als Ursache der skrotalen Schwellung primaer erkannt und auf eine Operation verzichtet . Ursaechlich fuer Nebennierenblutungen beim Neugeborenen sind vor allem Geburtstrauma , grosses Geburtsgewicht , Hypoxie und Asphyxie . Dies war auch bei unseren Kindern der Fall . Kann die klinische Situation des Kindes beherrscht werden , so ist die vollstaendige Ausheilung unter konservativer Therapie zu erwarten .

[ "Die", "haeufigsten", "Ursachen", "des", "akuten", "Skrotums", "\"", "\"", "beim", "Kind", "sind", "Hodentorsion", "Hydatidentorsion", ",", "Epididymoorchitis", ",", "idiopathisches", "Oedem", "und", "Haematom", ".", ",", "Selten", "kann", "der", "Ursprung", "eines", "skrotalen", "Haematoms", "eine", "extra-", "oder", "intraperitoneale", "Nebennierenblutung", "sein", ".", "Bislang", "wurden", "12", "Faelle", "beschrieben", ".", "Wir", "berichten", "ueber", "3", "weitere", "Faelle", ",", "die", "zwischen", "1992", "und", "1997", "in", "unserer", "Klinik", "behandelt", "wurden", ".", "Im", "ersten", "Fall", "erfolgte", "bei", "Verdacht", "auf", "Hodentorsion", "die", "operative", "Hodenfreilegung", ",", "und", "es", "fand", "sich", "neben", "einem", "unauffaelligen", "Hoden", "nur", "blutig", "-", "seroese", "Fluessigkeit", ".", "Sonographisch", "konnte", "postoperativ", "eine", "ipsilaterale", "Nebennierenblutung", "nachgewiesen", "werden", ".", "In", "den", "uebrigen", "2", "Faellen", "wurde", "die", "Nebennierenblutung", "als", "Ursache", "der", "skrotalen", "Schwellung", "primaer", "erkannt", "und", "auf", "eine", "Operation", "verzichtet", ".", "Ursaechlich", "fuer", "Nebennierenblutungen", "beim", "Neugeborenen", "sind", "vor", "allem", "Geburtstrauma", ",", "grosses", "Geburtsgewicht", ",", "Hypoxie", "und", "Asphyxie", ".", "Dies", "war", "auch", "bei", "unseren", "Kindern", "der", "Fall", ".", "Kann", "die", "klinische", "Situation", "des", "Kindes", "beherrscht", "werden", ",", "so", "ist", "die", "vollstaendige", "Ausheilung", "unter", "konservativer", "Therapie", "zu", "erwarten", "." ]

[ "umlsterm" ]

nuclear factor of activated T cells is a protein_molecule, Jurkat cell clones is a cell_line

30368_task0

Sentence: Regulation of the nuclear factor of activated T cells in stably transfected Jurkat cell clones. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: cell_line, protein_molecule

[ "O", "O", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "O", "O", "B-cell_line", "I-cell_line", "I-cell_line", "O" ]

Regulation of the nuclear factor of activated T cells in stably transfected Jurkat cell clones.

[ "Regulation", "of", "the", "nuclear", "factor", "of", "activated", "T", "cells", "in", "stably", "transfected", "Jurkat", "cell", "clones", "." ]

[ "protein_molecule", "other_organic_compound", "other_name", "cell_line", "DNA_family_or_group", "cell_type", "nucleotide" ]

nuclear factor of activated T cells is a protein_molecule, Jurkat cell clones is a cell_line

30368_task1

Sentence: Regulation of the nuclear factor of activated T cells in stably transfected Jurkat cell clones. Instructions: please typing these entity words according to sentence: nuclear factor of activated T cells, Jurkat cell clones Options: cell_line, protein_molecule

[ "O", "O", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "O", "O", "B-cell_line", "I-cell_line", "I-cell_line", "O" ]

Regulation of the nuclear factor of activated T cells in stably transfected Jurkat cell clones.

[ "Regulation", "of", "the", "nuclear", "factor", "of", "activated", "T", "cells", "in", "stably", "transfected", "Jurkat", "cell", "clones", "." ]

[ "protein_molecule", "other_organic_compound", "other_name", "cell_line", "DNA_family_or_group", "cell_type", "nucleotide" ]

nuclear factor of activated T cells, Jurkat cell clones

30368_task2

Sentence: Regulation of the nuclear factor of activated T cells in stably transfected Jurkat cell clones. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "O", "O", "B-cell_line", "I-cell_line", "I-cell_line", "O" ]

Regulation of the nuclear factor of activated T cells in stably transfected Jurkat cell clones.

[ "Regulation", "of", "the", "nuclear", "factor", "of", "activated", "T", "cells", "in", "stably", "transfected", "Jurkat", "cell", "clones", "." ]

[ "protein_molecule", "other_organic_compound", "other_name", "cell_line", "DNA_family_or_group", "cell_type", "nucleotide" ]

p65 subunit is a protein_subunit, NF - kappa B is a protein_molecule, I kappa B is a protein_molecule

81704_task0

Sentence: The p65 subunit of NF-kappa B regulates I kappa B by two distinct mechanisms. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: protein_molecule, protein_subunit

[ "O", "B-protein_subunit", "I-protein_subunit", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "O", "O", "O", "O" ]

The p65 subunit of NF-kappa B regulates I kappa B by two distinct mechanisms.

[ "The", "p65", "subunit", "of", "NF", "-", "kappa", "B", "regulates", "I", "kappa", "B", "by", "two", "distinct", "mechanisms", "." ]

[ "(AND cell_type cell_type)", "other_name", "RNA_molecule", "protein_subunit", "protein_molecule", "cell_component", "", "protein_complex" ]

p65 subunit is a protein_subunit, NF - kappa B is a protein_molecule, I kappa B is a protein_molecule

81704_task1

Sentence: The p65 subunit of NF-kappa B regulates I kappa B by two distinct mechanisms. Instructions: please typing these entity words according to sentence: p65 subunit, NF - kappa B, I kappa B Options: protein_molecule, protein_subunit

[ "O", "B-protein_subunit", "I-protein_subunit", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "O", "O", "O", "O" ]

The p65 subunit of NF-kappa B regulates I kappa B by two distinct mechanisms.

[ "The", "p65", "subunit", "of", "NF", "-", "kappa", "B", "regulates", "I", "kappa", "B", "by", "two", "distinct", "mechanisms", "." ]

[ "(AND cell_type cell_type)", "other_name", "RNA_molecule", "protein_subunit", "protein_molecule", "cell_component", "", "protein_complex" ]

p65 subunit, NF - kappa B, I kappa B

81704_task2

Sentence: The p65 subunit of NF-kappa B regulates I kappa B by two distinct mechanisms. Instructions: please extract entity words from the input sentence

[ "O", "B-protein_subunit", "I-protein_subunit", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "O", "O", "O", "O" ]

The p65 subunit of NF-kappa B regulates I kappa B by two distinct mechanisms.

[ "The", "p65", "subunit", "of", "NF", "-", "kappa", "B", "regulates", "I", "kappa", "B", "by", "two", "distinct", "mechanisms", "." ]

[ "(AND cell_type cell_type)", "other_name", "RNA_molecule", "protein_subunit", "protein_molecule", "cell_component", "", "protein_complex" ]

Dacryocystorhinostomy is an umlsterm, standard is an umlsterm, procedure is an umlsterm, stenosis is an umlsterm, nasolacrimal duct is an umlsterm, methods is an umlsterm, polyurethane is an umlsterm, stent is an umlsterm, nasolacrimal duct is an umlsterm, complications is an umlsterm, method is an umlsterm, prospective study is an umlsterm

DerOpthalmologe.90960658.eng.abstr_task0

Sentence: Dacryocystorhinostomy is still the standard procedure complete stenosis of the nasolacrimal duct . New methods try to preserve the natural lacrimal pathway . Song implanted in 1995 a nasolacrimal polyurethane stent through the nasolacrimal duct . The results and complications of this new method are described in this prospective study . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]

Dacryocystorhinostomy is still the standard procedure complete stenosis of the nasolacrimal duct . New methods try to preserve the natural lacrimal pathway . Song implanted in 1995 a nasolacrimal polyurethane stent through the nasolacrimal duct . The results and complications of this new method are described in this prospective study .

[ "Dacryocystorhinostomy", "is", "still", "the", "standard", "procedure", "complete", "stenosis", "of", "the", "nasolacrimal", "duct", ".", "New", "methods", "try", "to", "preserve", "the", "natural", "lacrimal", "pathway", ".", "Song", "implanted", "in", "1995", "a", "nasolacrimal", "polyurethane", "stent", "through", "the", "nasolacrimal", "duct", ".", "The", "results", "and", "complications", "of", "this", "new", "method", "are", "described", "in", "this", "prospective", "study", "." ]

[ "umlsterm" ]

Dacryocystorhinostomy is an umlsterm, standard is an umlsterm, procedure is an umlsterm, stenosis is an umlsterm, nasolacrimal duct is an umlsterm, methods is an umlsterm, polyurethane is an umlsterm, stent is an umlsterm, nasolacrimal duct is an umlsterm, complications is an umlsterm, method is an umlsterm, prospective study is an umlsterm

DerOpthalmologe.90960658.eng.abstr_task1

Sentence: Dacryocystorhinostomy is still the standard procedure complete stenosis of the nasolacrimal duct . New methods try to preserve the natural lacrimal pathway . Song implanted in 1995 a nasolacrimal polyurethane stent through the nasolacrimal duct . The results and complications of this new method are described in this prospective study . Instructions: please typing these entity words according to sentence: Dacryocystorhinostomy, standard, procedure, stenosis, nasolacrimal duct, methods, polyurethane, stent, nasolacrimal duct, complications, method, prospective study Options: umlsterm

[ "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]

Dacryocystorhinostomy is still the standard procedure complete stenosis of the nasolacrimal duct . New methods try to preserve the natural lacrimal pathway . Song implanted in 1995 a nasolacrimal polyurethane stent through the nasolacrimal duct . The results and complications of this new method are described in this prospective study .

[ "Dacryocystorhinostomy", "is", "still", "the", "standard", "procedure", "complete", "stenosis", "of", "the", "nasolacrimal", "duct", ".", "New", "methods", "try", "to", "preserve", "the", "natural", "lacrimal", "pathway", ".", "Song", "implanted", "in", "1995", "a", "nasolacrimal", "polyurethane", "stent", "through", "the", "nasolacrimal", "duct", ".", "The", "results", "and", "complications", "of", "this", "new", "method", "are", "described", "in", "this", "prospective", "study", "." ]

[ "umlsterm" ]

Dacryocystorhinostomy, standard, procedure, stenosis, nasolacrimal duct, methods, polyurethane, stent, nasolacrimal duct, complications, method, prospective study

DerOpthalmologe.90960658.eng.abstr_task2

Sentence: Dacryocystorhinostomy is still the standard procedure complete stenosis of the nasolacrimal duct . New methods try to preserve the natural lacrimal pathway . Song implanted in 1995 a nasolacrimal polyurethane stent through the nasolacrimal duct . The results and complications of this new method are described in this prospective study . Instructions: please extract entity words from the input sentence

[ "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]

Dacryocystorhinostomy is still the standard procedure complete stenosis of the nasolacrimal duct . New methods try to preserve the natural lacrimal pathway . Song implanted in 1995 a nasolacrimal polyurethane stent through the nasolacrimal duct . The results and complications of this new method are described in this prospective study .

[ "Dacryocystorhinostomy", "is", "still", "the", "standard", "procedure", "complete", "stenosis", "of", "the", "nasolacrimal", "duct", ".", "New", "methods", "try", "to", "preserve", "the", "natural", "lacrimal", "pathway", ".", "Song", "implanted", "in", "1995", "a", "nasolacrimal", "polyurethane", "stent", "through", "the", "nasolacrimal", "duct", ".", "The", "results", "and", "complications", "of", "this", "new", "method", "are", "described", "in", "this", "prospective", "study", "." ]

[ "umlsterm" ]

paricalcitol is a CHEMICAL, doxercalciferol is a CHEMICAL

20204178_task0

Sentence: Comparison of the pharmacological effects of paricalcitol and doxercalciferol on the factors involved in mineral homeostasis. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: CHEMICAL

[ "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O" ]

Comparison of the pharmacological effects of paricalcitol and doxercalciferol on the factors involved in mineral homeostasis.

[ "Comparison", "of", "the", "pharmacological", "effects", "of", "paricalcitol", "and", "doxercalciferol", "on", "the", "factors", "involved", "in", "mineral", "homeostasis", "." ]

[ "GENE-Y", "CHEMICAL", "GENE-N" ]

paricalcitol is a CHEMICAL, doxercalciferol is a CHEMICAL

20204178_task1

Sentence: Comparison of the pharmacological effects of paricalcitol and doxercalciferol on the factors involved in mineral homeostasis. Instructions: please typing these entity words according to sentence: paricalcitol, doxercalciferol Options: CHEMICAL

[ "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O" ]

Comparison of the pharmacological effects of paricalcitol and doxercalciferol on the factors involved in mineral homeostasis.

[ "Comparison", "of", "the", "pharmacological", "effects", "of", "paricalcitol", "and", "doxercalciferol", "on", "the", "factors", "involved", "in", "mineral", "homeostasis", "." ]

[ "GENE-Y", "CHEMICAL", "GENE-N" ]

paricalcitol, doxercalciferol

20204178_task2

Sentence: Comparison of the pharmacological effects of paricalcitol and doxercalciferol on the factors involved in mineral homeostasis. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O" ]

Comparison of the pharmacological effects of paricalcitol and doxercalciferol on the factors involved in mineral homeostasis.

[ "Comparison", "of", "the", "pharmacological", "effects", "of", "paricalcitol", "and", "doxercalciferol", "on", "the", "factors", "involved", "in", "mineral", "homeostasis", "." ]

[ "GENE-Y", "CHEMICAL", "GENE-N" ]

Arg is an amino-acid, F - actin is a protein

1.0alpha7.train.1151_task0

Sentence: The convex shape of the Scatchard plot indicated that Arg binds to F-actin with positive cooperativity (Fig. 1 G; ref. 19). Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: amino-acid, protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-amino-acid", "O", "O", "O", "B-protein", "I-protein", "I-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

The convex shape of the Scatchard plot indicated that Arg binds to F-actin with positive cooperativity (Fig. 1 G; ref. 19).

[ "The", "convex", "shape", "of", "the", "Scatchard", "plot", "indicated", "that", " ", "Arg", "binds", "to", " ", "F", "-", "actin", "with", "positive", "cooperativity", "(", "Fig", ".", " ", "1", "G", ";", "ref", ".", " ", "19", ")", "." ]

[ "protein", "protein-family", "amino-acid" ]

Arg is an amino-acid, F - actin is a protein

1.0alpha7.train.1151_task1

Sentence: The convex shape of the Scatchard plot indicated that Arg binds to F-actin with positive cooperativity (Fig. 1 G; ref. 19). Instructions: please typing these entity words according to sentence: Arg, F - actin Options: amino-acid, protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-amino-acid", "O", "O", "O", "B-protein", "I-protein", "I-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

The convex shape of the Scatchard plot indicated that Arg binds to F-actin with positive cooperativity (Fig. 1 G; ref. 19).

[ "The", "convex", "shape", "of", "the", "Scatchard", "plot", "indicated", "that", " ", "Arg", "binds", "to", " ", "F", "-", "actin", "with", "positive", "cooperativity", "(", "Fig", ".", " ", "1", "G", ";", "ref", ".", " ", "19", ")", "." ]

[ "protein", "protein-family", "amino-acid" ]

Arg, F - actin

1.0alpha7.train.1151_task2

Sentence: The convex shape of the Scatchard plot indicated that Arg binds to F-actin with positive cooperativity (Fig. 1 G; ref. 19). Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-amino-acid", "O", "O", "O", "B-protein", "I-protein", "I-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

The convex shape of the Scatchard plot indicated that Arg binds to F-actin with positive cooperativity (Fig. 1 G; ref. 19).

[ "The", "convex", "shape", "of", "the", "Scatchard", "plot", "indicated", "that", " ", "Arg", "binds", "to", " ", "F", "-", "actin", "with", "positive", "cooperativity", "(", "Fig", ".", " ", "1", "G", ";", "ref", ".", " ", "19", ")", "." ]

[ "protein", "protein-family", "amino-acid" ]

AT1 is a GENE-Y, eprosartan is a CHEMICAL

12927226_task0

Sentence: AT1 antagonism by eprosartan lowers heart rate variability and baroreflex gain. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y, CHEMICAL

[ "B-GENE-Y", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O" ]

AT1 antagonism by eprosartan lowers heart rate variability and baroreflex gain.

[ "AT1", "antagonism", "by", "eprosartan", "lowers", "heart", "rate", "variability", "and", "baroreflex", "gain", "." ]

[ "GENE-Y", "CHEMICAL" ]

AT1 is a GENE-Y, eprosartan is a CHEMICAL

12927226_task1

Sentence: AT1 antagonism by eprosartan lowers heart rate variability and baroreflex gain. Instructions: please typing these entity words according to sentence: AT1, eprosartan Options: GENE-Y, CHEMICAL

[ "B-GENE-Y", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O" ]

AT1 antagonism by eprosartan lowers heart rate variability and baroreflex gain.

[ "AT1", "antagonism", "by", "eprosartan", "lowers", "heart", "rate", "variability", "and", "baroreflex", "gain", "." ]

[ "GENE-Y", "CHEMICAL" ]

AT1, eprosartan

12927226_task2

Sentence: AT1 antagonism by eprosartan lowers heart rate variability and baroreflex gain. Instructions: please extract entity words from the input sentence

[ "B-GENE-Y", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O" ]

AT1 antagonism by eprosartan lowers heart rate variability and baroreflex gain.

[ "AT1", "antagonism", "by", "eprosartan", "lowers", "heart", "rate", "variability", "and", "baroreflex", "gain", "." ]

[ "GENE-Y", "CHEMICAL" ]

aim is an umlsterm, paper is an umlsterm, attention is an umlsterm, short - term psychotherapy is an umlsterm, rehabilitative is an umlsterm, treatment is an umlsterm, training is an umlsterm, method is an umlsterm, psychotherapy is an umlsterm, therapeutic process is an umlsterm, orientation is an umlsterm, therapy is an umlsterm, treatment is an umlsterm

Psychotherapeut.90440020.eng.abstr_task0

Sentence: It is the aim of this paper to draw attention to the problems of short-term psychotherapy in rehabilitative psychosomatical treatment with high demands in a professional training situation . It shows how the focal method of psychotherapy can help in this situation . The focus sets limits on the therapeutic process and as a central theme it provides orientation in therapy . It also provides for a better structure in treatment and is useful for the cooperation of the team and its integration , too . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

It is the aim of this paper to draw attention to the problems of short-term psychotherapy in rehabilitative psychosomatical treatment with high demands in a professional training situation . It shows how the focal method of psychotherapy can help in this situation . The focus sets limits on the therapeutic process and as a central theme it provides orientation in therapy . It also provides for a better structure in treatment and is useful for the cooperation of the team and its integration , too .

[ "It", "is", "the", "aim", "of", "this", "paper", "to", "draw", "attention", "to", "the", "problems", "of", "short", "-", "term", "psychotherapy", "in", "rehabilitative", "psychosomatical", "treatment", "with", "high", "demands", "in", "a", "professional", "training", "situation", ".", "It", "shows", "how", "the", "focal", "method", "of", "psychotherapy", "can", "help", "in", "this", "situation", ".", "The", "focus", "sets", "limits", "on", "the", "therapeutic", "process", "and", "as", "a", "central", "theme", "it", "provides", "orientation", "in", "therapy", ".", "It", "also", "provides", "for", "a", "better", "structure", "in", "treatment", "and", "is", "useful", "for", "the", "cooperation", "of", "the", "team", "and", "its", "integration", ",", "too", "." ]

[ "umlsterm" ]

aim is an umlsterm, paper is an umlsterm, attention is an umlsterm, short - term psychotherapy is an umlsterm, rehabilitative is an umlsterm, treatment is an umlsterm, training is an umlsterm, method is an umlsterm, psychotherapy is an umlsterm, therapeutic process is an umlsterm, orientation is an umlsterm, therapy is an umlsterm, treatment is an umlsterm

Psychotherapeut.90440020.eng.abstr_task1

Sentence: It is the aim of this paper to draw attention to the problems of short-term psychotherapy in rehabilitative psychosomatical treatment with high demands in a professional training situation . It shows how the focal method of psychotherapy can help in this situation . The focus sets limits on the therapeutic process and as a central theme it provides orientation in therapy . It also provides for a better structure in treatment and is useful for the cooperation of the team and its integration , too . Instructions: please typing these entity words according to sentence: aim, paper, attention, short - term psychotherapy, rehabilitative, treatment, training, method, psychotherapy, therapeutic process, orientation, therapy, treatment Options: umlsterm

[ "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

It is the aim of this paper to draw attention to the problems of short-term psychotherapy in rehabilitative psychosomatical treatment with high demands in a professional training situation . It shows how the focal method of psychotherapy can help in this situation . The focus sets limits on the therapeutic process and as a central theme it provides orientation in therapy . It also provides for a better structure in treatment and is useful for the cooperation of the team and its integration , too .

[ "It", "is", "the", "aim", "of", "this", "paper", "to", "draw", "attention", "to", "the", "problems", "of", "short", "-", "term", "psychotherapy", "in", "rehabilitative", "psychosomatical", "treatment", "with", "high", "demands", "in", "a", "professional", "training", "situation", ".", "It", "shows", "how", "the", "focal", "method", "of", "psychotherapy", "can", "help", "in", "this", "situation", ".", "The", "focus", "sets", "limits", "on", "the", "therapeutic", "process", "and", "as", "a", "central", "theme", "it", "provides", "orientation", "in", "therapy", ".", "It", "also", "provides", "for", "a", "better", "structure", "in", "treatment", "and", "is", "useful", "for", "the", "cooperation", "of", "the", "team", "and", "its", "integration", ",", "too", "." ]

[ "umlsterm" ]

aim, paper, attention, short - term psychotherapy, rehabilitative, treatment, training, method, psychotherapy, therapeutic process, orientation, therapy, treatment

Psychotherapeut.90440020.eng.abstr_task2

Sentence: It is the aim of this paper to draw attention to the problems of short-term psychotherapy in rehabilitative psychosomatical treatment with high demands in a professional training situation . It shows how the focal method of psychotherapy can help in this situation . The focus sets limits on the therapeutic process and as a central theme it provides orientation in therapy . It also provides for a better structure in treatment and is useful for the cooperation of the team and its integration , too . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

It is the aim of this paper to draw attention to the problems of short-term psychotherapy in rehabilitative psychosomatical treatment with high demands in a professional training situation . It shows how the focal method of psychotherapy can help in this situation . The focus sets limits on the therapeutic process and as a central theme it provides orientation in therapy . It also provides for a better structure in treatment and is useful for the cooperation of the team and its integration , too .

[ "It", "is", "the", "aim", "of", "this", "paper", "to", "draw", "attention", "to", "the", "problems", "of", "short", "-", "term", "psychotherapy", "in", "rehabilitative", "psychosomatical", "treatment", "with", "high", "demands", "in", "a", "professional", "training", "situation", ".", "It", "shows", "how", "the", "focal", "method", "of", "psychotherapy", "can", "help", "in", "this", "situation", ".", "The", "focus", "sets", "limits", "on", "the", "therapeutic", "process", "and", "as", "a", "central", "theme", "it", "provides", "orientation", "in", "therapy", ".", "It", "also", "provides", "for", "a", "better", "structure", "in", "treatment", "and", "is", "useful", "for", "the", "cooperation", "of", "the", "team", "and", "its", "integration", ",", "too", "." ]

[ "umlsterm" ]

chirurgischen Fachgebiete is an umlsterm, Gefaess - Medizin is an umlsterm, Praxis is an umlsterm, Literatur is an umlsterm, Chirurgie is an umlsterm

Gefaesschirurgie.80030132.ger.abstr_task0

Sentence: Die Gefaesschirurgie ist immer noch eines der wenigen chirurgischen Fachgebiete , fuer das es kein begleitendes medizinisches Spezialgebiet gibt . Ich erkenne durchaus an , dass die Gefaess-Medizin " " an Bedeutung gewinnt , dennoch ist sie fast ausschliesslich forschungsorientiert und zahlenmaessig begrenzt . Bis heute ist ihre Anwendung in der Praxis gering . Deshalb muss der Gefaesschirurg vertraut sein mit der zahlreichen Literatur zum gesamten Gefaesssystem und darf sich unter keinen Umstaenden auf die rein technischen Aspekte der Chirurgie beschraenken . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]

Die Gefaesschirurgie ist immer noch eines der wenigen chirurgischen Fachgebiete , fuer das es kein begleitendes medizinisches Spezialgebiet gibt . Ich erkenne durchaus an , dass die Gefaess-Medizin " " an Bedeutung gewinnt , dennoch ist sie fast ausschliesslich forschungsorientiert und zahlenmaessig begrenzt . Bis heute ist ihre Anwendung in der Praxis gering . Deshalb muss der Gefaesschirurg vertraut sein mit der zahlreichen Literatur zum gesamten Gefaesssystem und darf sich unter keinen Umstaenden auf die rein technischen Aspekte der Chirurgie beschraenken .

[ "Die", "Gefaesschirurgie", "ist", "immer", "noch", "eines", "der", "wenigen", "chirurgischen", "Fachgebiete", ",", "fuer", "das", "es", "kein", "begleitendes", "medizinisches", "Spezialgebiet", "gibt", ".", "Ich", "erkenne", "durchaus", "an", ",", "dass", "die", "Gefaess", "-", "Medizin", "\"", "\"", "an", "Bedeutung", "gewinnt", ",", "dennoch", "ist", "sie", "fast", "ausschliesslich", "forschungsorientiert", "und", "zahlenmaessig", "begrenzt", ".", "Bis", "heute", "ist", "ihre", "Anwendung", "in", "der", "Praxis", "gering", ".", "Deshalb", "muss", "der", "Gefaesschirurg", "vertraut", "sein", "mit", "der", "zahlreichen", "Literatur", "zum", "gesamten", "Gefaesssystem", "und", "darf", "sich", "unter", "keinen", "Umstaenden", "auf", "die", "rein", "technischen", "Aspekte", "der", "Chirurgie", "beschraenken", "." ]

[ "umlsterm" ]

chirurgischen Fachgebiete is an umlsterm, Gefaess - Medizin is an umlsterm, Praxis is an umlsterm, Literatur is an umlsterm, Chirurgie is an umlsterm

Gefaesschirurgie.80030132.ger.abstr_task1

Sentence: Die Gefaesschirurgie ist immer noch eines der wenigen chirurgischen Fachgebiete , fuer das es kein begleitendes medizinisches Spezialgebiet gibt . Ich erkenne durchaus an , dass die Gefaess-Medizin " " an Bedeutung gewinnt , dennoch ist sie fast ausschliesslich forschungsorientiert und zahlenmaessig begrenzt . Bis heute ist ihre Anwendung in der Praxis gering . Deshalb muss der Gefaesschirurg vertraut sein mit der zahlreichen Literatur zum gesamten Gefaesssystem und darf sich unter keinen Umstaenden auf die rein technischen Aspekte der Chirurgie beschraenken . Instructions: please typing these entity words according to sentence: chirurgischen Fachgebiete, Gefaess - Medizin, Praxis, Literatur, Chirurgie Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]

Die Gefaesschirurgie ist immer noch eines der wenigen chirurgischen Fachgebiete , fuer das es kein begleitendes medizinisches Spezialgebiet gibt . Ich erkenne durchaus an , dass die Gefaess-Medizin " " an Bedeutung gewinnt , dennoch ist sie fast ausschliesslich forschungsorientiert und zahlenmaessig begrenzt . Bis heute ist ihre Anwendung in der Praxis gering . Deshalb muss der Gefaesschirurg vertraut sein mit der zahlreichen Literatur zum gesamten Gefaesssystem und darf sich unter keinen Umstaenden auf die rein technischen Aspekte der Chirurgie beschraenken .

[ "Die", "Gefaesschirurgie", "ist", "immer", "noch", "eines", "der", "wenigen", "chirurgischen", "Fachgebiete", ",", "fuer", "das", "es", "kein", "begleitendes", "medizinisches", "Spezialgebiet", "gibt", ".", "Ich", "erkenne", "durchaus", "an", ",", "dass", "die", "Gefaess", "-", "Medizin", "\"", "\"", "an", "Bedeutung", "gewinnt", ",", "dennoch", "ist", "sie", "fast", "ausschliesslich", "forschungsorientiert", "und", "zahlenmaessig", "begrenzt", ".", "Bis", "heute", "ist", "ihre", "Anwendung", "in", "der", "Praxis", "gering", ".", "Deshalb", "muss", "der", "Gefaesschirurg", "vertraut", "sein", "mit", "der", "zahlreichen", "Literatur", "zum", "gesamten", "Gefaesssystem", "und", "darf", "sich", "unter", "keinen", "Umstaenden", "auf", "die", "rein", "technischen", "Aspekte", "der", "Chirurgie", "beschraenken", "." ]

[ "umlsterm" ]

chirurgischen Fachgebiete, Gefaess - Medizin, Praxis, Literatur, Chirurgie

Gefaesschirurgie.80030132.ger.abstr_task2

Sentence: Die Gefaesschirurgie ist immer noch eines der wenigen chirurgischen Fachgebiete , fuer das es kein begleitendes medizinisches Spezialgebiet gibt . Ich erkenne durchaus an , dass die Gefaess-Medizin " " an Bedeutung gewinnt , dennoch ist sie fast ausschliesslich forschungsorientiert und zahlenmaessig begrenzt . Bis heute ist ihre Anwendung in der Praxis gering . Deshalb muss der Gefaesschirurg vertraut sein mit der zahlreichen Literatur zum gesamten Gefaesssystem und darf sich unter keinen Umstaenden auf die rein technischen Aspekte der Chirurgie beschraenken . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]

Die Gefaesschirurgie ist immer noch eines der wenigen chirurgischen Fachgebiete , fuer das es kein begleitendes medizinisches Spezialgebiet gibt . Ich erkenne durchaus an , dass die Gefaess-Medizin " " an Bedeutung gewinnt , dennoch ist sie fast ausschliesslich forschungsorientiert und zahlenmaessig begrenzt . Bis heute ist ihre Anwendung in der Praxis gering . Deshalb muss der Gefaesschirurg vertraut sein mit der zahlreichen Literatur zum gesamten Gefaesssystem und darf sich unter keinen Umstaenden auf die rein technischen Aspekte der Chirurgie beschraenken .

[ "Die", "Gefaesschirurgie", "ist", "immer", "noch", "eines", "der", "wenigen", "chirurgischen", "Fachgebiete", ",", "fuer", "das", "es", "kein", "begleitendes", "medizinisches", "Spezialgebiet", "gibt", ".", "Ich", "erkenne", "durchaus", "an", ",", "dass", "die", "Gefaess", "-", "Medizin", "\"", "\"", "an", "Bedeutung", "gewinnt", ",", "dennoch", "ist", "sie", "fast", "ausschliesslich", "forschungsorientiert", "und", "zahlenmaessig", "begrenzt", ".", "Bis", "heute", "ist", "ihre", "Anwendung", "in", "der", "Praxis", "gering", ".", "Deshalb", "muss", "der", "Gefaesschirurg", "vertraut", "sein", "mit", "der", "zahlreichen", "Literatur", "zum", "gesamten", "Gefaesssystem", "und", "darf", "sich", "unter", "keinen", "Umstaenden", "auf", "die", "rein", "technischen", "Aspekte", "der", "Chirurgie", "beschraenken", "." ]

[ "umlsterm" ]

Pathophysiologie is an umlsterm, Fibromyalgie is an umlsterm, Fibromyalgie is an umlsterm, Konzentration is an umlsterm, Urin is an umlsterm, Patienten is an umlsterm, Methoden is an umlsterm, Patienten is an umlsterm, Fibromyalgie is an umlsterm, Urin- is an umlsterm, knochenumbaudeterminierende is an umlsterm, Marker is an umlsterm, Kollagenstoffwechsels is an umlsterm, HPLC is an umlsterm, Hydroxyprolinspiegel is an umlsterm, Marker is an umlsterm, Urin is an umlsterm, Urin is an umlsterm, Ausbildung is an umlsterm, Kollagenablagerungen is an umlsterm, Nervenfasern is an umlsterm, Haut is an umlsterm, Schmerzschwelle is an umlsterm, Analyse is an umlsterm, Urin is an umlsterm, Fibromyalgie is an umlsterm

ZfuerRheumatologie.8057s052.ger.abstr_task0

Sentence: Einleitung : Das Fehlen von Daten zur Pathophysiologie der Fibromyalgie sowie von kranheitsspezifischen Laborparametern bereitet Schwierigkeiten , die Erkrankung als Entitaet anzuerkennen . Auf der Suche nach charakteristischen Merkmalen der Fibromyalgie bestimmten wir die Konzentration der Kollagen-Crosslinks im Urin und im Serum der Patienten . Methoden : Die Patienten mit Fibromyalgie wurden entsprechend den American College of Rheumatology-Klassifikationskriterien in die Studie eingeschlossen . Von 39 Fibromyalgie-Patienten und von 55 gesunden Kontrollpersonen wurden unter standardisierten Bedingungen Urin- und Serumproben genommen . Pyridinolin Pyd ) und Desoxypyridinolin ( ( Dpyd ) , lysyloxidasevermittelte Produkte und bindegewebs- und knochenumbaudeterminierende Marker des Kollagenstoffwechsels , wurden mittels HPLC detektiert . Hydroxyprolinspiegel ( Hyp ) , ein Marker des Kollagen-Turnover , wurden ebenfalls gemessen . Die Ergebnisse wurden auf den Kreatininspiegel normiert und der Pyd/Dpyd-Quotient gebildet . Ergebnisse : Die Pyd/Dpyd-Ratio in Urin und Serum und der Hyp-Spiegel im Urin waren bei den Fibromyalgie-Patienten im Vergleich zu den Kontrollpersonen signifikant vermindert . Schlussfolgerung : Die gefundenen , verminderten Kollagen-Crosslinks-Spiegel sind moeglicherweise auf ein Remodelling der extrazellulaeren Matrix und der Ausbildung von Kollagenablagerungen um preterminale Nervenfasern in der Haut von Fibromyalgie-Patienten ( abgesenkte Schmerzschwelle ? ) zurueckzufuehren . Die Analyse eines gestoerten Kollagenmetabolismus durch histologische Untersuchungen oder , besser , durch HPLC-Analyse der Kollagen-Crosslinks im Urin oder Serum kann moeglicherweise zum weiteren Verstaendnis der Pathogenese der Fibromyalgie beitragen . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]

Einleitung : Das Fehlen von Daten zur Pathophysiologie der Fibromyalgie sowie von kranheitsspezifischen Laborparametern bereitet Schwierigkeiten , die Erkrankung als Entitaet anzuerkennen . Auf der Suche nach charakteristischen Merkmalen der Fibromyalgie bestimmten wir die Konzentration der Kollagen-Crosslinks im Urin und im Serum der Patienten . Methoden : Die Patienten mit Fibromyalgie wurden entsprechend den American College of Rheumatology-Klassifikationskriterien in die Studie eingeschlossen . Von 39 Fibromyalgie-Patienten und von 55 gesunden Kontrollpersonen wurden unter standardisierten Bedingungen Urin- und Serumproben genommen . Pyridinolin Pyd ) und Desoxypyridinolin ( ( Dpyd ) , lysyloxidasevermittelte Produkte und bindegewebs- und knochenumbaudeterminierende Marker des Kollagenstoffwechsels , wurden mittels HPLC detektiert . Hydroxyprolinspiegel ( Hyp ) , ein Marker des Kollagen-Turnover , wurden ebenfalls gemessen . Die Ergebnisse wurden auf den Kreatininspiegel normiert und der Pyd/Dpyd-Quotient gebildet . Ergebnisse : Die Pyd/Dpyd-Ratio in Urin und Serum und der Hyp-Spiegel im Urin waren bei den Fibromyalgie-Patienten im Vergleich zu den Kontrollpersonen signifikant vermindert . Schlussfolgerung : Die gefundenen , verminderten Kollagen-Crosslinks-Spiegel sind moeglicherweise auf ein Remodelling der extrazellulaeren Matrix und der Ausbildung von Kollagenablagerungen um preterminale Nervenfasern in der Haut von Fibromyalgie-Patienten ( abgesenkte Schmerzschwelle ? ) zurueckzufuehren . Die Analyse eines gestoerten Kollagenmetabolismus durch histologische Untersuchungen oder , besser , durch HPLC-Analyse der Kollagen-Crosslinks im Urin oder Serum kann moeglicherweise zum weiteren Verstaendnis der Pathogenese der Fibromyalgie beitragen .

[ "Einleitung", ":", "Das", "Fehlen", "von", "Daten", "zur", "Pathophysiologie", "der", "Fibromyalgie", "sowie", "von", "kranheitsspezifischen", "Laborparametern", "bereitet", "Schwierigkeiten", ",", "die", "Erkrankung", "als", "Entitaet", "anzuerkennen", ".", "Auf", "der", "Suche", "nach", "charakteristischen", "Merkmalen", "der", "Fibromyalgie", "bestimmten", "wir", "die", "Konzentration", "der", "Kollagen", "-", "Crosslinks", "im", "Urin", "und", "im", "Serum", "der", "Patienten", ".", "Methoden", ":", "Die", "Patienten", "mit", "Fibromyalgie", "wurden", "entsprechend", "den", "American", "College", "of", "Rheumatology", "-", "Klassifikationskriterien", "in", "die", "Studie", "eingeschlossen", ".", "Von", "39", "Fibromyalgie", "-", "Patienten", "und", "von", "55", "gesunden", "Kontrollpersonen", "wurden", "unter", "standardisierten", "Bedingungen", "Urin-", "und", "Serumproben", "genommen", ".", "Pyridinolin", "Pyd", ")", "und", "Desoxypyridinolin", "(", "(", "Dpyd", ")", ",", "lysyloxidasevermittelte", "Produkte", "und", "bindegewebs-", "und", "knochenumbaudeterminierende", "Marker", "des", "Kollagenstoffwechsels", ",", "wurden", "mittels", "HPLC", "detektiert", ".", "Hydroxyprolinspiegel", "(", "Hyp", ")", ",", "ein", "Marker", "des", "Kollagen", "-", "Turnover", ",", "wurden", "ebenfalls", "gemessen", ".", "Die", "Ergebnisse", "wurden", "auf", "den", "Kreatininspiegel", "normiert", "und", "der", "Pyd", "/", "Dpyd", "-", "Quotient", "gebildet", ".", "Ergebnisse", ":", "Die", "Pyd", "/", "Dpyd", "-", "Ratio", "in", "Urin", "und", "Serum", "und", "der", "Hyp", "-", "Spiegel", "im", "Urin", "waren", "bei", "den", "Fibromyalgie", "-", "Patienten", "im", "Vergleich", "zu", "den", "Kontrollpersonen", "signifikant", "vermindert", ".", "Schlussfolgerung", ":", "Die", "gefundenen", ",", "verminderten", "Kollagen", "-", "Crosslinks", "-", "Spiegel", "sind", "moeglicherweise", "auf", "ein", "Remodelling", "der", "extrazellulaeren", "Matrix", "und", "der", "Ausbildung", "von", "Kollagenablagerungen", "um", "preterminale", "Nervenfasern", "in", "der", "Haut", "von", "Fibromyalgie", "-", "Patienten", "(", "abgesenkte", "Schmerzschwelle", "?", ")", "zurueckzufuehren", ".", "Die", "Analyse", "eines", "gestoerten", "Kollagenmetabolismus", "durch", "histologische", "Untersuchungen", "oder", ",", "besser", ",", "durch", "HPLC", "-", "Analyse", "der", "Kollagen", "-", "Crosslinks", "im", "Urin", "oder", "Serum", "kann", "moeglicherweise", "zum", "weiteren", "Verstaendnis", "der", "Pathogenese", "der", "Fibromyalgie", "beitragen", "." ]

[ "umlsterm" ]

Pathophysiologie is an umlsterm, Fibromyalgie is an umlsterm, Fibromyalgie is an umlsterm, Konzentration is an umlsterm, Urin is an umlsterm, Patienten is an umlsterm, Methoden is an umlsterm, Patienten is an umlsterm, Fibromyalgie is an umlsterm, Urin- is an umlsterm, knochenumbaudeterminierende is an umlsterm, Marker is an umlsterm, Kollagenstoffwechsels is an umlsterm, HPLC is an umlsterm, Hydroxyprolinspiegel is an umlsterm, Marker is an umlsterm, Urin is an umlsterm, Urin is an umlsterm, Ausbildung is an umlsterm, Kollagenablagerungen is an umlsterm, Nervenfasern is an umlsterm, Haut is an umlsterm, Schmerzschwelle is an umlsterm, Analyse is an umlsterm, Urin is an umlsterm, Fibromyalgie is an umlsterm

ZfuerRheumatologie.8057s052.ger.abstr_task1

Sentence: Einleitung : Das Fehlen von Daten zur Pathophysiologie der Fibromyalgie sowie von kranheitsspezifischen Laborparametern bereitet Schwierigkeiten , die Erkrankung als Entitaet anzuerkennen . Auf der Suche nach charakteristischen Merkmalen der Fibromyalgie bestimmten wir die Konzentration der Kollagen-Crosslinks im Urin und im Serum der Patienten . Methoden : Die Patienten mit Fibromyalgie wurden entsprechend den American College of Rheumatology-Klassifikationskriterien in die Studie eingeschlossen . Von 39 Fibromyalgie-Patienten und von 55 gesunden Kontrollpersonen wurden unter standardisierten Bedingungen Urin- und Serumproben genommen . Pyridinolin Pyd ) und Desoxypyridinolin ( ( Dpyd ) , lysyloxidasevermittelte Produkte und bindegewebs- und knochenumbaudeterminierende Marker des Kollagenstoffwechsels , wurden mittels HPLC detektiert . Hydroxyprolinspiegel ( Hyp ) , ein Marker des Kollagen-Turnover , wurden ebenfalls gemessen . Die Ergebnisse wurden auf den Kreatininspiegel normiert und der Pyd/Dpyd-Quotient gebildet . Ergebnisse : Die Pyd/Dpyd-Ratio in Urin und Serum und der Hyp-Spiegel im Urin waren bei den Fibromyalgie-Patienten im Vergleich zu den Kontrollpersonen signifikant vermindert . Schlussfolgerung : Die gefundenen , verminderten Kollagen-Crosslinks-Spiegel sind moeglicherweise auf ein Remodelling der extrazellulaeren Matrix und der Ausbildung von Kollagenablagerungen um preterminale Nervenfasern in der Haut von Fibromyalgie-Patienten ( abgesenkte Schmerzschwelle ? ) zurueckzufuehren . Die Analyse eines gestoerten Kollagenmetabolismus durch histologische Untersuchungen oder , besser , durch HPLC-Analyse der Kollagen-Crosslinks im Urin oder Serum kann moeglicherweise zum weiteren Verstaendnis der Pathogenese der Fibromyalgie beitragen . Instructions: please typing these entity words according to sentence: Pathophysiologie, Fibromyalgie, Fibromyalgie, Konzentration, Urin, Patienten, Methoden, Patienten, Fibromyalgie, Urin-, knochenumbaudeterminierende, Marker, Kollagenstoffwechsels, HPLC, Hydroxyprolinspiegel, Marker, Urin, Urin, Ausbildung, Kollagenablagerungen, Nervenfasern, Haut, Schmerzschwelle, Analyse, Urin, Fibromyalgie Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]

Einleitung : Das Fehlen von Daten zur Pathophysiologie der Fibromyalgie sowie von kranheitsspezifischen Laborparametern bereitet Schwierigkeiten , die Erkrankung als Entitaet anzuerkennen . Auf der Suche nach charakteristischen Merkmalen der Fibromyalgie bestimmten wir die Konzentration der Kollagen-Crosslinks im Urin und im Serum der Patienten . Methoden : Die Patienten mit Fibromyalgie wurden entsprechend den American College of Rheumatology-Klassifikationskriterien in die Studie eingeschlossen . Von 39 Fibromyalgie-Patienten und von 55 gesunden Kontrollpersonen wurden unter standardisierten Bedingungen Urin- und Serumproben genommen . Pyridinolin Pyd ) und Desoxypyridinolin ( ( Dpyd ) , lysyloxidasevermittelte Produkte und bindegewebs- und knochenumbaudeterminierende Marker des Kollagenstoffwechsels , wurden mittels HPLC detektiert . Hydroxyprolinspiegel ( Hyp ) , ein Marker des Kollagen-Turnover , wurden ebenfalls gemessen . Die Ergebnisse wurden auf den Kreatininspiegel normiert und der Pyd/Dpyd-Quotient gebildet . Ergebnisse : Die Pyd/Dpyd-Ratio in Urin und Serum und der Hyp-Spiegel im Urin waren bei den Fibromyalgie-Patienten im Vergleich zu den Kontrollpersonen signifikant vermindert . Schlussfolgerung : Die gefundenen , verminderten Kollagen-Crosslinks-Spiegel sind moeglicherweise auf ein Remodelling der extrazellulaeren Matrix und der Ausbildung von Kollagenablagerungen um preterminale Nervenfasern in der Haut von Fibromyalgie-Patienten ( abgesenkte Schmerzschwelle ? ) zurueckzufuehren . Die Analyse eines gestoerten Kollagenmetabolismus durch histologische Untersuchungen oder , besser , durch HPLC-Analyse der Kollagen-Crosslinks im Urin oder Serum kann moeglicherweise zum weiteren Verstaendnis der Pathogenese der Fibromyalgie beitragen .

[ "Einleitung", ":", "Das", "Fehlen", "von", "Daten", "zur", "Pathophysiologie", "der", "Fibromyalgie", "sowie", "von", "kranheitsspezifischen", "Laborparametern", "bereitet", "Schwierigkeiten", ",", "die", "Erkrankung", "als", "Entitaet", "anzuerkennen", ".", "Auf", "der", "Suche", "nach", "charakteristischen", "Merkmalen", "der", "Fibromyalgie", "bestimmten", "wir", "die", "Konzentration", "der", "Kollagen", "-", "Crosslinks", "im", "Urin", "und", "im", "Serum", "der", "Patienten", ".", "Methoden", ":", "Die", "Patienten", "mit", "Fibromyalgie", "wurden", "entsprechend", "den", "American", "College", "of", "Rheumatology", "-", "Klassifikationskriterien", "in", "die", "Studie", "eingeschlossen", ".", "Von", "39", "Fibromyalgie", "-", "Patienten", "und", "von", "55", "gesunden", "Kontrollpersonen", "wurden", "unter", "standardisierten", "Bedingungen", "Urin-", "und", "Serumproben", "genommen", ".", "Pyridinolin", "Pyd", ")", "und", "Desoxypyridinolin", "(", "(", "Dpyd", ")", ",", "lysyloxidasevermittelte", "Produkte", "und", "bindegewebs-", "und", "knochenumbaudeterminierende", "Marker", "des", "Kollagenstoffwechsels", ",", "wurden", "mittels", "HPLC", "detektiert", ".", "Hydroxyprolinspiegel", "(", "Hyp", ")", ",", "ein", "Marker", "des", "Kollagen", "-", "Turnover", ",", "wurden", "ebenfalls", "gemessen", ".", "Die", "Ergebnisse", "wurden", "auf", "den", "Kreatininspiegel", "normiert", "und", "der", "Pyd", "/", "Dpyd", "-", "Quotient", "gebildet", ".", "Ergebnisse", ":", "Die", "Pyd", "/", "Dpyd", "-", "Ratio", "in", "Urin", "und", "Serum", "und", "der", "Hyp", "-", "Spiegel", "im", "Urin", "waren", "bei", "den", "Fibromyalgie", "-", "Patienten", "im", "Vergleich", "zu", "den", "Kontrollpersonen", "signifikant", "vermindert", ".", "Schlussfolgerung", ":", "Die", "gefundenen", ",", "verminderten", "Kollagen", "-", "Crosslinks", "-", "Spiegel", "sind", "moeglicherweise", "auf", "ein", "Remodelling", "der", "extrazellulaeren", "Matrix", "und", "der", "Ausbildung", "von", "Kollagenablagerungen", "um", "preterminale", "Nervenfasern", "in", "der", "Haut", "von", "Fibromyalgie", "-", "Patienten", "(", "abgesenkte", "Schmerzschwelle", "?", ")", "zurueckzufuehren", ".", "Die", "Analyse", "eines", "gestoerten", "Kollagenmetabolismus", "durch", "histologische", "Untersuchungen", "oder", ",", "besser", ",", "durch", "HPLC", "-", "Analyse", "der", "Kollagen", "-", "Crosslinks", "im", "Urin", "oder", "Serum", "kann", "moeglicherweise", "zum", "weiteren", "Verstaendnis", "der", "Pathogenese", "der", "Fibromyalgie", "beitragen", "." ]

[ "umlsterm" ]

Pathophysiologie, Fibromyalgie, Fibromyalgie, Konzentration, Urin, Patienten, Methoden, Patienten, Fibromyalgie, Urin-, knochenumbaudeterminierende, Marker, Kollagenstoffwechsels, HPLC, Hydroxyprolinspiegel, Marker, Urin, Urin, Ausbildung, Kollagenablagerungen, Nervenfasern, Haut, Schmerzschwelle, Analyse, Urin, Fibromyalgie

ZfuerRheumatologie.8057s052.ger.abstr_task2

Sentence: Einleitung : Das Fehlen von Daten zur Pathophysiologie der Fibromyalgie sowie von kranheitsspezifischen Laborparametern bereitet Schwierigkeiten , die Erkrankung als Entitaet anzuerkennen . Auf der Suche nach charakteristischen Merkmalen der Fibromyalgie bestimmten wir die Konzentration der Kollagen-Crosslinks im Urin und im Serum der Patienten . Methoden : Die Patienten mit Fibromyalgie wurden entsprechend den American College of Rheumatology-Klassifikationskriterien in die Studie eingeschlossen . Von 39 Fibromyalgie-Patienten und von 55 gesunden Kontrollpersonen wurden unter standardisierten Bedingungen Urin- und Serumproben genommen . Pyridinolin Pyd ) und Desoxypyridinolin ( ( Dpyd ) , lysyloxidasevermittelte Produkte und bindegewebs- und knochenumbaudeterminierende Marker des Kollagenstoffwechsels , wurden mittels HPLC detektiert . Hydroxyprolinspiegel ( Hyp ) , ein Marker des Kollagen-Turnover , wurden ebenfalls gemessen . Die Ergebnisse wurden auf den Kreatininspiegel normiert und der Pyd/Dpyd-Quotient gebildet . Ergebnisse : Die Pyd/Dpyd-Ratio in Urin und Serum und der Hyp-Spiegel im Urin waren bei den Fibromyalgie-Patienten im Vergleich zu den Kontrollpersonen signifikant vermindert . Schlussfolgerung : Die gefundenen , verminderten Kollagen-Crosslinks-Spiegel sind moeglicherweise auf ein Remodelling der extrazellulaeren Matrix und der Ausbildung von Kollagenablagerungen um preterminale Nervenfasern in der Haut von Fibromyalgie-Patienten ( abgesenkte Schmerzschwelle ? ) zurueckzufuehren . Die Analyse eines gestoerten Kollagenmetabolismus durch histologische Untersuchungen oder , besser , durch HPLC-Analyse der Kollagen-Crosslinks im Urin oder Serum kann moeglicherweise zum weiteren Verstaendnis der Pathogenese der Fibromyalgie beitragen . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]

Einleitung : Das Fehlen von Daten zur Pathophysiologie der Fibromyalgie sowie von kranheitsspezifischen Laborparametern bereitet Schwierigkeiten , die Erkrankung als Entitaet anzuerkennen . Auf der Suche nach charakteristischen Merkmalen der Fibromyalgie bestimmten wir die Konzentration der Kollagen-Crosslinks im Urin und im Serum der Patienten . Methoden : Die Patienten mit Fibromyalgie wurden entsprechend den American College of Rheumatology-Klassifikationskriterien in die Studie eingeschlossen . Von 39 Fibromyalgie-Patienten und von 55 gesunden Kontrollpersonen wurden unter standardisierten Bedingungen Urin- und Serumproben genommen . Pyridinolin Pyd ) und Desoxypyridinolin ( ( Dpyd ) , lysyloxidasevermittelte Produkte und bindegewebs- und knochenumbaudeterminierende Marker des Kollagenstoffwechsels , wurden mittels HPLC detektiert . Hydroxyprolinspiegel ( Hyp ) , ein Marker des Kollagen-Turnover , wurden ebenfalls gemessen . Die Ergebnisse wurden auf den Kreatininspiegel normiert und der Pyd/Dpyd-Quotient gebildet . Ergebnisse : Die Pyd/Dpyd-Ratio in Urin und Serum und der Hyp-Spiegel im Urin waren bei den Fibromyalgie-Patienten im Vergleich zu den Kontrollpersonen signifikant vermindert . Schlussfolgerung : Die gefundenen , verminderten Kollagen-Crosslinks-Spiegel sind moeglicherweise auf ein Remodelling der extrazellulaeren Matrix und der Ausbildung von Kollagenablagerungen um preterminale Nervenfasern in der Haut von Fibromyalgie-Patienten ( abgesenkte Schmerzschwelle ? ) zurueckzufuehren . Die Analyse eines gestoerten Kollagenmetabolismus durch histologische Untersuchungen oder , besser , durch HPLC-Analyse der Kollagen-Crosslinks im Urin oder Serum kann moeglicherweise zum weiteren Verstaendnis der Pathogenese der Fibromyalgie beitragen .

[ "Einleitung", ":", "Das", "Fehlen", "von", "Daten", "zur", "Pathophysiologie", "der", "Fibromyalgie", "sowie", "von", "kranheitsspezifischen", "Laborparametern", "bereitet", "Schwierigkeiten", ",", "die", "Erkrankung", "als", "Entitaet", "anzuerkennen", ".", "Auf", "der", "Suche", "nach", "charakteristischen", "Merkmalen", "der", "Fibromyalgie", "bestimmten", "wir", "die", "Konzentration", "der", "Kollagen", "-", "Crosslinks", "im", "Urin", "und", "im", "Serum", "der", "Patienten", ".", "Methoden", ":", "Die", "Patienten", "mit", "Fibromyalgie", "wurden", "entsprechend", "den", "American", "College", "of", "Rheumatology", "-", "Klassifikationskriterien", "in", "die", "Studie", "eingeschlossen", ".", "Von", "39", "Fibromyalgie", "-", "Patienten", "und", "von", "55", "gesunden", "Kontrollpersonen", "wurden", "unter", "standardisierten", "Bedingungen", "Urin-", "und", "Serumproben", "genommen", ".", "Pyridinolin", "Pyd", ")", "und", "Desoxypyridinolin", "(", "(", "Dpyd", ")", ",", "lysyloxidasevermittelte", "Produkte", "und", "bindegewebs-", "und", "knochenumbaudeterminierende", "Marker", "des", "Kollagenstoffwechsels", ",", "wurden", "mittels", "HPLC", "detektiert", ".", "Hydroxyprolinspiegel", "(", "Hyp", ")", ",", "ein", "Marker", "des", "Kollagen", "-", "Turnover", ",", "wurden", "ebenfalls", "gemessen", ".", "Die", "Ergebnisse", "wurden", "auf", "den", "Kreatininspiegel", "normiert", "und", "der", "Pyd", "/", "Dpyd", "-", "Quotient", "gebildet", ".", "Ergebnisse", ":", "Die", "Pyd", "/", "Dpyd", "-", "Ratio", "in", "Urin", "und", "Serum", "und", "der", "Hyp", "-", "Spiegel", "im", "Urin", "waren", "bei", "den", "Fibromyalgie", "-", "Patienten", "im", "Vergleich", "zu", "den", "Kontrollpersonen", "signifikant", "vermindert", ".", "Schlussfolgerung", ":", "Die", "gefundenen", ",", "verminderten", "Kollagen", "-", "Crosslinks", "-", "Spiegel", "sind", "moeglicherweise", "auf", "ein", "Remodelling", "der", "extrazellulaeren", "Matrix", "und", "der", "Ausbildung", "von", "Kollagenablagerungen", "um", "preterminale", "Nervenfasern", "in", "der", "Haut", "von", "Fibromyalgie", "-", "Patienten", "(", "abgesenkte", "Schmerzschwelle", "?", ")", "zurueckzufuehren", ".", "Die", "Analyse", "eines", "gestoerten", "Kollagenmetabolismus", "durch", "histologische", "Untersuchungen", "oder", ",", "besser", ",", "durch", "HPLC", "-", "Analyse", "der", "Kollagen", "-", "Crosslinks", "im", "Urin", "oder", "Serum", "kann", "moeglicherweise", "zum", "weiteren", "Verstaendnis", "der", "Pathogenese", "der", "Fibromyalgie", "beitragen", "." ]

[ "umlsterm" ]

chronically is a Temporal, HCV is a Condition, Genotype 1 is a Qualifier, HCV RNA viral load is a Measurement, ≥ 10 * 5 * IU / mL is a Value, 100,000 IU / mL is a Value, at screening is a Temporal

NCT01051414_inc_task0

Sentence: Subjects chronically infected with HCV Genotype 1 HCV RNA viral load of ≥ 10*5* IU/mL (100,000 IU/mL) at screening Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Temporal, Condition, Qualifier, Value, Measurement

[ "O", "B-Temporal", "O", "O", "B-Condition", "B-Qualifier", "I-Qualifier", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "O", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "B-Value", "I-Value", "I-Value", "I-Value", "O", "B-Temporal", "I-Temporal", "O" ]

Subjects chronically infected with HCV Genotype 1 HCV RNA viral load of ≥ 10*5* IU/mL (100,000 IU/mL) at screening

[ "Subjects", "chronically", "infected", "with", "HCV", "Genotype", "1", "\n", "HCV", "RNA", "viral", "load", "of", "≥", "10", "*", "5", "*", "IU", "/", "mL", "(", "100,000", "IU", "/", "mL", ")", "at", "screening", "\n" ]

[ "Measurement", "Value", "Temporal", "Multiplier", "Qualifier", "Reference_point", "Condition" ]

chronically is a Temporal, HCV is a Condition, Genotype 1 is a Qualifier, HCV RNA viral load is a Measurement, ≥ 10 * 5 * IU / mL is a Value, 100,000 IU / mL is a Value, at screening is a Temporal

NCT01051414_inc_task1

Sentence: Subjects chronically infected with HCV Genotype 1 HCV RNA viral load of ≥ 10*5* IU/mL (100,000 IU/mL) at screening Instructions: please typing these entity words according to sentence: chronically, HCV, Genotype 1, HCV RNA viral load, ≥ 10 * 5 * IU / mL, 100,000 IU / mL, at screening Options: Temporal, Condition, Qualifier, Value, Measurement

[ "O", "B-Temporal", "O", "O", "B-Condition", "B-Qualifier", "I-Qualifier", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "O", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "B-Value", "I-Value", "I-Value", "I-Value", "O", "B-Temporal", "I-Temporal", "O" ]

Subjects chronically infected with HCV Genotype 1 HCV RNA viral load of ≥ 10*5* IU/mL (100,000 IU/mL) at screening

[ "Subjects", "chronically", "infected", "with", "HCV", "Genotype", "1", "\n", "HCV", "RNA", "viral", "load", "of", "≥", "10", "*", "5", "*", "IU", "/", "mL", "(", "100,000", "IU", "/", "mL", ")", "at", "screening", "\n" ]

[ "Measurement", "Value", "Temporal", "Multiplier", "Qualifier", "Reference_point", "Condition" ]

chronically, HCV, Genotype 1, HCV RNA viral load, ≥ 10 * 5 * IU / mL, 100,000 IU / mL, at screening

NCT01051414_inc_task2

Sentence: Subjects chronically infected with HCV Genotype 1 HCV RNA viral load of ≥ 10*5* IU/mL (100,000 IU/mL) at screening Instructions: please extract entity words from the input sentence

[ "O", "B-Temporal", "O", "O", "B-Condition", "B-Qualifier", "I-Qualifier", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "O", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "B-Value", "I-Value", "I-Value", "I-Value", "O", "B-Temporal", "I-Temporal", "O" ]

Subjects chronically infected with HCV Genotype 1 HCV RNA viral load of ≥ 10*5* IU/mL (100,000 IU/mL) at screening

[ "Subjects", "chronically", "infected", "with", "HCV", "Genotype", "1", "\n", "HCV", "RNA", "viral", "load", "of", "≥", "10", "*", "5", "*", "IU", "/", "mL", "(", "100,000", "IU", "/", "mL", ")", "at", "screening", "\n" ]

[ "Measurement", "Value", "Temporal", "Multiplier", "Qualifier", "Reference_point", "Condition" ]